<!DOCTYPE html> <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Growth factors for treating diabetic foot ulcers - Martí‐Carvajal, AJ - 2015 | Cochrane Library</title> <meta property="og:title" content="Growth factors for treating diabetic foot ulcers - Martí‐Carvajal, AJ - 2015 | Cochrane Library" /> <meta property="og:url" content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD008548.pub2/references" /> <meta property="og:type" content="article" /> <meta property=”og:image” content=”https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png” /> <meta content="initial-scale=1.0, width=device-width" name="viewport" /> <meta name="dc.identifier" scheme="DOI" content="10.1002/14651858.CD008548.pub2" /> <meta name="citation_title" content="Growth factors for treating diabetic foot ulcers" /> <meta name="citation_author" content="Arturo J Mart&iacute;‐Carvajal" /> <meta name="citation_author_institution" content="Iberoamerican Cochrane Network" /> <meta name="citation_author_email" content="arturo.marti.carvajal@gmail.com" /> <meta name="citation_author" content="Christian Gluud" /> <meta name="citation_author_institution" content="Copenhagen Trial Unit, Centre for Clinical Intervention Research, Department 7812, Rigshospitalet, Copenhagen University Hospital" /> <meta name="citation_author" content="Susana Nicola" /> <meta name="citation_author_institution" content="Universidad Tecnol&oacute;gica Equinoccial" /> <meta name="citation_author" content="Daniel Simancas‐Racines" /> <meta name="citation_author_institution" content="Universidad Tecnol&oacute;gica Equinoccial" /> <meta name="citation_author" content="Ludovic Reveiz" /> <meta name="citation_author" content="Patricio Oliva" /> <meta name="citation_author_institution" content="Universidad del Desarrollo" /> <meta name="citation_author" content="Jorge Cede&ntilde;o‐Taborda" /> <meta name="citation_author_institution" content="Centro de Investigaci&oacute;n UNILIME / Universidad de Carabobo" /> <meta name="citation_journal_title" content="Cochrane Database of Systematic Reviews" /> <meta name="citation_publisher" content="John Wiley &amp; Sons, Ltd" /> <meta name="citation_issue" content="10" /> <meta name="citation_doi" content="10.1002/14651858.CD008548.pub2" /> <meta name="citation_date" content="2015" /> <meta name="citation_online_date" content="2015/10/28" /> <meta name="citation_abstract_html_url" content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD008548.pub2/abstract" /> <meta name="citation_fulltext_html_url" content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD008548.pub2/full" /> <meta name="citation_pdf_url" content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD008548.pub2/pdf/CDSR/CD008548/CD008548.pdf" /> <meta name="citation_issn" content="1465-1858" /> <meta name="citation_language" content="en" /> <meta name="citation_keywords" content="Amputation; Diabetes Mellitus, Type 1 [*complications]; Diabetes Mellitus, Type 2 [*complications]; Diabetic Foot [*therapy]; Growth Substances [adverse effects, *therapeutic use]; Randomized Controlled Trials as Topic; Wound Healing" /> <script type="text/javascript" src="//script.crazyegg.com/pages/scripts/0056/6375.js" async="async"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <script type="text/javascript">var o={auth:{customerIds:["P#DRAAEAC","EAL00000056729","DRAA3TITLES","TSINGH009S","EAL0001468","EAL00000045347"],individualId:null,brandedCustomer:"EAL0001468",roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=UTF-8" http-equiv="content-type" /> <link href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/cochrane-theme/images/favicon.ico" rel="Shortcut Icon" /> <link href="https&#x3a;&#x2f;&#x2f;www&#x2e;cochranelibrary&#x2e;com&#x2f;content&#x3f;templateType&#x3d;references&#x26;urlTitle&#x3d;&#x2f;cdsr&#x2f;doi&#x2f;10&#x2e;1002&#x2f;14651858&#x2e;CD008548&#x2e;pub2&#x26;doi&#x3d;10&#x2e;1002&#x2f;14651858&#x2e;CD008548&#x2e;pub2&#x26;type&#x3d;cdsr&#x26;contentLanguage&#x3d;" rel="canonical" /> <link href="https&#x3a;&#x2f;&#x2f;www&#x2e;cochranelibrary&#x2e;com&#x2f;zh&#x2f;content&#x3f;templateType&#x3d;references&#x26;urlTitle&#x3d;&#x2f;cdsr&#x2f;doi&#x2f;10&#x2e;1002&#x2f;14651858&#x2e;CD008548&#x2e;pub2&#x26;doi&#x3d;10&#x2e;1002&#x2f;14651858&#x2e;CD008548&#x2e;pub2&#x26;type&#x3d;cdsr&#x26;contentLanguage&#x3d;" hreflang="zh-CN" rel="alternate" /> <link href="https&#x3a;&#x2f;&#x2f;www&#x2e;cochranelibrary&#x2e;com&#x2f;zh_TW&#x2f;content&#x3f;templateType&#x3d;references&#x26;urlTitle&#x3d;&#x2f;cdsr&#x2f;doi&#x2f;10&#x2e;1002&#x2f;14651858&#x2e;CD008548&#x2e;pub2&#x26;doi&#x3d;10&#x2e;1002&#x2f;14651858&#x2e;CD008548&#x2e;pub2&#x26;type&#x3d;cdsr&#x26;contentLanguage&#x3d;" hreflang="zh-TW" rel="alternate" /> <link href="https&#x3a;&#x2f;&#x2f;www&#x2e;cochranelibrary&#x2e;com&#x2f;hr&#x2f;content&#x3f;templateType&#x3d;references&#x26;urlTitle&#x3d;&#x2f;cdsr&#x2f;doi&#x2f;10&#x2e;1002&#x2f;14651858&#x2e;CD008548&#x2e;pub2&#x26;doi&#x3d;10&#x2e;1002&#x2f;14651858&#x2e;CD008548&#x2e;pub2&#x26;type&#x3d;cdsr&#x26;contentLanguage&#x3d;" hreflang="hr-HR" rel="alternate" /> <link href="https&#x3a;&#x2f;&#x2f;www&#x2e;cochranelibrary&#x2e;com&#x2f;content&#x3f;templateType&#x3d;references&#x26;urlTitle&#x3d;&#x2f;cdsr&#x2f;doi&#x2f;10&#x2e;1002&#x2f;14651858&#x2e;CD008548&#x2e;pub2&#x26;doi&#x3d;10&#x2e;1002&#x2f;14651858&#x2e;CD008548&#x2e;pub2&#x26;type&#x3d;cdsr&#x26;contentLanguage&#x3d;" hreflang="x-default" rel="alternate" /> <link href="https&#x3a;&#x2f;&#x2f;www&#x2e;cochranelibrary&#x2e;com&#x2f;content&#x3f;templateType&#x3d;references&#x26;urlTitle&#x3d;&#x2f;cdsr&#x2f;doi&#x2f;10&#x2e;1002&#x2f;14651858&#x2e;CD008548&#x2e;pub2&#x26;doi&#x3d;10&#x2e;1002&#x2f;14651858&#x2e;CD008548&#x2e;pub2&#x26;type&#x3d;cdsr&#x26;contentLanguage&#x3d;" hreflang="en-US" rel="alternate" /> <link href="https&#x3a;&#x2f;&#x2f;www&#x2e;cochranelibrary&#x2e;com&#x2f;fr&#x2f;content&#x3f;templateType&#x3d;references&#x26;urlTitle&#x3d;&#x2f;cdsr&#x2f;doi&#x2f;10&#x2e;1002&#x2f;14651858&#x2e;CD008548&#x2e;pub2&#x26;doi&#x3d;10&#x2e;1002&#x2f;14651858&#x2e;CD008548&#x2e;pub2&#x26;type&#x3d;cdsr&#x26;contentLanguage&#x3d;" hreflang="fr-FR" rel="alternate" /> <link href="https&#x3a;&#x2f;&#x2f;www&#x2e;cochranelibrary&#x2e;com&#x2f;de&#x2f;content&#x3f;templateType&#x3d;references&#x26;urlTitle&#x3d;&#x2f;cdsr&#x2f;doi&#x2f;10&#x2e;1002&#x2f;14651858&#x2e;CD008548&#x2e;pub2&#x26;doi&#x3d;10&#x2e;1002&#x2f;14651858&#x2e;CD008548&#x2e;pub2&#x26;type&#x3d;cdsr&#x26;contentLanguage&#x3d;" hreflang="de-DE" rel="alternate" /> <link href="https&#x3a;&#x2f;&#x2f;www&#x2e;cochranelibrary&#x2e;com&#x2f;ja&#x2f;content&#x3f;templateType&#x3d;references&#x26;urlTitle&#x3d;&#x2f;cdsr&#x2f;doi&#x2f;10&#x2e;1002&#x2f;14651858&#x2e;CD008548&#x2e;pub2&#x26;doi&#x3d;10&#x2e;1002&#x2f;14651858&#x2e;CD008548&#x2e;pub2&#x26;type&#x3d;cdsr&#x26;contentLanguage&#x3d;" hreflang="ja-JP" rel="alternate" /> <link href="https&#x3a;&#x2f;&#x2f;www&#x2e;cochranelibrary&#x2e;com&#x2f;ko&#x2f;content&#x3f;templateType&#x3d;references&#x26;urlTitle&#x3d;&#x2f;cdsr&#x2f;doi&#x2f;10&#x2e;1002&#x2f;14651858&#x2e;CD008548&#x2e;pub2&#x26;doi&#x3d;10&#x2e;1002&#x2f;14651858&#x2e;CD008548&#x2e;pub2&#x26;type&#x3d;cdsr&#x26;contentLanguage&#x3d;" hreflang="ko-KR" rel="alternate" /> <link href="https&#x3a;&#x2f;&#x2f;www&#x2e;cochranelibrary&#x2e;com&#x2f;ms&#x2f;content&#x3f;templateType&#x3d;references&#x26;urlTitle&#x3d;&#x2f;cdsr&#x2f;doi&#x2f;10&#x2e;1002&#x2f;14651858&#x2e;CD008548&#x2e;pub2&#x26;doi&#x3d;10&#x2e;1002&#x2f;14651858&#x2e;CD008548&#x2e;pub2&#x26;type&#x3d;cdsr&#x26;contentLanguage&#x3d;" hreflang="ms-MY" rel="alternate" /> <link href="https&#x3a;&#x2f;&#x2f;www&#x2e;cochranelibrary&#x2e;com&#x2f;fa&#x2f;content&#x3f;templateType&#x3d;references&#x26;urlTitle&#x3d;&#x2f;cdsr&#x2f;doi&#x2f;10&#x2e;1002&#x2f;14651858&#x2e;CD008548&#x2e;pub2&#x26;doi&#x3d;10&#x2e;1002&#x2f;14651858&#x2e;CD008548&#x2e;pub2&#x26;type&#x3d;cdsr&#x26;contentLanguage&#x3d;" hreflang="fa-IR" rel="alternate" /> <link href="https&#x3a;&#x2f;&#x2f;www&#x2e;cochranelibrary&#x2e;com&#x2f;pl&#x2f;content&#x3f;templateType&#x3d;references&#x26;urlTitle&#x3d;&#x2f;cdsr&#x2f;doi&#x2f;10&#x2e;1002&#x2f;14651858&#x2e;CD008548&#x2e;pub2&#x26;doi&#x3d;10&#x2e;1002&#x2f;14651858&#x2e;CD008548&#x2e;pub2&#x26;type&#x3d;cdsr&#x26;contentLanguage&#x3d;" hreflang="pl-PL" rel="alternate" /> <link href="https&#x3a;&#x2f;&#x2f;www&#x2e;cochranelibrary&#x2e;com&#x2f;pt&#x2f;content&#x3f;templateType&#x3d;references&#x26;urlTitle&#x3d;&#x2f;cdsr&#x2f;doi&#x2f;10&#x2e;1002&#x2f;14651858&#x2e;CD008548&#x2e;pub2&#x26;doi&#x3d;10&#x2e;1002&#x2f;14651858&#x2e;CD008548&#x2e;pub2&#x26;type&#x3d;cdsr&#x26;contentLanguage&#x3d;" hreflang="pt-PT" rel="alternate" /> <link href="https&#x3a;&#x2f;&#x2f;www&#x2e;cochranelibrary&#x2e;com&#x2f;ru&#x2f;content&#x3f;templateType&#x3d;references&#x26;urlTitle&#x3d;&#x2f;cdsr&#x2f;doi&#x2f;10&#x2e;1002&#x2f;14651858&#x2e;CD008548&#x2e;pub2&#x26;doi&#x3d;10&#x2e;1002&#x2f;14651858&#x2e;CD008548&#x2e;pub2&#x26;type&#x3d;cdsr&#x26;contentLanguage&#x3d;" hreflang="ru-RU" rel="alternate" /> <link href="https&#x3a;&#x2f;&#x2f;www&#x2e;cochranelibrary&#x2e;com&#x2f;es&#x2f;content&#x3f;templateType&#x3d;references&#x26;urlTitle&#x3d;&#x2f;cdsr&#x2f;doi&#x2f;10&#x2e;1002&#x2f;14651858&#x2e;CD008548&#x2e;pub2&#x26;doi&#x3d;10&#x2e;1002&#x2f;14651858&#x2e;CD008548&#x2e;pub2&#x26;type&#x3d;cdsr&#x26;contentLanguage&#x3d;" hreflang="es-ES" rel="alternate" /> <link href="https&#x3a;&#x2f;&#x2f;www&#x2e;cochranelibrary&#x2e;com&#x2f;ta&#x2f;content&#x3f;templateType&#x3d;references&#x26;urlTitle&#x3d;&#x2f;cdsr&#x2f;doi&#x2f;10&#x2e;1002&#x2f;14651858&#x2e;CD008548&#x2e;pub2&#x26;doi&#x3d;10&#x2e;1002&#x2f;14651858&#x2e;CD008548&#x2e;pub2&#x26;type&#x3d;cdsr&#x26;contentLanguage&#x3d;" hreflang="ta-IN" rel="alternate" /> <link href="https&#x3a;&#x2f;&#x2f;www&#x2e;cochranelibrary&#x2e;com&#x2f;th&#x2f;content&#x3f;templateType&#x3d;references&#x26;urlTitle&#x3d;&#x2f;cdsr&#x2f;doi&#x2f;10&#x2e;1002&#x2f;14651858&#x2e;CD008548&#x2e;pub2&#x26;doi&#x3d;10&#x2e;1002&#x2f;14651858&#x2e;CD008548&#x2e;pub2&#x26;type&#x3d;cdsr&#x26;contentLanguage&#x3d;" hreflang="th-TH" rel="alternate" /> <link class="lfr-css-file" href="https&#x3a;&#x2f;&#x2f;www&#x2e;cochranelibrary&#x2e;com&#x2f;cochrane-theme&#x2f;css&#x2f;main&#x2e;css&#x3f;browserId&#x3d;other&#x26;themeId&#x3d;cochrane_WAR_cochranetheme&#x26;minifierType&#x3d;css&#x26;languageId&#x3d;en_US&#x26;b&#x3d;6210&#x26;t&#x3d;1581422282000" rel="stylesheet" type="text/css" /> <link class="lfr-css-file" href="https&#x3a;&#x2f;&#x2f;www&#x2e;cochranelibrary&#x2e;com&#x2f;cochrane-theme&#x2f;css&#x2f;aui&#x2e;css&#x3f;browserId&#x3d;other&#x26;themeId&#x3d;cochrane_WAR_cochranetheme&#x26;minifierType&#x3d;css&#x26;languageId&#x3d;en_US&#x26;b&#x3d;6210&#x26;t&#x3d;1581422282000" rel="stylesheet" type="text/css" /> <link href="&#x2f;html&#x2f;css&#x2f;main&#x2e;css&#x3f;browserId&#x3d;other&#x26;themeId&#x3d;cochrane_WAR_cochranetheme&#x26;minifierType&#x3d;css&#x26;languageId&#x3d;en_US&#x26;b&#x3d;6210&#x26;t&#x3d;1513680834000" rel="stylesheet" type="text/css" /> <link href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1581718153000" rel="stylesheet" type="text/css" /> <link href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1581718173000" rel="stylesheet" type="text/css" /> <link href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1581718256000" rel="stylesheet" type="text/css" /> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 13},getRevision:function(){return"605.1"},getVersion:function(){return"13.0"},isAir:function(){return false},isChrome:function(){return false},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return false},isMac:function(){return true},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513680837000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513680837000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513680837000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513680837000"}};Liferay.authToken="EfT7x5RD";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dreferences\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD008548\x2epub2\x26doi\x3d10\x2e1002\x2f14651858\x2eCD008548\x2epub2\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dreferences\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008548\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD008548\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513680837000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article References"},article:{availableLanguage:["en","es","de","ru","hr","fr"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD008548.pub2",title:"Growth factors for treating diabetic foot ulcers",firstPublishedDate:"Oct 28, 2015 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Wounds Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https&#x3a;&#x2f;&#x2f;www&#x2e;cochranelibrary&#x2e;com&#x2f;cochrane-theme&#x2f;css&#x2f;custom&#x2e;css&#x3f;browserId&#x3d;other&#x26;themeId&#x3d;cochrane_WAR_cochranetheme&#x26;minifierType&#x3d;css&#x26;languageId&#x3d;en_US&#x26;b&#x3d;6210&#x26;t&#x3d;1581422282000" rel="stylesheet" type="text/css" /> <style type="text/css"></style> <script src="//assets.adobedtm.com/6e626c9ec247e474f6b98eb15a79a185cf7e26a5/satelliteLib-b0f13d7a13ebe8b0b1b00a9f0730a084926e292f.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1581422282000" type="text/javascript"></script> <![endif]--> </head> <body class=" yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div id="js-cookie-message" class="cookie-message cookie-message--hidden system-message-container"> <div class="container"> <a href="#" class="fa fa-times js-cookie-close pull-right" aria-label="Close cookies message"></a> <div class="system-message-wrapper container"> <i class="fa fa-exclamation-triangle" aria-hidden="true"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/http/N7XGCZUQPW4C675JNSTYTLUDN7XB/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a href="#" class="btn secondary js-cookie-close js-cookie-accept">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/en/"> <span class="brand-name">The Cochrane Library</span> <img class="brand-logo" src="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/cochrane-theme/images/en-US_logo.png" alt="Cochrane Library logo" title="Cochrane Library" /> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end " id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img id="owel__null__null" src="/scolaris-search/icon.png" alt="" /> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class=" portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/en/content?p_auth=EfT7x5RD&p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=1&p_p_state=normal&p_p_mode=view&_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input type="hidden" name="searchType" value="basic" /> <input type="hidden" name="facetDisplayName" value="" /> <input type="hidden" name="facetQueryTerm" value="" /> <input type="hidden" name="facetQueryField" value="" /> <input type="hidden" name="facetCategory" value="" /> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select title="Search by options" aria-label="Search by options" name="searchBy" class="custom-select-enabled search-type"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" style="display: none;" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=topics-list&p_p_cacheability=cacheLevelPage"> <select class="search-select-topic-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input type="text" size="30" class="field browser-search search-text ui-autocomplete-input" value="" aria-label="Enter search term" id="searchText" name="searchText" placeholder="Search">
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button type="submit" class="searchByBtn" aria-label="Search">
<i class="fa fa-search" aria-hidden="true"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=references&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD008548.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD008548.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input type="hidden" name="freelabel" id="freelabel" value='Free access'>
<input type="hidden" name="openlabel" id="openlabel" value='Open access'>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a href="/en/browse-by-topic" class="btn secondary">Browse</a>
<a href="/en/advanced-search" class="btn primary advanced-search-button">Advanced search</a>
</div>
</div>
<a href="#" class="toggle-menu-switch"><i class="fa fa-bars" aria-hidden="true"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<p class="auxiliary-menu-item access">Access provided by: <strong>Tsinghua University</strong></p>
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_  portlet-static portlet-static-end  " id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img id="bvrs__null__null" src="/scolaris-language-portlet/icon.png" alt="" /> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class=" portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hr, ja, ko, ms, pl, pt, ru, ta, th, zh, za]"> <a title="Select your preferred language" class="open-language-modal" href="#"> <i class="fa fa-file-text"></i> English </a> <a title="Select your preferred language" class="open-language-modal" href="#"> <i class="fa fa-globe"></i> English </a> </div> <div class="language-selector-modal-content" style="display: none;" data-modal-title="Language selection" data-size="large"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane Review language</h3> <p>Select your preferred language for Cochrane Reviews. You will see translated Review sections in your preferred language. Sections without translation will be in English.</p> <div> <a href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=set-content-language&p_p_cacheability=cacheLevelPage&_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de" class="content-language-selector " data-languagecode="de">Deutsch</a> <a href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=set-content-language&p_p_cacheability=cacheLevelPage&_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en" class="content-language-selector is-active" data-languagecode="en">English</a> <a href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=set-content-language&p_p_cacheability=cacheLevelPage&_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es" class="content-language-selector " data-languagecode="es">Español</a> <a href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=set-content-language&p_p_cacheability=cacheLevelPage&_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa" class="content-language-selector " data-languagecode="fa">فارسی</a> <a href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=set-content-language&p_p_cacheability=cacheLevelPage&_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr" class="content-language-selector " data-languagecode="fr">Français</a> <a href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=set-content-language&p_p_cacheability=cacheLevelPage&_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr" class="content-language-selector " data-languagecode="hr">Hrvatski</a> <a href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=set-content-language&p_p_cacheability=cacheLevelPage&_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja" class="content-language-selector " data-languagecode="ja">日本語</a> <a href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=set-content-language&p_p_cacheability=cacheLevelPage&_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko" class="content-language-selector " data-languagecode="ko">한국어</a> <a href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=set-content-language&p_p_cacheability=cacheLevelPage&_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms" class="content-language-selector " data-languagecode="ms">Bahasa Malaysia</a> <a href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=set-content-language&p_p_cacheability=cacheLevelPage&_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl" class="content-language-selector " data-languagecode="pl">Polski</a> <a href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=set-content-language&p_p_cacheability=cacheLevelPage&_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt" class="content-language-selector " data-languagecode="pt">Português</a> <a href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=set-content-language&p_p_cacheability=cacheLevelPage&_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru" class="content-language-selector " data-languagecode="ru">Русский</a> <a href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=set-content-language&p_p_cacheability=cacheLevelPage&_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta" class="content-language-selector " data-languagecode="ta">தமிழ்</a> <a href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=set-content-language&p_p_cacheability=cacheLevelPage&_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th" class="content-language-selector " data-languagecode="th">ภาษาไทย</a> <a href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=set-content-language&p_p_cacheability=cacheLevelPage&_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh" class="content-language-selector " data-languagecode="zh">简体中文</a> <a href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=set-content-language&p_p_cacheability=cacheLevelPage&_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=za" class="content-language-selector " data-languagecode="za">繁體中文</a> </div> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div> <a href="/en/cdsr/doi/10.1002/14651858.CD008548.pub2/references/en" class="portal-language-selector is-active" data-portallanguage="en">English</a> <a href="/es/cdsr/doi/10.1002/14651858.CD008548.pub2/references/es" class="portal-language-selector " data-portallanguage="es">Español</a> </div> </div> <button class="btn primary btn-cancel" type="button">Cancel</button> <a class="btn secondary ok-btn pull-right" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=set-content-language&p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> <div style="display:none"> <input type="hidden" name="freelabel" id="freelabel" value='Free access'>
<input type="hidden" name="openlabel" id="openlabel" value='Open access'>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/c/portal/login?p_l_id=20757&redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD008548.pub2%2Freferences" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
</a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
<div class="access-provider-mobile">
<p class="access">Access provided by: <strong>Tsinghua University</strong></p>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class=" nav-root-item parent">
<a href="#">Cochrane Reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class=" child-nav-item" id="layout_14" role="presentation">
<a aria-labelledby="layout_14" href="https&#x3a;&#x2f;&#x2f;www&#x2e;cochranelibrary&#x2e;com&#x2f;en&#x2f;cdsr&#x2f;reviews" role="menuitem">
Search Reviews (CDSR)
</a>
</li>
<li class=" child-nav-item" id="layout_15" role="presentation">
<a aria-labelledby="layout_15" href="https&#x3a;&#x2f;&#x2f;www&#x2e;cochranelibrary&#x2e;com&#x2f;en&#x2f;cdsr&#x2f;reviews&#x2f;topics" role="menuitem">
Browse Reviews
</a>
</li>
<li class=" child-nav-item" id="layout_18" role="presentation">
<a aria-labelledby="layout_18" href="https&#x3a;&#x2f;&#x2f;www&#x2e;cochranelibrary&#x2e;com&#x2f;en&#x2f;cdsr&#x2f;table-of-contents" role="menuitem">
Issues
</a>
</li>
<li class=" child-nav-item" id="layout_17" role="presentation">
<a aria-labelledby="layout_17" href="https&#x3a;&#x2f;&#x2f;www&#x2e;cochranelibrary&#x2e;com&#x2f;en&#x2f;cdsr&#x2f;editorials" role="menuitem">
Editorials
</a>
</li>
<li class=" child-nav-item" id="layout_19" role="presentation">
<a aria-labelledby="layout_19" href="https&#x3a;&#x2f;&#x2f;www&#x2e;cochranelibrary&#x2e;com&#x2f;en&#x2f;special-collections" role="menuitem">
Special Collections
</a>
</li>
<li class=" child-nav-item" id="layout_20" role="presentation">
<a aria-labelledby="layout_20" href="https&#x3a;&#x2f;&#x2f;www&#x2e;cochranelibrary&#x2e;com&#x2f;en&#x2f;cdsr&#x2f;supplements" role="menuitem">
Supplements
</a>
</li>
<li class=" child-nav-item" id="layout_13" role="presentation">
<a aria-labelledby="layout_13" href="https&#x3a;&#x2f;&#x2f;www&#x2e;cochranelibrary&#x2e;com&#x2f;en&#x2f;cdsr&#x2f;about-cdsr" role="menuitem">
About the CDSR
</a>
</li>
</ul>
</li>
<li class=" nav-root-item parent">
<a href="#">Trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class=" child-nav-item" id="layout_22" role="presentation">
<a aria-labelledby="layout_22" href="https&#x3a;&#x2f;&#x2f;www&#x2e;cochranelibrary&#x2e;com&#x2f;en&#x2f;central" role="menuitem">
Search Trials (CENTRAL)
</a>
</li>
<li class=" child-nav-item" id="layout_114" role="presentation">
<a aria-labelledby="layout_114" href="https&#x3a;&#x2f;&#x2f;www&#x2e;cochranelibrary&#x2e;com&#x2f;en&#x2f;central&#x2f;about-central" role="menuitem">
About CENTRAL
</a>
</li>
</ul>
</li>
<li class=" nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class=" child-nav-item" id="layout_29" role="presentation">
<a aria-labelledby="layout_29" href="https&#x3a;&#x2f;&#x2f;www&#x2e;cochranelibrary&#x2e;com&#x2f;en&#x2f;cca" role="menuitem">
Browse Clinical Answers
</a>
</li>
<li class=" child-nav-item" id="layout_91" role="presentation">
<a aria-labelledby="layout_91" href="https&#x3a;&#x2f;&#x2f;www&#x2e;cochranelibrary&#x2e;com&#x2f;en&#x2f;cca&#x2f;about" role="menuitem">
About Clinical Answers
</a>
</li>
</ul>
</li>
<li class=" nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class=" child-nav-item" id="layout_116" role="presentation">
<a aria-labelledby="layout_116" href="https&#x3a;&#x2f;&#x2f;www&#x2e;cochranelibrary&#x2e;com&#x2f;en&#x2f;about&#x2f;about-cochrane-library" role="menuitem">
About the Cochrane Library
</a>
</li>
<li class=" child-nav-item" id="layout_34" role="presentation">
<a aria-labelledby="layout_34" href="https&#x3a;&#x2f;&#x2f;www&#x2e;cochrane&#x2e;org&#x2f;about-us" role="menuitem">
About Cochrane
</a>
</li>
<li class=" child-nav-item" id="layout_121" role="presentation">
<a aria-labelledby="layout_121" href="https&#x3a;&#x2f;&#x2f;www&#x2e;cochranelibrary&#x2e;com&#x2f;en&#x2f;about&#x2f;about-cochrane-reviews" role="menuitem">
About Cochrane Reviews
</a>
</li>
<li class=" child-nav-item" id="layout_92" role="presentation">
<a aria-labelledby="layout_92" href="https&#x3a;&#x2f;&#x2f;www&#x2e;cochranelibrary&#x2e;com&#x2f;en&#x2f;about&#x2f;author-information" role="menuitem">
Information for authors
</a>
</li>
<li class=" child-nav-item" id="layout_188" role="presentation">
<a aria-labelledby="layout_188" href="https&#x3a;&#x2f;&#x2f;www&#x2e;cochranelibrary&#x2e;com&#x2f;en&#x2f;about&#x2f;releases" role="menuitem">
What&#039;s new
</a>
</li>
</ul>
</li>
<li class=" nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class=" child-nav-item" id="layout_177" role="presentation">
<a aria-labelledby="layout_177" href="https&#x3a;&#x2f;&#x2f;www&#x2e;wiley&#x2e;com&#x2f;network&#x2f;cochranelibrarytraining" role="menuitem">
Cochrane Library Training
</a>
</li>
<li class=" child-nav-item" id="layout_44" role="presentation">
<a aria-labelledby="layout_44" href="https&#x3a;&#x2f;&#x2f;www&#x2e;cochranelibrary&#x2e;com&#x2f;en&#x2f;help&#x2f;access" role="menuitem">
Access options
</a>
</li>
<li class=" child-nav-item" id="layout_150" role="presentation">
<a aria-labelledby="layout_150" href="https&#x3a;&#x2f;&#x2f;www&#x2e;cochranelibrary&#x2e;com&#x2f;en&#x2f;help&#x2f;permissions" role="menuitem">
Permissions and reprints
</a>
</li>
<li class=" child-nav-item" id="layout_93" role="presentation">
<a aria-labelledby="layout_93" href="https&#x3a;&#x2f;&#x2f;www&#x2e;cochranelibrary&#x2e;com&#x2f;en&#x2f;help&#x2f;media" role="menuitem">
Media information
</a>
</li>
<li class=" child-nav-item" id="layout_97" role="presentation">
<a aria-labelledby="layout_97" href="https&#x3a;&#x2f;&#x2f;www&#x2e;cochranelibrary&#x2e;com&#x2f;en&#x2f;help&#x2f;contact-us" role="menuitem">
Contact us
</a>
</li>
<li class=" child-nav-item" id="layout_125" role="presentation">
<a aria-labelledby="layout_125" href="https&#x3a;&#x2f;&#x2f;www&#x2e;cochranelibrary&#x2e;com&#x2f;en&#x2f;about&#x2f;terms-and-conditions" role="menuitem">
Terms and conditions
</a>
</li>
<li class=" child-nav-item" id="layout_176" role="presentation">
<a aria-labelledby="layout_176" href="https&#x3a;&#x2f;&#x2f;hub&#x2e;wiley&#x2e;com&#x2f;docs&#x2f;cochrane-library&#x2f;cochrane-library-known-issues-DOC-16221&#x3f;referrer&#x3d;cochrane" role="menuitem">
Known issues
</a>
</li>
</ul>
</li>
<li class="about-link"><a href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TT655TMH/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_  portlet-static portlet-static-end  " id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img id="etlj__null__null" src="/scolaris-language-portlet/icon.png" alt="" /> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class=" portlet-content-container"> <div class="portlet-body"> <section class="content-language-banner system-message-container" data-content-language="en" data-portal-language="en" style="display: none"> <div class="container"> <a href="#0" class="fa fa-times content-language-banner-close pull-right" aria-label="Close"></a> <i class="fa fa-globe" aria-hidden="true"></i> <div class="system-message-title">Content Language Selection</div> <div class="system-message-description">Your language preference is set to <strong class="language">English</strong>. Where translations are available, article sections will display in this language. Return to <a href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=reset-content-language&p_p_cacheability=cacheLevelPage" class="language secondary">English</a>.</div> </div> </section> </div> </div> </div> <div style="display:none"> <input type="hidden" name="freelabel" id="freelabel" value='Free access'>
<input type="hidden" name="openlabel" id="openlabel" value='Open access'>
</div>
</section>
</div>
<div id="content" class="">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_  portlet-static portlet-static-end scolaris-content-display-portlet " id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img id="rjus__column1__0" src="/scolaris-content-display/icon.png" alt="" /> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class=" portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools"> <li class="cdsr-nav-link pulldown-menu readcube-menu closed"> <a href="#0" class="pulldown-menu-trigger"> <i class="icon fa fa-file-pdf-o"></i>View PDF <i aria-hidden="true" class="fa fa-caret-up"></i> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a href="/cdsr/doi/10.1002/14651858.CD008548.pub2/pdf/full/en" class="download media pdf-link-full pdf-link" title="Article in PDF format"> <span class="readcube-label "> Full </span> <span class="readcube-description "> All content </span> </a> <a href="/cdsr/doi/10.1002/14651858.CD008548.pub2/epdf/full/en" class="download media pdf-link-full readcube-epdf-link" title="Article in PDF format"> <span class="readcube-label "> Full </span> <span class="readcube-description "> All content </span> </a> </li> <li class=""> <a href="/cdsr/doi/10.1002/14651858.CD008548.pub2/pdf/standard/en" class="download media pdf-link-standard pdf-link" title="Article in PDF format"> <span class="readcube-label "> Standard </span> <span class="readcube-description "> Excludes data and analyses, and appendices </span> </a> <a href="/cdsr/doi/10.1002/14651858.CD008548.pub2/epdf/standard/en" class="download media pdf-link-standard readcube-epdf-link" title="Article in PDF format"> <span class="readcube-label "> Standard </span> <span class="readcube-description "> Excludes data and analyses, and appendices </span> </a> </li> <li class=""> <a href="/cdsr/doi/10.1002/14651858.CD008548.pub2/pdf/abstract/en" class="download media pdf-link-abstract pdf-link" title="Article in PDF format"> <span class="readcube-label "> Summary </span> <span class="readcube-description "> Abstract and plain language summary only </span> </a> <a href="/cdsr/doi/10.1002/14651858.CD008548.pub2/epdf/abstract/en" class="download media pdf-link-abstract readcube-epdf-link" title="Article in PDF format"> <span class="readcube-label "> Summary </span> <span class="readcube-description "> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="cdsr-nav-link cite-article-link" data-article-id="CD008548.PUB2" data-modal-title="Cite this Review"> <a href="/cdsr/doi/10.1002/14651858.CD008548.pub2/#"> <i class="icon fa fa-share"></i>Cite this Review </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-english-only-message="Please note, that requesting permissions is available in English only. Apologies for any inconvenience." href="/cdsr/doi/10.1002/14651858.CD008548.pub2/#" data-copyright="Copyright © 2015 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false"> <span class="request-permissions-icon"></span> Request Permissions </a> </li> <li class="cdsr-nav-link comment-on-review"> <a id="comment-on-review" class="js-old-version-modal-trigger" href="/cdsr/doi/10.1002/14651858.CD008548.pub2/comment" data-new-version="" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience."> <i class="icon fa fa-comment"></i>Comment on Review </a> </li> <li class="cdsr-nav-link comment-on"> <span>Read comments on this Review(0)</span> </li> </ul> <ul class="share clearfix"> <li class="cdsr-nav-link print-cdsr-link" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD008548.pub2/print" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé scientifique&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;de&quot;,&quot;title&quot;:&quot;Laienverständliche Zusammenfassung&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé simplifié&quot;},{&quot;language&quot;:&quot;hr&quot;,&quot;title&quot;:&quot;Laički sažetak&quot;},{&quot;language&quot;:&quot;ru&quot;,&quot;title&quot;:&quot;Резюме на простом языке&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Conclusiones de los autores&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Antecedentes&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Objetivos&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Métodos&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Discusión&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Data and analysis&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;}]}]"> <a href="/cdsr/doi/10.1002/14651858.CD008548.pub2/#"> <i class="icon fa fa-print"></i>Print </a> </li> <li class="cdsr-nav-link share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD008548.pub2/full"> <a href="/cdsr/doi/10.1002/14651858.CD008548.pub2/#"> <i class="icon fa fa-share-alt"></i>Share </a> </li> <li class="cdsr-nav-link"> <a href="/c/portal/login" class="article-not-followed cochrane-link signin"> <span class="article-follow-display"><i class="icon fa fa-plus"></i>Follow</span> </a> </li> </ul> <ul id="linked-articles" data-type="cdsr" class="linked-content tools clearfix linked-content-trigger"> <li> <a href="#0"> <span class="linked-to-this"> Linked to this Review <span class="linked-content-count"></span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> </li> </ul> <ul class="linked-content-dropdown"> <li data-type="cca" class="linked-cca"> <p>Cochrane Clinical Answers</p> </li> <li data-type="editorial" class="linked-editorials"> <p>Editorials</p> </li> <li data-type="podcast" class="linked-podcasts"> <p>Podcasts</p> </li> <li data-type="sc" class="linked-sc"> <p>Special Collections</p> </li> </ul> <ul class="nav-long-form"> <li class="cdsr-nav-link bold-nav-link "> <a href="/cdsr/doi/10.1002/14651858.CD008548.pub2/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link "> <a href="/cdsr/doi/10.1002/14651858.CD008548.pub2/full#CD008548-abs-0004"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link "> <a href="/cdsr/doi/10.1002/14651858.CD008548.pub2/full#CD008548-sec1-0007"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link "> <a href="/cdsr/doi/10.1002/14651858.CD008548.pub2/full#CD008548-sec1-0001"> Summary of findings </a> </li> <li class="cdsr-nav-link "> <a href="/cdsr/doi/10.1002/14651858.CD008548.pub2/full#CD008548-sec1-0002"> Background </a> </li> <li class="cdsr-nav-link "> <a href="/cdsr/doi/10.1002/14651858.CD008548.pub2/full#CD008548-sec1-0003"> Objectives </a> </li> <li class="cdsr-nav-link "> <a href="/cdsr/doi/10.1002/14651858.CD008548.pub2/full#CD008548-sec1-0004"> Methods </a> </li> <li class="cdsr-nav-link "> <a href="/cdsr/doi/10.1002/14651858.CD008548.pub2/full#CD008548-sec1-0005"> Results </a> </li> <li class="cdsr-nav-link "> <a href="/cdsr/doi/10.1002/14651858.CD008548.pub2/full#CD008548-sec1-0006"> Discussion </a> </li> </ul> <ul class="tools"> <li class="cdsr-nav-link "> <a href="/cdsr/doi/10.1002/14651858.CD008548.pub2/appendices#CD008548-sec1-0012"> Appendices </a> </li> </ul> <ul> <li class="cdsr-nav-link article-section-link"> <a href="/cdsr/doi/10.1002/14651858.CD008548.pub2/information"> Information </a> </li> <li class="cdsr-nav-link article-section-link"> <a href="/cdsr/doi/10.1002/14651858.CD008548.pub2/information#authors"> Authors </a> </li> <li class="cdsr-nav-link article-section-link"> <a href="/cdsr/doi/10.1002/14651858.CD008548.pub2/information#history"> History </a> </li> <li class="cdsr-nav-link article-section-link"> <a href="/cdsr/doi/10.1002/14651858.CD008548.pub2/information#keywords"> Keywords </a> </li> </ul> <ul> <li class="cdsr-nav-link bold-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD008548.pub2/#"> <i class="icon fa fa-globe"></i>Translation notes </a> </li> </ul> <ul> <li class="cdsr-nav-link references-link"> <a href="/cdsr/doi/10.1002/14651858.CD008548.pub2/references"> References </a> </li> <li class="cdsr-nav-link references-link"> <a href="/cdsr/doi/10.1002/14651858.CD008548.pub2/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link references-link"> <a href="/cdsr/doi/10.1002/14651858.CD008548.pub2/references#dataAndAnalyses"> Data and analyses </a> </li> </ul> <ul class="tools"> <li class="cdsr-nav-link "> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD008548.pub2/#"> <i class="icon fa fa-line-chart"></i>Figures and tables </a> </li> <li class="cdsr-nav-link download-stats-data-link " data-download-href="/cdsr/doi/10.1002/14651858.CD008548.pub2/media/CDSR/CD008548/table_n/CD008548StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD008548.pub2/media/CDSR/CD008548/table_n/CD008548StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <i class="icon fa fa-download"></i>Download statistical data </a> </li> <li class="cdsr-nav-link "> <a href="/cdsr/doi/10.1002/14651858.CD008548.pub2/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i>Related content <span class="note podcast-indicator">Podcast available</span> </a> </li> </ul> </nav> </div> <article class="information" data-article-id="CD008548.PUB2"> <header> <h1 class="publication-title"><h1 lang="en" class="publication-title">Growth factors for treating diabetic foot ulcers</h1></h1> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div><h2 class="title section-collapse-title"> References <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <section class="references bibliographies" id="references"> <section> <div class="section-header" id="CD008548-bbs1-0001"> <h3 class="title">References to studies included in this review</h3> <div class="jump-to"> <p>Jump to: </p> <ul class="jump-to-links"> <li><a class="jump-to" href="#CD008548-bbs1-0002">excluded studies</a></li> <li><a class="jump-to" href="#CD008548-bbs1-0003">studies awaiting assessment</a></li> <li><a class="jump-to" href="#CD008548-bbs1-0004">ongoing studies</a></li> <li><a class="jump-to" href="#CD008548-bbs1-0005">additional references</a></li> </ul> </div> </div> <div class="bibliographies references_includedStudies" id="CD008548-bbs2-0001"> <div class="reference-title-banner"> <h4 class="title">Afshari 2005 {published data only} </h4> </div> <div class="bibliography-section" id="CD008548-bib-0001"> <div class="citation-journal">Afshari M, Larijani B, Fadayee M, Ghahary A, Pajouhi M, Bastanhagh M, et al. <span class="citation-title">Efficacy of topical epidermal growth factor in healing diabetic foot ulcers</span>. <span class="citation"> Therapy </span><span class="pubYear">2005</span>;<span class="volume">2</span>:759‐65. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Efficacy+of+topical+epidermal+growth+factor+in+healing+diabetic+foot+ulcers&author=M+Afshari&author=B+Larijani&author=M+Fadayee&author=A+Ghahary&author=M+Pajouhi&author=M+Bastanhagh&publication_year=2005&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_includedStudies" id="CD008548-bbs2-0002"> <div class="reference-title-banner"> <h4 class="title">Agrawal 2009 {published data only} </h4> </div> <div class="bibliography-section" id="CD008548-bib-0002"> <div class="citation-journal">Agrawal RP, Jhajharia A, Motha N, Dogra R, Chaudhari V, Nayak KC. <span class="citation-title">Use of a platelet‐derived growth factor gel in chronic diabetic foot ulcers</span>. <span class="citation"> Diabetic Foot Journal </span><span class="pubYear">2009</span>;<span class="volume">12</span>(2):80‐8. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Use+of+a+platelet%E2%80%90derived+growth+factor+gel+in+chronic+diabetic+foot+ulcers&author=RP+Agrawal&author=A+Jhajharia&author=N+Motha&author=R+Dogra&author=V+Chaudhari&author=KC+Nayak&publication_year=2009&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_includedStudies" id="CD008548-bbs2-0003"> <div class="reference-title-banner"> <h4 class="title">Bhansali 2009 {published data only} </h4> </div> <div class="bibliography-section" id="CD008548-bib-0003"> <div class="citation-journal">Bhansali A, Venkatesh S, Dutta P, Dhillon MS, Das S, Agrawal A. <span class="citation-title">Which is the better option: recombinant human PDGF‐BB 0.01% gel or standard wound care, in diabetic neuropathic large plantar ulcers off‐loaded by a customized contact cast?</span>. <span class="citation"> Diabetes Research and Clinical Practice </span><span class="pubYear">2009</span>;<span class="volume">83</span>(1):e13‐6. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/19081156" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Which+is+the+better+option:+recombinant+human+PDGF%E2%80%90BB+0.01%+gel+or+standard+wound+care,+in+diabetic+neuropathic+large+plantar+ulcers+off%E2%80%90loaded+by+a+customized+contact+cast?+&author=A+Bhansali&author=S+Venkatesh&author=P+Dutta&author=MS+Dhillon&author=S+Das&author=A+Agrawal&publication_year=2009&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_includedStudies" id="CD008548-bbs2-0004"> <div class="reference-title-banner"> <h4 class="title">Chen 2004 {published data only} </h4> </div> <div class="bibliography-section" id="CD008548-bib-0004"> <div class="citation-journal">Chen A, Long XH, Huang C. <span class="citation-title">Analysis of the effect of recombined human epidermal growth factor derivate applied externally in treating diabetic foot</span>. <span class="citation"> Modern Nursing </span><span class="pubYear">2004</span>;<span class="volume">10</span>(3):274‐5. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Analysis+of+the+effect+of+recombined+human+epidermal+growth+factor+derivate+applied+externally+in+treating+diabetic+foot+&author=A+Chen&author=XH+Long&author=C+Huang&publication_year=2004&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_includedStudies" id="CD008548-bbs2-0005"> <div class="reference-title-banner"> <h4 class="title">d'Hemecourt 1998 {published data only} </h4> </div> <div class="bibliography-section" id="CD008548-bib-0005"> <div class="citation-other">d'Hemecourt PA, Smeill JM, Hugill JV, Prigoff MM. <span class="citation-title">The effect of topically applied sodium carboxymethylcellulose gel in nonhealing, lower extremity ulcers in patients with diabetes</span>. European Tissue Repair Society. Koln, Germany, 23‐27 August 1997:Abstracts. <ul class="citation-link-group"> </ul> </div> </div> <div class="bibliography-section" id="CD008548-bib-0006"> <div class="citation-journal">d'Hemecourt PA, Smiell JM, Karim MR. <span class="citation-title">Sodium carboxymethyl cellulose aqueous‐based gel vs becaplermin gel in patients with nonhealing lower extremity diabetic ulcers</span>. <span class="citation"> Wounds </span><span class="pubYear">1998</span>;<span class="volume">10</span>(3):69‐75. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Sodium+carboxymethyl+cellulose+aqueous%E2%80%90based+gel+vs+becaplermin+gel+in+patients+with+nonhealing+lower+extremity+diabetic+ulcers+&author=PA+d'Hemecourt&author=JM+Smiell&author=MR+Karim&publication_year=1998&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_includedStudies" id="CD008548-bbs2-0006"> <div class="reference-title-banner"> <h4 class="title">Driver 2006 {published data only} </h4> </div> <div class="bibliography-section" id="CD008548-bib-0008"> <div class="citation-journal">Driver VR. <span class="citation-title">A prospective, randomized, controlled, blinded, multicenter pivotal trial of a platelet rich plasma gel versus control when added to the standard of care in the treatment of non‐healing diabetic foot ulcers</span>. <span class="citation"> Diabetes </span><span class="pubYear">2006</span>;<span class="volume">55</span>(Suppl 1):A25. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=A+prospective,+randomized,+controlled,+blinded,+multicenter+pivotal+trial+of+a+platelet+rich+plasma+gel+versus+control+when+added+to+the+standard+of+care+in+the+treatment+of+non%E2%80%90healing+diabetic+foot+ulcers+&author=VR+Driver&publication_year=2006&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD008548-bib-0007"> <div class="citation-journal">Driver VR, Hanft J, Fylling CP, Beriou JM, AutoGel Diabetic Foot Ulcer Study Group. <span class="citation-title">A prospective, randomized, controlled trial of autologous platelet‐rich plasma gel for the treatment of diabetic foot ulcers</span>. <span class="citation"> Ostomy/Wound Management </span><span class="pubYear">2006</span>;<span class="volume">52</span>(6):68‐87. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=A+prospective,+randomized,+controlled+trial+of+autologous+platelet%E2%80%90rich+plasma+gel+for+the+treatment+of+diabetic+foot+ulcers+&author=VR+Driver&author=J+Hanft&author=CP+Fylling&author=JM+Beriou&publication_year=2006&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_includedStudies" id="CD008548-bbs2-0007"> <div class="reference-title-banner"> <h4 class="title">Fernández‐Montequin 2007 {published data only} </h4> </div> <div class="bibliography-section" id="CD008548-bib-0009"> <div class="citation-journal">Fernández‐Montequin JI, Infante‐Cristia E, Valenzuela‐Silva C, Franco‐Perez N, Savigne‐Gutierrez W, Artaza‐Sanz H, et al. <span class="citation-title">Intralesional injections of Citoprot‐P (recombinant human epidermal growth factor) in advanced diabetic foot ulcers with risk of amputation</span>. <span class="citation"> International Wound Journal </span><span class="pubYear">2007</span>;<span class="volume">4</span>:333‐43. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/17953679" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Intralesional+injections+of+Citoprot%E2%80%90P+(recombinant+human+epidermal+growth+factor)+in+advanced+diabetic+foot+ulcers+with+risk+of+amputation+&author=JI+Fern%C3%A1ndez%E2%80%90Montequin&author=E+Infante%E2%80%90Cristia&author=C+Valenzuela%E2%80%90Silva&author=N+Franco%E2%80%90Perez&author=W+Savigne%E2%80%90Gutierrez&author=H+Artaza%E2%80%90Sanz&publication_year=2007&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_includedStudies" id="CD008548-bbs2-0008"> <div class="reference-title-banner"> <h4 class="title">Fernández‐Montequin 2009 {published data only} </h4> </div> <div class="bibliography-section" id="CD008548-bib-0010"> <div class="citation-journal">Fernández‐Montequín JI, Betancourt BY, Leyva‐Gonzalez G, Mola EL, Galán‐Naranjo K, Ramírez‐Navas M, et al. <span class="citation-title">Intralesional administration of epidermal growth factor‐based formulation (Heberprot‐P) in chronic diabetic foot ulcer: treatment up to complete wound closure</span>. <span class="citation"> International Wound Journal </span><span class="pubYear">2009</span>;<span class="volume">6</span>:67‐72. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/19291119" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Intralesional+administration+of+epidermal+growth+factor%E2%80%90based+formulation+(Heberprot%E2%80%90P)+in+chronic+diabetic+foot+ulcer:+treatment+up+to+complete+wound+closure+&author=JI+Fern%C3%A1ndez%E2%80%90Montequ%C3%ADn&author=BY+Betancourt&author=G+Leyva%E2%80%90Gonzalez&author=EL+Mola&author=K+Gal%C3%A1n%E2%80%90Naranjo&author=M+Ram%C3%ADrez%E2%80%90Navas&publication_year=2009&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD008548-bib-0011"> <div class="citation-journal">Fernández‐Montequín JI, Valenzuela‐Silva CM, Díaz OG, Savigne W, Sancho‐Soutelo N, Rivero‐Fernández F, Cuban Diabetic Foot Study Group. <span class="citation-title">Intra‐lesional injections of recombinant human epidermal growth factor promote granulation and healing in advanced diabetic foot ulcers: multicenter, randomised, placebo‐controlled, double‐blind study</span>. <span class="citation"> International Wound Journal </span><span class="pubYear">2009</span>;<span class="volume">6</span>:432‐43. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/20051095" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Intra%E2%80%90lesional+injections+of+recombinant+human+epidermal+growth+factor+promote+granulation+and+healing+in+advanced+diabetic+foot+ulcers:+multicenter,+randomised,+placebo%E2%80%90controlled,+double%E2%80%90blind+study+&author=JI+Fern%C3%A1ndez%E2%80%90Montequ%C3%ADn&author=CM+Valenzuela%E2%80%90Silva&author=OG+D%C3%ADaz&author=W+Savigne&author=N+Sancho%E2%80%90Soutelo&author=F+Rivero%E2%80%90Fern%C3%A1ndez&publication_year=2009&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_includedStudies" id="CD008548-bbs2-0009"> <div class="reference-title-banner"> <h4 class="title">Hanft 2008 {published data only} </h4> </div> <div class="bibliography-section" id="CD008548-bib-0012"> <div class="citation-journal">Hanft JR, Pollak RA, Barbul A, Gils C, Kwon PS, Gray SM, et al. <span class="citation-title">Phase I trial on the safety of topical rhVEGF on chronic neuropathic diabetic foot ulcers</span>. <span class="citation"> Journal of Wound Care </span><span class="pubYear">2008</span>;<span class="volume">17</span>:30‐2, 34‐7. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/18210954" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Phase+I+trial+on+the+safety+of+topical+rhVEGF+on+chronic+neuropathic+diabetic+foot+ulcers+&author=JR+Hanft&author=RA+Pollak&author=A+Barbul&author=C+Gils&author=PS+Kwon&author=SM+Gray&publication_year=2008&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD008548-bib-0013"> <div class="citation-journal">Kwon P, Breen TJ, Gray S, Lynch CJ, Semba CP, Hanft JR, et al. <span class="citation-title">Results of a phase I, randomized, double‐blind, placebo‐controlled trial of topical rhVEGF (telbermin) for the treatment of diabetic foot ulcers</span>. <span class="citation"> Wound Management </span><span class="pubYear">2006</span>;<span class="volume">54</span>:102. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Results+of+a+phase+I,+randomized,+double%E2%80%90blind,+placebo%E2%80%90controlled+trial+of+topical+rhVEGF+(telbermin)+for+the+treatment+of+diabetic+foot+ulcers+&author=P+Kwon&author=TJ+Breen&author=S+Gray&author=CJ+Lynch&author=CP+Semba&author=JR+Hanft&publication_year=2006&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_includedStudies" id="CD008548-bbs2-0010"> <div class="reference-title-banner"> <h4 class="title">Hardikar 2005 {published data only} </h4> </div> <div class="bibliography-section" id="CD008548-bib-0014"> <div class="citation-journal">Hardikar JV, Reddy YC, Bung DD, Varma N, Shilotri PP, Prasad ED, et al. <span class="citation-title">Efficacy of recombinant human platelet‐derived growth factor (rhPDGF) based gel in diabetic foot ulcers: a randomized, multicenter, double‐blind, placebo‐controlled study in India</span>. <span class="citation"> Wounds </span><span class="pubYear">2005</span>;<span class="volume">17</span>:141‐52. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Efficacy+of+recombinant+human+platelet%E2%80%90derived+growth+factor+(rhPDGF)+based+gel+in+diabetic+foot+ulcers:+a+randomized,+multicenter,+double%E2%80%90blind,+placebo%E2%80%90controlled+study+in+India+&author=JV+Hardikar&author=YC+Reddy&author=DD+Bung&author=N+Varma&author=PP+Shilotri&author=ED+Prasad&publication_year=2005&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_includedStudies" id="CD008548-bbs2-0011"> <div class="reference-title-banner"> <h4 class="title">Holloway 1993 {published data only} </h4> </div> <div class="bibliography-section" id="CD008548-bib-0015"> <div class="citation-journal">Holloway GA, Steed DL, DeMarco MJ, Matsumoto T, Moosa HH, Webster MW, et al. <span class="citation-title">A randomised controlled dose response trial of activated platelet supernatant, topical CT‐102 in chronic, non healing diabetic wounds</span>. <span class="citation"> Wounds </span><span class="pubYear">1993</span>;<span class="volume">5</span>:198–206. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=A+randomised+controlled+dose+response+trial+of+activated+platelet+supernatant,+topical+CT%E2%80%90102+in+chronic,+non+healing+diabetic+wounds+&author=GA+Holloway&author=DL+Steed&author=MJ+DeMarco&author=T+Matsumoto&author=HH+Moosa&author=MW+Webster&publication_year=1993&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_includedStudies" id="CD008548-bbs2-0012"> <div class="reference-title-banner"> <h4 class="title">Jaiswal 2010 {published data only} </h4> </div> <div class="bibliography-section" id="CD008548-bib-0016"> <div class="citation-journal">Jaiswal SS, Gambhir RPS, Harish AA. <span class="citation-title">Efficacy of topical recombinant human platelet derived growth factor on wound healing in patients with chronic diabetic lower limb ulcers</span>. <span class="citation"> Indian Journal of Surgery </span><span class="pubYear">2010</span>;<span class="volume">72</span>:31‐5. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Efficacy+of+topical+recombinant+human+platelet+derived+growth+factor+on+wound+healing+in+patients+with+chronic+diabetic+lower+limb+ulcers+&author=SS+Jaiswal&author=RPS+Gambhir&author=AA+Harish&publication_year=2010&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_includedStudies" id="CD008548-bbs2-0013"> <div class="reference-title-banner"> <h4 class="title">Kakagia 2007 {published data only} </h4> </div> <div class="bibliography-section" id="CD008548-bib-0017"> <div class="citation-journal">Kakagia DD, Kazakos KJ, Xarchas KC, Karanikas M, Georgiadis GS, Tripsiannis G, et al. <span class="citation-title">Synergistic action of protease‐modulating matrix and autologous growth factors in healing of diabetic foot ulcers. A prospective randomized trial</span>. <span class="citation"> Journal of Diabetes and its Complications </span><span class="pubYear">2007</span>;<span class="volume">21</span>:387‐91. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/17967712" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Synergistic+action+of+protease%E2%80%90modulating+matrix+and+autologous+growth+factors+in+healing+of+diabetic+foot+ulcers.+A+prospective+randomized+trial+&author=DD+Kakagia&author=KJ+Kazakos&author=KC+Xarchas&author=M+Karanikas&author=GS+Georgiadis&author=G+Tripsiannis&publication_year=2007&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_includedStudies" id="CD008548-bbs2-0014"> <div class="reference-title-banner"> <h4 class="title">Landsman 2010 {published data only} </h4> </div> <div class="bibliography-section" id="CD008548-bib-0018"> <div class="citation-journal">Landsman A, Agnew P, Parish L, Joseph R, Galiano RD. <span class="citation-title">Diabetic foot ulcers treated with becaplermin and TheraGauze, a moisture‐controlling smart dressing: a randomized, multicenter, prospective analysis</span>. <span class="citation"> Journal of the American Podiatric Medical Association </span><span class="pubYear">2010</span>;<span class="volume">100</span>(3):155‐60. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/20479444" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Diabetic+foot+ulcers+treated+with+becaplermin+and+TheraGauze,+a+moisture%E2%80%90controlling+smart+dressing:+a+randomized,+multicenter,+prospective+analysis+&author=A+Landsman&author=P+Agnew&author=L+Parish&author=R+Joseph&author=RD+Galiano&publication_year=2010&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD008548-bib-0019"> <div class="citation-journal">Parish L, Routh H, Parish J. <span class="citation-title">Diabetic foot ulcers: a randomized multicenter study comparing a moisture‐controlling dressing with a topical growth factor</span>. <span class="citation"> Journal of the American Academy of Dermatology </span><span class="pubYear">2009</span>;<span class="volume">60</span>(Suppl):AB202. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Diabetic+foot+ulcers:+a+randomized+multicenter+study+comparing+a+moisture%E2%80%90controlling+dressing+with+a+topical+growth+factor+&author=L+Parish&author=H+Routh&author=J+Parish&publication_year=2009&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_includedStudies" id="CD008548-bbs2-0015"> <div class="reference-title-banner"> <h4 class="title">Lyons 2007 {published data only} </h4> </div> <div class="bibliography-section" id="CD008548-bib-0020"> <div class="citation-journal">Lyons TE, Miller MS, Serena T, Sheehan P, Lavery L, Kirsner RS, et al. <span class="citation-title">Talactoferrin alfa, a recombinant human lactoferrin promotes healing of diabetic neuropathic ulcers: a phase 1/2 clinical study</span>. <span class="citation"> American Journal of Surgery </span><span class="pubYear">2007</span>;<span class="volume">193</span>(1):49‐54. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/17188087" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Talactoferrin+alfa,+a+recombinant+human+lactoferrin+promotes+healing+of+diabetic+neuropathic+ulcers:+a+phase+1/2+clinical+study+&author=TE+Lyons&author=MS+Miller&author=T+Serena&author=P+Sheehan&author=L+Lavery&author=RS+Kirsner&publication_year=2007&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_includedStudies" id="CD008548-bbs2-0016"> <div class="reference-title-banner"> <h4 class="title">Niezgoda 2005 {published data only} </h4> </div> <div class="bibliography-section" id="CD008548-bib-0021"> <div class="citation-journal">Niezgoda JA, Gils CC, Frykberg RG, Hodde JP. <span class="citation-title">Randomized clinical trial comparing OASIS wound matrix to Regranex gel for diabetic ulcers</span>. <span class="citation"> Advances in Skin and Wound Care </span><span class="pubYear">2005</span>;<span class="volume">18</span>:258‐66. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/15942317" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Randomized+clinical+trial+comparing+OASIS+wound+matrix+to+Regranex+gel+for+diabetic+ulcers+&author=JA+Niezgoda&author=CC+Gils&author=RG+Frykberg&author=JP+Hodde&publication_year=2005&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_includedStudies" id="CD008548-bbs2-0017"> <div class="reference-title-banner"> <h4 class="title">Richard 1995 {published data only} </h4> </div> <div class="bibliography-section" id="CD008548-bib-0022"> <div class="citation-journal">Richard JL, Parer‐Richard C, Daures JP, Clouet S, Vannereau D, Bringer J, et al. <span class="citation-title">Effect of topical basic fibroblast growth factor on the healing of chronic diabetic neuropathic ulcer of the foot: A pilot, randomized, double‐blind, placebo‐controlled study</span>. <span class="citation"> Diabetes Care </span><span class="pubYear">1995</span>;<span class="volume">18</span>:64‐9. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/7698050" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Effect+of+topical+basic+fibroblast+growth+factor+on+the+healing+of+chronic+diabetic+neuropathic+ulcer+of+the+foot:+A+pilot,+randomized,+double%E2%80%90blind,+placebo%E2%80%90controlled+study+&author=JL+Richard&author=C+Parer%E2%80%90Richard&author=JP+Daures&author=S+Clouet&author=D+Vannereau&author=J+Bringer&publication_year=1995&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_includedStudies" id="CD008548-bbs2-0018"> <div class="reference-title-banner"> <h4 class="title">Robson 2002 {published data only} </h4> </div> <div class="bibliography-section" id="CD008548-bib-0023"> <div class="citation-journal">Robson MC, Steed DL, McPherson JM, Pratt BM. <span class="citation-title">Effects of transforming growth factor +ƒ2 on wound healing in diabetic foot ulcers: a randomized controlled safety and dose‐ranging trial</span>. <span class="citation"> Journal of Applied Research </span><span class="pubYear">2002</span>;<span class="volume">2</span>:133‐45. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Effects+of+transforming+growth+factor++%C6%922+on+wound+healing+in+diabetic+foot+ulcers:+a+randomized+controlled+safety+and+dose%E2%80%90ranging+trial+&author=MC+Robson&author=DL+Steed&author=JM+McPherson&author=BM+Pratt&publication_year=2002&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_includedStudies" id="CD008548-bbs2-0019"> <div class="reference-title-banner"> <h4 class="title">Saldalamacchia 2004 {published data only} </h4> </div> <div class="bibliography-section" id="CD008548-bib-0024"> <div class="citation-journal">Saldalamacchia G, Lapice E, Cuomo V, Feo E, D'Agostino E, Rivellese AA, et al. <span class="citation-title">A controlled study of the use of autologous platelet gel for the treatment of diabetic foot ulcers</span>. <span class="citation"> Nutrition Metabolism and Cardiovascular Diseases </span><span class="pubYear">2004</span>;<span class="volume">14</span>:395‐6. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=A+controlled+study+of+the+use+of+autologous+platelet+gel+for+the+treatment+of+diabetic+foot+ulcers+&author=G+Saldalamacchia&author=E+Lapice&author=V+Cuomo&author=E+Feo&author=E+D'Agostino&author=AA+Rivellese&publication_year=2004&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD008548-bib-0025"> <div class="citation-journal">Saldalamacchia G, Lapice E, Cuomo V, Feo ME, D'Agostino E, Rivellese AA, et al. <span class="citation-title">Use of autologous platelet gel for the treatment of diabetic foot ulcers</span>. <span class="citation"> Giornale Italiano di Diabetologia e Metabolismo </span><span class="pubYear">2004</span>;<span class="volume">24</span>:103‐5. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Use+of+autologous+platelet+gel+for+the+treatment+of+diabetic+foot+ulcers&author=G+Saldalamacchia&author=E+Lapice&author=V+Cuomo&author=ME+Feo&author=E+D'Agostino&author=AA+Rivellese&publication_year=2004&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_includedStudies" id="CD008548-bbs2-0020"> <div class="reference-title-banner"> <h4 class="title">Steed 1992 {published data only} </h4> </div> <div class="bibliography-section" id="CD008548-bib-0026"> <div class="citation-journal">Steed D, Goslen JB, Holloway GA, Malone JM, Bunt TJ, Webster MW. <span class="citation-title">Randomised prospective double blind trial in healing chronic diabetic foot ulcers: CT‐102 activated platelet supernatant, topical versus placebo</span>. <span class="citation"> Diabetes Care </span><span class="pubYear">1992</span>;<span class="volume">15</span>:1598–604. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/1468291" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Randomised+prospective+double+blind+trial+in+healing+chronic+diabetic+foot+ulcers:+CT%E2%80%90102+activated+platelet+supernatant,+topical+versus+placebo+&author=D+Steed&author=JB+Goslen&author=GA+Holloway&author=JM+Malone&author=TJ+Bunt&author=MW+Webster&publication_year=1992&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_includedStudies" id="CD008548-bbs2-0021"> <div class="reference-title-banner"> <h4 class="title">Steed 1995a {published data only} </h4> </div> <div class="bibliography-section" id="CD008548-bib-0028"> <div class="citation-journal">Steed DL. <span class="citation-title">Clinical evaluation of recombinant human platelet‐derived growth factor for the treatment of lower extremity ulcers</span>. <span class="citation"> Plastic and Reconstructive Surgery </span><span class="pubYear">2006</span>;<span class="volume">117 (Suppl7)</span>:143‐9. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Clinical+evaluation+of+recombinant+human+platelet%E2%80%90derived+growth+factor+for+the+treatment+of+lower+extremity+ulcers+&author=DL+Steed&publication_year=2006&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD008548-bib-0027"> <div class="citation-journal">Steed DL, Webster MW, Ricotta JJ, Luterman A, Brown S, Comerota AJ, et al. <span class="citation-title">Clinical evaluation of recombinant human platelet‐derived growth factor for the treatment of lower extremity diabetic ulcers</span>. <span class="citation"> Journal of Vascular Surgery </span><span class="pubYear">1995</span>;<span class="volume">21</span>:71‐81. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/7823364" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Clinical+evaluation+of+recombinant+human+platelet%E2%80%90derived+growth+factor+for+the+treatment+of+lower+extremity+diabetic+ulcers+&author=DL+Steed&author=MW+Webster&author=JJ+Ricotta&author=A+Luterman&author=S+Brown&author=AJ+Comerota&publication_year=1995&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_includedStudies" id="CD008548-bbs2-0022"> <div class="reference-title-banner"> <h4 class="title">Steed 1995b {published data only} </h4> </div> <div class="bibliography-section" id="CD008548-bib-0029"> <div class="citation-journal">Steed D, Ricotta JJ, Prendergast JJ, Kaplan RJ, Webster MW, McGill JB, et al. <span class="citation-title">Promotion and acceleration of diabetic ulcer healing by arginine glycine‐aspartic acid (RGD) peptide matrix</span>. <span class="citation"> Diabetes Care </span><span class="pubYear">1995</span>;<span class="volume">18</span>:39–46. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/7698046" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Promotion+and+acceleration+of+diabetic+ulcer+healing+by+arginine+glycine%E2%80%90aspartic+acid+(RGD)+peptide+matrix+&author=D+Steed&author=JJ+Ricotta&author=JJ+Prendergast&author=RJ+Kaplan&author=MW+Webster&author=JB+McGill&publication_year=1995&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_includedStudies" id="CD008548-bbs2-0023"> <div class="reference-title-banner"> <h4 class="title">Steed 1996 {published data only} </h4> </div> <div class="bibliography-section" id="CD008548-bib-0030"> <div class="citation-journal">Steed DL, Edington HD, Webster MW. <span class="citation-title">Recurrence rate of diabetic neurotrophic foot ulcers healed using topical application of growth factors released from platelets</span>. <span class="citation"> Wound Repair and Regeneration </span><span class="pubYear">1996</span>;<span class="volume">4</span>:230‐3. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/17177818" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Recurrence+rate+of+diabetic+neurotrophic+foot+ulcers+healed+using+topical+application+of+growth+factors+released+from+platelets+&author=DL+Steed&author=HD+Edington&author=MW+Webster&publication_year=1996&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_includedStudies" id="CD008548-bbs2-0024"> <div class="reference-title-banner"> <h4 class="title">Tan 2008 {published data only} </h4> </div> <div class="bibliography-section" id="CD008548-bib-0031"> <div class="citation-journal">Tan Y, Xiao J, Huang Z, Xiao Y, Lin S, Jin L, et al. <span class="citation-title">Comparison of the therapeutic effects of recombinant human acidic and basic fibroblast growth factors in wound healing in diabetic patients</span>. <span class="citation"> Journal of Health Science </span><span class="pubYear">2008</span>;<span class="volume">54</span>:432‐40. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Comparison+of+the+therapeutic+effects+of+recombinant+human+acidic+and+basic+fibroblast+growth+factors+in+wound+healing+in+diabetic+patients+&author=Y+Tan&author=J+Xiao&author=Z+Huang&author=Y+Xiao&author=S+Lin&author=L+Jin&publication_year=2008&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_includedStudies" id="CD008548-bbs2-0025"> <div class="reference-title-banner"> <h4 class="title">Tsang 2003 {published data only} </h4> </div> <div class="bibliography-section" id="CD008548-bib-0032"> <div class="citation-journal">Tsang MW, Wong WK, Hung CS, Lai KM, Tang W, Cheung EY, et al. <span class="citation-title">Human epidermal growth factor enhances healing of diabetic foot ulcers</span>. <span class="citation"> Diabetes Care </span><span class="pubYear">2003</span>;<span class="volume">26</span>:1856‐61. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/12766123" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Human+epidermal+growth+factor+enhances+healing+of+diabetic+foot+ulcers&author=MW+Tsang&author=WK+Wong&author=CS+Hung&author=KM+Lai&author=W+Tang&author=EY+Cheung&publication_year=2003&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_includedStudies" id="CD008548-bbs2-0026"> <div class="reference-title-banner"> <h4 class="title">Uchi 2009 {published data only} </h4> </div> <div class="bibliography-section" id="CD008548-bib-0033"> <div class="citation-journal">Uchi H, Igarashi A, Urabe K, Koga T, Nakayama J, Kawamori R, et al. <span class="citation-title">Clinical efficacy of basic fibroblast growth factor (bFGF) for diabetic ulcer</span>. <span class="citation"> European Journal of Dermatology </span><span class="pubYear">2009</span>;<span class="volume">19</span>:461‐8. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/19638336" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Clinical+efficacy+of+basic+fibroblast+growth+factor+(bFGF)+for+diabetic+ulcer&author=H+Uchi&author=A+Igarashi&author=K+Urabe&author=T+Koga&author=J+Nakayama&author=R+Kawamori&publication_year=2009&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_includedStudies" id="CD008548-bbs2-0027"> <div class="reference-title-banner"> <h4 class="title">Viswanathan 2006 {published data only} </h4> </div> <div class="bibliography-section" id="CD008548-bib-0034"> <div class="citation-journal">Viswanathan V, Pendsey S, Sekar N, Murthy GSR. <span class="citation-title">A phase III study to evaluate the safety and efficacy of recombinant human epidermal growth factor (REGEN‐D 150) in healing diabetic foot ulcers</span>. <span class="citation"> Wounds </span><span class="pubYear">2006</span>;<span class="volume">18</span>:186‐96. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=A+phase+III+study+to+evaluate+the+safety+and+efficacy+of+recombinant+human+epidermal+growth+factor+(REGEN%E2%80%90D+150)+in+healing+diabetic+foot+ulcers+&author=V+Viswanathan&author=S+Pendsey&author=N+Sekar&author=GSR+Murthy&publication_year=2006&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_includedStudies" id="CD008548-bbs2-0028"> <div class="reference-title-banner"> <h4 class="title">Wieman 1998a {published data only} </h4> </div> <div class="bibliography-section" id="CD008548-bib-0035"> <div class="citation-journal">Wieman TJ, Smiell JM, Su Y. <span class="citation-title">Efficacy and safety of a topical gel formulation of recombinant human platelet‐derived growth factor‐BB (becaplermin) in patients with chronic neuropathic diabetic ulcers. A phase III randomized placebo‐controlled double‐blind study</span>. <span class="citation"> Diabetes Care </span><span class="pubYear">1998</span>;<span class="volume">21</span>(5):822‐7. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/9589248" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Efficacy+and+safety+of+a+topical+gel+formulation+of+recombinant+human+platelet%E2%80%90derived+growth+factor%E2%80%90BB+(becaplermin)+in+patients+with+chronic+neuropathic+diabetic+ulcers.+A+phase+III+randomized+placebo%E2%80%90controlled+double%E2%80%90blind+study+&author=TJ+Wieman&author=JM+Smiell&author=Y+Su&publication_year=1998&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> </section> <section> <div class="section-header" id="CD008548-bbs1-0002"> <h3 class="title">References to studies excluded from this review</h3> <div class="jump-to"> <p>Jump to: </p> <ul class="jump-to-links"> <li><a class="jump-to" href="#CD008548-bbs1-0001">included studies</a></li> <li><a class="jump-to" href="#CD008548-bbs1-0003">studies awaiting assessment</a></li> <li><a class="jump-to" href="#CD008548-bbs1-0004">ongoing studies</a></li> <li><a class="jump-to" href="#CD008548-bbs1-0005">additional references</a></li> </ul> </div> </div> <div class="bibliographies references_excludedStudies" id="CD008548-bbs2-0029"> <div class="reference-title-banner"> <h4 class="title">Acosta 2006 {published data only} </h4> </div> <div class="bibliography-section" id="CD008548-bib-0036"> <div class="citation-journal">Acosta JB, Savigne W, Valdez C, Franco N, Alba JS, Rio A, et al. <span class="citation-title">Epidermal growth factor intralesional infiltrations can prevent amputation in patients with advanced diabetic foot wounds</span>. <span class="citation"> International Wound Journal </span><span class="pubYear">2006</span>;<span class="volume">3</span>(3):232‐9. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/16984579" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Epidermal+growth+factor+intralesional+infiltrations+can+prevent+amputation+in+patients+with+advanced+diabetic+foot+wounds+&author=JB+Acosta&author=W+Savigne&author=C+Valdez&author=N+Franco&author=JS+Alba&author=A+Rio&publication_year=2006&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_excludedStudies" id="CD008548-bbs2-0030"> <div class="reference-title-banner"> <h4 class="title">Aminian 2000 {published data only} </h4> </div> <div class="bibliography-section" id="CD008548-bib-0037"> <div class="citation-other">Aminian B, Shams M, Soveyd M, Omrani GhR. <span class="citation-title">Topical autologous platelet‐derived growth factors in the treatment of chronic diabetes ulcers</span>. Archives of Iranian Medicine<span class="pubYear">2000</span>; Vol. 3, issue 2:55‐9. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Topical+autologous+platelet%E2%80%90derived+growth+factors+in+the+treatment+of+chronic+diabetes+ulcers+&author=B+Aminian&author=M+Shams&author=M+Soveyd&author=GhR+Omrani&publication_year=2000&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_excludedStudies" id="CD008548-bbs2-0031"> <div class="reference-title-banner"> <h4 class="title">Embil 2000 {published data only} </h4> </div> <div class="bibliography-section" id="CD008548-bib-0038"> <div class="citation-journal">Embil JM, Papp K, Sibbald G, Tousignant J, Smiell JM, Wong B, The Canadian Becaplermin Study Group. <span class="citation-title">Recombinant human platelet‐derived growth factor‐BB (becaplermin) for healing chronic lower extremity diabetic ulcers: an open‐label clinical evaluation of efficacy</span>. <span class="citation"> Wound Repair and Regeneration </span><span class="pubYear">2000</span>;<span class="volume">8</span>:162‐8. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/10886806" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Recombinant+human+platelet%E2%80%90derived+growth+factor%E2%80%90BB+(becaplermin)+for+healing+chronic+lower+extremity+diabetic+ulcers:+an+open%E2%80%90label+clinical+evaluation+of+efficacy+&author=JM+Embil&author=K+Papp&author=G+Sibbald&author=J+Tousignant&author=JM+Smiell&author=B+Wong&publication_year=2000&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_excludedStudies" id="CD008548-bbs2-0032"> <div class="reference-title-banner"> <h4 class="title">Hong 2006 {published data only} </h4> </div> <div class="bibliography-section" id="CD008548-bib-0039"> <div class="citation-journal">Hong JP, Jung HD, Kim YW. <span class="citation-title">Recombinant human epidermal growth factor (EGF) to enhance healing for diabetic foot ulcers</span>. <span class="citation"> Annals of Plastic Surgery </span><span class="pubYear">2006</span>;<span class="volume">56</span>:394‐8. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/16557070" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Recombinant+human+epidermal+growth+factor+(EGF)+to+enhance+healing+for+diabetic+foot+ulcers+&author=JP+Hong&author=HD+Jung&author=YW+Kim&publication_year=2006&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_excludedStudies" id="CD008548-bbs2-0033"> <div class="reference-title-banner"> <h4 class="title">Miller 1999 {published data only} </h4> </div> <div class="bibliography-section" id="CD008548-bib-0040"> <div class="citation-journal">Miller MS. <span class="citation-title">Use of topical recombinant human platelet‐derived growth factor‐BB (becaplermin) in healing of chronic mixed arteriovenous lower extremity diabetic ulcers</span>. <span class="citation"> The Journal of Foot and Ankle Surgery </span><span class="pubYear">1999</span>;<span class="volume">38</span>:227‐31. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/10384364" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Use+of+topical+recombinant+human+platelet%E2%80%90derived+growth+factor%E2%80%90BB+(becaplermin)+in+healing+of+chronic+mixed+arteriovenous+lower+extremity+diabetic+ulcers+&author=MS+Miller&publication_year=1999&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_excludedStudies" id="CD008548-bbs2-0034"> <div class="reference-title-banner"> <h4 class="title">Mohan 2007 {published data only} </h4> </div> <div class="bibliography-section" id="CD008548-bib-0041"> <div class="citation-journal">Mohan VK. <span class="citation-title">Recombinant human epidermal growth factor (REGEN‐D 150): effect on healing of diabetic foot ulcers</span>. <span class="citation"> Diabetes Research and Clinical Practice </span><span class="pubYear">2007</span>;<span class="volume">78</span>:405‐11. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/17655964" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Recombinant+human+epidermal+growth+factor+(REGEN%E2%80%90D+150):+effect+on+healing+of+diabetic+foot+ulcers+&author=VK+Mohan&publication_year=2007&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_excludedStudies" id="CD008548-bbs2-0035"> <div class="reference-title-banner"> <h4 class="title">Saad Setta 2011 {published data only} </h4> </div> <div class="bibliography-section" id="CD008548-bib-0042"> <div class="citation-journal">Saad Setta H, Elshahat A, Elsherbiny K, Massoud K, Safe I. <span class="citation-title">Platelet‐rich plasma versus platelet‐poor plasma in the management of chronic diabetic foot ulcers: a comparative study</span>. <span class="citation"> International Wound Journal </span><span class="pubYear">2011</span>;<span class="volume">8</span>(3):307‐12. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/21470370" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Platelet%E2%80%90rich+plasma+versus+platelet%E2%80%90poor+plasma+in+the+management+of+chronic+diabetic+foot+ulcers:+a+comparative+study+&author=H+SaadSetta&author=A+Elshahat&author=K+Elsherbiny&author=K+Massoud&author=I+Safe&publication_year=2011&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_excludedStudies" id="CD008548-bbs2-0036"> <div class="reference-title-banner"> <h4 class="title">Tuyet 2009 {published data only} </h4> </div> <div class="bibliography-section" id="CD008548-bib-0043"> <div class="citation-journal">Tuyet HL, Quynh TTN, Minh HVH, Bich DNT, Dinh TD, Tan DL, et al. <span class="citation-title">The efficacy and safety of epidermal growth factor in treatment of diabetic foot ulcers: the preliminary results</span>. <span class="citation"> International Wound Journal </span><span class="pubYear">2009</span>;<span class="volume">6</span>:159‐66. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/19432666" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=The+efficacy+and+safety+of+epidermal+growth+factor+in+treatment+of+diabetic+foot+ulcers:+the+preliminary+results+&author=HL+Tuyet&author=TTN+Quynh&author=HVH+Minh&author=DNT+Bich&author=TD+Dinh&author=DL+Tan&publication_year=2009&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_excludedStudies" id="CD008548-bbs2-0037"> <div class="reference-title-banner"> <h4 class="title">Yera‐Alos 2013 {published data only} </h4> </div> <div class="bibliography-section" id="CD008548-bib-0044"> <div class="citation-journal">Yera‐Alos IB, Alonso‐Carbonell L, Valenzuela‐Silva CM, Tuero‐Iglesias AD, Moreira‐Martinez M, Marrero‐Rodriguez I, et al. <span class="citation-title">Active post‐marketing surveillance of the intralesional administration of human recombinant epidermal growth factor in diabetic foot ulcers</span>. <span class="citation"> BMC Pharmacology and Toxicology </span><span class="pubYear">2013</span>;<span class="volume">14</span>:44. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/24004460" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Active+post%E2%80%90marketing+surveillance+of+the+intralesional+administration+of+human+recombinant+epidermal+growth+factor+in+diabetic+foot+ulcers+&author=IB+Yera%E2%80%90Alos&author=L+Alonso%E2%80%90Carbonell&author=CM+Valenzuela%E2%80%90Silva&author=AD+Tuero%E2%80%90Iglesias&author=M+Moreira%E2%80%90Martinez&author=I+Marrero%E2%80%90Rodriguez&publication_year=2013&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> </section> <section> <div class="section-header" id="CD008548-bbs1-0003"> <h3 class="title">References to studies awaiting assessment</h3> <div class="jump-to"> <p>Jump to: </p> <ul class="jump-to-links"> <li><a class="jump-to" href="#CD008548-bbs1-0001">included studies</a></li> <li><a class="jump-to" href="#CD008548-bbs1-0002">excluded studies</a></li> <li><a class="jump-to" href="#CD008548-bbs1-0004">ongoing studies</a></li> <li><a class="jump-to" href="#CD008548-bbs1-0005">additional references</a></li> </ul> </div> </div> <div class="bibliographies references_awaitingAssessmentStudies" id="CD008548-bbs2-0038"> <div class="reference-title-banner"> <h4 class="title">Gomez‐Villa 2014 {published data only} </h4> </div> <div class="bibliography-section" id="CD008548-bib-0045"> <div class="citation-journal">Gomez‐Villa R, Aguilar‐Rebolledo F, Lozano‐Platonoff A, Teran‐Soto JM, Fabian‐Victoriano MR, Kresch‐Tronik NS, et al. <span class="citation-title">Efficacy of intralesional recombinant human epidermal growth factor in diabetic foot ulcers in Mexican patients: a randomized double‐blinded controlled trial</span>. <span class="citation"> Wound Repair and Regeneration </span><span class="pubYear">2014</span>;<span class="volume">22</span>(4):497‐503. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/25041620" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Efficacy+of+intralesional+recombinant+human+epidermal+growth+factor+in+diabetic+foot+ulcers+in+Mexican+patients:+a+randomized+double%E2%80%90blinded+controlled+trial+&author=R+Gomez%E2%80%90Villa&author=F+Aguilar%E2%80%90Rebolledo&author=A+Lozano%E2%80%90Platonoff&author=JM+Teran%E2%80%90Soto&author=MR+Fabian%E2%80%90Victoriano&author=NS+Kresch%E2%80%90Tronik&publication_year=2014&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_awaitingAssessmentStudies" id="CD008548-bbs2-0039"> <div class="reference-title-banner"> <h4 class="title">Morimoto 2013 {published data only} </h4> </div> <div class="bibliography-section" id="CD008548-bib-0046"> <div class="citation-journal">Morimoto N, Yoshimura K, Niimi M, Ito T, Aya R, Fujitaka J, et al. <span class="citation-title">Novel collagen/gelatin scaffold with sustained release of basic fibroblast growth factor: clinical trial for chronic skin ulcers</span>. <span class="citation"> Tissue engineering </span><span class="pubYear">2013 Part A</span>;<span class="volume">19</span>(17‐18):1931‐40. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/23541061" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Novel+collagen/gelatin+scaffold+with+sustained+release+of+basic+fibroblast+growth+factor:+clinical+trial+for+chronic+skin+ulcers+&author=N+Morimoto&author=K+Yoshimura&author=M+Niimi&author=T+Ito&author=R+Aya&author=J+Fujitaka&publication_year=2013PartA&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_awaitingAssessmentStudies" id="CD008548-bbs2-0040"> <div class="reference-title-banner"> <h4 class="title">Singla 2014 {published data only} </h4> </div> <div class="bibliography-section" id="CD008548-bib-0047"> <div class="citation-journal">Singla S, Garg R, Kumar A, Gill C. <span class="citation-title">Efficacy of topical application of beta urogastrone (recombinant human epidermal growth factor) in Wagner's Grade 1 and 2 diabetic foot ulcers: Comparative analysis of 50 patients</span>. <span class="citation"> Journal of Natural Science, Biology and Medicine </span><span class="pubYear">2014</span>;<span class="volume">5</span>(2):273‐7. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Efficacy+of+topical+application+of+beta+urogastrone+(recombinant+human+epidermal+growth+factor)+in+Wagner's+Grade+1+and+2+diabetic+foot+ulcers:+Comparative+analysis+of+50+patients+&author=S+Singla&author=R+Garg&author=A+Kumar&author=C+Gill&publication_year=2014&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_awaitingAssessmentStudies" id="CD008548-bbs2-0041"> <div class="reference-title-banner"> <h4 class="title">Young 1992 {published data only} </h4> </div> <div class="bibliography-section" id="CD008548-bib-0048"> <div class="citation-journal">Young MJ, Larsen J, Knowles A, Parnell L, Ward JD. <span class="citation-title">The treatment of diabetic neuropathic foot ulcers with biosynthetic platelet derived growth factor</span>. <span class="citation"> Diabetic Medicine </span><span class="pubYear">1992</span>, (Suppl 2):S42. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=The+treatment+of+diabetic+neuropathic+foot+ulcers+with+biosynthetic+platelet+derived+growth+factor+&author=MJ+Young&author=J+Larsen&author=A+Knowles&author=L+Parnell&author=JD+Ward&publication_year=1992&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> </section> <section> <div class="section-header" id="CD008548-bbs1-0004"> <h3 class="title">References to ongoing studies</h3> <div class="jump-to"> <p>Jump to: </p> <ul class="jump-to-links"> <li><a class="jump-to" href="#CD008548-bbs1-0001">included studies</a></li> <li><a class="jump-to" href="#CD008548-bbs1-0002">excluded studies</a></li> <li><a class="jump-to" href="#CD008548-bbs1-0003">studies awaiting assessment</a></li> <li><a class="jump-to" href="#CD008548-bbs1-0005">additional references</a></li> </ul> </div> </div> <div class="bibliographies references_ongoingStudies" id="CD008548-bbs2-0042"> <div class="reference-title-banner"> <h4 class="title">NCT00521937 {published data only} </h4> </div> <div class="bibliography-section" id="CD008548-bib-0049"> <div class="citation-other">NCT00521937. <span class="citation-title">Efficacy and Safety Study of DERMAGEN® vs Conventional Treatment to Treat Diabetic Neuropathic Foot Ulcer</span>. https://clinicaltrials.gov/ct2/show/NCT00521937. <ul class="citation-link-group"> </ul> </div> </div> </div> <div class="bibliographies references_ongoingStudies" id="CD008548-bbs2-0043"> <div class="reference-title-banner"> <h4 class="title">NCT00709514 {published data only} </h4> </div> <div class="bibliography-section" id="CD008548-bib-0050"> <div class="citation-other">NCT00709514. <span class="citation-title">Clinical Evaluation of DCB‐WH1 in Healing of Chronic Diabetic Foot Ulcers</span>. https://clinicaltrials.gov/ct2/show/NCT00709514. <ul class="citation-link-group"> </ul> </div> </div> </div> <div class="bibliographies references_ongoingStudies" id="CD008548-bbs2-0044"> <div class="reference-title-banner"> <h4 class="title">NCT00915486 {published data only} </h4> </div> <div class="bibliography-section" id="CD008548-bib-0051"> <div class="citation-other">NCT00915486. <span class="citation-title">A Dose Finding Study of Topically Applied I‐020201 as an Adjunct to Good Standard‐of‐care in Patients With Chronic Diabetic Foot Ulcers (DFU)</span>. https://clinicaltrials.gov/ct2/show/NCT00915486. <ul class="citation-link-group"> </ul> </div> </div> </div> <div class="bibliographies references_ongoingStudies" id="CD008548-bbs2-0045"> <div class="reference-title-banner"> <h4 class="title">NCT00926068 {published data only} </h4> </div> <div class="bibliography-section" id="CD008548-bib-0052"> <div class="citation-other">NCT00926068. <span class="citation-title">Safety and Efficacy of HO/03/03 10μg in the Treatment of Plantar Neuropathic Diabetic Foot Ulcers (Truheal)</span>. https://clinicaltrials.gov/ct2/show/NCT00926068. <ul class="citation-link-group"> </ul> </div> </div> </div> <div class="bibliographies references_ongoingStudies" id="CD008548-bbs2-0046"> <div class="reference-title-banner"> <h4 class="title">NCT01060670 {published data only} </h4> </div> <div class="bibliography-section" id="CD008548-bib-0053"> <div class="citation-other">NCT01060670. <span class="citation-title">A Safety and Efficacy Study of INTEGRA® Dermal Regeneration Template for the Treatment of Diabetic Foot Ulcers</span>. https://clinicaltrials.gov/ct2/show/NCT01060670. <ul class="citation-link-group"> </ul> </div> </div> </div> <div class="bibliographies references_ongoingStudies" id="CD008548-bbs2-0047"> <div class="reference-title-banner"> <h4 class="title">NCT01098357 {published data only} </h4> </div> <div class="bibliography-section" id="CD008548-bib-0054"> <div class="citation-other">NCT01098357. <span class="citation-title">Comparative Study of 3 Dose Regimens of BioChaperone to Becaplermin Gel for the Treatment of Diabetic Foot Ulcer</span>. https://clinicaltrials.gov/ct2/show/NCT01098357. <ul class="citation-link-group"> </ul> </div> </div> </div> </section> <section> <div class="section-header" id="CD008548-bbs1-0005"> <h3 class="title">Additional references</h3> <div class="jump-to"> <p>Jump to: </p> <ul class="jump-to-links"> <li><a class="jump-to" href="#CD008548-bbs1-0001">included studies</a></li> <li><a class="jump-to" href="#CD008548-bbs1-0002">excluded studies</a></li> <li><a class="jump-to" href="#CD008548-bbs1-0003">studies awaiting assessment</a></li> <li><a class="jump-to" href="#CD008548-bbs1-0004">ongoing studies</a></li> </ul> </div> </div> <div class="bibliographies references_additionalReferences" id="CD008548-bbs2-0048"> <div class="reference-title-banner"> <h4 class="title">Abbott 2002</h4> </div> <div class="bibliography-section" id="CD008548-bib-0055"> <div class="citation-journal">Abbott CA, Carrington AL, Ashe H, Bath S, Every LC, Griffiths J, et al. North‐West Diabetes Foot Care Study. <span class="citation-title">The North‐West Diabetes Foot Care Study: incidence of, and risk factors for, new diabetic foot ulceration in a community‐based patient cohort</span>. <span class="citation"> Diabetes Medicine </span><span class="pubYear">2002</span>;<span class="volume">19</span>:377‐84. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=The+North%E2%80%90West+Diabetes+Foot+Care+Study:+incidence+of,+and+risk+factors+for,+new+diabetic+foot+ulceration+in+a+community%E2%80%90based+patient+cohort+&author=CA+Abbott&author=AL+Carrington&author=H+Ashe&author=S+Bath&author=LC+Every&author=J+Griffiths&publication_year=2002&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD008548-bbs2-0049"> <div class="reference-title-banner"> <h4 class="title">Albert 2002</h4> </div> <div class="bibliography-section" id="CD008548-bib-0056"> <div class="citation-journal">Albert S. <span class="citation-title">Cost‐effective management of recalcitrant diabetic foot ulcers</span>. <span class="citation"> Clinics in Podiatric Medicine and Surgery </span><span class="pubYear">2002</span>;<span class="volume">19</span>:483‐91. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/12471856" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Cost%E2%80%90effective+management+of+recalcitrant+diabetic+foot+ulcers&author=S+Albert&publication_year=2002&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD008548-bbs2-0050"> <div class="reference-title-banner"> <h4 class="title">Ali 2008</h4> </div> <div class="bibliography-section" id="CD008548-bib-0057"> <div class="citation-other">Ali S, Fareed A, Humail S, Basit A, Ahmedani M, Fawwad A, et al. <span class="citation-title">The personal cost of diabetic foot disease in the developing world ‐ a study from Pakistan</span>. Diabetic Medicine<span class="pubYear">2008</span>; Vol. 25:1231‐3. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=The+personal+cost+of+diabetic+foot+disease+in+the+developing+world+%E2%80%90+a+study+from+Pakistan+&author=S+Ali&author=A+Fareed&author=S+Humail&author=A+Basit&author=M+Ahmedani&author=A+Fawwad&publication_year=2008&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD008548-bbs2-0051"> <div class="reference-title-banner"> <h4 class="title">Amery 2005</h4> </div> <div class="bibliography-section" id="CD008548-bib-0058"> <div class="citation-journal">Amery CM. <span class="citation-title">Growth factors and the management of the diabetic foot</span>. <span class="citation"> Diabetic Medicine </span><span class="pubYear">2005</span>;<span class="volume">22 Suppl 1</span>:12‐4. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/15610150" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Growth+factors+and+the+management+of+the+diabetic+foot&author=CM+Amery&publication_year=2005&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD008548-bbs2-0052"> <div class="reference-title-banner"> <h4 class="title">Andersen 2004</h4> </div> <div class="bibliography-section" id="CD008548-bib-0059"> <div class="citation-journal">Andersen JH. <span class="citation-title">Technology evaluation: rh lactoferrin, Agennix</span>. <span class="citation"> Current Opinion in Molecular Therapeutics </span><span class="pubYear">2004</span>;<span class="volume">6</span>(3):344‐9. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/15264438" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Technology+evaluation:+rh+lactoferrin,+Agennix&author=JH+Andersen&publication_year=2004&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD008548-bbs2-0053"> <div class="reference-title-banner"> <h4 class="title">Armstrong 2008</h4> </div> <div class="bibliography-section" id="CD008548-bib-0060"> <div class="citation-journal">Armstrong DG, Lavery LA, Wrobel JS, Vileikyte L. <span class="citation-title">Quality of life in healing diabetic wounds: does the end justify the means?</span>. <span class="citation"> Journal of Foot and Ankle Surgery </span><span class="pubYear">2008</span>;<span class="volume">47</span>:278‐82. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/18590888" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Quality+of+life+in+healing+diabetic+wounds:+does+the+end+justify+the+means?&author=DG+Armstrong&author=LA+Lavery&author=JS+Wrobel&author=L+Vileikyte&publication_year=2008&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD008548-bbs2-0054"> <div class="reference-title-banner"> <h4 class="title">Ashry 1998</h4> </div> <div class="bibliography-section" id="CD008548-bib-0061"> <div class="citation-journal">Ashry HR, Lavery LA, Armstrong DG, Lavery DC, Houtum WH. <span class="citation-title">Cost of diabetes‐related amputations in minorities</span>. <span class="citation"> The Journal of Foot and Ankle Surgery </span><span class="pubYear">1998</span>;<span class="volume">37</span>:186‐90. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/9638541" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Cost+of+diabetes%E2%80%90related+amputations+in+minorities&author=HR+Ashry&author=LA+Lavery&author=DG+Armstrong&author=DC+Lavery&author=WH+Houtum&publication_year=1998&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD008548-bbs2-0055"> <div class="reference-title-banner"> <h4 class="title">Bakker 2012a</h4> </div> <div class="bibliography-section" id="CD008548-bib-0062"> <div class="citation-journal">Bakker K, Schaper NC. <span class="citation-title">The development of global consensus guidelines on the management and prevention of the diabetic foot 2011</span>. <span class="citation"> Diabetes/Metabolism Research and Reviews </span><span class="pubYear">2012</span>;<span class="volume">28</span>(Suppl 1):116‐8. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=The+development+of+global+consensus+guidelines+on+the+management+and+prevention+of+the+diabetic+foot+2011+&author=K+Bakker&author=NC+Schaper&publication_year=2012&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD008548-bbs2-0056"> <div class="reference-title-banner"> <h4 class="title">Bakker 2012b</h4> </div> <div class="bibliography-section" id="CD008548-bib-0063"> <div class="citation-journal">Bakker K, Apelqvist J, Schaper NC. <span class="citation-title">Practical guidelines on the management and prevention of the diabetic foot 2011</span>. <span class="citation"> Diabetes/Metabolism Research and Reviews </span><span class="pubYear">2012</span>;<span class="volume">28</span>(Suppl 1):225‐31. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Practical+guidelines+on+the+management+and+prevention+of+the+diabetic+foot+2011&author=K+Bakker&author=J+Apelqvist&author=NC+Schaper&publication_year=2012&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD008548-bbs2-0057"> <div class="reference-title-banner"> <h4 class="title">Balshem 2011</h4> </div> <div class="bibliography-section" id="CD008548-bib-0064"> <div class="citation-journal">Balshem H, Helfand M, Schunemann HJ, Oxman AD, Kunz R, Brozek J, et al. <span class="citation-title">GRADE guidelines: 3. Rating the quality of evidence</span>. <span class="citation"> Journal of Clinical Epidemiology </span><span class="pubYear">2011</span>;<span class="volume">64</span>(4):401‐6. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/21208779" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=GRADE+guidelines:+3.+Rating+the+quality+of+evidence&author=H+Balshem&author=M+Helfand&author=HJ+Schunemann&author=AD+Oxman&author=R+Kunz&author=J+Brozek&publication_year=2011&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD008548-bbs2-0058"> <div class="reference-title-banner"> <h4 class="title">Barrientos 2008</h4> </div> <div class="bibliography-section" id="CD008548-bib-0065"> <div class="citation-journal">Barrientos S, Stojadinovic O, Golinko MS, Brem H, Tomic‐Canic M. <span class="citation-title">Growth factors and cytokines in wound healing</span>. <span class="citation"> Wound Repair and Regeneration </span><span class="pubYear">2008</span>;<span class="volume">16</span>:585‐601. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/19128254" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Growth+factors+and+cytokines+in+wound+healing&author=S+Barrientos&author=O+Stojadinovic&author=MS+Golinko&author=H+Brem&author=M+Tomic%E2%80%90Canic&publication_year=2008&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD008548-bbs2-0059"> <div class="reference-title-banner"> <h4 class="title">Bartus 2004</h4> </div> <div class="bibliography-section" id="CD008548-bib-0066"> <div class="citation-journal">Bartus CL, Margolis DJ. <span class="citation-title">Reducing the incidence of foot ulceration and amputation in diabetes</span>. <span class="citation"> Current Diabetes Reports </span><span class="pubYear">2004</span>;<span class="volume">4</span>:413‐8. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/15539004" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Reducing+the+incidence+of+foot+ulceration+and+amputation+in+diabetes&author=CL+Bartus&author=DJ+Margolis&publication_year=2004&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD008548-bbs2-0060"> <div class="reference-title-banner"> <h4 class="title">Basch 2012</h4> </div> <div class="bibliography-section" id="CD008548-bib-0067"> <div class="citation-journal">Basch E, Aronson N, Berg A, Flum D, Gabriel S, Goodman SN, et al. <span class="citation-title">Methodological standards and patient‐centeredness in comparative effectiveness research: the PCORI perspective</span>. <span class="citation"> JAMA </span><span class="pubYear">2012</span>;<span class="volume">307</span>(15):1636‐40. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/22511692" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Methodological+standards+and+patient%E2%80%90centeredness+in+comparative+effectiveness+research:+the+PCORI+perspective+&author=E+Basch&author=N+Aronson&author=A+Berg&author=D+Flum&author=S+Gabriel&author=SN+Goodman&publication_year=2012&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD008548-bbs2-0061"> <div class="reference-title-banner"> <h4 class="title">Beckert 2006</h4> </div> <div class="bibliography-section" id="CD008548-bib-0068"> <div class="citation-journal">Beckert S, Witte M, Wicke C, Königsrainer A, Coerper S. <span class="citation-title">A new wound‐based severity score for diabetic foot ulcers: a prospective analysis of 1,000 patients</span>. <span class="citation"> Diabetes Care </span><span class="pubYear">2006</span>;<span class="volume">29</span>:988‐92. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/16644625" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=A+new+wound%E2%80%90based+severity+score+for+diabetic+foot+ulcers:+a+prospective+analysis+of+1,000+patients+&author=S+Beckert&author=M+Witte&author=C+Wicke&author=A+K%C3%B6nigsrainer&author=S+Coerper&publication_year=2006&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD008548-bbs2-0062"> <div class="reference-title-banner"> <h4 class="title">Bennet 2003</h4> </div> <div class="bibliography-section" id="CD008548-bib-0069"> <div class="citation-journal">Bennett SP, Griffiths GD, Schor AM, Leese GP, Schor SL. <span class="citation-title">Growth factors in the treatment of diabetic foot ulcers</span>. <span class="citation"> The British Journal of Surgery </span><span class="pubYear">2003</span>;<span class="volume">90</span>:133‐46. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/12555288" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Growth+factors+in+the+treatment+of+diabetic+foot+ulcers&author=SP+Bennett&author=GD+Griffiths&author=AM+Schor&author=GP+Leese&author=SL+Schor&publication_year=2003&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD008548-bbs2-0063"> <div class="reference-title-banner"> <h4 class="title">Blair 2009</h4> </div> <div class="bibliography-section" id="CD008548-bib-0070"> <div class="citation-journal">Blair P, Flaumenhaft R. <span class="citation-title">Platelet alpha‐granules: basic biology and clinical correlates</span>. <span class="citation"> Blood Reviews </span><span class="pubYear">2009</span>;<span class="volume">23</span>(4):177‐89. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/19450911" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Platelet+alpha%E2%80%90granules:+basic+biology+and+clinical+correlates&author=P+Blair&author=R+Flaumenhaft&publication_year=2009&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD008548-bbs2-0064"> <div class="reference-title-banner"> <h4 class="title">Boulton 2005</h4> </div> <div class="bibliography-section" id="CD008548-bib-0071"> <div class="citation-journal">Boulton AJ, Vileikyte L, Ragnarson‐Tennvall G, Apelqvist J. <span class="citation-title">The global burden of diabetic foot disease</span>. <span class="citation"> Lancet </span><span class="pubYear">2005</span>;<span class="volume">366</span>:1719‐24. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/16291066" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=The+global+burden+of+diabetic+foot+disease&author=AJ+Boulton&author=L+Vileikyte&author=G+Ragnarson%E2%80%90Tennvall&author=J+Apelqvist&publication_year=2005&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD008548-bbs2-0065"> <div class="reference-title-banner"> <h4 class="title">Boulton 2008</h4> </div> <div class="bibliography-section" id="CD008548-bib-0072"> <div class="citation-journal">Boulton AJ. <span class="citation-title">The diabetic foot: grand overview, epidemiology and pathogenesis</span>. <span class="citation"> Diabetes/Metabolism Research and Reviews </span><span class="pubYear">2008</span>;<span class="volume">24 (Suppl 1)</span>:3‐6. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=The+diabetic+foot:+grand+overview,+epidemiology+and+pathogenesis&author=AJ+Boulton&publication_year=2008&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD008548-bbs2-0066"> <div class="reference-title-banner"> <h4 class="title">Boutoille 2008</h4> </div> <div class="bibliography-section" id="CD008548-bib-0073"> <div class="citation-journal">Boutoille D, Féraille A, Maulaz D, Krempf M. <span class="citation-title">Quality of life with diabetes‐associated foot complications: comparison between lower‐limb amputation and chronic foot ulceration</span>. <span class="citation"> Foot and Ankle International </span><span class="pubYear">2008</span>;<span class="volume">29</span>:1074‐8. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/19026199" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Quality+of+life+with+diabetes%E2%80%90associated+foot+complications:+comparison+between+lower%E2%80%90limb+amputation+and+chronic+foot+ulceration+&author=D+Boutoille&author=A+F%C3%A9raille&author=D+Maulaz&author=M+Krempf&publication_year=2008&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD008548-bbs2-0067"> <div class="reference-title-banner"> <h4 class="title">Buchberger 2010</h4> </div> <div class="bibliography-section" id="CD008548-bib-0074"> <div class="citation-journal">Buchberger B, Follmann M, Freyer D, Huppertz H, Ehm A, Wasem J. <span class="citation-title">The importance of growth factors for the treatment of chronic wounds in the case of diabetic foot ulcers</span>. <span class="citation"> GMS Health Technology Assessment </span><span class="pubYear">2010</span>;<span class="volume">6</span>:Doc12. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/21289885" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=The+importance+of+growth+factors+for+the+treatment+of+chronic+wounds+in+the+case+of+diabetic+foot+ulcers+&author=B+Buchberger&author=M+Follmann&author=D+Freyer&author=H+Huppertz&author=A+Ehm&author=J+Wasem&publication_year=2010&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD008548-bbs2-0068"> <div class="reference-title-banner"> <h4 class="title">Buchmayer 2011</h4> </div> <div class="bibliography-section" id="CD008548-bib-0075"> <div class="citation-journal">Buchmayer F, Pleiner J, Elmlinger MW, Lauer G, Nell G, Sitte HH. <span class="citation-title">Actovegin(R): a biological drug for more than 5 decades</span>. <span class="citation"> Wiener Medizinische Wochenschrift </span><span class="pubYear">2011</span>;<span class="volume">161</span>(3‐4):80‐8. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/21404144" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Actovegin(R):+a+biological+drug+for+more+than+5+decades&author=F+Buchmayer&author=J+Pleiner&author=MW+Elmlinger&author=G+Lauer&author=G+Nell&author=HH+Sitte&publication_year=2011&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD008548-bbs2-0069"> <div class="reference-title-banner"> <h4 class="title">Chan 2013</h4> </div> <div class="bibliography-section" id="CD008548-bib-0076"> <div class="citation-journal">Chan AW, Tetzlaff JM, Gøtzsche PC, Altman DG, Mann H, Berlin JA, et al. <span class="citation-title">SPIRIT 2013 explanation and elaboration: guidance for protocols of clinical trials</span>. <span class="citation"> BMJ </span><span class="pubYear">2013</span>;<span class="volume">346</span>:e7586. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/23303884" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=SPIRIT+2013+explanation+and+elaboration:+guidance+for+protocols+of+clinical+trials&author=AW+Chan&author=JM+Tetzlaff&author=PC+G%C3%B8tzsche&author=DG+Altman&author=H+Mann&author=JA+Berlin&publication_year=2013&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD008548-bbs2-0070"> <div class="reference-title-banner"> <h4 class="title">Chao 2009</h4> </div> <div class="bibliography-section" id="CD008548-bib-0077"> <div class="citation-journal">Chao CY, Cheing GL. <span class="citation-title">Microvascular dysfunction in diabetic foot disease and ulceration</span>. <span class="citation"> Diabetes/Metabolism Research and Reviews </span><span class="pubYear">2009</span>;<span class="volume">25</span>:604‐14. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Microvascular+dysfunction+in+diabetic+foot+disease+and+ulceration&author=CY+Chao&author=GL+Cheing&publication_year=2009&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD008548-bbs2-0071"> <div class="reference-title-banner"> <h4 class="title">Clarke 2007</h4> </div> <div class="bibliography-section" id="CD008548-bib-0078"> <div class="citation-journal">Clarke M. <span class="citation-title">Standardising outcomes for clinical trials and systematic reviews</span>. <span class="citation"> Trials </span><span class="pubYear">2007</span>;<span class="volume">8</span>:39. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/18039365" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Standardising+outcomes+for+clinical+trials+and+systematic+reviews&author=M+Clarke&publication_year=2007&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD008548-bbs2-0072"> <div class="reference-title-banner"> <h4 class="title">CMA 2011 [Computer program]</h4> </div> <div class="bibliography-section" id="CD008548-bib-0079"> <div class="citation-other">Comprehensive Meta‐Analysis team. <span class="citation-title">Comprehensive Meta‐Analysis Sofware</span>. Version 2.2.064. Englewood, NJ: Biostat, Inc, <span class="pubYear">2011</span>. <ul class="citation-link-group"> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD008548-bbs2-0073"> <div class="reference-title-banner"> <h4 class="title">Cruciani 2009</h4> </div> <div class="bibliography-section" id="CD008548-bib-0080"> <div class="citation-journal">Cruciani M, Lipsky BA, Mengoli C, Lalla F. <span class="citation-title">Granulocyte‐colony stimulating factors as adjunctive therapy for diabetic foot infections</span>. <span class="citation"> Cochrane Database of Systematic Reviews </span><span class="pubYear">2009</span>, Issue 3. [DOI: <a href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/http/MS6C63DQNEYG86UH/10.1002/14651858.CD006810" target="_blank"><span>10.1002/14651858.CD006810</span></a>] <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/19588405" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Granulocyte%E2%80%90colony+stimulating+factors+as+adjunctive+therapy+for+diabetic+foot+infections&author=M+Cruciani&author=BA+Lipsky&author=C+Mengoli&author=F+Lalla&publication_year=2009&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD008548-bbs2-0074"> <div class="reference-title-banner"> <h4 class="title">Enoch 2008</h4> </div> <div class="bibliography-section" id="CD008548-bib-0081"> <div class="citation-journal">Enoch S, Leaper DJ. <span class="citation-title">Basic science of wound healing</span>. <span class="citation"> Surgery </span><span class="pubYear">2008</span>;<span class="volume">26</span>(2):31‐7. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Basic+science+of+wound+healing&author=S+Enoch&author=DJ+Leaper&publication_year=2008&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD008548-bbs2-0075"> <div class="reference-title-banner"> <h4 class="title">FDA 2008</h4> </div> <div class="bibliography-section" id="CD008548-bib-0082"> <div class="citation-other">Food, Drug Administration. <span class="citation-title">Regranex (becaplermin) Gel</span>. http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm094968.htm (accessed 6 July 2011). <ul class="citation-link-group"> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD008548-bbs2-0076"> <div class="reference-title-banner"> <h4 class="title">Figueroa‐Romero 2008</h4> </div> <div class="bibliography-section" id="CD008548-bib-0083"> <div class="citation-journal">Figueroa‐Romero C, Sadidi M, Feldman EL. <span class="citation-title">Mechanisms of disease: the oxidative stress theory of diabetic neuropathy</span>. <span class="citation"> Reviews in Endocrine &amp; Metabolic Disorders </span><span class="pubYear">2008</span>;<span class="volume">9</span>:301‐14. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/18709457" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Mechanisms+of+disease:+the+oxidative+stress+theory+of+diabetic+neuropathy&author=C+Figueroa%E2%80%90Romero&author=M+Sadidi&author=EL+Feldman&publication_year=2008&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD008548-bbs2-0077"> <div class="reference-title-banner"> <h4 class="title">Foster 2009</h4> </div> <div class="bibliography-section" id="CD008548-bib-0084"> <div class="citation-journal">Foster TE, Puskas BL, Mandelbaum BR, Gerhardt MB, Rodeo SA. <span class="citation-title">Platelet‐rich plasma: from basic science to clinical applications</span>. <span class="citation"> The American Journal of Sports Medicine </span><span class="pubYear">2009</span>;<span class="volume">37</span>(11):2259‐72. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/19875361" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Platelet%E2%80%90rich+plasma:+from+basic+science+to+clinical+applications&author=TE+Foster&author=BL+Puskas&author=BR+Mandelbaum&author=MB+Gerhardt&author=SA+Rodeo&publication_year=2009&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD008548-bbs2-0078"> <div class="reference-title-banner"> <h4 class="title">Gabriel 2012</h4> </div> <div class="bibliography-section" id="CD008548-bib-0085"> <div class="citation-journal">Gabriel SE, Normand SL. <span class="citation-title">Getting the methods right ‐ the foundation of patient‐centered outcomes research</span>. <span class="citation"> The New England Journal of Medicine </span><span class="pubYear">2012</span>;<span class="volume">367</span>(9):787‐90. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/22830434" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Getting+the+methods+right+%E2%80%90+the+foundation+of+patient%E2%80%90centered+outcomes+research&author=SE+Gabriel&author=SL+Normand&publication_year=2012&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD008548-bbs2-0079"> <div class="reference-title-banner"> <h4 class="title">Galkoswka 2006</h4> </div> <div class="bibliography-section" id="CD008548-bib-0086"> <div class="citation-journal">Galkowska H, Wojewodzka U, Olszewski WL. <span class="citation-title">Chemokines, cytokines, and growth factors in keratinocytes and dermal endothelial cells in the margin of chronic diabetic foot ulcers</span>. <span class="citation"> Wound Repair and Regeneration </span><span class="pubYear">2006</span>;<span class="volume">14</span>:558‐65. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/17014667" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Chemokines,+cytokines,+and+growth+factors+in+keratinocytes+and+dermal+endothelial+cells+in+the+margin+of+chronic+diabetic+foot+ulcers+&author=H+Galkowska&author=U+Wojewodzka&author=WL+Olszewski&publication_year=2006&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD008548-bbs2-0080"> <div class="reference-title-banner"> <h4 class="title">Girod 2003</h4> </div> <div class="bibliography-section" id="CD008548-bib-0087"> <div class="citation-journal">Girod I, Valensi P, Laforêt C, Moreau‐Defarges T, Guillon P, Baron F. <span class="citation-title">An economic evaluation of the cost of diabetic foot ulcers: results of a retrospective study on 239 patients</span>. <span class="citation"> Diabetes and Metabolism </span><span class="pubYear">2003</span>;<span class="volume">29</span>:269‐77. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/12909815" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=An+economic+evaluation+of+the+cost+of+diabetic+foot+ulcers:+results+of+a+retrospective+study+on+239+patients+&author=I+Girod&author=P+Valensi&author=C+Lafor%C3%AAt&author=T+Moreau%E2%80%90Defarges&author=P+Guillon&author=F+Baron&publication_year=2003&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD008548-bbs2-0081"> <div class="reference-title-banner"> <h4 class="title">Goodridge 2006</h4> </div> <div class="bibliography-section" id="CD008548-bib-0088"> <div class="citation-journal">Goodridge D, Trepman E, Sloan J, Guse L, Strain LA, McIntyre J, et al. <span class="citation-title">Quality of life of adults with unhealed and healed diabetic foot ulcers</span>. <span class="citation"> Foot and Ankle International </span><span class="pubYear">2006</span>;<span class="volume">27</span>:274‐80. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/16624217" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Quality+of+life+of+adults+with+unhealed+and+healed+diabetic+foot+ulcers&author=D+Goodridge&author=E+Trepman&author=J+Sloan&author=L+Guse&author=LA+Strain&author=J+McIntyre&publication_year=2006&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD008548-bbs2-0082"> <div class="reference-title-banner"> <h4 class="title">Grazul‐Bilska 2003</h4> </div> <div class="bibliography-section" id="CD008548-bib-0089"> <div class="citation-journal">Grazul‐Bilska AT, Johnson ML, Bilski JJ, Redmer DA, Reynolds LP, Abdullah A, et al. <span class="citation-title">Wound healing: the role of growth factors</span>. <span class="citation"> Drugs of Today </span><span class="pubYear">2003</span>;<span class="volume">39</span>:787‐800. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/14668934" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Wound+healing:+the+role+of+growth+factors&author=AT+Grazul%E2%80%90Bilska&author=ML+Johnson&author=JJ+Bilski&author=DA+Redmer&author=LP+Reynolds&author=A+Abdullah&publication_year=2003&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD008548-bbs2-0083"> <div class="reference-title-banner"> <h4 class="title">Guyatt 2011a</h4> </div> <div class="bibliography-section" id="CD008548-bib-0090"> <div class="citation-journal">Guyatt GH, Oxman AD, Schunemann HJ, Tugwell P, Knottnerus A. <span class="citation-title">GRADE guidelines: a new series of articles in the Journal of Clinical Epidemiology</span>. <span class="citation"> Journal of Clinical Epidemiology </span><span class="pubYear">2011</span>;<span class="volume">64</span>(4):380‐2. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/21185693" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=GRADE+guidelines:+a+new+series+of+articles+in+the+Journal+of+Clinical+Epidemiology&author=GH+Guyatt&author=AD+Oxman&author=HJ+Schunemann&author=P+Tugwell&author=A+Knottnerus&publication_year=2011&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD008548-bbs2-0084"> <div class="reference-title-banner"> <h4 class="title">Guyatt 2011b</h4> </div> <div class="bibliography-section" id="CD008548-bib-0091"> <div class="citation-journal">Guyatt G, Oxman AD, Akl EA, Kunz R, Vist G, Brozek J, et al. <span class="citation-title">GRADE guidelines: 1. Introduction ‐ GRADE evidence profiles and summary of findings tables</span>. <span class="citation"> Journal of Clinical Epidemiology </span><span class="pubYear">2011</span>;<span class="volume">64</span>(4):383‐94. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/21195583" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=GRADE+guidelines:+1.+Introduction+%E2%80%90+GRADE+evidence+profiles+and+summary+of+findings+tables+&author=G+Guyatt&author=AD+Oxman&author=EA+Akl&author=R+Kunz&author=G+Vist&author=J+Brozek&publication_year=2011&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD008548-bbs2-0085"> <div class="reference-title-banner"> <h4 class="title">Guyatt 2011c</h4> </div> <div class="bibliography-section" id="CD008548-bib-0092"> <div class="citation-journal">Guyatt GH, Oxman AD, Kunz R, Atkins D, Brozek J, Vist G, et al. <span class="citation-title">GRADE guidelines: 2. Framing the question and deciding on important outcomes</span>. <span class="citation"> Journal of Clinical Epidemiology </span><span class="pubYear">2011</span>;<span class="volume">64</span>(4):395‐400. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/21194891" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=GRADE+guidelines:+2.+Framing+the+question+and+deciding+on+important+outcomes&author=GH+Guyatt&author=AD+Oxman&author=R+Kunz&author=D+Atkins&author=J+Brozek&author=G+Vist&publication_year=2011&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD008548-bbs2-0086"> <div class="reference-title-banner"> <h4 class="title">Guyatt 2011d</h4> </div> <div class="bibliography-section" id="CD008548-bib-0093"> <div class="citation-journal">Guyatt GH, Oxman AD, Vist G, Kunz R, Brozek J, Alonso‐Coello P, et al. <span class="citation-title">GRADE guidelines: 4. Rating the quality of evidence ‐ study limitations (risk of bias)</span>. <span class="citation"> Journal of Clinical Epidemiology </span><span class="pubYear">2011</span>;<span class="volume">64</span>(4):407‐15. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/21247734" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=GRADE+guidelines:+4.+Rating+the+quality+of+evidence+%E2%80%90+study+limitations+(risk+of+bias)&author=GH+Guyatt&author=AD+Oxman&author=G+Vist&author=R+Kunz&author=J+Brozek&author=P+Alonso%E2%80%90Coello&publication_year=2011&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD008548-bbs2-0087"> <div class="reference-title-banner"> <h4 class="title">Guyatt 2011e</h4> </div> <div class="bibliography-section" id="CD008548-bib-0094"> <div class="citation-journal">Guyatt GH, Oxman AD, Montori V, Vist G, Kunz R, Brozek J, et al. <span class="citation-title">GRADE guidelines: 5. Rating the quality of evidence ‐ publication bias</span>. <span class="citation"> Journal of Clinical Epidemiology </span><span class="pubYear">2011</span>;<span class="volume">64</span>(12):1277‐82. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/21802904" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=GRADE+guidelines:+5.+Rating+the+quality+of+evidence+%E2%80%90+publication+bias&author=GH+Guyatt&author=AD+Oxman&author=V+Montori&author=G+Vist&author=R+Kunz&author=J+Brozek&publication_year=2011&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD008548-bbs2-0088"> <div class="reference-title-banner"> <h4 class="title">Guyatt 2011f</h4> </div> <div class="bibliography-section" id="CD008548-bib-0095"> <div class="citation-journal">Guyatt GH, Oxman AD, Kunz R, Brozek J, Alonso‐Coello P, Rind D, et al. <span class="citation-title">GRADE guidelines 6. Rating the quality of evidence ‐ imprecision</span>. <span class="citation"> Journal of Clinical Epidemiology </span><span class="pubYear">2011</span>;<span class="volume">64</span>(12):1283‐93. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/21839614" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=GRADE+guidelines+6.+Rating+the+quality+of+evidence+%E2%80%90+imprecision&author=GH+Guyatt&author=AD+Oxman&author=R+Kunz&author=J+Brozek&author=P+Alonso%E2%80%90Coello&author=D+Rind&publication_year=2011&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD008548-bbs2-0089"> <div class="reference-title-banner"> <h4 class="title">Guyatt 2011g</h4> </div> <div class="bibliography-section" id="CD008548-bib-0096"> <div class="citation-journal">Guyatt GH, Oxman AD, Kunz R, Woodcock J, Brozek J, Helfand M, et al. <span class="citation-title">GRADE guidelines: 7. Rating the quality of evidence ‐ inconsistency</span>. <span class="citation"> Journal of Clinical Epidemiology </span><span class="pubYear">2011</span>;<span class="volume">64</span>(12):1294‐302. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/21803546" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=GRADE+guidelines:+7.+Rating+the+quality+of+evidence+%E2%80%90+inconsistency&author=GH+Guyatt&author=AD+Oxman&author=R+Kunz&author=J+Woodcock&author=J+Brozek&author=M+Helfand&publication_year=2011&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD008548-bbs2-0090"> <div class="reference-title-banner"> <h4 class="title">Guyatt 2011h</h4> </div> <div class="bibliography-section" id="CD008548-bib-0097"> <div class="citation-journal">Guyatt GH, Oxman AD, Kunz R, Woodcock J, Brozek J, Helfand M, et al. <span class="citation-title">GRADE guidelines: 8. Rating the quality of evidence ‐ indirectness</span>. <span class="citation"> Journal of Clinical Epidemiology </span><span class="pubYear">2011</span>;<span class="volume">64</span>(12):1303‐10. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/21802903" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=GRADE+guidelines:+8.+Rating+the+quality+of+evidence+%E2%80%90+indirectness&author=GH+Guyatt&author=AD+Oxman&author=R+Kunz&author=J+Woodcock&author=J+Brozek&author=M+Helfand&publication_year=2011&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD008548-bbs2-0091"> <div class="reference-title-banner"> <h4 class="title">Guyatt 2011i</h4> </div> <div class="bibliography-section" id="CD008548-bib-0098"> <div class="citation-journal">Guyatt GH, Oxman AD, Sultan S, Glasziou P, Akl EA, Alonso‐Coello P, et al. <span class="citation-title">GRADE guidelines: 9. Rating up the quality of evidence</span>. <span class="citation"> Journal of Clinical Epidemiology </span><span class="pubYear">2011</span>;<span class="volume">64</span>(12):1311‐6. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/21802902" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=GRADE+guidelines:+9.+Rating+up+the+quality+of+evidence&author=GH+Guyatt&author=AD+Oxman&author=S+Sultan&author=P+Glasziou&author=EA+Akl&author=P+Alonso%E2%80%90Coello&publication_year=2011&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD008548-bbs2-0092"> <div class="reference-title-banner"> <h4 class="title">Guyatt 2012</h4> </div> <div class="bibliography-section" id="CD008548-bib-0099"> <div class="citation-journal">Guyatt G, Oxman AD, Sultan S, Brozek J, Glasziou P, Alonso‐Coello P, et al. <span class="citation-title">GRADE guidelines: 11. Making an overall rating of confidence in effect estimates for a single outcome and for all outcomes</span>. <span class="citation"> Journal of Clinical Epidemiology </span><span class="pubYear">2013</span>;<span class="volume">66</span>(2):151‐7. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/22542023" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=GRADE+guidelines:+11.+Making+an+overall+rating+of+confidence+in+effect+estimates+for+a+single+outcome+and+for+all+outcomes+&author=G+Guyatt&author=AD+Oxman&author=S+Sultan&author=J+Brozek&author=P+Glasziou&author=P+Alonso%E2%80%90Coello&publication_year=2013&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD008548-bbs2-0093"> <div class="reference-title-banner"> <h4 class="title">Habib 2010</h4> </div> <div class="bibliography-section" id="CD008548-bib-0100"> <div class="citation-journal">Habib SH, Biswas KB, Akter S, Saha S, Ali L. <span class="citation-title">Cost‐effectiveness analysis of medical intervention in patients with early detection of diabetic foot in a tertiary care hospital in Bangladesh</span>. <span class="citation"> Journal of Diabetes and its Complications </span><span class="pubYear">2010</span>;<span class="volume">24</span>(4):259‐64. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/19231246" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Cost%E2%80%90effectiveness+analysis+of+medical+intervention+in+patients+with+early+detection+of+diabetic+foot+in+a+tertiary+care+hospital+in+Bangladesh+&author=SH+Habib&author=KB+Biswas&author=S+Akter&author=S+Saha&author=L+Ali&publication_year=2010&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD008548-bbs2-0094"> <div class="reference-title-banner"> <h4 class="title">Herber 2007</h4> </div> <div class="bibliography-section" id="CD008548-bib-0101"> <div class="citation-journal">Herber OR, Schnepp W, Rieger MA. <span class="citation-title">A systematic review on the impact of leg ulceration on patients' quality of life</span>. <span class="citation"> Health and Quality of Life Outcomes </span><span class="pubYear">2007</span>;<span class="volume">25</span>:44. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=A+systematic+review+on+the+impact+of+leg+ulceration+on+patients'+quality+of+life&author=OR+Herber&author=W+Schnepp&author=MA+Rieger&publication_year=2007&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD008548-bbs2-0095"> <div class="reference-title-banner"> <h4 class="title">Higgins 2003</h4> </div> <div class="bibliography-section" id="CD008548-bib-0102"> <div class="citation-journal">Higgins JPT, Thompson SG, Deeks JJ, Altman DG. <span class="citation-title">Measuring inconsistency in meta‐analyses</span>. <span class="citation"> BMJ </span><span class="pubYear">2003</span>;<span class="volume">327</span>(7414):557‐60. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/12958120" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Measuring+inconsistency+in+meta%E2%80%90analyses&author=JPT+Higgins&author=SG+Thompson&author=JJ+Deeks&author=DG+Altman&publication_year=2003&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD008548-bbs2-0096"> <div class="reference-title-banner"> <h4 class="title">Higgins 2011</h4> </div> <div class="bibliography-section" id="CD008548-bib-0103"> <div class="citation-other">Higgins JPT, Green S (editors). <span class="citation-title"><i>Cochrane Handbook for Systematic Reviews of Interventions</i> Version 5.1.0 [updated March 2011]</span>. The Cochrane Collaboration. Available from www.cochrane‐handbook.org. <ul class="citation-link-group"> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD008548-bbs2-0097"> <div class="reference-title-banner"> <h4 class="title">Hinchliffe 2008</h4> </div> <div class="bibliography-section" id="CD008548-bib-0104"> <div class="citation-journal">Hinchliffe RJ, Valk GD, Apelqvist J, Armstrong DG, Bakker K, Game FL, et al. <span class="citation-title">A systematic review of the effectiveness of interventions to enhance the healing of chronic ulcers of the foot in diabetes</span>. <span class="citation"> Diabetes/Metabolism Research and Reviews </span><span class="pubYear">2008</span>;<span class="volume">24</span>(Suppl 1):119–44. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=A+systematic+review+of+the+effectiveness+of+interventions+to+enhance+the+healing+of+chronic+ulcers+of+the+foot+in+diabetes+&author=RJ+Hinchliffe&author=GD+Valk&author=J+Apelqvist&author=DG+Armstrong&author=K+Bakker&author=FL+Game&publication_year=2008&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD008548-bbs2-0098"> <div class="reference-title-banner"> <h4 class="title">Hollis 1999</h4> </div> <div class="bibliography-section" id="CD008548-bib-0105"> <div class="citation-journal">Hollis S, Campbell F. <span class="citation-title">What is meant by intention to treat analysis? Survey of published randomised controlled trials</span>. <span class="citation"> BMJ </span><span class="pubYear">1999</span>;<span class="volume">319</span>(7211):670‐4. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/10480822" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=What+is+meant+by+intention+to+treat+analysis?+Survey+of+published+randomised+controlled+trials+&author=S+Hollis&author=F+Campbell&publication_year=1999&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD008548-bbs2-0099"> <div class="reference-title-banner"> <h4 class="title">Humphrey 1996</h4> </div> <div class="bibliography-section" id="CD008548-bib-0106"> <div class="citation-journal">Humphrey AR, Dowse GK, Thoma K, Zimmet PZ. <span class="citation-title">Diabetes and nontraumatic lower extremity amputations. Incidence, risk factors, and prevention ‐ a 12‐year follow‐up study in Nauru</span>. <span class="citation"> Diabetes Care </span><span class="pubYear">1996</span>;<span class="volume">19</span>:710‐4. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/8799624" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Diabetes+and+nontraumatic+lower+extremity+amputations.+Incidence,+risk+factors,+and+prevention+%E2%80%90+a+12%E2%80%90year+follow%E2%80%90up+study+in+Nauru+&author=AR+Humphrey&author=GK+Dowse&author=K+Thoma&author=PZ+Zimmet&publication_year=1996&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD008548-bbs2-0100"> <div class="reference-title-banner"> <h4 class="title">ICH‐GCP 1997</h4> </div> <div class="bibliography-section" id="CD008548-bib-0107"> <div class="citation-book">International Conference on Harmonisation Expert Working Group. <span class="citation">International Conference on Harmonisation of technical requirements for registration of pharmaceuticals for human use. ICH harmonised tripartite guideline. Guideline for good clinical practice 1997 CFR &amp; ICH Guidelines</span>. Vol. <span class="volume">1</span>, PA 19063‐2043, USA: Barnett International/PAREXEL, <span class="pubYear">1997</span>. <ul class="citation-link-group"> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD008548-bbs2-0101"> <div class="reference-title-banner"> <h4 class="title">Ince 2007</h4> </div> <div class="bibliography-section" id="CD008548-bib-0108"> <div class="citation-journal">Ince P, Kendrick D, Game F, Jeffcoate W. <span class="citation-title">The association between baseline characteristics and the outcome of foot lesions in a UK population with diabetes</span>. <span class="citation"> Diabetic Medicine </span><span class="pubYear">2007</span>;<span class="volume">24</span>:977‐81. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/17559429" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=The+association+between+baseline+characteristics+and+the+outcome+of+foot+lesions+in+a+UK+population+with+diabetes+&author=P+Ince&author=D+Kendrick&author=F+Game&author=W+Jeffcoate&publication_year=2007&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD008548-bbs2-0102"> <div class="reference-title-banner"> <h4 class="title">Ince 2008</h4> </div> <div class="bibliography-section" id="CD008548-bib-0109"> <div class="citation-journal">Ince P, Abbas ZG, Lutale JK, Basit A, Ali SM, Chohan F, et al. <span class="citation-title">Use of the SINBAD classification system and score in comparing outcome of foot ulcer management on three continents</span>. <span class="citation"> Diabetes Care </span><span class="pubYear">2008</span>;<span class="volume">31</span>:964‐7. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/18299441" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Use+of+the+SINBAD+classification+system+and+score+in+comparing+outcome+of+foot+ulcer+management+on+three+continents+&author=P+Ince&author=ZG+Abbas&author=JK+Lutale&author=A+Basit&author=SM+Ali&author=F+Chohan&publication_year=2008&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD008548-bbs2-0103"> <div class="reference-title-banner"> <h4 class="title">Ioannidis 2004</h4> </div> <div class="bibliography-section" id="CD008548-bib-0110"> <div class="citation-journal">Ioannidis JP, Evans SJ, Gotzsche PC, O'Neill RT, Altman DG, Schulz K, et al. <span class="citation-title">Better reporting of harms in randomized trials: an extension of the CONSORT statement</span>. <span class="citation"> Annals of Internal Medicine </span><span class="pubYear">2004</span>;<span class="volume">141</span>(10):781‐8. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/15545678" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Better+reporting+of+harms+in+randomized+trials:+an+extension+of+the+CONSORT+statement&author=JP+Ioannidis&author=SJ+Evans&author=PC+Gotzsche&author=RT+O'Neill&author=DG+Altman&author=K+Schulz&publication_year=2004&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD008548-bbs2-0104"> <div class="reference-title-banner"> <h4 class="title">Ioannidis 2010</h4> </div> <div class="bibliography-section" id="CD008548-bib-0111"> <div class="citation-journal">Ioannidis JP. <span class="citation-title">Meta‐research: the art of getting it wrong</span>. <span class="citation"> Research Synthesis Methods </span><span class="pubYear">2010</span>;<span class="volume">1</span>(3‐4):169‐84. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/26061464" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Meta%E2%80%90research:+the+art+of+getting+it+wrong&author=JP+Ioannidis&publication_year=2010&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD008548-bbs2-0105"> <div class="reference-title-banner"> <h4 class="title">Iversen 2008</h4> </div> <div class="bibliography-section" id="CD008548-bib-0112"> <div class="citation-journal">Iversen MM, Midthjell K, Østbye T, Tell GS, Clipp E, Sloane R, et al. <span class="citation-title">History of and factors associated with diabetic foot ulcers in Norway: the Nord‐Trøndelag Health Study</span>. <span class="citation"> Scandinavian Journal of Public Health </span><span class="pubYear">2008</span>;<span class="volume">36</span>:62‐8. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/18426786" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=History+of+and+factors+associated+with+diabetic+foot+ulcers+in+Norway:+the+Nord%E2%80%90Tr%C3%B8ndelag+Health+Study+&author=MM+Iversen&author=K+Midthjell&author=T+%C3%98stbye&author=GS+Tell&author=E+Clipp&author=R+Sloane&publication_year=2008&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD008548-bbs2-0106"> <div class="reference-title-banner"> <h4 class="title">Izumi 2009</h4> </div> <div class="bibliography-section" id="CD008548-bib-0113"> <div class="citation-journal">Izumi Y, Satterfield K, Lee S, Harkless LB, Lavery LA. <span class="citation-title">Mortality of first‐time amputees in diabetics: a 10‐year observation</span>. <span class="citation"> Diabetes Research and Clinical Practice </span><span class="pubYear">2009</span>;<span class="volume">83</span>(1):126‐31. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/19097667" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Mortality+of+first%E2%80%90time+amputees+in+diabetics:+a+10%E2%80%90year+observation&author=Y+Izumi&author=K+Satterfield&author=S+Lee&author=LB+Harkless&author=LA+Lavery&publication_year=2009&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD008548-bbs2-0107"> <div class="reference-title-banner"> <h4 class="title">Jeffcoate 2003</h4> </div> <div class="bibliography-section" id="CD008548-bib-0114"> <div class="citation-journal">Jeffcoate WJ, Harding KG. <span class="citation-title">Diabetic Foot Ulcers</span>. <span class="citation"> Lancet </span><span class="pubYear">2003</span>;<span class="volume">361</span>:1545‐51. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/12737879" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Diabetic+Foot+Ulcers&author=WJ+Jeffcoate&author=KG+Harding&publication_year=2003&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD008548-bbs2-0108"> <div class="reference-title-banner"> <h4 class="title">Jeffcoate 2004</h4> </div> <div class="bibliography-section" id="CD008548-bib-0115"> <div class="citation-journal">Jeffcoate WJ, Houtum WH. <span class="citation-title">Amputation as a marker of the quality of foot care in diabetes</span>. <span class="citation"> Diabetologia </span><span class="pubYear">2004</span>;<span class="volume">47</span>:2051‐8. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/15662547" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Amputation+as+a+marker+of+the+quality+of+foot+care+in+diabetes&author=WJ+Jeffcoate&author=WH+Houtum&publication_year=2004&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD008548-bbs2-0109"> <div class="reference-title-banner"> <h4 class="title">Jeffcoate 2005</h4> </div> <div class="bibliography-section" id="CD008548-bib-0116"> <div class="citation-journal">Jeffcoate WJ. <span class="citation-title">The incidence of amputation in diabetes</span>. <span class="citation"> Acta Chirurgica Belgica </span><span class="pubYear">2005</span>;<span class="volume">105</span>:140‐2. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/15906903" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=The+incidence+of+amputation+in+diabetes&author=WJ+Jeffcoate&publication_year=2005&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD008548-bbs2-0110"> <div class="reference-title-banner"> <h4 class="title">Kanade 2007</h4> </div> <div class="bibliography-section" id="CD008548-bib-0117"> <div class="citation-journal">Kanade R, Deursen R, Burton J, Davies V, Harding K, Price P. <span class="citation-title">Re‐amputation occurrence in the diabetic population in South Wales, UK</span>. <span class="citation"> International Wound Journal </span><span class="pubYear">2007</span>;<span class="volume">4</span>:344‐52. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/17961158" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Re%E2%80%90amputation+occurrence+in+the+diabetic+population+in+South+Wales,+UK&author=R+Kanade&author=R+Deursen&author=J+Burton&author=V+Davies&author=K+Harding&author=P+Price&publication_year=2007&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD008548-bbs2-0111"> <div class="reference-title-banner"> <h4 class="title">Kinmond 2003</h4> </div> <div class="bibliography-section" id="CD008548-bib-0118"> <div class="citation-journal">Kinmond K, McGee P, Gough S, Ashford R. <span class="citation-title">'Loss of self': a psychosocial study of the quality of life of adults with diabetic foot ulceration</span>. <span class="citation"> Journal of Tisssue Viability </span><span class="pubYear">2003</span>;<span class="volume">13</span>:6‐8, 10, 12. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title='Loss+of+self':+a+psychosocial+study+of+the+quality+of+life+of+adults+with+diabetic+foot+ulceration+&author=K+Kinmond&author=P+McGee&author=S+Gough&author=R+Ashford&publication_year=2003&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD008548-bbs2-0112"> <div class="reference-title-banner"> <h4 class="title">Kirkham 2010</h4> </div> <div class="bibliography-section" id="CD008548-bib-0119"> <div class="citation-journal">Kirkham JJ, Dwan KM, Altman DG, Gamble C, Dodd S, Smyth R, et al. <span class="citation-title">The impact of outcome reporting bias in randomised controlled trials on a cohort of systematic reviews</span>. <span class="citation"> BMJ </span><span class="pubYear">2010</span>;<span class="volume">340</span>:c365. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/20156912" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=The+impact+of+outcome+reporting+bias+in+randomised+controlled+trials+on+a+cohort+of+systematic+reviews+&author=JJ+Kirkham&author=KM+Dwan&author=DG+Altman&author=C+Gamble&author=S+Dodd&author=R+Smyth&publication_year=2010&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD008548-bbs2-0113"> <div class="reference-title-banner"> <h4 class="title">Köveker 2000</h4> </div> <div class="bibliography-section" id="CD008548-bib-0120"> <div class="citation-journal">Köveker GB. <span class="citation-title">Growth factors in clinical practice</span>. <span class="citation"> International Journal of Clinical Practice </span><span class="pubYear">2000</span>;<span class="volume">54</span>:590‐3. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/11220987" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Growth+factors+in+clinical+practice&author=GB+K%C3%B6veker&publication_year=2000&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD008548-bbs2-0114"> <div class="reference-title-banner"> <h4 class="title">Lacci 2010</h4> </div> <div class="bibliography-section" id="CD008548-bib-0121"> <div class="citation-journal">Lacci KM, Dardik A. <span class="citation-title">Platelet‐rich plasma: support for its use in wound healing</span>. <span class="citation"> The Yale Journal of Biology and Medicine </span><span class="pubYear">2010</span>;<span class="volume">83</span>(1):1‐9. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/20351977" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Platelet%E2%80%90rich+plasma:+support+for+its+use+in+wound+healing&author=KM+Lacci&author=A+Dardik&publication_year=2010&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD008548-bbs2-0115"> <div class="reference-title-banner"> <h4 class="title">Lantis 2009</h4> </div> <div class="bibliography-section" id="CD008548-bib-0122"> <div class="citation-journal">Lantis JC, Boone D, Gendics C, Todd G. <span class="citation-title">Analysis of patient cost for recombinant human platelet‐derived growth factor therapy as the first‐line treatment of the insured patient with a diabetic foot ulcer</span>. <span class="citation"> Advances in Skin and Wound Care </span><span class="pubYear">2009</span>;<span class="volume">22</span>:167‐71. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/19325276" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Analysis+of+patient+cost+for+recombinant+human+platelet%E2%80%90derived+growth+factor+therapy+as+the+first%E2%80%90line+treatment+of+the+insured+patient+with+a+diabetic+foot+ulcer+&author=JC+Lantis&author=D+Boone&author=C+Gendics&author=G+Todd&publication_year=2009&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD008548-bbs2-0116"> <div class="reference-title-banner"> <h4 class="title">Lavery 1996</h4> </div> <div class="bibliography-section" id="CD008548-bib-0123"> <div class="citation-journal">Lavery LA, Armstrong DG, Harkless LB. <span class="citation-title">Classification of diabetic foot wounds</span>. <span class="citation"> The Journal of Foot and Ankle Surgery </span><span class="pubYear">1996</span>;<span class="volume">35</span>:528‐31. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/8986890" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Classification+of+diabetic+foot+wounds&author=LA+Lavery&author=DG+Armstrong&author=LB+Harkless&publication_year=1996&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD008548-bbs2-0117"> <div class="reference-title-banner"> <h4 class="title">Lavery 2008</h4> </div> <div class="bibliography-section" id="CD008548-bib-0124"> <div class="citation-journal">Lavery LA, Peters EJ, Williams JR, Murdoch DP, Hudson A, Lavery DC, International Working Group on the Diabetic Foot. <span class="citation-title">Reevaluating the way we classify the diabetic foot: restructuring the diabetic foot risk classification system of the International Working Group on the Diabetic Foot</span>. <span class="citation"> Diabetes Care </span><span class="pubYear">2008</span>;<span class="volume">31</span>:154‐6. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/17934155" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Reevaluating+the+way+we+classify+the+diabetic+foot:+restructuring+the+diabetic+foot+risk+classification+system+of+the+International+Working+Group+on+the+Diabetic+Foot+&author=LA+Lavery&author=EJ+Peters&author=JR+Williams&author=DP+Murdoch&author=A+Hudson&author=DC+Lavery&publication_year=2008&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD008548-bbs2-0118"> <div class="reference-title-banner"> <h4 class="title">Lavery 2009</h4> </div> <div class="bibliography-section" id="CD008548-bib-0125"> <div class="citation-journal">Lavery LA, Peters EJ, Armstrong DG, Wendel CS, Murdoch DP, Lipsky BA. <span class="citation-title">Risk factors for developing osteomyelitis in patients with diabetic foot wounds</span>. <span class="citation"> Diabetes Research and Clinical Practice </span><span class="pubYear">2009</span>;<span class="volume">83</span>:347‐52. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/19117631" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Risk+factors+for+developing+osteomyelitis+in+patients+with+diabetic+foot+wounds&author=LA+Lavery&author=EJ+Peters&author=DG+Armstrong&author=CS+Wendel&author=DP+Murdoch&author=BA+Lipsky&publication_year=2009&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD008548-bbs2-0119"> <div class="reference-title-banner"> <h4 class="title">Lee 1993</h4> </div> <div class="bibliography-section" id="CD008548-bib-0126"> <div class="citation-journal">Lee JS, Lu M, Lee VS, Russell D, Bahr C, Lee ET. <span class="citation-title">Lower‐extremity amputation. Incidence, risk factors, and mortality in the Oklahoma Indian Diabetes Study</span>. <span class="citation"> Diabetes </span><span class="pubYear">1993</span>;<span class="volume">42</span>:876‐82. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/8495811" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Lower%E2%80%90extremity+amputation.+Incidence,+risk+factors,+and+mortality+in+the+Oklahoma+Indian+Diabetes+Study+&author=JS+Lee&author=M+Lu&author=VS+Lee&author=D+Russell&author=C+Bahr&author=ET+Lee&publication_year=1993&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD008548-bbs2-0120"> <div class="reference-title-banner"> <h4 class="title">Lefevbre 2011</h4> </div> <div class="bibliography-section" id="CD008548-bib-0127"> <div class="citation-other">Lefebvre C, Manheimer E, Glanville J, on behalf of the Cochrane Information Retrieval Methods Group. <span class="citation-title">Chapter 6: Searching for studies. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.1 (updated March 2011). The Cochrane Collaboration, 2011</span>. Available from www.cochrane‐handbook.org. <ul class="citation-link-group"> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD008548-bbs2-0121"> <div class="reference-title-banner"> <h4 class="title">Lehto 1996</h4> </div> <div class="bibliography-section" id="CD008548-bib-0128"> <div class="citation-journal">Lehto S, Rönnemaa T, Pyörälä K, Laakso M. <span class="citation-title">Risk factors predicting lower extremity amputations in patients with NIDDM</span>. <span class="citation"> Diabetes Care </span><span class="pubYear">1996</span>;<span class="volume">19</span>:607‐12. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/8725860" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Risk+factors+predicting+lower+extremity+amputations+in+patients+with+NIDDM&author=S+Lehto&author=T+R%C3%B6nnemaa&author=K+Py%C3%B6r%C3%A4l%C3%A4&author=M+Laakso&publication_year=1996&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD008548-bbs2-0122"> <div class="reference-title-banner"> <h4 class="title">Leymarie 2005</h4> </div> <div class="bibliography-section" id="CD008548-bib-0129"> <div class="citation-journal">Leymarie F, Richard JL, Malgrange D. <span class="citation-title">Factors associated with diabetic patients at high risk for foot ulceration</span>. <span class="citation"> Diabetes and Metabolism </span><span class="pubYear">2005</span>;<span class="volume">31</span>:603‐5. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/16357811" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Factors+associated+with+diabetic+patients+at+high+risk+for+foot+ulceration&author=F+Leymarie&author=JL+Richard&author=D+Malgrange&publication_year=2005&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD008548-bbs2-0123"> <div class="reference-title-banner"> <h4 class="title">Lipsky 2004</h4> </div> <div class="bibliography-section" id="CD008548-bib-0130"> <div class="citation-journal">Lipsky BA, Berendt AR, Deery HG, Embil JM, Joseph WS, Karchmer AW, Infectious Diseases Society of America. <span class="citation-title">Diagnosis and treatment of diabetic foot infections</span>. <span class="citation"> Clinical Infectious Disease </span><span class="pubYear">2004</span>;<span class="volume">39</span>:885‐910. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Diagnosis+and+treatment+of+diabetic+foot+infections&author=BA+Lipsky&author=AR+Berendt&author=HG+Deery&author=JM+Embil&author=WS+Joseph&author=AW+Karchmer&publication_year=2004&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD008548-bbs2-0124"> <div class="reference-title-banner"> <h4 class="title">McKinney 2012</h4> </div> <div class="bibliography-section" id="CD008548-bib-0131"> <div class="citation-other">McKinney M. <span class="citation-title">'Time is of the essence'. PCORI moves to implement comparative effectiveness research, funding</span>. Modern Healthcare<span class="pubYear">2012</span>; Vol. 42, issue 5:12‐3. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title='Time+is+of+the+essence'.+PCORI+moves+to+implement+comparative+effectiveness+research,+funding+&author=M+McKinney&publication_year=2012&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD008548-bbs2-0125"> <div class="reference-title-banner"> <h4 class="title">Meatherall 2005</h4> </div> <div class="bibliography-section" id="CD008548-bib-0132"> <div class="citation-journal">Meatherall BL, Garrett MR, Kaufert J, Martin BD, Fricke MW, Arneja AS, et al. <span class="citation-title">Disability and quality of life in Canadian aboriginal and non‐aboriginal diabetic lower‐extremity amputees</span>. <span class="citation"> Archives of Physical Medicine and Rehabilitation </span><span class="pubYear">2005</span>;<span class="volume">86</span>:1594‐602. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/16084813" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Disability+and+quality+of+life+in+Canadian+aboriginal+and+non%E2%80%90aboriginal+diabetic+lower%E2%80%90extremity+amputees+&author=BL+Meatherall&author=MR+Garrett&author=J+Kaufert&author=BD+Martin&author=MW+Fricke&author=AS+Arneja&publication_year=2005&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD008548-bbs2-0126"> <div class="reference-title-banner"> <h4 class="title">Milman 2001</h4> </div> <div class="bibliography-section" id="CD008548-bib-0133"> <div class="citation-journal">Milman MHSA, Leme CBM, Borelli DT, Kater FR, Baccili ECDC, Rocha RCM, et al. <span class="citation-title">Diabetic foot: evaluation of evolution and hospital cost of hospitalized patients in Conjunto Hospitalar de Sorocaba</span>. <span class="citation"> Arquivos Brasileiros de Endocrinologia e Metabologia </span><span class="pubYear">2001</span>;<span class="volume">45</span>:447‐51. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Diabetic+foot:+evaluation+of+evolution+and+hospital+cost+of+hospitalized+patients+in+Conjunto+Hospitalar+de+Sorocaba+&author=MHSA+Milman&author=CBM+Leme&author=DT+Borelli&author=FR+Kater&author=ECDC+Baccili&author=RCM+Rocha&publication_year=2001&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD008548-bbs2-0127"> <div class="reference-title-banner"> <h4 class="title">Moher 2010</h4> </div> <div class="bibliography-section" id="CD008548-bib-0134"> <div class="citation-journal">Moher D, Hopewell S, Schulz KF, Montori V, Gotzsche PC, Devereaux PJ. <span class="citation-title">CONSORT 2010 explanation and elaboration: updated guidelines for reporting parallel group randomised trials</span>. <span class="citation"> BMJ </span><span class="pubYear">2010</span>;<span class="volume">340</span>:c869. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/20332511" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=CONSORT+2010+explanation+and+elaboration:+updated+guidelines+for+reporting+parallel+group+randomised+trials+&author=D+Moher&author=S+Hopewell&author=KF+Schulz&author=V+Montori&author=PC+Gotzsche&author=PJ+Devereaux&publication_year=2010&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD008548-bbs2-0128"> <div class="reference-title-banner"> <h4 class="title">Moss 1996</h4> </div> <div class="bibliography-section" id="CD008548-bib-0135"> <div class="citation-journal">Moss SE, Klein R, Klein BE. <span class="citation-title">Long‐term incidence of lower‐extremity amputations in a diabetic population</span>. <span class="citation"> Archives of Family Medicine </span><span class="pubYear">1996</span>;<span class="volume">5</span>:391‐8. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/8664997" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Long%E2%80%90term+incidence+of+lower%E2%80%90extremity+amputations+in+a+diabetic+population&author=SE+Moss&author=R+Klein&author=BE+Klein&publication_year=1996&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD008548-bbs2-0129"> <div class="reference-title-banner"> <h4 class="title">Nabuurs‐Frassen 2005</h4> </div> <div class="bibliography-section" id="CD008548-bib-0136"> <div class="citation-journal">Nabuurs‐Franssen MH, Huijberts MS, Nieuwenhuijzen Kruseman AC, Willems J, Schaper NC. <span class="citation-title">Health‐related quality of life of diabetic foot ulcer patients and their caregivers</span>. <span class="citation"> Diabetologia </span><span class="pubYear">2005</span>;<span class="volume">48</span>:1906‐10. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/15995846" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Health%E2%80%90related+quality+of+life+of+diabetic+foot+ulcer+patients+and+their+caregivers&author=MH+Nabuurs%E2%80%90Franssen&author=MS+Huijberts&author=AC+NieuwenhuijzenKruseman&author=J+Willems&author=NC+Schaper&publication_year=2005&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD008548-bbs2-0130"> <div class="reference-title-banner"> <h4 class="title">Nelson 1988</h4> </div> <div class="bibliography-section" id="CD008548-bib-0137"> <div class="citation-journal">Nelson RG, Gohdes DM, Everhart JE, Hartner JA, Zwemer FL, Pettitt DJ, et al. <span class="citation-title">Lower‐extremity amputations in NIDDM. 12‐year follow‐up study in Pima Indians</span>. <span class="citation"> Diabetes Care </span><span class="pubYear">1988</span>;<span class="volume">11</span>:8‐16. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/3338381" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Lower%E2%80%90extremity+amputations+in+NIDDM.+12%E2%80%90year+follow%E2%80%90up+study+in+Pima+Indians&author=RG+Nelson&author=DM+Gohdes&author=JE+Everhart&author=JA+Hartner&author=FL+Zwemer&author=DJ+Pettitt&publication_year=1988&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD008548-bbs2-0131"> <div class="reference-title-banner"> <h4 class="title">O'Meara 2000</h4> </div> <div class="bibliography-section" id="CD008548-bib-0138"> <div class="citation-journal">O'Meara S, Cullum N, Majid M, Sheldon T. <span class="citation-title">Systematic reviews of wound care management: (3) antimicrobial agents for chronic wounds; (4) diabetic foot ulceration</span>. <span class="citation"> Health Technology Assessment </span><span class="pubYear">2000</span>;<span class="volume">4</span>(21):1‐237. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Systematic+reviews+of+wound+care+management:+(3)+antimicrobial+agents+for+chronic+wounds;+(4)+diabetic+foot+ulceration+&author=S+O'Meara&author=N+Cullum&author=M+Majid&author=T+Sheldon&publication_year=2000&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD008548-bbs2-0132"> <div class="reference-title-banner"> <h4 class="title">Oyibo 2001</h4> </div> <div class="bibliography-section" id="CD008548-bib-0139"> <div class="citation-journal">Oyibo SO, Jude EB, Tarawneh I, Nguyen HC, Armstrong DG, Harkless LB. <span class="citation-title">The effects of ulcer size and site, patient’s age, sex and type and duration of diabetes on the outcome of diabetic foot ulcers</span>. <span class="citation"> Diabetic Medicine </span><span class="pubYear">2001</span>;<span class="volume">18</span>:133‐8. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/11251677" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=The+effects+of+ulcer+size+and+site,+patient%E2%80%99s+age,+sex+and+type+and+duration+of+diabetes+on+the+outcome+of+diabetic+foot+ulcers+&author=SO+Oyibo&author=EB+Jude&author=I+Tarawneh&author=HC+Nguyen&author=DG+Armstrong&author=LB+Harkless&publication_year=2001&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD008548-bbs2-0133"> <div class="reference-title-banner"> <h4 class="title">Papanas 2007</h4> </div> <div class="bibliography-section" id="CD008548-bib-0140"> <div class="citation-journal">Papanas N, Maltezos E. <span class="citation-title">Growth factors in the treatment of diabetic foot ulcers: new technologies, any promises?</span>. <span class="citation"> The International Journal of Lower Extremity Wounds </span><span class="pubYear">2007</span>;<span class="volume">6</span>:37‐53. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/17344201" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Growth+factors+in+the+treatment+of+diabetic+foot+ulcers:+new+technologies,+any+promises?&author=N+Papanas&author=E+Maltezos&publication_year=2007&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD008548-bbs2-0134"> <div class="reference-title-banner"> <h4 class="title">Papanas 2008</h4> </div> <div class="bibliography-section" id="CD008548-bib-0141"> <div class="citation-journal">Papanas N, Maltezos E. <span class="citation-title">Becaplermin gel in the treatment of diabetic neuropathic foot ulcers</span>. <span class="citation"> Clinical Interventions in Aging </span><span class="pubYear">2008</span>;<span class="volume">3</span>:233‐40. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/18686746" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Becaplermin+gel+in+the+treatment+of+diabetic+neuropathic+foot+ulcers&author=N+Papanas&author=E+Maltezos&publication_year=2008&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD008548-bbs2-0135"> <div class="reference-title-banner"> <h4 class="title">Papanas 2010</h4> </div> <div class="bibliography-section" id="CD008548-bib-0142"> <div class="citation-journal">Papanas N, Maltezos E. <span class="citation-title">Benefit‐risk assessment of becaplermin in the treatment of diabetic foot ulcers</span>. <span class="citation"> Drug Safety </span><span class="pubYear">2010</span>;<span class="volume">33</span>(6):455‐61. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/20486728" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Benefit%E2%80%90risk+assessment+of+becaplermin+in+the+treatment+of+diabetic+foot+ulcers&author=N+Papanas&author=E+Maltezos&publication_year=2010&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD008548-bbs2-0136"> <div class="reference-title-banner"> <h4 class="title">PCORI 2012</h4> </div> <div class="bibliography-section" id="CD008548-bib-0143"> <div class="citation-other">Patient‐Centered Outcomes Research Institute (PCORI). <span class="citation-title">Preliminary draft methodology report: 'Our questions, our decisions: Standards for patient‐centered outcomes research'</span>. http://www.pcori.org/assets/Preliminary‐Draft‐Methodology‐Report.pdf (accessed 2 August 2012). <ul class="citation-link-group"> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD008548-bbs2-0137"> <div class="reference-title-banner"> <h4 class="title">Porta 2008</h4> </div> <div class="bibliography-section" id="CD008548-bib-0144"> <div class="citation-book">Porta M. <span class="citation">A Dictionary of Epidemiology</span>. Fifth. New York: Oxford University Press, <span class="pubYear">2008</span>. <ul class="citation-link-group"> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD008548-bbs2-0138"> <div class="reference-title-banner"> <h4 class="title">Pradhan 2009</h4> </div> <div class="bibliography-section" id="CD008548-bib-0145"> <div class="citation-journal">Pradhan L, Nabzdyk C, Andersen ND, LoGerfo FW, Veves A. <span class="citation-title">Inflammation and neuropeptides: the connection in diabetic wound healing</span>. <span class="citation"> Expert Reviews in Molecular Medicine </span><span class="pubYear">2009</span>;<span class="volume">11</span>:e2. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/19138453" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Inflammation+and+neuropeptides:+the+connection+in+diabetic+wound+healing&author=L+Pradhan&author=C+Nabzdyk&author=ND+Andersen&author=FW+LoGerfo&author=A+Veves&publication_year=2009&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD008548-bbs2-0139"> <div class="reference-title-banner"> <h4 class="title">Price 2004</h4> </div> <div class="bibliography-section" id="CD008548-bib-0146"> <div class="citation-journal">Price P. <span class="citation-title">The diabetic foot: quality of life</span>. <span class="citation"> Clinical Infectious Diseases </span><span class="pubYear">2004</span>;<span class="volume">39</span>(Suppl 2):129‐31. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/15206064" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=The+diabetic+foot:+quality+of+life&author=P+Price&publication_year=2004&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD008548-bbs2-0140"> <div class="reference-title-banner"> <h4 class="title">Quattrini 2008</h4> </div> <div class="bibliography-section" id="CD008548-bib-0147"> <div class="citation-journal">Quattrini C, Jeziorska M, Boulton AJ, Malik RA. <span class="citation-title">Reduced vascular endothelial growth factor expression and intra‐epidermal nerve fiber loss in human diabetic neuropathy</span>. <span class="citation"> Diabetes Care </span><span class="pubYear">2008</span>;<span class="volume">31</span>:140‐5. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/17934147" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Reduced+vascular+endothelial+growth+factor+expression+and+intra%E2%80%90epidermal+nerve+fiber+loss+in+human+diabetic+neuropathy+&author=C+Quattrini&author=M+Jeziorska&author=AJ+Boulton&author=RA+Malik&publication_year=2008&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD008548-bbs2-0141"> <div class="reference-title-banner"> <h4 class="title">Ramsey 1999</h4> </div> <div class="bibliography-section" id="CD008548-bib-0148"> <div class="citation-journal">Ramsey SD, Newton K, Blough D, McCulloch DK, Sandhu N, Reiber GE, et al. <span class="citation-title">Incidence, outcomes, and cost of foot ulcers in patients with diabetes</span>. <span class="citation"> Diabetes Care </span><span class="pubYear">1999</span>;<span class="volume">22</span>:382‐7. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/10097914" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Incidence,+outcomes,+and+cost+of+foot+ulcers+in+patients+with+diabetes&author=SD+Ramsey&author=K+Newton&author=D+Blough&author=DK+McCulloch&author=N+Sandhu&author=GE+Reiber&publication_year=1999&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD008548-bbs2-0142"> <div class="reference-title-banner"> <h4 class="title">Rathur 2007</h4> </div> <div class="bibliography-section" id="CD008548-bib-0149"> <div class="citation-journal">Rathur HM, Boulton AJ. <span class="citation-title">The diabetic foot</span>. <span class="citation"> Clinics in Dermatology </span><span class="pubYear">2007</span>;<span class="volume">25</span>:109‐20. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/17276208" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=The+diabetic+foot&author=HM+Rathur&author=AJ+Boulton&publication_year=2007&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD008548-bbs2-0143"> <div class="reference-title-banner"> <h4 class="title">Redekop 2004</h4> </div> <div class="bibliography-section" id="CD008548-bib-0150"> <div class="citation-journal">Redekop WK, Stolk EA, Kok E, Lovas K, Kalo Z, Busschbach JJ. <span class="citation-title">Diabetic foot ulcers and amputations: estimates of health utility for use in cost‐effectiveness analyses of new treatments</span>. <span class="citation"> Diabetes and Metabolism </span><span class="pubYear">2004</span>;<span class="volume">30</span>:549‐56. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/15671925" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Diabetic+foot+ulcers+and+amputations:+estimates+of+health+utility+for+use+in+cost%E2%80%90effectiveness+analyses+of+new+treatments+&author=WK+Redekop&author=EA+Stolk&author=E+Kok&author=K+Lovas&author=Z+Kalo&author=JJ+Busschbach&publication_year=2004&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD008548-bbs2-0144"> <div class="reference-title-banner"> <h4 class="title">Ribu 2008</h4> </div> <div class="bibliography-section" id="CD008548-bib-0151"> <div class="citation-journal">Ribu L, Birkeland K, Hanestad BR, Moum T, Rustoen T. <span class="citation-title">A longitudinal study of patients with diabetes and foot ulcers and their health‐related quality of life: wound healing and quality‐of‐life changes</span>. <span class="citation"> Journal of Diabetes Complications </span><span class="pubYear">2008</span>;<span class="volume">22</span>:400‐7. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=A+longitudinal+study+of+patients+with+diabetes+and+foot+ulcers+and+their+health%E2%80%90related+quality+of+life:+wound+healing+and+quality%E2%80%90of%E2%80%90life+changes+&author=L+Ribu&author=K+Birkeland&author=BR+Hanestad&author=T+Moum&author=T+Rustoen&publication_year=2008&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD008548-bbs2-0145"> <div class="reference-title-banner"> <h4 class="title">Richard 2008</h4> </div> <div class="bibliography-section" id="CD008548-bib-0152"> <div class="citation-journal">Richard JL, Schuldiner S. <span class="citation-title">Epidemiology of diabetic foot problems</span> [Épidémiologie du pied diabétique]. <span class="citation"> La Revue Médicine Interne </span><span class="pubYear">2008</span>;<span class="volume">29</span>(Suppl 2):222‐30. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Epidemiology+of+diabetic+foot+problems&author=JL+Richard&author=S+Schuldiner&publication_year=2008&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD008548-bbs2-0146"> <div class="reference-title-banner"> <h4 class="title">Rith‐Najarian 1992</h4> </div> <div class="bibliography-section" id="CD008548-bib-0153"> <div class="citation-journal">Rith‐Najarian SJ, Stolusky T, Gohdes DM. <span class="citation-title">Identifying diabetic patients at high risk for lower‐extremity amputation in a primary health care setting. A prospective evaluation of simple screening criteria</span>. <span class="citation"> Diabetes Care </span><span class="pubYear">1992</span>;<span class="volume">15</span>:1386‐9. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/1425105" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Identifying+diabetic+patients+at+high+risk+for+lower%E2%80%90extremity+amputation+in+a+primary+health+care+setting.+A+prospective+evaluation+of+simple+screening+criteria+&author=SJ+Rith%E2%80%90Najarian&author=T+Stolusky&author=DM+Gohdes&publication_year=1992&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD008548-bbs2-0147"> <div class="reference-title-banner"> <h4 class="title">Rozman 2007</h4> </div> <div class="bibliography-section" id="CD008548-bib-0154"> <div class="citation-journal">Rozman P, Bolta Z. <span class="citation-title">Use of platelet growth factors in treating wounds and soft‐tissue injuries</span>. <span class="citation"> Acta Dermatovenerologica Alpina, Panonica, et Adriatica </span><span class="pubYear">2007</span>;<span class="volume">16</span>(4):156‐65. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Use+of+platelet+growth+factors+in+treating+wounds+and+soft%E2%80%90tissue+injuries&author=P+Rozman&author=Z+Bolta&publication_year=2007&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD008548-bbs2-0148"> <div class="reference-title-banner"> <h4 class="title">Schaper 2004</h4> </div> <div class="bibliography-section" id="CD008548-bib-0155"> <div class="citation-journal">Schaper NC. <span class="citation-title">Diabetic foot ulcer classification system for research purposes: a progress report on criteria for including patients in research studies</span>. <span class="citation"> Diabetes/Metabolism Research and Reviews </span><span class="pubYear">2004</span>;<span class="volume">20</span>(Suppl 1):90‐5. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Diabetic+foot+ulcer+classification+system+for+research+purposes:+a+progress+report+on+criteria+for+including+patients+in+research+studies+&author=NC+Schaper&publication_year=2004&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD008548-bbs2-0149"> <div class="reference-title-banner"> <h4 class="title">Schaper 2012a</h4> </div> <div class="bibliography-section" id="CD008548-bib-0156"> <div class="citation-journal">Schaper NC, Apelqvist J, Bakker K. <span class="citation-title">Reducing lower leg amputations in diabetes: a challenge for patients, healthcare providers and the healthcare system</span>. <span class="citation"> Diabetologia </span><span class="pubYear">2012</span>;<span class="volume">55</span>(7):1869‐72. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/22622617" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Reducing+lower+leg+amputations+in+diabetes:+a+challenge+for+patients,+healthcare+providers+and+the+healthcare+system+&author=NC+Schaper&author=J+Apelqvist&author=K+Bakker&publication_year=2012&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD008548-bbs2-0150"> <div class="reference-title-banner"> <h4 class="title">Schaper 2012b</h4> </div> <div class="bibliography-section" id="CD008548-bib-0157"> <div class="citation-journal">Schaper NC, Andros G, Apelqvist J, Bakker K, Lammer J, Lepantalo M, et al. <span class="citation-title">Diagnosis and treatment of peripheral arterial disease in diabetic patients with a foot ulcer. A progress report of the International Working Group on the Diabetic Foot</span>. <span class="citation"> Diabetes/Metabolism Research and Reviews </span><span class="pubYear">2012</span>;<span class="volume">28</span>(Suppl 1):218‐24. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Diagnosis+and+treatment+of+peripheral+arterial+disease+in+diabetic+patients+with+a+foot+ulcer.+A+progress+report+of+the+International+Working+Group+on+the+Diabetic+Foot+&author=NC+Schaper&author=G+Andros&author=J+Apelqvist&author=K+Bakker&author=J+Lammer&author=M+Lepantalo&publication_year=2012&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD008548-bbs2-0151"> <div class="reference-title-banner"> <h4 class="title">Schulz 2010</h4> </div> <div class="bibliography-section" id="CD008548-bib-0158"> <div class="citation-journal">Schulz KF, Altman DG, Moher D, CONSORT Group. <span class="citation-title">CONSORT 2010 Statement: Updated guidelines for reporting parallel group randomised trials</span>. <span class="citation"> Journal of Clinical Epidemiology </span><span class="pubYear">2010</span>;<span class="volume">63</span>(8):834‐40. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/20346629" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=CONSORT+2010+Statement:+Updated+guidelines+for+reporting+parallel+group+randomised+trials+&author=KF+Schulz&author=DG+Altman&author=D+Moher&publication_year=2010&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD008548-bbs2-0152"> <div class="reference-title-banner"> <h4 class="title">Selby 2012</h4> </div> <div class="bibliography-section" id="CD008548-bib-0159"> <div class="citation-journal">Selby JV, Beal AC, Frank L. <span class="citation-title">The Patient‐Centered Outcomes Research Institute (PCORI) national priorities for research and initial research agenda</span>. <span class="citation"> JAMA </span><span class="pubYear">2012</span>;<span class="volume">307</span>(15):1583‐4. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/22511682" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=The+Patient%E2%80%90Centered+Outcomes+Research+Institute+(PCORI)+national+priorities+for+research+and+initial+research+agenda+&author=JV+Selby&author=AC+Beal&author=L+Frank&publication_year=2012&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD008548-bbs2-0153"> <div class="reference-title-banner"> <h4 class="title">Sheehan 2006</h4> </div> <div class="bibliography-section" id="CD008548-bib-0160"> <div class="citation-journal">Sheehan P, Jones P, Giurini JM, Caselli A, Veves A. <span class="citation-title">Percent change in wound area of diabetic foot ulcers over a 4‐week period is a robust predictor of complete healing in a 12‐week prospective trial</span>. <span class="citation"> Plastic and Reconstructive Surgery </span><span class="pubYear">2006</span>;<span class="volume">117(7 Suppl)</span>:239‐44. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Percent+change+in+wound+area+of+diabetic+foot+ulcers+over+a+4%E2%80%90week+period+is+a+robust+predictor+of+complete+healing+in+a+12%E2%80%90week+prospective+trial+&author=P+Sheehan&author=P+Jones&author=JM+Giurini&author=A+Caselli&author=A+Veves&publication_year=2006&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD008548-bbs2-0154"> <div class="reference-title-banner"> <h4 class="title">Sibbald 2008</h4> </div> <div class="bibliography-section" id="CD008548-bib-0161"> <div class="citation-journal">Sibbald RG, Woo KY. <span class="citation-title">The biology of chronic foot ulcers in persons with diabetes</span>. <span class="citation"> Diabetes/Metabolism Research and Reviews </span><span class="pubYear">2008</span>;<span class="volume">24</span>(Suppl 1):25‐30. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=The+biology+of+chronic+foot+ulcers+in+persons+with+diabetes&author=RG+Sibbald&author=KY+Woo&publication_year=2008&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD008548-bbs2-0155"> <div class="reference-title-banner"> <h4 class="title">SIGN 2010</h4> </div> <div class="bibliography-section" id="CD008548-bib-0162"> <div class="citation-other">Scottish Intercollegiate Guidelines Network (SIGN). <span class="citation-title">Search filters</span>. http://www.sign.ac.uk/methodology/filters.html#random (accessed 12 March 2010). <ul class="citation-link-group"> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD008548-bbs2-0156"> <div class="reference-title-banner"> <h4 class="title">Siriwardana 2007</h4> </div> <div class="bibliography-section" id="CD008548-bib-0163"> <div class="citation-journal">Siriwardana HD, Weerasekera D. <span class="citation-title">The cost of diabetic foot conditions</span>. <span class="citation"> The Ceylon Medical Journal </span><span class="pubYear">2007</span>;<span class="volume">52</span>:89‐91. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/18020025" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=The+cost+of+diabetic+foot+conditions&author=HD+Siriwardana&author=D+Weerasekera&publication_year=2007&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD008548-bbs2-0157"> <div class="reference-title-banner"> <h4 class="title">Skoutas 2009</h4> </div> <div class="bibliography-section" id="CD008548-bib-0164"> <div class="citation-journal">Skoutas D, Papanas N, Georgiadis GS, Zervas V, Manes C, Maltezos E, et al. <span class="citation-title">Risk factors for ipsilateral reamputation in patients with diabetic foot lesions</span>. <span class="citation"> The International Journal of Lower Extremity Wounds </span><span class="pubYear">2009</span>;<span class="volume">8</span>:69‐74. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/19443895" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Risk+factors+for+ipsilateral+reamputation+in+patients+with+diabetic+foot+lesions&author=D+Skoutas&author=N+Papanas&author=GS+Georgiadis&author=V+Zervas&author=C+Manes&author=E+Maltezos&publication_year=2009&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD008548-bbs2-0158"> <div class="reference-title-banner"> <h4 class="title">Smith 2004</h4> </div> <div class="bibliography-section" id="CD008548-bib-0165"> <div class="citation-journal">Smith D, Cullen MJ, Nolan JJ. <span class="citation-title">The cost of managing diabetic foot ulceration in an Irish hospital</span>. <span class="citation"> Irish Journal of Medical Science </span><span class="pubYear">2004</span>;<span class="volume">173</span>:89‐92. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/15540710" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=The+cost+of+managing+diabetic+foot+ulceration+in+an+Irish+hospital&author=D+Smith&author=MJ+Cullen&author=JJ+Nolan&publication_year=2004&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD008548-bbs2-0159"> <div class="reference-title-banner"> <h4 class="title">Smyth 2009</h4> </div> <div class="bibliography-section" id="CD008548-bib-0166"> <div class="citation-journal">Smyth SS, McEver RP, Weyrich AS, Morrell CN, Hoffman MR, Arepally GM, et al. <span class="citation-title">Platelet functions beyond hemostasis</span>. <span class="citation"> Journal of Thrombosis and Haemotasis </span><span class="pubYear">2009</span>;<span class="volume">7</span>(11):1759‐66. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Platelet+functions+beyond+hemostasis&author=SS+Smyth&author=RP+McEver&author=AS+Weyrich&author=CN+Morrell&author=MR+Hoffman&author=GM+Arepally&publication_year=2009&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD008548-bbs2-0160"> <div class="reference-title-banner"> <h4 class="title">Sterne 2011</h4> </div> <div class="bibliography-section" id="CD008548-bib-0167"> <div class="citation-journal">Sterne JA, Sutton AJ, Ioannidis JP, Terrin N, Jones DR, Lau J, et al. <span class="citation-title">Recommendations for examining and interpreting funnel plot asymmetry in meta‐analyses of randomised controlled trials</span>. <span class="citation"> BMJ </span><span class="pubYear">2011</span>;<span class="volume">343</span>:d4002. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/21784880" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Recommendations+for+examining+and+interpreting+funnel+plot+asymmetry+in+meta%E2%80%90analyses+of+randomised+controlled+trials+&author=JA+Sterne&author=AJ+Sutton&author=JP+Ioannidis&author=N+Terrin&author=DR+Jones&author=J+Lau&publication_year=2011&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD008548-bbs2-0161"> <div class="reference-title-banner"> <h4 class="title">Szabo 2009</h4> </div> <div class="bibliography-section" id="CD008548-bib-0168"> <div class="citation-journal">Szabo C. <span class="citation-title">Role of nitrosative stress in the pathogenesis of diabetic vascular dysfunction</span>. <span class="citation"> British Journal of Pharmacology </span><span class="pubYear">2009</span>;<span class="volume">156</span>:713‐27. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/19210748" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Role+of+nitrosative+stress+in+the+pathogenesis+of+diabetic+vascular+dysfunction&author=C+Szabo&publication_year=2009&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD008548-bbs2-0162"> <div class="reference-title-banner"> <h4 class="title">Valensi 2007</h4> </div> <div class="bibliography-section" id="CD008548-bib-0169"> <div class="citation-journal">Valensi P, Girod I, Baron F, Moreau‐Defarges T, Guillon P. <span class="citation-title">Quality of life and clinical correlates in patients with diabetic foot ulcers</span>. <span class="citation"> Diabetes and Metabolism </span><span class="pubYear">2005</span>;<span class="volume">31</span>(3 Pt 1):263‐71. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/16142017" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Quality+of+life+and+clinical+correlates+in+patients+with+diabetic+foot+ulcers&author=P+Valensi&author=I+Girod&author=F+Baron&author=T+Moreau%E2%80%90Defarges&author=P+Guillon&publication_year=2005&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD008548-bbs2-0163"> <div class="reference-title-banner"> <h4 class="title">Van Acker 2000</h4> </div> <div class="bibliography-section" id="CD008548-bib-0170"> <div class="citation-journal">Acker K, Oleen‐Burkey M, Decker L, Vanmaele R, Schil P, Matricali G, et al. <span class="citation-title">Cost and resource utilization for prevention and treatment of foot lesions in a diabetic foot clinic in Belgium</span>. <span class="citation"> Diabetes Research and Clinical Practice </span><span class="pubYear">2000</span>;<span class="volume">50</span>:87‐95. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/10960718" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Cost+and+resource+utilization+for+prevention+and+treatment+of+foot+lesions+in+a+diabetic+foot+clinic+in+Belgium+&author=K+Acker&author=M+Oleen%E2%80%90Burkey&author=L+Decker&author=R+Vanmaele&author=P+Schil&author=G+Matricali&publication_year=2000&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD008548-bbs2-0164"> <div class="reference-title-banner"> <h4 class="title">Van Houtum 2008</h4> </div> <div class="bibliography-section" id="CD008548-bib-0171"> <div class="citation-journal">Houtum WH. <span class="citation-title">Amputations and ulceration; pitfalls in assessing incidence</span>. <span class="citation"> Diabetes/Metabolism Research and Reviews </span><span class="pubYear">2008</span>;<span class="volume">24</span>(Suppl 1):14‐8. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Amputations+and+ulceration;+pitfalls+in+assessing+incidence&author=WH+Houtum&publication_year=2008&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD008548-bbs2-0165"> <div class="reference-title-banner"> <h4 class="title">Veves 1992</h4> </div> <div class="bibliography-section" id="CD008548-bib-0172"> <div class="citation-journal">Veves A, Murray HJ, Young MJ, Boulton AJ. <span class="citation-title">The risk of foot ulceration in diabetic patients with high foot pressure: a prospective study</span>. <span class="citation"> Diabetologia </span><span class="pubYear">1992</span>;<span class="volume">35</span>:660‐3. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/1644245" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=The+risk+of+foot+ulceration+in+diabetic+patients+with+high+foot+pressure:+a+prospective+study+&author=A+Veves&author=HJ+Murray&author=MJ+Young&author=AJ+Boulton&publication_year=1992&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD008548-bbs2-0166"> <div class="reference-title-banner"> <h4 class="title">Viswanathan 2005</h4> </div> <div class="bibliography-section" id="CD008548-bib-0173"> <div class="citation-journal">Viswanathan V, Thomas N, Tandon N, Asirvatham A, Rajasekar S, Ramachandran A, et al. <span class="citation-title">Profile of diabetic foot complications and its associated complications ‐ a multicentric study from India</span>. <span class="citation"> The Journal of Association Physicians of India </span><span class="pubYear">2005</span>;<span class="volume">53</span>:933‐6. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Profile+of+diabetic+foot+complications+and+its+associated+complications+%E2%80%90+a+multicentric+study+from+India+&author=V+Viswanathan&author=N+Thomas&author=N+Tandon&author=A+Asirvatham&author=S+Rajasekar&author=A+Ramachandran&publication_year=2005&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD008548-bbs2-0167"> <div class="reference-title-banner"> <h4 class="title">Viswanathan 2006</h4> </div> <div class="bibliography-section" id="CD008548-bib-0174"> <div class="citation-journal">Viswanathan V, Pendsey S. <span class="citation-title">A phase III study to evaluate the safety and efficacy of recombinant human epidermal growth factor (REGEN‐D<sup>TM</sup> 150) in healing diabetic foot ulcers</span>. <span class="citation"> Wounds </span><span class="pubYear">2006</span>;<span class="volume">18</span>:186‐96. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=A+phase+III+study+to+evaluate+the+safety+and+efficacy+of+recombinant+human+epidermal+growth+factor+(REGEN%E2%80%90DTM+150)+in+healing+diabetic+foot+ulcers+&author=V+Viswanathan&author=S+Pendsey&publication_year=2006&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD008548-bbs2-0168"> <div class="reference-title-banner"> <h4 class="title">Wagner 1981</h4> </div> <div class="bibliography-section" id="CD008548-bib-0175"> <div class="citation-journal">Wagner FW. <span class="citation-title">The dysvascular foot: a system of diagnosis and treatment</span>. <span class="citation"> Foot and Ankle International </span><span class="pubYear">1981</span>;<span class="volume">2</span>:64‐122. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=The+dysvascular+foot:+a+system+of+diagnosis+and+treatment&author=FW+Wagner&publication_year=1981&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD008548-bbs2-0169"> <div class="reference-title-banner"> <h4 class="title">Weinberg 2003</h4> </div> <div class="bibliography-section" id="CD008548-bib-0176"> <div class="citation-journal">Weinberg ED. <span class="citation-title">The therapeutic potential of lactoferrin</span>. <span class="citation"> Expert Opinion on Investigational Drugs </span><span class="pubYear">2003</span>;<span class="volume">12</span>(5):841‐51. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/12720494" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=The+therapeutic+potential+of+lactoferrin&author=ED+Weinberg&publication_year=2003&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD008548-bbs2-0170"> <div class="reference-title-banner"> <h4 class="title">Wieman 1998b</h4> </div> <div class="bibliography-section" id="CD008548-bib-0177"> <div class="citation-journal">Wieman TJ. <span class="citation-title">Clinical efficacy of becaplermin (rhPDGF‐BB) gel. Becaplermin Gel Studies Group</span>. <span class="citation"> American Journal of Surgery </span><span class="pubYear">1998</span>;<span class="volume">176</span>(2A Suppl):74S‐9S. [PUBMED: 9777976] <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/9777976" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Clinical+efficacy+of+becaplermin+(rhPDGF%E2%80%90BB)+gel.+Becaplermin+Gel+Studies+Group&author=TJ+Wieman&publication_year=1998&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD008548-bbs2-0171"> <div class="reference-title-banner"> <h4 class="title">Willrich 2005</h4> </div> <div class="bibliography-section" id="CD008548-bib-0178"> <div class="citation-journal">Willrich A, Pinzur M, McNeil M, Juknelis D, Lavery L. <span class="citation-title">Health related quality of life, cognitive function, and depression in diabetic patients with foot ulcer or amputation. A preliminary study</span>. <span class="citation"> Foot and Ankle International </span><span class="pubYear">2005</span>;<span class="volume">26</span>:128‐34. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/15737254" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Health+related+quality+of+life,+cognitive+function,+and+depression+in+diabetic+patients+with+foot+ulcer+or+amputation.+A+preliminary+study+&author=A+Willrich&author=M+Pinzur&author=M+McNeil&author=D+Juknelis&author=L+Lavery&publication_year=2005&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD008548-bbs2-0172"> <div class="reference-title-banner"> <h4 class="title">Winkley 2007</h4> </div> <div class="bibliography-section" id="CD008548-bib-0179"> <div class="citation-journal">Winkley K, Stahl D, Chalder T, Edmonds ME, Ismail K. <span class="citation-title">Risk factors associated with adverse outcomes in a population‐based prospective cohort study of people with their first diabetic foot ulcer</span>. <span class="citation"> Journal of Diabetes and its Complications </span><span class="pubYear">2007</span>;<span class="volume">21</span>:341‐9. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/17967704" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Risk+factors+associated+with+adverse+outcomes+in+a+population%E2%80%90based+prospective+cohort+study+of+people+with+their+first+diabetic+foot+ulcer+&author=K+Winkley&author=D+Stahl&author=T+Chalder&author=ME+Edmonds&author=K+Ismail&publication_year=2007&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD008548-bbs2-0173"> <div class="reference-title-banner"> <h4 class="title">Younes 2004</h4> </div> <div class="bibliography-section" id="CD008548-bib-0180"> <div class="citation-journal">Younes NA, Albsoul AM, Awad H. <span class="citation-title">Diabetic heel ulcers: a major risk factor for lower extremity amputation</span>. <span class="citation"> Ostomy/Wound Management </span><span class="pubYear">2004</span>;<span class="volume">50</span>:50‐60. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Diabetic+heel+ulcers:+a+major+risk+factor+for+lower+extremity+amputation&author=NA+Younes&author=AM+Albsoul&author=H+Awad&publication_year=2004&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD008548-bbs2-0174"> <div class="reference-title-banner"> <h4 class="title">Young 1994</h4> </div> <div class="bibliography-section" id="CD008548-bib-0181"> <div class="citation-journal">Young MJ, Breddy JL, Veves A, Boulton AJ. <span class="citation-title">The prediction of diabetic neuropathic foot ulceration using vibration perception thresholds. A prospective study</span>. <span class="citation"> Diabetes Care </span><span class="pubYear">1994</span>;<span class="volume">17</span>:557‐60. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/8082524" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=The+prediction+of+diabetic+neuropathic+foot+ulceration+using+vibration+perception+thresholds.+A+prospective+study+&author=MJ+Young&author=JL+Breddy&author=A+Veves&author=AJ+Boulton&publication_year=1994&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD008548-bbs2-0175"> <div class="reference-title-banner"> <h4 class="title">Zavala 2007 [Computer program]</h4> </div> <div class="bibliography-section" id="CD008548-bib-0182"> <div class="citation-other">Zavala D, Martí‐Carvajal A, Peña‐Marti G, Comunián‐Carrasco G. <span class="citation-title">Software for data transformation for time‐to‐event outcomes (alfa version)</span>. Valencia: Universidad de Carabobo, <span class="pubYear">2007</span>. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Software+for+data+transformation+for+time%E2%80%90to%E2%80%90event+outcomes+(alfa+version)&author=D+Zavala&author=A+Mart%C3%AD%E2%80%90Carvajal&author=G+Pe%C3%B1a%E2%80%90Marti&author=G+Comuni%C3%A1n%E2%80%90Carrasco&publication_year=2007&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD008548-bbs2-0176"> <div class="reference-title-banner"> <h4 class="title">Ziyadeh 2011</h4> </div> <div class="bibliography-section" id="CD008548-bib-0183"> <div class="citation-journal">Ziyadeh N, Fife D, Walker AM, Wilkinson GS, Seeger JD. <span class="citation-title">A matched cohort study of the risk of cancer in users of becaplermin</span>. <span class="citation"> Advances in Skin and Wound Care </span><span class="pubYear">2011</span>;<span class="volume">24</span>(1):31‐9. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/21173589" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=A+matched+cohort+study+of+the+risk+of+cancer+in+users+of+becaplermin&author=N+Ziyadeh&author=D+Fife&author=AM+Walker&author=GS+Wilkinson&author=JD+Seeger&publication_year=2011&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> </section> </section> <section class="characteristicStudies" id="characteristicStudies"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title"> Characteristics of studies <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="characteristicIncludedStudiesContent" lang=""> <div class="section-header" id="CD008548-sec2-0029"> <h3 class="title">Characteristics of included studies [ordered by study ID]</h3> <div class="jump-to"> <p>Jump to: </p> <ul class="jump-to-links"> <li><a href="#CD008548-sec2-0030" class="jump-to">excluded studies</a></li> <li><a href="#CD008548-sec2-0031" class="jump-to">awaiting classification</a></li> <li><a href="#CD008548-sec2-0032" class="jump-to">ongoing studies</a></li> </ul> </div> </div> <p> <div class="table" id=""> <table> <div class="table-heading"><span class="table-label"></span><span class="table-title">Afshari 2005 </span></div> <tbody> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Methods</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p> <ol id="CD008548-lst1-0035"> <li> <p>Parallel‐design (2 arms)</p> </li> <li> <p>Study period: 4 weeks</p> </li> <li> <p>Country: Iran</p> </li> <li> <p>Unit of randomisation: participant</p> </li> <li> <p>Unit of analysis: participant</p> </li> </ol> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Participants</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p> <ol id="CD008548-lst1-0036"> <li> <p>Randomised: 50 (50 ulcers)</p> <ol id="CD008548-lst2-0006"> <li> <p>Intervention group: 60% (30/50) (30 ulcers)</p> </li> <li> <p>Control group: 40% (20/50) (20 ulcers)</p> </li> </ol> </li> <li> <p>Age (range)</p> <ol id="CD008548-lst2-0007"> <li> <p>Intervention group (27‐77 years)</p> </li> <li> <p>Control group (32‐75 years)</p> </li> </ol> </li> <li> <p>Gender (male)</p> <ol id="CD008548-lst2-0008"> <li> <p>Intervention group: 72.7%</p> </li> <li> <p>Control group: 53.3%</p> </li> </ol> </li> <li> <p>Inclusion criteria</p> <ol id="CD008548-lst2-0009"> <li> <p>Grade 1 or 2 ulcer (grade 1: superficial ulcer; grade 2 deep ulcer to tendon, capsule, or bone) </p> </li> <li> <p>Ulcer with adequate perfusion, as indicated by an ABPI and ultrasound</p> </li> </ol> </li> <li> <p>Exclusion criteria: not reported</p> </li> </ol> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Interventions</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p> <ol id="CD008548-lst1-0037"> <li> <p>Intervention group: epidermal growth factor formulation (Hebermin<sup>®</sup>: Herber Biotec<sup>®</sup>) containing 1 mg recombinant human epidermal growth factor/1000&nbsp;mg silver sulphadiazine in a hydrophilic base </p> </li> <li> <p>Control: placebo consisting of 1% silver sulphadiazine in the same hydrophilic base</p> </li> </ol> </p> <p>Co‐interventions: both groups received wound debridement and irrigation with normal saline solution, systemic antibiotic therapy and daily wound dressing </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Outcomes</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p>Primary: complete wound closure</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Notes</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p> <ol id="CD008548-lst1-0038"> <li> <p>A priori sample size estimation: not reported</p> </li> <li> <p>Sponsor: not reported</p> </li> </ol> </p> </td> </tr> <tr> <td align="" valign="" colspan="3" rowspan="1" bgcolor="#ffffff"> <p><b><i>Risk of bias</i> </b> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Bias</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Authors' judgement</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Support for judgement</b> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Random sequence generation (selection bias)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Unclear risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Quote: "patients were entered to the study randomly until a total of 50 patients" (p 760)<br> Insufficient information provided to permit a judgment of 'low risk' or 'high risk' </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Allocation concealment (selection bias)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Unclear risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Insufficient information provided to permit a judgment of 'low risk' or 'high risk'</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Blinding of participants and personnel (performance bias) <br> All outcomes </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Unclear risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Quote: " . . . The placebo formulation contained . . . in the same hydrophilic base . . . " (p 760) </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Blinding of outcome assessment (detection bias) <br> All outcomes </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Unclear risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Insufficient information provided to permit a judgment of 'low risk' or 'high risk'</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Incomplete outcome data (attrition bias) <br> All outcomes </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Unclear risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Insufficient information provided to permit judgment of 'low risk' or 'high risk'</p> <p>Withdrawals were not reported</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Selective reporting (reporting bias)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>High risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>This trial did not report safety data</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Other bias</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>High risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p> <ol id="CD008548-lst1-0039"> <li> <p>There was imbalance between the groups with regard to: number of participants and at least three major variables: sex (% male), age and wound size </p> </li> <li> <p>Bias of the presentation data, see <a href="appendices#CD008548-sec2-0016">Appendix 1</a> </p> </li> </ol> </p> </td> </tr> </tbody> </table> </div> <div class="table" id=""> <table> <div class="table-heading"><span class="table-label"></span><span class="table-title">Agrawal 2009 </span></div> <tbody> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Methods</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p> <ol id="CD008548-lst1-0040"> <li> <p>Parallel‐design (2 arms)</p> </li> <li> <p>Study period: 12 weeks</p> </li> <li> <p>Country: India</p> </li> <li> <p>Unit of randomisation: participant</p> </li> <li> <p>Unit of analysis: participant</p> </li> <li> <p>Follow‐up: 12 weeks</p> </li> </ol> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Participants</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p> <ol id="CD008548-lst1-0041"> <li> <p>Randomised: 28</p> <ol id="CD008548-lst2-0010"> <li> <p>Intervention group: 50% (14/28) (number of ulcers not reported)</p> </li> <li> <p>Control group: 50% (14/28) (number of ulcers not reported)</p> </li> </ol> </li> <li> <p>&nbsp;Age (years, mean ± standard deviation)</p> <ol id="CD008548-lst2-0011"> <li> <p>Intervention group (54.38 ± 8.7)</p> </li> <li> <p>Control group (56.24 ± 8.75)</p> </li> </ol> </li> <li> <p>Gender (male)</p> <ol id="CD008548-lst2-0012"> <li> <p>Intervention group: 64.3% (9/14)</p> </li> <li> <p>Control group: 71.4% (10/14)</p> </li> </ol> </li> <li> <p>Inclusion criteria</p> <ol id="CD008548-lst2-0013"> <li> <p>≥ 30 years of age</p> </li> <li> <p>A glycaemic target of HbA1c ≤ 7.0%, but HbA1c &gt; 7.0% was not an exclusion criterion</p> </li> <li> <p>Ulcer stage I, II, III or IV according to the Wagner (1981) classification</p> </li> <li> <p>Foot ulcer duration of &gt; 3 months, free of infection, with an adequate lower‐limb blood supply demonstrated by a TcPO2 ≥ 30 mmHg </p> </li> <li> <p>Free of, or a moderate degree of, peripheral vascular disease</p> </li> </ol> </li> <li> <p>Exclusion criteria</p> <ol id="CD008548-lst2-0014"> <li> <p>Active neoplastic disease</p> </li> <li> <p>Diagnosis of active infection</p> </li> <li> <p>Those who had received immunosuppressive therapy during the preceding 3 months</p> </li> <li> <p>Those with liver disease, pulmonary tuberculosis, thyroid disorder, uraemia, alcoholism, or renal insufficiency, and those undergoing vascular reconstruction or receiving steroid or anticoagulant therapy </p> </li> </ol> </li> </ol> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Interventions</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p> <ol id="CD008548-lst1-0042"> <li> <p>Intervention group: recombinant human platelet‐derived growth factor (becaplermin) (0.01%) gel/day. </p> </li> <li> <p>Control: placebo gel, no further details provided</p> </li> </ol> </p> <p>Co‐interventions: both groups received debridement, dressing, pressure relief and glycaemic control </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Outcomes</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p>Healing: participants categorised as complete responders, partial responders, non‐complete responders (p 84). </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Notes</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p> <ol id="CD008548-lst1-0043"> <li> <p>A priori sample size estimation: not provided</p> </li> <li> <p>Sponsor: not reported</p> </li> </ol> </p> </td> </tr> <tr> <td align="" valign="" colspan="3" rowspan="1" bgcolor="#ffffff"> <p><b><i>Risk of bias</i> </b> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Bias</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Authors' judgement</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Support for judgement</b> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Random sequence generation (selection bias)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Unclear risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Quote: "participants were randomised to receive either . . . " (p 81)<br> Insufficient information provided to permit a judgment of 'low risk' or 'high risk' </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Allocation concealment (selection bias)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Unclear risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Insufficient information provided to permit a judgment of 'low risk' or 'high risk'</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Blinding of participants and personnel (performance bias) <br> All outcomes </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Unclear risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Insufficient information provided to permit a judgment of 'low risk' or 'high risk'</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Blinding of outcome assessment (detection bias) <br> All outcomes </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Unclear risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Insufficient information provided to permit a judgment of 'low risk' or 'high risk'</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Incomplete outcome data (attrition bias) <br> All outcomes </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Unclear risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Imbalance between groups for participants lost after randomisation (18% (5/28) in total) </p> <p>Control group: 36% (5/14) during the final week (week 12), reasons not reported</p> <p>Experimental group: none</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Selective reporting (reporting bias)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>The study protocol is not available but it is clear that the published report included all expected outcomes, including those that were pre‐specified </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Other bias</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>High risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p> <ol id="CD008548-lst1-0044"> <li> <p>Quote " . . . matched for all variables except sex and ulcer area . . . " (p 83)</p> </li> <li> <p>Design bias, see <a href="appendices#CD008548-sec2-0016">Appendix 1</a> </p> </li> </ol> </p> </td> </tr> </tbody> </table> </div> <div class="table" id=""> <table> <div class="table-heading"><span class="table-label"></span><span class="table-title">Bhansali 2009 </span></div> <tbody> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Methods</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p> <ol id="CD008548-lst1-0045"> <li> <p>Parallel‐design (2 arms)</p> </li> <li> <p>Country: India</p> </li> <li> <p>Follow‐up period: 20 weeks</p> </li> <li> <p>Unit of randomisation: participant</p> </li> <li> <p>Analysis unit: participant</p> </li> </ol> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Participants</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p> <ol id="CD008548-lst1-0046"> <li> <p>Randomised: 20 (24 ulcers)</p> <ol id="CD008548-lst2-0015"> <li> <p>Intervention group: 50% (10/20) (13 ulcers)</p> </li> <li> <p>Control group: 50% (10/20) (11 ulcers)</p> </li> </ol> </li> <li> <p>Age (years, mean ± SD)</p> <ol id="CD008548-lst2-0016"> <li> <p>Intervention group: 51.7 ± 13.6</p> </li> <li> <p>Control group: 49.5 ± 8.83</p> </li> </ol> </li> <li> <p>Gender (male)</p> <ol id="CD008548-lst2-0017"> <li> <p>Intervention group: 70% (7/10)</p> </li> <li> <p>Control group: 50% (5/10)</p> </li> </ol> </li> <li> <p>Inclusion criteria</p> <ol id="CD008548-lst2-0018"> <li> <p>&gt; 20 years of age with type 1 or 2 diabetes</p> </li> <li> <p>At least 1 neuropathic plantar ulcer of Wagner grade ≥ 2 without X‐ray evidence of osteomyelitis </p> </li> <li> <p>ABPI &gt; 0.9</p> </li> </ol> </li> <li> <p>Exclusion criteria: not reported</p> </li> </ol> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Interventions</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p> <ol id="CD008548-lst1-0047"> <li> <p>Intervention group: recombinant human platelet‐derived growth factor (becaplermin) 0.01% gel (once daily) </p> </li> <li> <p>Control: placebo consisting of moist saline (once daily)</p> </li> </ol> </p> <p>Co‐interventions: debridement at baseline, offloading</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Outcomes</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p>Incidence of complete wound closure, duration of complete healing, rate of healing and safety </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Notes</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p> <ol id="CD008548-lst1-0048"> <li> <p>A priori sample size estimation: not reported</p> </li> <li> <p>Sponsor: not reported</p> </li> </ol> </p> </td> </tr> <tr> <td align="" valign="" colspan="3" rowspan="1" bgcolor="#ffffff"> <p><b><i>Risk of bias</i> </b> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Bias</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Authors' judgement</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Support for judgement</b> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Random sequence generation (selection bias)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Unclear risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Quote "Patients were randomized . . " (p e14)</p> <p>Insufficient information provided to permit a judgment of 'low risk' or 'high risk'</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Allocation concealment (selection bias)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Unclear risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Insufficient information provided to permit a judgment of 'low risk' or 'high risk'</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Blinding of participants and personnel (performance bias) <br> All outcomes </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>High risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Open label (p e14)</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Blinding of outcome assessment (detection bias) <br> All outcomes </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>High risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Open label (p e14)</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Incomplete outcome data (attrition bias) <br> All outcomes </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Unclear risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Insufficient reporting of attrition/exclusions to permit a judgement of ‘low risk’ or ‘high risk’ (e.g. number randomized not stated, no reasons for missing data provided) </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Selective reporting (reporting bias)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>High risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Safety data were not reported</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Other bias</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>High risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Bias in the presentation of data and design bias, see <a href="appendices#CD008548-sec2-0016">Appendix 1</a> </p> </td> </tr> </tbody> </table> </div> <div class="table" id=""> <table> <div class="table-heading"><span class="table-label"></span><span class="table-title">Chen 2004 </span></div> <tbody> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Methods</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p> <ol id="CD008548-lst1-0049"> <li> <p>Parallel‐design (2 arms)</p> </li> <li> <p>Country: China (Zhenjiang Centre People’s Hospital, Guangdong Province)</p> </li> <li> <p>Phase: unclear</p> </li> <li> <p>Follow‐up period: not reported</p> </li> <li> <p>Unit of randomisation: participant</p> </li> <li> <p>Analysis unit: participant</p> </li> </ol> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Participants</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p> <ol id="CD008548-lst1-0050"> <li> <p>Randomised: 59</p> <ol id="CD008548-lst2-0019"> <li> <p>Intervention group: 30 (59.84%)</p> </li> <li> <p>Control group: 29 (49.15%)</p> </li> </ol> </li> <li> <p>Age (years)</p> <ol id="CD008548-lst2-0020"> <li> <p>Intervention group: 70 (mean, SD not reported)</p> </li> <li> <p>Control group: 68 (mean, SD not reported)</p> </li> <li> <p>Overall: &nbsp;44‐92</p> </li> </ol> </li> <li> <p>Gender (male)</p> <ol id="CD008548-lst2-0021"> <li> <p>Intervention group: 18%</p> </li> <li> <p>Control group: 17%</p> </li> </ol> </li> <li> <p>Inclusion criteria: not reported</p> </li> <li> <p>Exclusion criteria: not reported</p> </li> </ol> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Interventions</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p> <ol id="CD008548-lst1-0051"> <li> <p>Intervention group: recombinant human epidermal growth factor spray</p> </li> <li> <p>Control: regular insulin 8 U</p> </li> </ol> </p> <p>Co‐interventions: 3% hydrogen peroxide, normal saline, ethacridine lactate (rivanol), gentamicin, diabetic diet, blood sugar control </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Outcomes</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p>Unclear</p> <p>This trial reported data for time‐to complete healing of diabetic foot ulcers</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Notes</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p> <ol id="CD008548-lst1-0052"> <li> <p>A priori sample size estimation: not reported</p> </li> <li> <p>Sponsor: not reported</p> </li> <li> <p>Dates during which trial conducted: not reported</p> </li> <li> <p>Financial disclosures: not reported</p> </li> <li> <p>Funding/support: not reported</p> </li> <li> <p>Disclosure statement: not reported</p> </li> </ol> </p> </td> </tr> <tr> <td align="" valign="" colspan="3" rowspan="1" bgcolor="#ffffff"> <p><b><i>Risk of bias</i> </b> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Bias</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Authors' judgement</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Support for judgement</b> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Random sequence generation (selection bias)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Random number table</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Allocation concealment (selection bias)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Unclear risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>No information about allocation concealment</p> <p>Insufficient information provided to permit a judgment of 'low risk' or 'high risk'</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Blinding of participants and personnel (performance bias) <br> All outcomes </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>High risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Difference between intervention and control treatments easy to identify</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Blinding of outcome assessment (detection bias) <br> All outcomes </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Unclear risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Insufficient information provided to permit a judgment of 'low risk' or 'high risk'</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Incomplete outcome data (attrition bias) <br> All outcomes </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Unclear risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>No participants lost to follow‐up</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Selective reporting (reporting bias)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>High risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Only one outcome reported; it was not pre‐specified</p> <p>Author reported 'time‐to complete healing of the diabetic foot ulcer' as a continuous measure </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Other bias</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>High risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Failure to report inclusion/exclusion criteria</p> <p>Bias of presentation of the data, see <a href="appendices#CD008548-sec2-0016">Appendix 1</a> <br> Design bias, see <a href="appendices#CD008548-sec2-0016">Appendix 1</a> </p> </td> </tr> </tbody> </table> </div> <div class="table" id=""> <table> <div class="table-heading"><span class="table-label"></span><span class="table-title">d'Hemecourt 1998 </span></div> <tbody> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Methods</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p> <ol id="CD008548-lst1-0053"> <li> <p>Parallel‐design (2 arms)</p> </li> <li> <p>Country: USA</p> </li> <li> <p>Study period: 20 weeks</p> </li> <li> <p>Unit of randomisation: participant</p> </li> <li> <p>Analysis unit: participant</p> </li> </ol> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Participants</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p> <ol id="CD008548-lst1-0054"> <li> <p>Randomised: 172</p> <ol id="CD008548-lst2-0022"> <li> <p>Intervention group 1 (becaplermin): 20% (34/172)</p> </li> <li> <p>Intervention group 2 (sodium carboxymethylcellulose (NaCMC)): 41% (70/172)</p> </li> <li> <p>Control group: 39% (68/172)</p> </li> </ol> </li> <li> <p>Age (years; mean ± standard deviation): overall: 58.3 ± 12.13</p> <ol id="CD008548-lst2-0023"> <li> <p>Intervention group 1 (becaplermin): 58.5 ± 11.90</p> </li> <li> <p>Intervention group 2 (NaCMC): 56.9 ±13.02</p> </li> <li> <p>Control group: 59.6 ±11.2</p> </li> </ol> </li> <li> <p>Gender (male)</p> <ol id="CD008548-lst2-0024"> <li> <p>Intervention group 1 (becaplermin): 70.6% (24/34)</p> </li> <li> <p>Intervention group 2 (NaCMC): 70.0% (49/70)</p> </li> <li> <p>Control group: 79.4% (54/68)</p> </li> </ol> </li> <li> <p>Inclusion criteria</p> <ol id="CD008548-lst2-0025"> <li> <p>Presence of chronic diabetic ulcer on lower extremity for at least 8 weeks prior to the study </p> </li> </ol> </li> <li> <p>&nbsp;Exclusion criteria</p> <ol id="CD008548-lst2-0026"> <li> <p>Osteomyelitis affecting the area of the target ulcer</p> </li> <li> <p>Target ulcer area after debridement (measured by multiplying length by width) &lt; 1 cm<sup>2</sup> or &gt; 10 cm<sup>2</sup> </p> </li> <li> <p>&gt; 3 chronic ulcers present at baseline</p> </li> <li> <p>Ulcers resulting from any cause other than diabetes</p> </li> <li> <p>Use of concomitant medications known to affect wound healing (corticosteroids, chemotherapy, or immunosuppressive agents) </p> </li> <li> <p>Women who were pregnant, nursing, or of childbearing potential who were not using an acceptable method of birth control </p> </li> </ol> </li> </ol> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Interventions</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p> <ol id="CD008548-lst1-0055"> <li> <p>Intervention groups</p> <ol id="CD008548-lst2-0027"> <li> <p>Intervention group 1: recombinant human platelet‐derived growth factor (becaplermin) gel 100 μg/g (Regranex<sup>®</sup> Gel 0.01%) </p> </li> <li> <p>Intervention group 2: sodium carboxymethylcellulose (NaCMC) aqueous‐based gel</p> </li> </ol> </li> <li> <p>Control group: good wound care</p> </li> </ol> </p> <p>Co‐interventions: all groups received good wound care consisting of initial sharp debridement of ulcers to remove nonviable tissue, daily moist saline dressing changes, offloading of pressure, and systemic control of infection </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Outcomes</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p> <ol id="CD008548-lst1-0056"> <li> <p>Primary: percentage of participants achieving complete wound closure without drainage or need for dressing </p> </li> <li> <p>Secondary:</p> <ol id="CD008548-lst2-0028"> <li> <p>time to achieve complete wound closure</p> </li> <li> <p>relative ulcer area from baseline to endpoint</p> </li> <li> <p>wound evaluation score (6 parameters: erythema, oedema, purulence, necrotic tissue, fibrin, and drainage) </p> </li> </ol> </li> </ol> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Notes</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p> <ol id="CD008548-lst1-0057"> <li> <p>A priori sample size estimation: not reported</p> </li> <li> <p>Sponsor: not reported</p> </li> </ol> </p> </td> </tr> <tr> <td align="" valign="" colspan="3" rowspan="1" bgcolor="#ffffff"> <p><b><i>Risk of bias</i> </b> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Bias</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Authors' judgement</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Support for judgement</b> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Random sequence generation (selection bias)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Unclear risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Quote "patients were randomly assigned in a 2:2:1 ratio to one of three treatment groups" (p 71) </p> <p>Insufficient information provided to permit a judgment of 'low risk' or 'high risk'</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Allocation concealment (selection bias)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Unclear risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Insufficient information provided to permit a judgment of 'low risk' or 'high risk'</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Blinding of participants and personnel (performance bias) <br> All outcomes </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Unclear risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Quote "were conducted in double‐blind fashion" (p 71)<br> Insufficient information provided to permit a judgment of 'low risk' or 'high risk' </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Blinding of outcome assessment (detection bias) <br> All outcomes </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Unclear risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Insufficient information provided to permit a judgment of 'low risk' or 'high risk'</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Incomplete outcome data (attrition bias) <br> All outcomes </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>High risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Overall lost: 24% (41/172 participants)</p> <p> <ol id="CD008548-lst1-0058"> <li> <p>Intervention group 1 (becaplermin): 26% (9/34)</p> </li> <li> <p>Intervention group 2 (NaCMC): 16% (11/70)</p> </li> <li> <p>Control group: 31% (21/68)</p> </li> </ol> </p> <p>Reasons: main reasons for withdrawals were</p> <p> <ol id="CD008548-lst1-0059"> <li> <p>Adverse event<b>:</b> </p> <ol id="CD008548-lst2-0029"> <li> <p>Intervention group 1 (becaplemerin): 15%</p> </li> <li> <p>Intervention group 2 (NaCMC): 11%</p> </li> <li> <p>Control group: 24%</p> </li> </ol> </li> <li> <p>Lost to follow‐up:</p> <ol id="CD008548-lst2-0030"> <li> <p>Intervention group 1 (becaplemerin): 6%</p> </li> <li> <p>Intervention group 2 (NaCMC): 3%</p> </li> <li> <p>Control group: 1%</p> </li> </ol> </li> <li> <p>Participants' choice:</p> <ol id="CD008548-lst2-0031"> <li> <p>Intervention group 1 (becaplemerin): 3%</p> </li> <li> <p>Intervention group 2 (NaCMC): 0%</p> </li> <li> <p>Control group: 4%</p> </li> </ol> </li> <li> <p>Other:</p> <ol id="CD008548-lst2-0032"> <li> <p>Intervention group 1 (becaplemerin): 3%</p> </li> <li> <p>Intervention group 2 (NaCMC): 1%</p> </li> <li> <p>Control group: 1%</p> </li> </ol> </li> </ol> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Selective reporting (reporting bias)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>High risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>One or more outcomes of interest in the review were reported incompletely so that they could not be entered in a meta‐analysis </p> <p>This trial did not report time to complete wound closure</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Other bias</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>High risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Bias in the presentation of data and design bias, see <a href="appendices#CD008548-sec2-0016">Appendix 1</a> </p> </td> </tr> </tbody> </table> </div> <div class="table" id=""> <table> <div class="table-heading"><span class="table-label"></span><span class="table-title">Driver 2006 </span></div> <tbody> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Methods</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p> <ol id="CD008548-lst1-0060"> <li> <p>Parallel‐design (2 arms)</p> </li> <li> <p>Country: USA (14 sites)</p> </li> <li> <p>Follow‐up: 12 weeks</p> </li> <li> <p>Unit of randomisation: participant</p> </li> <li> <p>Analysis unit: participant</p> </li> </ol> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Participants</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p> <ol id="CD008548-lst1-0061"> <li> <p>Randomised: 72</p> <ol id="CD008548-lst2-0033"> <li> <p>Intervention group: 56% (40/72)</p> </li> <li> <p>Control group: 44% (32/72)</p> </li> </ol> </li> <li> <p>Age (years ±(SD))</p> <ol id="CD008548-lst2-0034"> <li> <p>Intervention group: 56.4 ± 10.2</p> </li> <li> <p>Control group: 57.5 ± 9.1</p> </li> </ol> </li> <li> <p>Gender (male %)</p> <ol id="CD008548-lst2-0035"> <li> <p>Intervention group: 80% (32/40)</p> </li> <li> <p>Control group: 84% (27/32)</p> </li> </ol> </li> <li> <p>Inclusion criteria</p> <ol id="CD008548-lst2-0036"> <li> <p>People with type 1 or type 2 diabetes aged 18‐95 years, with an ulcer of at least 4 weeks’ duration </p> </li> <li> <p>HbA1c &lt; 12</p> </li> <li> <p>Index foot ulcer located on the plantar, medial, or lateral aspect of the foot (including all toe surfaces) </p> </li> <li> <p>Wound area (length x width) measurement between 0.5 cm<sup>2</sup> and 20 cm<sup>2</sup> </p> </li> <li> <p>Wounds located under a Charcot deformity had to be free of acute changes and must have undergone appropriate structural consolidation </p> </li> <li> <p>Index ulcer had to be clinically noninfected (cultures taken, but infection diagnosed through clinical signs and symptoms rather than culture results) and full‐thickness without exposure of bone, muscle, ligaments, or tendons (University of Texas Treatment‐Based Diabetic Foot Classification System: Grade 1A) </p> </li> <li> <p>Ulcer free of necrotic debris, foreign bodies, sinus tracts, tunnelling, and undermining after debridement </p> </li> <li> <p>Comprised of healthy vascularized tissue, and at least 4 cm from any additional wound</p> </li> <li> <p>Adequate limb perfusion assessed by examination and non‐invasive vascular testing, ABPI and toe brachial index </p> </li> <li> <p>Pregnant or lactating women; both men and women had to be willing to use a medically‐accepted form of birth control throughout the trial and for 6 months following </p> </li> </ol> </li> <li> <p>Exclusion criteria</p> <ol id="CD008548-lst2-0037"> <li> <p>People currently enrolled in another investigational device or drug trial or previously enrolled (within last 30 days) in investigative research of a device or pharmaceutical agent </p> </li> <li> <p>≥ 50% decrease in ulcer area during the 7‐day screening period</p> </li> <li> <p>Ulcer due to non‐diabetic aetiology</p> </li> <li> <p>Blood vessels non‐compressible for ABPI testing</p> </li> <li> <p>Evidence of gangrene in ulcer or on any part of the foot</p> </li> <li> <p>Radiographic evidence consistent with diagnosis of acute Charcot foot</p> </li> <li> <p>Currently receiving or had received radiation or chemotherapy within 3 months of randomisation</p> </li> <li> <p>Use of topical, oral or IV antibiotic/antimicrobial agents or medications within 2 days (48 hours) of randomisation </p> </li> <li> <p>Growth factor therapy administered within 7 days of randomisation (e.g. autologous platelet‐rich plasma gel, becaplermin, bilayered cell therapy, dermal substitute, extracellular matrix) </p> </li> <li> <p>Screening serum albumin level &lt; 2.5 g/dL</p> </li> <li> <p>Screening haemoglobin &lt; 10.5 mg/dL</p> </li> <li> <p>Screening platelet count &lt; 100 x10<sup>9</sup>/L </p> </li> <li> <p>Undergoing renal dialysis, known immune insufficiency, known abnormal platelet activation disorders i.e. gray platelet syndrome, liver disease, active cancer (except remote basal cell of the skin), eating/nutritional, haematologic, collagen vascular disease, rheumatic disease, or bleeding disorders </p> </li> <li> <p>History of peripheral vascular repair within 30 days of randomisation</p> </li> <li> <p>Known or suspected osteomyelitis</p> </li> <li> <p>Surgical correction (other than debridement) required for ulcer to heal</p> </li> <li> <p>Exposed tendons, ligaments, muscle, or bone in Index ulcer</p> </li> <li> <p>Known psychological, developmental, physical, emotional, or social disorder, or any other situation that might interfere with compliance with study requirements or healing of the ulcer, or both </p> </li> <li> <p>History of alcohol or drug abuse within the year prior to randomisation</p> </li> <li> <p>Inadequate venous access for blood draw</p> </li> <li> <p>Religious or cultural conflict with the use of platelet gel treatment</p> </li> </ol> </li> </ol> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Interventions</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p> <ol id="CD008548-lst1-0062"> <li> <p>Intervention group: platelet‐rich plasma gel (AutoloGel™, Cytomedix, Inc, Rockville, Md), frequency of administration not reported </p> </li> <li> <p>Control group: saline gel (Normlgel<sup>®</sup>, Mölnlycke Health Care, Norcross, Ga), frequency of administration not reported </p> </li> </ol> </p> <p>Co‐interventions: cleaning and interim wound assessment of vital signs, offloading orthosis walker </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Outcomes</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p>Primary: proportion of participants with a healed wound</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Notes</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p> <ol id="CD008548-lst1-0063"> <li> <p>A priori sample size estimation: yes (p 72)</p> </li> <li> <p>Sponsor: not reported</p> </li> </ol> </p> </td> </tr> <tr> <td align="" valign="" colspan="3" rowspan="1" bgcolor="#ffffff"> <p><b><i>Risk of bias</i> </b> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Bias</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Authors' judgement</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Support for judgement</b> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Random sequence generation (selection bias)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Quote "was electronically generated, blocked per investigational center" (p 70)</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Allocation concealment (selection bias)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Unclear risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Insufficient information provided to permit a judgment of 'low risk' or 'high risk'</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Blinding of participants and personnel (performance bias) <br> All outcomes </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Unclear risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Quote " . . . to maintain blinding of the investigators, investigative sites staff, patients, sponsor, and CRO staff, and monitor" (p 70) </p> <p>This trial did not report the approach used to guarantee adequate blinding</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Blinding of outcome assessment (detection bias) <br> All outcomes </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Unclear risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Quote ". . . to maintain blinding of the investigators, investigative sites staff, patients, sponsor, and CRO staff, and monitor" (p 70) </p> <p>This trial did not report the approach used to guarantee adequate blinding</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Incomplete outcome data (attrition bias) <br> All outcomes </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>High risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Overall lost: 44% (32/72 participants)</p> <p>Reasons: failure to complete treatment (25%; 8/32) and protocol violations (75%; 24/32)</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Selective reporting (reporting bias)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>The study protocol was not available, but it is clear that the published reports included all expected outcomes, including those that were pre‐specified </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Other bias</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>High risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Bias in the presentation of data and design bias, see <a href="appendices#CD008548-sec2-0016">Appendix 1</a> </p> </td> </tr> </tbody> </table> </div> <div class="table" id=""> <table> <div class="table-heading"><span class="table-label"></span><span class="table-title">Fernández‐Montequin 2007 </span></div> <tbody> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Methods</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p> <ol id="CD008548-lst1-0064"> <li> <p>Parallel‐design (2 arms)</p> </li> <li> <p>Country: Cuba (5 sites)</p> </li> <li> <p>Follow‐up: 5‐8 weeks</p> </li> <li> <p>Unit of randomisation: participant</p> </li> <li> <p>Analysis unit: participant</p> </li> </ol> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Participants</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p> <ol id="CD008548-lst1-0065"> <li> <p>Randomised: 41</p> <ol id="CD008548-lst2-0038"> <li> <p>Intervention group 1 (rhEGF 75 µg): 56% (23/41)</p> </li> <li> <p>Intervention group 2 (rhEGF 25 µg): 44% (18/41)</p> </li> </ol> </li> <li> <p>Age (years, mean ± SD)</p> <ol id="CD008548-lst2-0039"> <li> <p>Intervention group 1 (rhEGF 75 µg): 63 ± 12</p> </li> <li> <p>Intervention group 2 (rhEGF 25 µg): 67.5 ± 19.5</p> </li> </ol> </li> <li> <p>Gender (male)</p> <ol id="CD008548-lst2-0040"> <li> <p>Intervention group 1 (rhEGF 75 µg): 52.2%</p> </li> <li> <p>Intervention group 2 (rhEGF 25 µg): 56%</p> </li> </ol> </li> <li> <p>Inclusion criteria</p> <ol id="CD008548-lst2-0041"> <li> <p>Diabetic participants (type 1 or 2) of both sexes</p> </li> <li> <p>&gt; 18 years</p> </li> <li> <p>Grade 3 or 4 foot ulcer according to Wagner's classification, with high risk of amputation</p> </li> </ol> </li> <li> <p>Exclusion criteria</p> <ol id="CD008548-lst2-0042"> <li> <p>Foot ulcer area ≤ 1 cm<sup>2</sup> </p> </li> <li> <p>Hb &lt; 100 g/l</p> </li> <li> <p>Uncontrolled chronic diseases (coronary or heart disease, diabetic coma or ketoacidosis, renal failure defined as a creatinine &gt; 200 µmol/L and oligoanuria) </p> </li> <li> <p>Malignancies, psychiatric or neurological diseases that could impair proper reasoning for consent </p> </li> <li> <p>Pregnancy and nursing</p> </li> </ol> </li> </ol> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Interventions</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p> <ol id="CD008548-lst1-0066"> <li> <p>Intervention group 1: intralesional injections of rhEGF 75 µg (Citoprot‐P<sup>®</sup>; Herber Biotec, Havana, Cuba), in hospital, 3 times/week (alternate days) </p> </li> <li> <p>Intervention group 2: intralesional injections rhEGF 25 µg (Citoprot‐P<sup>®</sup>; Herber Biotec, Havana, Cuba), in hospital, 3 times/week (alternate days) </p> </li> </ol> </p> <p>Co‐interventions: standardised wound care regimen, ulcers were sharply debrided, gangrenous and necrotic tissue removed whenever necessary, and broad‐spectrum antibiotics and metabolic control as required </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Outcomes</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p>Primary: response at 5 to 8 weeks (percentage of ulcer area covered by granulation tissue). </p> <p> <ol id="CD008548-lst1-0067"> <li> <p>Complete (75‐100%)</p> </li> <li> <p>Partial (50‐75%)</p> </li> <li> <p>Minimal (25‐50%)</p> </li> <li> <p>No response (&lt;25%)</p> </li> </ol> </p> <p>Secondary efficacy endpoints</p> <p> <ol id="CD008548-lst1-0068"> <li> <p>Time to obtain complete response</p> </li> <li> <p>Complete healing (no exudates or need of dressing)</p> </li> <li> <p>Prevention of limb amputation</p> </li> <li> <p>Recurrence during 1‐year‐follow‐up</p> </li> </ol> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Notes</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p> <ol id="CD008548-lst1-0069"> <li> <p>Sample size a priori calculation: yes (pp 335‐6)</p> </li> <li> <p>Sponsor: Curative technologies Inc, Heber Biotec SA, and The Ministry of Public Health of Cuba </p> </li> <li> <p>Role of sponsor: financed the study, "the authors received free drug (rhEGF) . . . " (p 341) </p> </li> <li> <p>Conflict of interest: some authors were employees of the Centre for Biological Research, which is part of the Centre for Genetic Engineering and Biotechnology, Havana network, where rhEGF is produced and the new formulation was developed </p> </li> <li> <p>E‐mail was sent to main author</p> </li> </ol> </p> </td> </tr> <tr> <td align="" valign="" colspan="3" rowspan="1" bgcolor="#ffffff"> <p><b><i>Risk of bias</i> </b> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Bias</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Authors' judgement</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Support for judgement</b> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Random sequence generation (selection bias)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Quote "computer‐generated random list" (p 335)</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Allocation concealment (selection bias)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Unclear risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Insufficient information provided to permit a judgment of 'low risk' or 'high risk'</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Blinding of participants and personnel (performance bias) <br> All outcomes </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Quote "both vials were indistinguishable . . . " (p 335)</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Blinding of outcome assessment (detection bias) <br> All outcomes </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Quote "both vials were indistinguishable . . . " (p 335)</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Incomplete outcome data (attrition bias) <br> All outcomes </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>High risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Loss of participants: 36.5% (15/41)</p> <p> <ol id="CD008548-lst1-0070"> <li> <p>Adverse event: Intervention group 1 = 66% (4/6); Intervention group 2 = 33.3% (3/9)</p> </li> <li> <p>Mortality: Intervention group 1 = 4% (1/23)</p> </li> <li> <p>Voluntary withdrawal: Intervention group 2 = 22.2% (2/9)</p> </li> <li> <p>Lesion progression: Intervention group 1 = 33.3% (2/6);Intervention group 2 = 44.4% (4/9) </p> </li> </ol> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Selective reporting (reporting bias)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>High risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>One or more outcomes of interest in the review were reported incompletely so that they could not be entered into a meta‐analysis </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Other bias</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>High risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Bias in the presentation of data and design bias, see <a href="appendices#CD008548-sec2-0016">Appendix 1</a> </p> </td> </tr> </tbody> </table> </div> <div class="table" id=""> <table> <div class="table-heading"><span class="table-label"></span><span class="table-title">Fernández‐Montequin 2009 </span></div> <tbody> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Methods</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p> <ol id="CD008548-lst1-0071"> <li> <p>Parallel‐design (3 arms)</p> </li> <li> <p>Country: Cuba (20 sites)</p> </li> <li> <p>Follow‐up: 8 weeks</p> </li> <li> <p>Unit of randomisation: participant</p> </li> <li> <p>Analysis unit: participant</p> </li> </ol> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Participants</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p> <ol id="CD008548-lst1-0072"> <li> <p>Randomised: 149</p> <ol id="CD008548-lst2-0043"> <li> <p>Intervention group 1: 53 (35.6%)</p> </li> <li> <p>Intervention group 2: 48 (32.2%)</p> </li> <li> <p>Control group: 48 (32.2%)</p> </li> </ol> </li> <li> <p>Loss prior to randomisation: 54%</p> <ol id="CD008548-lst2-0044"> <li> <p>Uncompensated chronic diseases (54)</p> </li> <li> <p>Hb &lt; 10 g/dL (25)</p> </li> <li> <p>HbA1c &gt;10% (18)</p> </li> <li> <p>Antecedents/suspected of malignancies (17)</p> </li> <li> <p>Refused consent (13)</p> </li> <li> <p>Other exclusion criteria (48)</p> </li> </ol> </li> <li> <p>Age in years: median (25th–75th percentiles)</p> <ol id="CD008548-lst2-0045"> <li> <p>Intervention group 1: 63 (55‐69)</p> </li> <li> <p>Intervention group 2: 65.5 (56‐72)</p> </li> <li> <p>Control group: 64.0 (51‐70)</p> </li> </ol> </li> <li> <p>Gender (male)</p> <ol id="CD008548-lst2-0046"> <li> <p>Intervention group 1: 28 (52.8%)</p> </li> <li> <p>Intervention group 2: 21 (43.8%)</p> </li> <li> <p>Control group: 27 (56.3%)</p> </li> </ol> </li> <li> <p>Inclusion criteria</p> <ol id="CD008548-lst2-0047"> <li> <p>People with type 1 or 2 diabetes</p> </li> <li> <p>Aged ≥18 years</p> </li> <li> <p>Presence of Wagner’s grade 3 or 4 diabetic foot ulcers: <i>&gt;</i> 1 cm<sup>2</sup> </p> </li> </ol> </li> <li> <p>Exclusion criteria</p> <ol id="CD008548-lst2-0048"> <li> <p>Revascularisation surgery possible (for ischaemic ulcers)</p> </li> <li> <p>Hb <i>&lt;</i> 100 g/L </p> </li> <li> <p>Uncompensated chronic diseases such as signs of heart failure, diabetic coma or ketoacidosis</p> </li> <li> <p>Renal failure (creatinine <i>&gt;</i> 200 mg/dL) </p> </li> <li> <p>Malignancies</p> </li> <li> <p>Psychiatric or neurological diseases (use of immunosuppressing drugs or corticosteroids)</p> </li> <li> <p>Pregnancy and nursing</p> </li> </ol> </li> </ol> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Interventions</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p> <ol id="CD008548-lst1-0073"> <li> <p>Intervention group 1: 75 μg rhEGF (Herberprot‐P<sup>®</sup>, Herber Biotec, Havana) </p> </li> <li> <p>Intervention group 2: 25 μg rhEGF (Herberprot‐P<sup>®</sup>, Herber Biotec, Havana). In both Intervention groups the product was dissolved in 5 ml of water for injection, 3 times/week, on alternate days </p> </li> <li> <p>Control group: placebo, characteristics and administration schedules not reported</p> </li> </ol> </p> <p>Co‐intervention: standard wound care</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Outcomes</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p> <ol id="CD008548-lst1-0074"> <li> <p>Primary: proportion of participants with partial or complete response after 2 weeks of treatment </p> </li> <li> <p>Secondary:</p> <ol id="CD008548-lst2-0049"> <li> <p>Complete response rate at 8 weeks (Quote " . . . and &gt; 75% (complete response) (p 434) </p> </li> <li> <p>Time‐to complete response</p> </li> <li> <p>Complete wound closure</p> </li> <li> <p>Need for amputation</p> </li> <li> <p>Recurrences within 1‐year follow‐up</p> </li> </ol> </li> </ol> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Notes</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p> <ol id="CD008548-lst1-0075"> <li> <p>A priori sample size estimation: yes (p 434)</p> </li> <li> <p>Sponsor: Heber Biotec SA and The Ministry of Public Health of Cuba</p> </li> <li> <p>Role of sponsor: supplied the investigational product, supported the work</p> </li> <li> <p>Conflict of interest: some authors were employees of the Centre for Biological Research, which is part of the Centre for Genetic Engineering and Biotechnology (CIGB), Havana network, where rhEGF is produced and the new formulation was developed and produced (p 440) </p> </li> <li> <p>E‐mail was sent to main author</p> </li> </ol> </p> </td> </tr> <tr> <td align="" valign="" colspan="3" rowspan="1" bgcolor="#ffffff"> <p><b><i>Risk of bias</i> </b> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Bias</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Authors' judgement</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Support for judgement</b> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Random sequence generation (selection bias)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Quote " Randomisation was simple, central and stratified by investigation sites" (p 434) </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Allocation concealment (selection bias)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Unclear risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Insufficient information provided to permit a judgment of 'low risk' or 'high risk'</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Blinding of participants and personnel (performance bias) <br> All outcomes </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Quote "both vials were indistinguishable . . . " (p 434)</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Blinding of outcome assessment (detection bias) <br> All outcomes </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Unclear risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Placebo, characteristics of nature and schedules were not given</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Incomplete outcome data (attrition bias) <br> All outcomes </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>High risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Loss of participants: 27% (40/149)</p> <p> <ol id="CD008548-lst1-0076"> <li> <p>Adverse event: Intervention group 1 = 22% (2/9); Intervention group 2 = (26% (4/15); Control group = 19% (3/16) </p> </li> <li> <p>Lost to follow‐up: Intervention group 1 = 22% (2/9); Intervention group 2 = 13% (2/15); Control group = 13% (2/16) </p> </li> <li> <p>Mortality: Intervention group 1 = 22% (3/9); Intervention group 2 = 13% (2/15); Control group = 13% (2/16) </p> </li> <li> <p>Lesion progression: Intervention group 1 = 44% (4/9); Intervention group 2 = 27% (4/15); Control group = 19% (3/16) </p> </li> <li> <p>No response at week 2: Intervention group 1 = 11% (1/9); Intervention group 2 = 33% (5/15); Control group = 50% (8/16) </p> </li> </ol> </p> <p>Quote "Nine patients in the lower EGF dose and placebo groups switched treatment at week 2 and are defined as non healers in further analysis. This design could have some impact on outcome regarding granulation rates at the week 8 visit and closure rates at 1 year follow‐up" (p 437) </p> <p>It is likely that the principle of ITT analysis was violated</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Selective reporting (reporting bias)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>High risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>One or more outcomes of interest in the review were reported incompletely so that they could not be entered in a meta‐analysis </p> <p>Time‐to‐complete response was reported using odds ratio (p 435)</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Other bias</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>High risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p> <ol id="CD008548-lst1-0077"> <li> <p>This trial did not report hazard ratios for time to complete wound closure</p> </li> <li> <p>Bias in the presentation of data and design bias, see <a href="appendices#CD008548-sec2-0016">Appendix 1</a> </p> </li> </ol> </p> </td> </tr> </tbody> </table> </div> <div class="table" id=""> <table> <div class="table-heading"><span class="table-label"></span><span class="table-title">Hanft 2008 </span></div> <tbody> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Methods</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p> <ol id="CD008548-lst1-0078"> <li> <p>Parallel‐design (2 arms)</p> </li> <li> <p>Country: USA (9 sites)</p> </li> <li> <p>Follow‐up period: 12 weeks</p> </li> <li> <p>Unit of randomisation: participant</p> </li> <li> <p>Analysis unit: participant</p> </li> </ol> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Participants</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p> <ol id="CD008548-lst1-0079"> <li> <p>Randomised: 55</p> <ol id="CD008548-lst2-0050"> <li> <p>Intervention group (telbermin): 53% (29/55)</p> </li> <li> <p>Control group (placebo): 47% (26/55)</p> </li> </ol> </li> <li> <p>Age (years; mean and range)</p> <ol id="CD008548-lst2-0051"> <li> <p>Intervention group (telbermin): 59.5 (42‐74)</p> </li> <li> <p>Control group (placebo): 59.3 (38‐81)</p> </li> <li> <p>All participants: 59.4 (38‐81)</p> </li> </ol> </li> <li> <p>Gender (male)</p> <ol id="CD008548-lst2-0052"> <li> <p>Intervention group (telbermin): 66% (19/29)</p> </li> <li> <p>Control group (placebo): 69% (18/26)</p> </li> </ol> </li> <li> <p>Inclusion criteria</p> <ol id="CD008548-lst2-0053"> <li> <p>People aged 18‐80 years with type 1 or 2 diabetes mellitus</p> </li> <li> <p>HbA1c ≤ 12%</p> </li> <li> <p>Grade 1A ulcer, as defined by the University of Texas Diabetic Wound Classification</p> </li> <li> <p>Chronic ulcer with a duration of ≥ 4 weeks but &lt; 6 months</p> </li> <li> <p>Ulcer area, following sharp debridement, of 1‐4 cm<sup>2</sup> </p> </li> <li> <p>ABPI of 0.6‐1.2 on the study foot</p> </li> <li> <p>For females of childbearing potential, use of an effective method of contraception</p> </li> <li> <p>Subjects with Charcot or another deformity of the study foot were included provided the deformity did not involve the study ulcer </p> </li> </ol> </li> <li> <p>Exclusion criteria</p> <ol id="CD008548-lst2-0054"> <li> <p>Active ulcer infection or cellulitis of any ulcer</p> </li> <li> <p>Ulcers with an aetiology unrelated to diabetes</p> </li> <li> <p>Active osteomyelitis in the study foot</p> </li> <li> <p>Subjects with ulcers related to an incompletely healed amputation wound</p> </li> <li> <p>Use of any investigational drug/therapy on the study foot within the past month</p> </li> <li> <p>Previous use of platelet‐derived or other growth factors on the study ulcer within the past 3 months </p> </li> <li> <p>Immunosuppressive treatment</p> </li> <li> <p>History of neoplasia or current neoplasia (with the exception of non‐melanoma skin cancer) </p> </li> <li> <p>Proliferatuve diabetic retinopathy or wet age‐related macular degeneration</p> </li> <li> <p>Connective tissue disease</p> </li> <li> <p>Pregnancy or lactation</p> </li> <li> <p>Multiple ulcers on the study foot</p> </li> <li> <p>Renal failure (serum creatinine of &gt; 3.0 mg/dL)</p> </li> <li> <p>Poor nutritional status (albumin of &lt; 3.0 g/dL)</p> </li> <li> <p>Known hypersensitivity to any ingredients of telbermin, placebo or vehicle including usually inactive substances in the formulation of telbermin or placebo gel </p> </li> <li> <p>Known prior instability likely to affect completion of required study visits during the treatment period </p> </li> </ol> </li> </ol> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Interventions</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p> <ol id="CD008548-lst1-0080"> <li> <p>Intervention group: recombinant human vascular endothelial growth factor (telbermin), 72 µg/cm<sup>2</sup> over the entire ulcer surface and margins, 3 times/week, for 6 weeks </p> </li> <li> <p>Control: placebo (formulated bulk solution without telbermin) in methylcellulose gel for 6 weeks </p> </li> </ol> </p> <p>Co‐interventions: standard good wound care including periodic sharp debridement at the clinician's discretion, also offloading </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Outcomes</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p> <ol id="CD008548-lst1-0081"> <li> <p>Primary:</p> <ol id="CD008548-lst2-0055"> <li> <p>Safety, measured as incidence of clinically significant hypotension (a drop of ≥ 35 mmHg in systolic blood pressure relative to pre‐dose level) 60 minutes after application of the study drug during the first week of treatment. </p> </li> <li> <p>Efficacy, assessed as percentage reduction in total ulcer surface area at day 43 (up to day 49 as the week 7 study visit could occur any time between days 43 and 49 for scheduling flexibility) from baseline (day 1), as determined by quantitative analysis of the planimetric tracings </p> </li> </ol> </li> <li> <p>Secondary</p> <ol id="CD008548-lst2-0056"> <li> <p>Safety:</p> <ol id="CD008548-lst3-0001"> <li> <p>incidence of clinical significant ulcer infection, defined as increased discharge and malodorous exudates from the ulcer, fever (≥ 38.6 °C) and white blood cell count &gt; 10000/µl </p> </li> <li> <p>development of anti‐telbermin antibodies</p> </li> <li> <p>incidence of adverse events</p> </li> </ol> </li> <li> <p>Efficacy:</p> <ol id="CD008548-lst3-0002"> <li> <p>percentage reduction in total ulcer surface area at days 29 and 84 from baseline (day 1) </p> </li> <li> <p>incidence of ulcer healing at days 29, 43 and 84</p> </li> <li> <p>time (days) to complete ulcer healing</p> </li> <li> <p>time (days) to recurrence for subjects whose ulcers had healed completely before day 84 </p> </li> <li> <p>incidence of increased total ulcer surface area (more than 15%), compared with baseline (day 1) </p> </li> <li> <p>incidence of a progression in ulcer stage (University of Texas Classification Diabetic Wound Classification) </p> </li> </ol> </li> </ol> </li> </ol> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Notes</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p> <ol id="CD008548-lst1-0082"> <li> <p>A priori sample size estimation: yes (p 32)</p> </li> <li> <p>Sponsor: Genentech, South San Francisco, CA</p> </li> <li> <p>Role of sponsor: assistance with writing</p> </li> </ol> </p> </td> </tr> <tr> <td align="" valign="" colspan="3" rowspan="1" bgcolor="#ffffff"> <p><b><i>Risk of bias</i> </b> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Bias</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Authors' judgement</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Support for judgement</b> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Random sequence generation (selection bias)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Unclear risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Insufficient information provided to permit a judgment of 'low risk' or 'high risk'</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Allocation concealment (selection bias)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Unclear risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Insufficient information provided to permit a judgment of 'low risk' or 'high risk'</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Blinding of participants and personnel (performance bias) <br> All outcomes </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Unclear risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Insufficient information provided to permit a judgment of 'low risk' or 'high risk'</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Blinding of outcome assessment (detection bias) <br> All outcomes </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Quote " . . . a masked, third‐party, reading centre . . performed the quantitative measurements" (p 31) </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Incomplete outcome data (attrition bias) <br> All outcomes </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>High risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Lost participants: total loss = 20% (11/55): Intervention group 24% (7/29); Control group 15% (4/26) </p> <p>Reasons:</p> <p> <ol id="CD008548-lst1-0083"> <li> <p>infections: Intervention group 14% (1/7); Control group 25% (1/4)</p> </li> <li> <p>mortality: Intervention group 14% (1/7); Control group 0% (0/4)</p> </li> <li> <p>lost to follow‐up: Intervention group 0% (0/7); Control group 25% (1/4)</p> </li> <li> <p>participant choice: Intervention group 42% (3/7); Control group 50% (2/4)</p> </li> </ol> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Selective reporting (reporting bias)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>High risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>One or more outcomes of interest in the review were reported incompletely so they could not be entered in a meta‐analysis </p> <p>Quote "Median time to complete healing was 58 days for telbermin‐treated subjects. This could not be estimated for placebo‐treated subjects because fewer than 50% healed completely during the 12‐week study period." (p 35) </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Other bias</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>High risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Bias in the presentation of data and design bias, see <a href="appendices#CD008548-sec2-0016">Appendix 1</a> </p> <p>Funding bias</p> <p>Many trial authors are or have been employed by Genentech or own Genentech stock</p> </td> </tr> </tbody> </table> </div> <div class="table" id=""> <table> <div class="table-heading"><span class="table-label"></span><span class="table-title">Hardikar 2005 </span></div> <tbody> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Methods</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p> <ol id="CD008548-lst1-0084"> <li> <p>Parallel‐design (2 arms)</p> </li> <li> <p>Country: India (8 sites)</p> </li> <li> <p>Follow‐up: 20 weeks</p> </li> <li> <p>Unit of randomisation: participant</p> </li> <li> <p>Analysis unit: participant</p> </li> </ol> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Participants</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p> <ol id="CD008548-lst1-0085"> <li> <p>Randomised: 113</p> <ol id="CD008548-lst2-0057"> <li> <p>Treatment group: 55 (48.67%)</p> </li> <li> <p>Control group: 58 (51.33%)</p> </li> </ol> </li> <li> <p>Age (years mean ± standard deviation (SD))</p> <ol id="CD008548-lst2-0058"> <li> <p>Treatment group: 54.5 ± 9.9</p> </li> <li> <p>Control group: 54.7 ± 9.0</p> </li> </ol> </li> <li> <p>Gender (male)</p> <ol id="CD008548-lst2-0059"> <li> <p>Treatment group: 73% (40/55)</p> </li> <li> <p>Control group: 69% (40/58)</p> </li> </ol> </li> <li> <p>Inclusion criteria</p> <ol id="CD008548-lst2-0060"> <li> <p>Type 1 or 2 diabetes mellitus</p> </li> <li> <p>Age ≥ 18 years but ≤ 80 years</p> </li> <li> <p>At least 1, but &lt; 3 full‐thickness chronic neuropathic ulcers of at least 4 weeks duration on the lower extremity </p> </li> <li> <p>Only ulcers categorized as stage III or stage IV (according to the Wound, Ostomy, and Continence Nurses Society) </p> </li> <li> <p>Ulcers with infection control as determined by a wound evaluation score could be included</p> </li> <li> <p>Evidence of adequate perfusion of the foot, assessed by colour arterial Doppler ultrasonography</p> </li> </ol> </li> <li> <p>Exclusion criteria</p> <ol id="CD008548-lst2-0061"> <li> <p>Arterial venous ulcers</p> </li> <li> <p>Ulcers caused by osteomyelitis or burns</p> </li> <li> <p>Poor nutritional status (serum total proteins &lt; 6.5 g/dL)</p> </li> <li> <p>Persistent infection</p> </li> <li> <p>Life‐threatening concomitant diseases</p> </li> <li> <p>Deformities like Charcot foot</p> </li> <li> <p>Chronic renal insufficiency (serum creatinine &gt; 3 mg/dL)</p> </li> <li> <p>Uncontrolled hyperglycaemia (HbA1c &gt; 12%)</p> </li> <li> <p>History of use of corticosteroids or immunosuppressants</p> </li> <li> <p>Hypersensitivity to the gel components of the intervention</p> </li> <li> <p>Women who were pregnant or nursing</p> </li> <li> <p>Women of childbearing age who were not taking contraceptives or were not willing to use them </p> </li> </ol> </li> </ol> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Interventions</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p> <ol id="CD008548-lst1-0086"> <li> <p>Intervention group: recombinant human platelet‐derived growth factor (becaplermin), 0.01% gel containing 100 μg of experimental drug, daily application&nbsp; </p> </li> <li> <p>Control: placebo, details not reported</p> </li> </ol> </p> <p>Co‐interventions: standard wound care regimen consisting of appropriate sharp surgical debridement; daily ulcer cleaning and dressing; and offloading (e.g. crutches or wheelchair), or, where possible, complete bed rest. During this 1‐week period, before the baseline visit (visit 2), a regimen of daily wound cleaning and dressing with appropriate non‐weight bearing was followed. The use of antidiabetic medication and appropriate use of systemic antibiotics was advised during the treatment period </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Outcomes</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p> <ol id="CD008548-lst1-0087"> <li> <p>Primary: percentage of participants achieving complete wound closure</p> </li> <li> <p>Secondary</p> <ol id="CD008548-lst2-0062"> <li> <p>Time to achieve complete wound closure</p> </li> <li> <p>Percentage reduction in the ulcer surface area at each visit</p> </li> <li> <p>Total wound evaluation score at endpoint</p> </li> <li> <p>Safety</p> </li> </ol> </li> </ol> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Notes</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p> <ol id="CD008548-lst1-0088"> <li> <p>A priori sample size estimation: not reported</p> </li> <li> <p>Sponsor: Research and Development Department, Virchow Biotech Pvt Ltd, Hyderabad, India </p> </li> <li> <p>Role of sponsor: supported the study</p> </li> </ol> </p> </td> </tr> <tr> <td align="" valign="" colspan="3" rowspan="1" bgcolor="#ffffff"> <p><b><i>Risk of bias</i> </b> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Bias</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Authors' judgement</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Support for judgement</b> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Random sequence generation (selection bias)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Unclear risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Insufficient information provided to permit a judgment of 'low risk' or 'high risk'</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Allocation concealment (selection bias)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Unclear risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Insufficient information provided to permit a judgment of 'low risk' or 'high risk'</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Blinding of participants and personnel (performance bias) <br> All outcomes </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Quote " the authors are not privy to the differences in the formulation available commercially" (p 2/11) </p> <p>Comment: both comparisons probably had similar appearances</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Blinding of outcome assessment (detection bias) <br> All outcomes </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Unclear risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Insufficient information provided to permit a judgment of 'low risk' or 'high risk'</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Incomplete outcome data (attrition bias) <br> All outcomes </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>High risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Lost to follow‐up: total = 19% (21/113)<br> Intervention group: 13% (7/55) and placebo group 24% (14/58) </p> <p>Imbalance between comparison groups: 11%.</p> <p>Reasons:</p> <p> <ol id="CD008548-lst1-0089"> <li> <p>lost to follow‐up: Intervention group 1/7; Control group 6/14</p> </li> <li> <p>no compliance: Intervention group 2/7; Control group 1/14</p> </li> <li> <p> Intervention group 4/7; Control group 6/14</p> </li> <li> <p>other reasons: Intervention group 0/7; Control group 1/14</p> </li> </ol> </p> <p>Comment: reason for missing outcome data likely to be related to true outcome, with either imbalance in numbers or reasons for missing data across intervention groups </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Selective reporting (reporting bias)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>High risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Safety data were poorly reported, and, therefore, could not be entered in a meta‐analysis</p> <p>This trial did not report hazard ratios for assessing time to complete wound closure</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Other bias</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>High risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Design bias, bias of presentation bias, see <a href="appendices#CD008548-sec2-0016">Appendix 1</a> </p> <p>Funding bias</p> </td> </tr> </tbody> </table> </div> <div class="table" id=""> <table> <div class="table-heading"><span class="table-label"></span><span class="table-title">Holloway 1993 </span></div> <tbody> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Methods</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p> <ol id="CD008548-lst1-0090"> <li> <p>Parallel‐design (4 arms), 2‐phase study</p> </li> <li> <p>Country: USA</p> </li> <li> <p>Follow‐up: 20 weeks</p> </li> <li> <p>Unit of randomisation: participant</p> </li> <li> <p>Analysis unit: participant</p> </li> </ol> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Participants</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p> <ol id="CD008548-lst1-0091"> <li> <p>Total randomised participants: unclear</p> <ol id="CD008548-lst2-0063"> <li> <p>First phase</p> <ol id="CD008548-lst3-0003"> <li> <p>Randomised: 14</p> </li> <li> <p>Intervention group: number not specified</p> </li> <li> <p>Control group: number not specified</p> </li> </ol> </li> <li> <p>Second phase</p> <ol id="CD008548-lst3-0004"> <li> <p>Randomised: 97 (number of wounds: not specified)</p> </li> <li> <p>Randomised and treated: 81 (91 wounds)</p> </li> <li> <p>Randomised and analysed: 70 (77 wounds)</p> <ol id="CD008548-lstN-0001"> <li> <p>platelet‐derived wound healing formula 0.01 dilution group: 15</p> </li> <li> <p>platelet‐derived wound healing formula 0.033 dilution group: 13</p> </li> <li> <p>platelet‐derived wound healing formula 0.1 dilution group: 21</p> </li> <li> <p>Control (placebo) group: 21</p> </li> </ol> </li> </ol> </li> </ol> </li> <li> <p>Age of randomised and analysed participants: (mean years): 59.4 to 62.6 years</p> </li> <li> <p>Gender (male):</p> <ol id="CD008548-lst2-0064"> <li> <p>platelet‐derived wound healing formula 0.01: 73% (11/15)</p> </li> <li> <p>platelet‐derived wound healing formula 0.033: 77% (10/13)</p> </li> <li> <p>platelet‐derived wound healing formula 0.1: 81% (17/21)</p> </li> <li> <p>Placebo: 67% (14/21)</p> </li> </ol> </li> <li> <p>Inclusion criteria</p> <ol id="CD008548-lst2-0065"> <li> <p>People with diabetes mellitus with at least 1 chronic, nonhealing diabetic ulcer of 8 weeks duration </p> </li> <li> <p>Wounds 500 mm<sup>3</sup>‐50,000 mm<sup>3</sup> </p> </li> </ol> </li> <li> <p>Exclusion criteria</p> <ol id="CD008548-lst2-0066"> <li> <p>Wounds possibly containing malignant cells</p> </li> <li> <p>Pre‐existing diseases or terminal disease</p> </li> <li> <p>Pregnant, nursing or of childbearing potential</p> </li> </ol> </li> </ol> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Interventions</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p> <ol id="CD008548-lst1-0092"> <li> <p>Intervention group</p> <ol id="CD008548-lst2-0067"> <li> <p>First phase: thrombin‐induced, platelet‐released platelet‐derived wound healing formula 0.01 dilution </p> </li> <li> <p>Second phase: thrombin‐induced, platelet‐released platelet‐derived wound healing formula (0.01, 0.1, and 0.033 dilutions) </p> </li> </ol> </li> <li> <p>Control group:</p> <ol id="CD008548-lst2-0068"> <li> <p>First phase: physiologic saline solution</p> </li> <li> <p>Second phase: isotonic platelet buffer containing 2‐[4‐(2‐hydroxyethyl)piperazin‐1‐yl]ethanesulfonic acid (HEPES), glucose sodium chloride and potassium chloride (pH 6.6) </p> </li> </ol> </li> </ol> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Outcomes</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p>Primary: healed (functional assessment points 3 &amp; 4 in original paper):</p> <p>"3: 100% epithelized; maturing skin with a small amount of drainage; requires protective dressing only. </p> <p>4: 100% epithelized; maturing skin with a small amount of drainage; no dressing required" (p 200) </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Notes</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p> <ol id="CD008548-lst1-0093"> <li> <p>This trial had 2 phases using 2 random sequence generations:</p> <ol id="CD008548-lst2-0069"> <li> <p>first phase included the first 14 participants, platelet‐derived wound healing formula 0.01 dilution (experimental group) and physiologic saline solution as placebo </p> </li> <li> <p>second phase (second randomisation) was conducted to include 2 additional dilutions of platelet‐derived wound healing formula (0.1 and 0.033) and a new placebo (isotonic platelet buffer containing 2‐[4‐(2‐hydroxyethyl)piperazin‐1‐yl]ethanesulfonic acid, glucose sodium chloride and potassium chloride). </p> </li> </ol> </li> <li> <p>A priori sample size estimation: not reported</p> </li> <li> <p>Sponsor: Curative Technologies, Inc</p> </li> <li> <p>Role of sponsor: financial</p> </li> </ol> </p> </td> </tr> <tr> <td align="" valign="" colspan="3" rowspan="1" bgcolor="#ffffff"> <p><b><i>Risk of bias</i> </b> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Bias</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Authors' judgement</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Support for judgement</b> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Random sequence generation (selection bias)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Quote " . . . computer generated list of random numbers . . . " (p 200)</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Allocation concealment (selection bias)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Unclear risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Insufficient information provided to permit a judgment of 'low risk' or 'high risk'</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Blinding of participants and personnel (performance bias) <br> All outcomes </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Quote "the appearance of the double‐blind medication and the packaging were identical for drug and placebo to prevent unblinding" (p 200) </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Blinding of outcome assessment (detection bias) <br> All outcomes </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Unclear risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Insufficient information provided to permit a judgment of 'low risk' or 'high risk'</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Incomplete outcome data (attrition bias) <br> All outcomes </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Unclear risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Lost 16% (16/97) post randomisation because failed to meet inclusion criteria ‐ no details provided regarding loss according to group </p> <p>Loss of randomised and treated participants (total = 81) by comparison group</p> <p> <ol id="CD008548-lst1-0094"> <li> <p>Intervention group 1 = 1</p> </li> <li> <p>Intervention group 2 = 3</p> </li> <li> <p>Intervention group 3 = 6</p> </li> <li> <p>Control group = 1</p> </li> <li> <p>All intervention groups = 10</p> </li> </ol> </p> <p>Quote "eleven patients with 14 wounds were excluded from the efficacy analysis due to noncompliance with protocol" (p 201) </p> <p>Reasons:</p> <p> <ol id="CD008548-lst1-0095"> <li> <p>Lost to follow up:</p> <ol id="CD008548-lst2-0070"> <li> <p>Intervention group 2: 33% (1/3)</p> </li> </ol> </li> <li> <p>Non compliance:</p> <ol id="CD008548-lst2-0071"> <li> <p>Intervention group 1: 100% (1/1)</p> </li> <li> <p>Intervention group 2: 66% (2/3)</p> </li> <li> <p>Intervention group 3: 50% (3/6)</p> </li> <li> <p>Control group: 100% (1/1)</p> </li> </ol> </li> <li> <p>Early amputation:</p> <ol id="CD008548-lst2-0072"> <li> <p>Intervention group 3: 33% (2/6)</p> </li> </ol> </li> <li> <p>Occluded vascular graft:</p> <ol id="CD008548-lst2-0073"> <li> <p>Intervention group 3: 16% (1/6)</p> </li> </ol> </li> </ol> </p> <p>Imbalance between comparison groups: unclear</p> <p>Quote "four patients were lost to follow up after 12 weeks and 5 patients missed the last or second‐to‐last visit" (p 201) </p> <p>Authors did not report whether these losses were in addition to those specified above and did not supply information about the timing of the losses </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Selective reporting (reporting bias)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>High risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>One outcome (complete wound closure) was reported incompletely</p> <p>This trial did not report safety data</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Other bias</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>High risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Bias of the presentation data and information bias, see <a href="appendices#CD008548-sec2-0016">Appendix 1</a> </p> <p>Quote " . . . The first 14 patients were given either 0.01 dilution of CT‐102 or a placebo consisting of physiologic saline solution. The study was later revised to include two additional dilutions of CT‐102 at 0.1 and 0.033. At that time a new randomization scheme was generated. A limited analysis conducted on the first 14 patients to ensure that there were no problems with the protocol. The placebo solution was at that time changed to an isotonic platelet buffer containing N<sup>1</sup>‐2‐hydroxiethiyl piperazine‐N‐2‐ethanesulfonic acid (HEPES), glucose sodium chloride and potassium chloride (pH=6.6) . . . " (p 200) </p> <p>Funding bias</p> </td> </tr> </tbody> </table> </div> <div class="table" id=""> <table> <div class="table-heading"><span class="table-label"></span><span class="table-title">Jaiswal 2010 </span></div> <tbody> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Methods</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p> <ol id="CD008548-lst1-0096"> <li> <p>Parallel‐design (2 arms)</p> </li> <li> <p>Country: India</p> </li> <li> <p>Follow‐up: 10 weeks</p> </li> <li> <p>Unit of randomisation: participant</p> </li> <li> <p>Analysis unit: participant</p> </li> </ol> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Participants</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p> <ol id="CD008548-lst1-0097"> <li> <p>Randomised: 50</p> <ol id="CD008548-lst2-0074"> <li> <p>Intervention group: 25 (50%)</p> </li> <li> <p>Control group: 25 (50%)</p> </li> </ol> </li> <li> <p>Age (mean years)</p> <ol id="CD008548-lst2-0075"> <li> <p>Intervention group: 56.2</p> </li> <li> <p>Control group: 49.9</p> </li> </ol> </li> <li> <p>Gender (male)</p> <ol id="CD008548-lst2-0076"> <li> <p>Intervention group: 76% (19/25)</p> </li> <li> <p>Control group: 92% (23/25)</p> </li> </ol> </li> <li> <p>Inclusion criteria</p> <ol id="CD008548-lst2-0077"> <li> <p>Type 1 or type 2 diabetes mellitus and chronic ulcers of at least 4 weeks duration of IAET stage III and IV </p> </li> </ol> </li> <li> <p>Exclusion criteria:</p> <ol id="CD008548-lst2-0078"> <li> <p>ABPI &lt; 0.9</p> </li> </ol> </li> </ol> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Interventions</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p> <ol id="CD008548-lst1-0098"> <li> <p>Intervention group: recombinant human platelet‐derived growth factor (Plermin, Dr Reddy's Laboratories Ltd) 0.01% gel topical application </p> </li> <li> <p>Control group: topically applied placebo (KY Jelly (Ethnor) ‐ a lubricating jelly containing glycerin 11.2%, methylparaben 0.1% and propylparaben 0.04%) </p> </li> </ol> </p> <p>Co‐interventions: standardised regimen of good wound care; pressure offloading for participants with plantar ulcers </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Outcomes</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p>Primary outcome: healing or percent reduction in size of the wound</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Notes</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p> <ol id="CD008548-lst1-0099"> <li> <p>Sample size a priori calculation: not reported</p> </li> <li> <p>Sponsor: not reported</p> </li> </ol> </p> </td> </tr> <tr> <td align="" valign="" colspan="3" rowspan="1" bgcolor="#ffffff"> <p><b><i>Risk of bias</i> </b> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Bias</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Authors' judgement</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Support for judgement</b> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Random sequence generation (selection bias)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Quote "on the basis of computer generated numbers" (p 32)</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Allocation concealment (selection bias)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Unclear risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Insufficient information provided to permit a judgment of 'low risk' or 'high risk'</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Blinding of participants and personnel (performance bias) <br> All outcomes </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Unclear risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Insufficient information provided to permit a judgment of 'low risk' or 'high risk'</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Blinding of outcome assessment (detection bias) <br> All outcomes </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Unclear risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Insufficient information provided to permit a judgment of 'low risk' or 'high risk'</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Incomplete outcome data (attrition bias) <br> All outcomes </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Unclear risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Insufficient reporting of attrition/exclusions to permit a judgement of ‘low risk’ or ‘high risk’ (i.e. no reasons provided for missing data) </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Selective reporting (reporting bias)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>High risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Information on time to healed and safety was not provided</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Other bias</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>High risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Bias of presentation data, see <a href="appendices#CD008548-sec2-0016">Appendix 1</a> </p> </td> </tr> </tbody> </table> </div> <div class="table" id=""> <table> <div class="table-heading"><span class="table-label"></span><span class="table-title">Kakagia 2007 </span></div> <tbody> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Methods</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p> <ol id="CD008548-lst1-0100"> <li> <p>Parallel‐design (3 arms)</p> </li> <li> <p>Country: Greece</p> </li> <li> <p>Study period: 8 weeks</p> </li> <li> <p>Unit of randomisation: participant</p> </li> <li> <p>Unit analysis: participant</p> </li> </ol> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Participants</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p> <ol id="CD008548-lst1-0101"> <li> <p>Enrolled: 72</p> </li> <li> <p>Randomised: 51</p> <ol id="CD008548-lst2-0079"> <li> <p>Intervention group 1 (oxidized regenerated cellulose/collagen biomaterial): 33.33% (17/51) </p> </li> <li> <p>Intervention group 2 (autologous growth factor delivered by gravitational platelet separation system): 33.33% (17/51) </p> </li> <li> <p>Intervention group 3 (both above interventions): 33.33% (17/51)</p> </li> </ol> </li> <li> <p>Age (years, mean ± standard deviation (SD))</p> <ol id="CD008548-lst2-0080"> <li> <p>Intervention group 1 (oxidized regenerated cellulose/collagen biomaterial): 58 ± 10</p> </li> <li> <p>Intervention group 2 (Autologous growth factor delivered by gravitational platelet separation system): 57 ± 12 </p> </li> <li> <p>Intervention group 3 (both above interventions): 61 ± 9</p> </li> </ol> </li> <li> <p>Gender (male)</p> <ol id="CD008548-lst2-0081"> <li> <p>Global: 43.13% (22/51).</p> </li> </ol> </li> <li> <p>Inclusion criteria</p> <ol id="CD008548-lst2-0082"> <li> <p>Diabetic participants with significant soft tissue defects of the foot that had been present for at least 3 months </p> </li> <li> <p>Target ulcers ≥ 2.5 cm in any dimension after debridement</p> </li> </ol> </li> <li> <p>Exclusion criteria</p> <ol id="CD008548-lst2-0083"> <li> <p>Previous treatment with vacuum, hyperbaric oxygen, corticosteroid, immunosuppressive agents, radiation, or growth factors </p> </li> <li> <p>Anaemia</p> </li> <li> <p>Presence of cellulitis or venous stasis</p> </li> <li> <p>Inadequate perfusion determined by toe pulses of &lt; 40</p> </li> <li> <p>Osteomyelitis</p> </li> <li> <p>Malignancy in the wound</p> </li> <li> <p>Inability to attend clinics for follow‐up</p> </li> </ol> </li> </ol> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Interventions</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p> <ol id="CD008548-lst1-0102"> <li> <p>Intervention group 1: oxidized regenerated cellulose/collagen biomaterial (Promogran, Johnson &amp; Johnson, New Brunswick, NJ) </p> </li> <li> <p>Intervention group 2: autologous growth factor delivered by gravitational platelet separation system (GPS, Biomet) </p> </li> <li> <p>Intervention group 3: combination of both treatments above</p> </li> </ol> </p> <p>Co‐interventions: all wounds were sharply debrided prior to the first application of dressings and were assessed weekly for 8 weeks </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Outcomes</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p>Change in ulcer dimensions within the 8‐week follow‐up</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Notes</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p> <ol id="CD008548-lst1-0103"> <li> <p>A priori sample size estimation: not reported</p> </li> <li> <p>Sponsor: not reported</p> </li> </ol> </p> </td> </tr> <tr> <td align="" valign="" colspan="3" rowspan="1" bgcolor="#ffffff"> <p><b><i>Risk of bias</i> </b> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Bias</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Authors' judgement</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Support for judgement</b> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Random sequence generation (selection bias)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Quote " . . . random number generator" (p 388)</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Allocation concealment (selection bias)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Unclear risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Insufficient information provided to permit a judgment of 'low risk' or 'high risk'</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Blinding of participants and personnel (performance bias) <br> All outcomes </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Unclear risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Insufficient information provided to permit a judgment of 'low risk' or 'high risk'</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Blinding of outcome assessment (detection bias) <br> All outcomes </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Unclear risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Insufficient information provided to permit a judgment of 'low risk' or 'high risk'</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Incomplete outcome data (attrition bias) <br> All outcomes </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Unclear risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Insufficient reporting of attrition/exclusions to permit a judgement of ‘low risk’ or ‘high risk’ (i.e. no reasons provided for missing data) </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Selective reporting (reporting bias)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>High risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>This trial did not report safety data</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Other bias</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>High risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Bias of presentation data, see <a href="appendices#CD008548-sec2-0016">Appendix 1</a> </p> <p>Author did not supply information on wound area at the end of the trial</p> </td> </tr> </tbody> </table> </div> <div class="table" id=""> <table> <div class="table-heading"><span class="table-label"></span><span class="table-title">Landsman 2010 </span></div> <tbody> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Methods</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p>Randomized, controlled trial, parallel design (2 arms)<br> Country study: USA<br> Intention to treat: unclear<br> Follow up period: 20 weeks </p> <p>Unit of randomization: unclear<br> Unit of analysis: ulcers </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Participants</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p>Randomised: 32, no further details provided</p> <p>Age (years)<br> Intervention group (becaplermin plus TheraGauze): 58.1<br> Control group (TheraGauze): 56.2 </p> <p>Gender (male): not reported<br> Inclusion criteria </p> <p> <ol id="CD008548-lst1-0104"> <li> <p>Forefoot or midfoot ulcer</p> </li> <li> <p>Wagner grade 1 or 2</p> </li> <li> <p>Tolerate offloading with healing shoe, fixed ankle walker, or non‐weight‐bearing</p> </li> <li> <p>Age 18‐70 years</p> </li> <li> <p>Insulin dependent diabetes mellitus or non insulin dependent diabetes mellitus (IDDM or NIDDM) </p> </li> <li> <p>HbA1c ≤ 10% of total Hb</p> </li> <li> <p>Palpable dorsalis pedis and posterior tibial pulses</p> </li> <li> <p>1‐8 cm<sup>2</sup> wound surface area </p> </li> </ol> </p> <p>Exclusion criteria</p> <p> <ul class="plain" id="CD008548-lst1-0105"> <li> <ol id="CD008548-lst2-0084"> <li> <p>Active infection, including purulent discharge, cellulitis, or both</p> </li> <li> <p>Exposed bone</p> </li> <li> <p>Osteomyelitis associated with ulcer</p> </li> <li> <p>Dorsal ulcer</p> </li> <li> <p>Ischaemic ulcers</p> </li> <li> <p>Evidence of gangrene</p> </li> </ol> </li> </ul> </p> <p>Withdrawal: not reported</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Interventions</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p> <ol id="CD008548-lst1-0106"> <li> <p>Intervention group: recombinant human platelet‐derived growth factor (becaplermin, Regranex 0.01%) daily in accordance with the manufacturer's recommendations, plus moisture‐regulating dressing (TheraGauze<sup>®</sup>, Soluble systems LLC, Newport News, Virginia) </p> </li> <li> <p>Control group: moisture‐regulating dressing (TheraGauze<sup>®</sup>, Soluble systems LLC, Newport News, Virginia) applied directly to the wound surface every other day </p> </li> </ol> </p> <p>Co‐interventions: standard wound debridement as needed, offloading with a fixed ankle walker (Royce Medical Diabetic Boot; Ossur Medical, Camarillo, California), and dressing changes every other day </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Outcomes</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p> <ol id="CD008548-lst1-0107"> <li> <p>Time to closure (full epithelialisation)</p> </li> <li> <p>Rate of change in wound surface area</p> </li> </ol> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Notes</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p> <ol id="CD008548-lst1-0108"> <li> <p>A priori sample size estimation: not reported</p> </li> <li> <p>Sponsor: Soluble systems LLC, Newport News, Virginia</p> </li> <li> <p>Role of the sponsor: sponsor funded the study</p> </li> <li> <p>Conflict of interest: the main author is a paid consultant for Soluble systems LLC</p> </li> <li> <p>Email was sent to the main author requesting data on main outcome</p> </li> </ol> </p> </td> </tr> <tr> <td align="" valign="" colspan="3" rowspan="1" bgcolor="#ffffff"> <p><b><i>Risk of bias</i> </b> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Bias</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Authors' judgement</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Support for judgement</b> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Random sequence generation (selection bias)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Unclear risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Quote "Professional, independent monitoring and centralized randomization" (p 156)</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Allocation concealment (selection bias)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Unclear risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Insufficient information provided to permit a judgment of 'low risk' or 'high risk'</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Blinding of participants and personnel (performance bias) <br> All outcomes </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Unclear risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Insufficient information provided to permit a judgment of 'low risk' or 'high risk'</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Blinding of outcome assessment (detection bias) <br> All outcomes </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Unclear risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Insufficient information provided to permit a judgment of 'low risk' or 'high risk'</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Incomplete outcome data (attrition bias) <br> All outcomes </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Unclear risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Insufficient reporting of attrition/exclusions to permit a judgement of ‘low risk’ or ‘high risk’ (i.e. no reasons provided for missing data) </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Selective reporting (reporting bias)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>High risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>One outcome (Time to closure (full epithelialization) was reported incompletely so that it could not be included in the meta‐analysis. This trial did not report safety data </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Other bias</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>High risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Design bias and bias of presentation data, see <a href="appendices#CD008548-sec2-0016">Appendix 1</a> </p> <p>Funding bias</p> </td> </tr> </tbody> </table> </div> <div class="table" id=""> <table> <div class="table-heading"><span class="table-label"></span><span class="table-title">Lyons 2007 </span></div> <tbody> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Methods</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p> <ol id="CD008548-lst1-0109"> <li> <p>Parallel‐design (3 arms), 2 phases</p> </li> <li> <p>Country: USA (7 sites)</p> </li> <li> <p>Follow‐up period: 6 months</p> </li> <li> <p>Unit of randomisation: participant</p> </li> <li> <p>Analysis unit: participant</p> </li> <li> <p>The study was conducted in 2 phases: phase 1 was an open‐label, sequential, dose‐escalation design. Phase 2 was a single‐blind, randomized, stratified, placebo‐controlled pilot study to evaluate the efficacy of the 2 highest dose levels below the maximum tolerated dose (if any, up to 8.5% talactoferrin gel) of topically applied talactoferrin compared with placebo. </p> </li> </ol> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Participants</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p> <ol id="CD008548-lst1-0110"> <li> <p>Randomised: 46</p> <ol id="CD008548-lst2-0085"> <li> <p>Intervention group 1 (talactoferrin (recombinant human lactoferrin) 2.5% gel): 32.6% (15/46) </p> </li> <li> <p>Intervention group 2 (talactoferrin (recombinant human lactoferrin) 8.5% gel): 32.6% (15/46) </p> </li> <li> <p>Control group (placebo gel): 34.8% (16/46)</p> </li> </ol> </li> <li> <p>Age (years, mean ± standard deviation (SD))</p> <ol id="CD008548-lst2-0086"> <li> <p>Intervention group 1 (talactoferrin (recombinant human lactoferrin) 2.5% gel): 58 ± 10 </p> </li> <li> <p>Intervention group 2 (talactoferrin (recombinant human lactoferrin) 8.5% gel): 53 ± 15 </p> </li> <li> <p>Control group (placebo gel): 56 ± 14</p> </li> </ol> </li> <li> <p>Gender (male)</p> <ol id="CD008548-lst2-0087"> <li> <p>Intervention group 1 (talactoferrin (recombinant human lactoferrin) 2.5% gel): 93% (14/15) </p> </li> <li> <p>Intervention group 2 (talactoferrin (recombinant human lactoferrin) 8.5% gel): 80% (12/15) </p> </li> <li> <p>Control group (placebo gel): 56% (9/16)</p> </li> </ol> </li> <li> <p>Inclusion criteria</p> <ol id="CD008548-lst2-0088"> <li> <p>Age:≥ 18 years</p> </li> <li> <p>Diabetes mellitus with HbA1c between 6%‐13%</p> </li> <li> <p>Presence of 1 or more diabetic neuropathic foot ulcers at, or below, the ankle that had not healed or decreased in size (≥ 30%) within the prior 4 weeks despite appropriate standard treatment </p> </li> <li> <p>Index ulcer required to be full thickness, extending through the dermis, but without tendon, muscle, joint capsule, or bone exposure, and without sinus tract, with post debridement size of 0.5 to 10 cm<sup>2</sup> </p> </li> <li> <p>Transcutaneous oxygen tension of ≥ 30 mmHg or ABPI ≥ 0.7</p> </li> </ol> </li> <li> <p>Exclusion criteria</p> <ol id="CD008548-lst2-0089"> <li> <p>Target ulcer from any cause other than diabetes</p> </li> <li> <p>Signs of clinical wound related infection, including ‐ but not limited to ‐ cellulitis, osteomyelitis, gangrene, or deep tissue infection in the study extremity </p> </li> <li> <p>Active Charcot's foot on the limb under study</p> </li> <li> <p>Prior treatment of the target ulcer with Regranex (Ortho‐McNeil Pharmaceutical, Inc, New Brunswick, NJ) within the previous 14 days, or autologous or allogeneic graft, or Dermagraft to the target ulcer within the preceding 4 weeks </p> </li> </ol> </li> </ol> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Interventions</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p> <ol id="CD008548-lst1-0111"> <li> <p>Intervention group 1: talactoferrin (recombinant human lactoferrin) 2.5% gel applied topically twice daily for 12 weeks </p> </li> <li> <p>Intervention group 2: talactoferrin (recombinant human lactoferrin) 8.5% gel applied topically twice daily for 12 weeks </p> </li> <li> <p>Control group: placebo gel applied topically twice daily for 12 weeks, no details provided about the nature of placebo </p> </li> </ol> </p> <p>Co‐interventions: standard care consisted of:</p> <p> <ol id="CD008548-lst1-0112"> <li> <p>initial and periodic (as needed) sharp debridement;</p> </li> <li> <p>twice daily saline dressing change, including cleansing with saline;</p> </li> <li> <p>offloading using standardised devices (DH Pressure Relief Walkers; Royce Medical, Camarillo, CA); </p> </li> <li> <p>systemic control of any infection</p> </li> </ol> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Outcomes</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p>Primary endpoint of phase 2: percentage of participants achieving ≥ 75% closure of the target ulcer </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Notes</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p> <ol id="CD008548-lst1-0113"> <li> <p>A priori sample size estimation: no</p> </li> <li> <p>Sponsor: Agennix Inc, Houston, TX, and the National Institute of Arthritis and Musculoskeletal and Skin Diseases of the National Institute of Health </p> </li> <li> <p>Role of the sponsor: supplied the drugs and placebo for study (p 50) and support in part (p 49) </p> </li> </ol> </p> </td> </tr> <tr> <td align="" valign="" colspan="3" rowspan="1" bgcolor="#ffffff"> <p><b><i>Risk of bias</i> </b> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Bias</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Authors' judgement</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Support for judgement</b> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Random sequence generation (selection bias)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Unclear risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Quote " . . . randomization was central . . . " (p 50)</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Allocation concealment (selection bias)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Unclear risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Insufficient information provided to permit a judgment of 'low risk' or 'high risk'</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Blinding of participants and personnel (performance bias) <br> All outcomes </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Unclear risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Quote " . . . and none of the personnel of any of the site were informed of the blinding code before completion of the study" (p 50) </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Blinding of outcome assessment (detection bias) <br> All outcomes </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Unclear risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Insufficient information provided to permit a judgment of 'low risk' or 'high risk'</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Incomplete outcome data (attrition bias) <br> All outcomes </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Unclear risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Insufficient reporting of attrition/exclusions to permit a judgement of ‘low risk’ or ‘high risk’ (i.e. no reasons provided for missing data) </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Selective reporting (reporting bias)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Unclear risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>The study protocol is not available, but it is clear that the published reports included all expected outcomes, including those that were pre‐specified </p> <p>However, this trial failed to provide separate data for each study arm</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Other bias</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>High risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Bias of presentation data, see <a href="appendices#CD008548-sec2-0016">Appendix 1</a> </p> </td> </tr> </tbody> </table> </div> <div class="table" id=""> <table> <div class="table-heading"><span class="table-label"></span><span class="table-title">Niezgoda 2005 </span></div> <tbody> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Methods</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p> <ol id="CD008548-lst1-0114"> <li> <p>Parallel‐design (2 arms)</p> </li> <li> <p>Study period: 12 weeks</p> </li> <li> <p>Follow‐up: 6 months</p> </li> <li> <p>Country: USA and Canada (9 sites)</p> </li> <li> <p>Unit of randomisation: participant</p> </li> <li> <p>Analysis unit: participant</p> </li> </ol> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Participants</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p> <ol id="CD008548-lst1-0115"> <li> <p>Enrolled: 98</p> </li> <li> <p>Randomised: 98</p> <ol id="CD008548-lst2-0090"> <li> <p>Intervention group 1 (OASIS Wound Matrix): 51% (50/98); 37 completed assigned treatment</p> </li> <li> <p>Intervention group 2 (Regranex gel): 49% (48/98); 36 completed assigned treatment</p> </li> <li> <p>Cross‐over: "Patients whose wounds were not healing by 12th week were given the option to cross over to the other treatment arm" (p 260). 12 participants in the Regranex Gel group crossed over to receive OASIS, 1 participant healed; 9 participants in the OASIS arm crossed over to receive Regranex Gel, 2 healed </p> </li> </ol> </li> <li> <p>Age (years, mean ± standard deviation (SD))</p> <ol id="CD008548-lst2-0091"> <li> <p>Intervention group 1 (OASIS Wound Matrix): 58 ± 2.3</p> </li> <li> <p>Intervention group 2 (becaplermin (Regranex gel)): 57 ± 1.9</p> </li> </ol> </li> <li> <p>Gender (male)</p> <ol id="CD008548-lst2-0092"> <li> <p>Intervention group 1 (OASIS Wound Matrix): 62% (23/37)</p> </li> <li> <p>Intervention group 2 (becaplermin (Regranex gel)): 58% (21/36)</p> </li> </ol> </li> <li> <p>Inclusion criteria</p> <ol id="CD008548-lst2-0093"> <li> <p>≥18 years</p> </li> <li> <p>Type 1 or type 2 diabetes mellitus</p> </li> <li> <p>Ulcer size 1‐49 cm<sup>2</sup> </p> </li> <li> <p>Ulcer depth required to extend through both the epidermis and dermis</p> </li> <li> <p>Grade I, Stage A (University of Texas classification)</p> </li> <li> <p>Present for &gt; 1 month and nonhealing</p> </li> <li> <p>Viable wound bed with granulation tissue</p> </li> </ol> </li> <li> <p>Exclusion criteria</p> <ol id="CD008548-lst2-0094"> <li> <p>Exposed bone, tendon, or fascia</p> </li> <li> <p>Clinically defined and documented severe arterial disease</p> </li> <li> <p>History of radiation therapy to the ulcer site</p> </li> <li> <p>Ulcer of nondiabetic pathophysiology</p> </li> <li> <p>Receiving corticosteroids or suppression of the immune system</p> </li> <li> <p>History of collagen vascular disease malnutrition (albumin &lt; 2.5 g/dL)</p> </li> <li> <p>Known allergy to porcine‐derived products</p> </li> <li> <p>Known hypersensitivity to any component of Regranex Gel (e.g. parabens)</p> </li> <li> <p>Religious or cultural objection to the use of porcine products</p> </li> <li> <p>Uncontrolled diabetes (HbA1c &gt; 12%)</p> </li> <li> <p>Previous organ transplant</p> </li> <li> <p>Clinically infected ulcer</p> </li> <li> <p>Signs of cellulitis, osteomyelitis, necrotic or avascular ulcer bed</p> </li> <li> <p>Undergoing haemodialysis</p> </li> <li> <p>Insufficient blood supply to the ulcer (TcPO2 &lt; 30 mmHg or toe‐brachial index &lt; 0.70)</p> </li> <li> <p>Active Charcot or sickle cell disease</p> </li> <li> <p>Received treatment with any other investigational drug or device within the last 30 days </p> </li> <li> <p>Unable to comply with the procedures described in the protocol</p> </li> <li> <p>Enrolled in a clinical evaluation for another investigational wound care device or drug </p> </li> </ol> </li> </ol> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Interventions</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p> <ol id="CD008548-lst1-0116"> <li> <p>Intervention group 1: recombinant human platelet‐derived growth factor (becaplermin (Regranex gel)), applied topically daily and removed after 12 hours </p> </li> <li> <p>Control group: OASIS Wound Matrix (HEALTHPOINT, Ltd, Fort Worth, TX) applied topically weekly </p> </li> </ol> </p> <p>Co‐interventions: standard wound care, pressure‐relief shoes (DH Pressure Relief Shoe; Royce Medical Co, Camarillo, CA) </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Outcomes</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p>Primary outcome: incidence of complete wound healing by 12 weeks</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Notes</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p> <ol id="CD008548-lst1-0117"> <li> <p>A priori sample size estimation: not reported</p> </li> <li> <p>Sponsor: Cook Biotech Incorporated, West Lafayette, IN, and DH Pressure RElief Shoe; Royce Medical Co, Camarillo, CA </p> </li> <li> <p>Role of sponsors: provided the study supplies, including treatment products, dressing supplies, and pressure‐relief shoes </p> </li> <li> <p>Conflict of interest: one trial author is a research scientist with Cook Biotech Incorporated</p> </li> </ol> </p> </td> </tr> <tr> <td align="" valign="" colspan="3" rowspan="1" bgcolor="#ffffff"> <p><b><i>Risk of bias</i> </b> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Bias</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Authors' judgement</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Support for judgement</b> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Random sequence generation (selection bias)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Quote " were assigned to a treatment group using a centralized computer system" (p 259) </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Allocation concealment (selection bias)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Quote " individual investigators were blinded to the size of the block" (p 259)</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Blinding of participants and personnel (performance bias) <br> All outcomes </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Unclear risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Insufficient information provided to permit a judgment of 'low risk' or 'high risk'</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Blinding of outcome assessment (detection bias) <br> All outcomes </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Unclear risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Insufficient information provided to permit a judgment of 'low risk' or 'high risk'</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Incomplete outcome data (attrition bias) <br> All outcomes </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>High risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Lost post randomisation (treated): total = 26% (25/98)</p> <p> <ol id="CD008548-lst1-0118"> <li> <p>Experimental group: 26% (13/50)</p> </li> <li> <p>Control group: 25% (12/48)</p> </li> <li> <p>Imbance between groups: 1%</p> </li> </ol> </p> <p>Reasons for loss:</p> <p> <ol id="CD008548-lst1-0119"> <li> <p>infection: Intervention group = 23% (3/13); Control group = 17% (2/12)</p> </li> <li> <p>mortality: Intervention group = 8% (1/13); Control group = (0/12)</p> </li> <li> <p>non‐adherence to follow up visits: Intervention group = 31% (4/13); Control group = 58% (7/12) </p> </li> <li> <p>hospitalisation and related to the study or target wound: Intervention group = 23% (3/13); Control group = 0% (0/12) </p> </li> <li> <p>tendon/ bone exposure: Intervention group = 8% (1/13); Control group = 0% (0/12)</p> </li> <li> <p>withdrew consent: Intervention group = 0% (0/13); Control group = 17% (2/12)</p> </li> <li> <p>received other wound care therapy: Intervention group = 8% (1/13); Control group = 8% (1/12) </p> </li> </ol> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Selective reporting (reporting bias)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Unclear risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>One or more outcomes of interest in the review were reported incompletely so that they could not be included in a meta‐analysis </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Other bias</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>High risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Bias of presentation data, see <a href="appendices#CD008548-sec2-0016">Appendix 1</a> <br> Funding bias </p> </td> </tr> </tbody> </table> </div> <div class="table" id=""> <table> <div class="table-heading"><span class="table-label"></span><span class="table-title">Richard 1995 </span></div> <tbody> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Methods</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p> <ol id="CD008548-lst1-0120"> <li> <p>Parallel‐design (2 arms)</p> </li> <li> <p>Country: France and Italy</p> </li> <li> <p>Study period: 18 weeks</p> </li> <li> <p>Unit of randomisation: participant</p> </li> <li> <p>Analysis unit : participant</p> </li> </ol> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Participants</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p> <ol id="CD008548-lst1-0121"> <li> <p>Randomised: 17</p> <ol id="CD008548-lst2-0095"> <li> <p>Intervention group (basic fibroblastic growth factor): 53% (9/17)</p> </li> <li> <p>Control group (physiologic saline solution): 47% (8/17)</p> </li> </ol> </li> <li> <p>Age (years, mean ± SD)</p> <ol id="CD008548-lst2-0096"> <li> <p>Intervention group (basic fibroblastic growth factor): 61.9 ± 10.0</p> </li> <li> <p>Control group (physiologic saline solution): 63.6 ± 7.9</p> </li> </ol> </li> <li> <p>Gender (male)</p> <ol id="CD008548-lst2-0097"> <li> <p>Intervention group (basic fibroblastic growth factor): 100% (9/9)</p> </li> <li> <p>Control group (physiologic saline solution): 87.5% (7/8)</p> </li> </ol> </li> <li> <p>Inclusion criteria</p> <ol id="CD008548-lst2-0098"> <li> <p>Typical, chronic, nonhealing neuropathic ulcer on the plantar surface of the foot</p> </li> <li> <p>Grade 1‐3, according to Wagner´s classification</p> </li> <li> <p>After mechanical excision, the largest part of the wound had to measure more than 0.5 cm </p> </li> <li> <p>Vibration perception threshold higher than 30 V either at the big toe or at the medial malleolus </p> </li> </ol> </li> <li> <p>Exclusion criteria: not reported</p> </li> </ol> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Interventions</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p> <ol id="CD008548-lst1-0122"> <li> <p>Intervention group: basic fibroblastic growth factor (Farmitalia Carlo Erba, Milano, Italy) 50 μg (5 μg/ml), applied once a day on an in‐patient basis during the first 6 weeks. During the last 12 weeks, it was applied twice a week, and participants were allowed to return home if ulcer progression was satisfactory </p> </li> <li> <p>Control group: placebo (normal saline), applied once a day on an in‐patient basis during the first 6 weeks. During the last 12 weeks, it was applied twice a week, and participants were allowed to return home if ulcer progression was satisfactory </p> </li> </ol> </p> <p>Co‐interventions:</p> <p> <ol id="CD008548-lst1-0123"> <li> <p>Intensive insulin therapy using 3 subcutaneous injections a day or continuous subcutaneous insulin infusion maintained during the entire experimental period </p> </li> <li> <p>Participants were totally non weight‐bearing</p> </li> </ol> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Outcomes</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p> <ol id="CD008548-lst1-0124"> <li> <p>Healing</p> </li> <li> <p>Improvement</p> </li> <li> <p>No progression</p> </li> <li> <p>Worsening</p> </li> <li> <p>Ulcer perimeter reduction (% of initial perimeter)</p> </li> <li> <p>Time for 50% healing (weeks)</p> </li> </ol> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Notes</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p> <ol id="CD008548-lst1-0125"> <li> <p>A priori sample size estimation: not reported</p> </li> <li> <p>Sponsor: Farmitalia Carlo Erba Laboratory, Milano, Italy; P Dang</p> </li> <li> <p>Role of sponsor: supported the study; reviewed the manuscript</p> </li> </ol> </p> </td> </tr> <tr> <td align="" valign="" colspan="3" rowspan="1" bgcolor="#ffffff"> <p><b><i>Risk of bias</i> </b> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Bias</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Authors' judgement</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Support for judgement</b> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Random sequence generation (selection bias)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Unclear risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Insufficient information provided to permit a judgment of 'low risk' or 'high risk'</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Allocation concealment (selection bias)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Unclear risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Insufficient information provided to permit a judgment of 'low risk' or 'high risk'</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Blinding of participants and personnel (performance bias) <br> All outcomes </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Unclear risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Insufficient information provided to permit a judgment of 'Yes'or 'No</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Blinding of outcome assessment (detection bias) <br> All outcomes </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Quote " . . . ulcer perimeter and area were measured by one of us (J.P.D), unaware of the patient's identity, data of photographs, and nature of the treatment" (p 65) </p> <p>Comment: J.P.D is Jean‐Pierre Daures</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Incomplete outcome data (attrition bias) <br> All outcomes </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>All participants were analysed</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Selective reporting (reporting bias)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>The study protocol is not available but it is clear that the published reports included all expected outcomes, including those that were pre‐specified </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Other bias</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>High risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Design bias, see <a href="appendices#CD008548-sec2-0016">Appendix 1</a> </p> <p>Funding bias</p> </td> </tr> </tbody> </table> </div> <div class="table" id=""> <table> <div class="table-heading"><span class="table-label"></span><span class="table-title">Robson 2002 </span></div> <tbody> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Methods</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p> <ol id="CD008548-lst1-0126"> <li> <p>Parallel‐design (5 arms)</p> </li> <li> <p>Country: USA (15 sites)</p> </li> <li> <p>Follow‐up: 20 weeks</p> </li> <li> <p>Unit of randomisation: participant</p> </li> <li> <p>Analysis unit: participant</p> </li> </ol> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Participants</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p> <ol id="CD008548-lst1-0127"> <li> <p>Randomised: 177</p> <ol id="CD008548-lst2-0099"> <li> <p>Intervention group 1 (transforming growth factor ß2 0.05%): 24.3% (43/177)</p> </li> <li> <p>Intervention group 2 (transforming growth factor ß2 0.5%): 24.85% (44/177)</p> </li> <li> <p>Intervention group 3 (transforming growth factor ß2 5%): 24.85% (44/177)</p> </li> <li> <p>Control group 1 (standard wound care): 14% (24/177)</p> </li> <li> <p>Control group 2 (placebo): 12% (22/177)</p> </li> </ol> </li> <li> <p>Age (years, mean ± standard deviation):</p> <ol id="CD008548-lst2-0100"> <li> <p>Intervention group 1 (transforming growth factor ß2 0.05%): 56 ± 11</p> </li> <li> <p>Intervention group 2 (transforming growth factor ß2 0.5%): 56 ± 12</p> </li> <li> <p>Intervention group 3 (transforming growth factor ß2 5%): 56 ± 8</p> </li> <li> <p>Control group 1 (standard wound care): 55 ± 9</p> </li> <li> <p>Control group 2 (placebo): 60 ± 10</p> </li> </ol> </li> <li> <p>Gender (male)</p> <ol id="CD008548-lst2-0101"> <li> <p>Intervention group 1 (transforming growth factor ß2 0.05%): 77%</p> </li> <li> <p>Intervention group 2 (transforming growth factor ß2 0.5%): 77%</p> </li> <li> <p>Intervention group 3 (transforming growth factor ß2 5%): 77%</p> </li> <li> <p>Control group 1 (standard wound care): 92%</p> </li> <li> <p>Control group 2 (placebo): 82%</p> </li> </ol> </li> <li> <p>Inclusion criteria</p> <ol id="CD008548-lst2-0102"> <li> <p>≥ 18 years of age</p> </li> <li> <p>People with diabetes mellitus and a neuropathic ulcer present for at least 8 weeks on the plantar surface of the forefoot, toes, metatarsals, or dorsum of the foot </p> </li> <li> <p>Ulcer 1‐20 cm<sup>2</sup> in area after debridement, and of full thickness without exposed bone or tendon </p> </li> <li> <p>Adequate peripheral arterial circulation determined by an ABPI 0.7‐1.3, or TcPO2 measurement on the foot ≥ 30 mmHg </p> </li> </ol> </li> <li> <p>Exclusion criteria:</p> <ol id="CD008548-lst2-0103"> <li> <p>Radiographically documented osteomyelitis</p> </li> <li> <p>Clinical infection of the ulcer</p> </li> <li> <p>Use of systemic steroids within the previous 30 days</p> </li> <li> <p>HbA1c greater than 13%</p> </li> <li> <p>Serum creatinine &gt; 2.5 mg/dL</p> </li> <li> <p>Serum albumin &lt; 2 mg/dL</p> </li> </ol> </li> </ol> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Interventions</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p> <ol id="CD008548-lst1-0128"> <li> <p>Intervention group 1 (transforming growth factor ß2 0.05%): topical collagen sponges containing recombinant human transforming growth factor‐ß2 at 0.05 µg/cm<sup>2</sup>applied twice weekly </p> </li> <li> <p>Intervention group 2 (transforming growth factor ß2 0.5%): topical collagen sponges containing recombinant human transforming growth factor‐ß2 at 0.5 µg/cm<sup>2</sup> applied twice weekly </p> </li> <li> <p>Intervention group 3 (transforming growth factor ß2 5%): topical collagen sponges containing recombinant human transforming growth factor‐ß2 at 5.0 µg/cm<sup>2</sup> applied twice weekly </p> </li> <li> <p>Control group 1 (standard wound care): sharp debridement, coverage with non‐adherent dressing, and weight offloading for the affected foot </p> </li> <li> <p>Control group 2 (placebo): placebo</p> </li> </ol> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Outcomes</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p>Primary</p> <p> <ol id="CD008548-lst1-0129"> <li> <p>Proportion of participants with complete ulcer closure at or before week 21</p> </li> <li> <p>Percentage of ulcer area reduction by week 21</p> </li> </ol> </p> <p>Secondary</p> <p> <ol id="CD008548-lst1-0130"> <li> <p>Proportion of participants with complete closure of the ulcer at each weekly visit</p> </li> <li> <p>Percentage of ulcer area reduction at each weekly visit</p> </li> <li> <p>Time to wound closure</p> </li> <li> <p>3‐month follow‐up assessment of durability of wound closure</p> </li> <li> <p>Safety</p> </li> </ol> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Notes</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p> <ol id="CD008548-lst1-0131"> <li> <p>A priori sample size estimation: not reported</p> </li> <li> <p>Sponsor: Genzyme Corporation</p> </li> <li> <p>Role of sponsor: created computer‐generated treatment randomisation lists, generated the coded labelling key, provided editorial comment and review, program management, management of the clinical trial </p> </li> </ol> </p> </td> </tr> <tr> <td align="" valign="" colspan="3" rowspan="1" bgcolor="#ffffff"> <p><b><i>Risk of bias</i> </b> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Bias</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Authors' judgement</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Support for judgement</b> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Random sequence generation (selection bias)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Quote " . . . computer‐generation patients numbers" (p 3)</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Allocation concealment (selection bias)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Unclear risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Insufficient information provided to permit a judgment of 'low risk' or 'high risk'</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Blinding of participants and personnel (performance bias) <br> All outcomes </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>High risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Quote "Double blinding for all 4 groups receiving collagen sponge was maintaining by code labelling for all collagen‐sponge packaging materials . . . the standardized care group could not be blinded since these patients did not receive a collagen sponge like the other four treatment groups" (p 2/10) </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Blinding of outcome assessment (detection bias) <br> All outcomes </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Unclear risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Insufficient information provided to permit a judgment of 'low risk' or 'high risk'</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Incomplete outcome data (attrition bias) <br> All outcomes </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>High risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Lost post randomisation: 15% (27/177)<br> Lost after treatment: 7% (11/150) </p> <p>Total lost: 21% (38/177)</p> <p>Reasons: not reported</p> <p>Losses by intervention group: not reported</p> <p>Potentially inappropriate application of simple imputation</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Selective reporting (reporting bias)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>High risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Safety was reported incompletely so the data could not be entered in a meta‐analysis</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Other bias</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>High risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Bias of presentation data, see <a href="appendices#CD008548-sec2-0016">Appendix 1</a> </p> </td> </tr> </tbody> </table> </div> <div class="table" id=""> <table> <div class="table-heading"><span class="table-label"></span><span class="table-title">Saldalamacchia 2004 </span></div> <tbody> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Methods</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p> <ol id="CD008548-lst1-0132"> <li> <p>Parallel‐design (2 arms)</p> </li> <li> <p>Country: Italy</p> </li> <li> <p>Follow‐up period: 5 weeks</p> </li> <li> <p>Unit of randomisation: participant</p> </li> <li> <p>Analysis unit: participant</p> </li> </ol> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Participants</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p> <ol id="CD008548-lst1-0133"> <li> <p>Randomised: 14</p> <ol id="CD008548-lst2-0104"> <li> <p>Intervention group: 50% (7/7)</p> </li> <li> <p>Control group: 50% (7/7)</p> </li> </ol> </li> <li> <p>Age (years, mean ± SD)</p> <ol id="CD008548-lst2-0105"> <li> <p>Intervention group: 61.1 ± 9.4</p> </li> <li> <p>Control group: 58.1 ± 7.8</p> </li> </ol> </li> <li> <p>Gender (male)</p> <ol id="CD008548-lst2-0106"> <li> <p>Intervention group: 57.14% (4/7)</p> </li> <li> <p>Control group: 28.57% (2/7)</p> </li> </ol> </li> <li> <p>Inclusion criteria</p> <ol id="CD008548-lst2-0107"> <li> <p>Diabetic participant</p> </li> <li> <p>Grade 2 or 3 ulcer according to Wagner, lasting for at least 8 weeks, and without signs of infection </p> </li> </ol> </li> <li> <p>Exclusion criteria: not reported</p> </li> </ol> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Interventions</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p> <ol id="CD008548-lst1-0134"> <li> <p>Intervention: topic application of autologous platelet gel plus standard care plus, frequency not reported </p> </li> <li> <p>Control: standard care</p> </li> </ol> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Outcomes</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p>Reduction rate (%)</p> <p>Complete healing or reduction of at least 50%</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Notes</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p> <ol id="CD008548-lst1-0135"> <li> <p>This trial was reported as a letter to editor</p> </li> <li> <p>A priori sample size estimation: not reported</p> </li> <li> <p>Sponsor: not reported</p> </li> </ol> </p> </td> </tr> <tr> <td align="" valign="" colspan="3" rowspan="1" bgcolor="#ffffff"> <p><b><i>Risk of bias</i> </b> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Bias</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Authors' judgement</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Support for judgement</b> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Random sequence generation (selection bias)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Unclear risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Quote ". . . were randomly . . . " (p 395)</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Allocation concealment (selection bias)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Unclear risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Insufficient information provided to permit a judgment of 'low risk' or 'high risk'</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Blinding of participants and personnel (performance bias) <br> All outcomes </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Unclear risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Quote "observers were blind with respect to treatment assignments" (p 395)</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Blinding of outcome assessment (detection bias) <br> All outcomes </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Unclear risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Quote "observers were blind with respect to treatment assignments" (p 395)</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Incomplete outcome data (attrition bias) <br> All outcomes </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Unclear risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Insufficient reporting of attrition/exclusions to permit a judgement of ‘low risk’ or ‘high risk’ (i.e. no reasons provided for missing data) </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Selective reporting (reporting bias)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>High risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>This trial did not report safety data</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Other bias</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>High risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Bias of presentation data, see <a href="appendices#CD008548-sec2-0016">Appendix 1</a> </p> </td> </tr> </tbody> </table> </div> <div class="table" id=""> <table> <div class="table-heading"><span class="table-label"></span><span class="table-title">Steed 1992 </span></div> <tbody> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Methods</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p> <ol id="CD008548-lst1-0136"> <li> <p>Parallel‐design (2 arms)</p> </li> <li> <p>Follow‐up: 20 weeks</p> </li> <li> <p>Country: USA</p> </li> <li> <p>Unit of randomisation: participant</p> </li> <li> <p>Analysis unit: participant</p> </li> </ol> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Participants</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p> <ol id="CD008548-lst1-0137"> <li> <p>Randomised: 13</p> <ol id="CD008548-lst2-0108"> <li> <p>Intervention group (platelet‐derived wound healing formula, homologous): 54% (7/13)</p> </li> <li> <p>Control group (placebo):46% (6/13)</p> </li> </ol> </li> <li> <p>Age: (years, ± SD)</p> <ol id="CD008548-lst2-0109"> <li> <p>Intervention group (platelet‐derived wound healing formula, homologous): 58.7 ± 12.4</p> </li> <li> <p>Control group (placebo): 54.2 ± 12.9</p> </li> </ol> </li> <li> <p>Gender (male)</p> <ol id="CD008548-lst2-0110"> <li> <p>Intervention group (platelet‐derived wound healing formula, homologous): 71.4% (5/7)</p> </li> <li> <p>Control group (placebo): 67% (4/6)</p> </li> </ol> </li> <li> <p>Inclusion criteria</p> <ol id="CD008548-lst2-0111"> <li> <p>A neurotrophic ulcer of the lower extremity that had not healed after at least 8 weeks of standard treatment </p> </li> <li> <p>Diabetes mellitus</p> </li> <li> <p>Platelet count ≥ 100,000/mm<sup>3</sup> </p> </li> <li> <p>TcPO<sub>2</sub> &gt; 30 mmHg </p> </li> </ol> </li> <li> <p>Exclusion criteria</p> <ol id="CD008548-lst2-0112"> <li> <p>Clinical signs of infection such as erythema, induration, tenderness, fever, or chills</p> </li> </ol> </li> </ol> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Interventions</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p> <ol id="CD008548-lst1-0138"> <li> <p>Intervention group: platelet‐derived wound healing formula was applied to a cotton gauze sponge and placed on the ulcer in the evening. The intervention was prepared from blood donors. </p> </li> <li> <p>Control group: placebo (normal saline) was applied to a cotton gauze sponge and placed on the ulcer in the evening </p> </li> </ol> </p> <p>Co‐interventions: normal cotton gauze applied to the wound for the next 12 hours; participants were supplied with a half‐shoe (IPOS North American Niagara Fakks, NY) that transferred the weight to their heel and could be used for balance, they also had access to wheel‐chairs, crutches, or walkers to avoid weight‐bearing; debridements </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Outcomes</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p> <ol id="CD008548-lst1-0139"> <li> <p>Funtional assessment (healing)</p> </li> <li> <p>Reduction in wound volume</p> </li> </ol> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Notes</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p> <ol id="CD008548-lst1-0140"> <li> <p>A priori sample size estimation: not reported</p> </li> <li> <p>Sponsor: Curative technologies, Inc</p> </li> <li> <p>Role of sponsor: supported part of this research</p> </li> <li> <p>Half shoes IPOS North American, Niagara Falls, NY</p> </li> </ol> </p> </td> </tr> <tr> <td align="" valign="" colspan="3" rowspan="1" bgcolor="#ffffff"> <p><b><i>Risk of bias</i> </b> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Bias</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Authors' judgement</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Support for judgement</b> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Random sequence generation (selection bias)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Unclear risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Insufficient information provided to permit a judgment of 'low risk' or 'high risk'</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Allocation concealment (selection bias)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Unclear risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Insufficient information provided to permit a judgment of 'low risk' or 'high risk'</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Blinding of participants and personnel (performance bias) <br> All outcomes </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Quote " . . . were identical in appearance. Neither the investigators nor the patients were able to distinguish between the two products" (p 1599) </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Blinding of outcome assessment (detection bias) <br> All outcomes </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Unclear risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Insufficient information provided to permit a judgment of 'low risk' or 'high risk'</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Incomplete outcome data (attrition bias) <br> All outcomes </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Unclear risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Insufficient reporting of attrition/exclusions to permit a judgement of ‘low risk’ or ‘high risk’ (i.e. no reasons provided for missing data) </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Selective reporting (reporting bias)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>High risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>This trial did not report safety data</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Other bias</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>High risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Design bias, see <a href="appendices#CD008548-sec2-0016">Appendix 1</a> </p> <p>Funding bias</p> <p>Imbalance in wound area (mm<sup>2</sup>) and initial volume (mm<sup>3</sup>) at baseline </p> </td> </tr> </tbody> </table> </div> <div class="table" id=""> <table> <div class="table-heading"><span class="table-label"></span><span class="table-title">Steed 1995a </span></div> <tbody> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Methods</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p> <ol id="CD008548-lst1-0141"> <li> <p>Parallel‐design (2 arms)</p> </li> <li> <p>Country: USA (10 sites)</p> </li> <li> <p>Follow‐up period: 20 weeks</p> </li> <li> <p>Unit of randomisation: participant</p> </li> <li> <p>Analysis unit: participant</p> </li> </ol> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Participants</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p> <ol id="CD008548-lst1-0142"> <li> <p>Randomised: 118 (118 ulcers)</p> <ol id="CD008548-lst2-0113"> <li> <p>Intervention group (recombinant human platelet‐derived growth factor): 51.7% (61/118) (61 ulcers) </p> </li> <li> <p>Control group: 48.30% (57/118) (57 ulcers)</p> </li> </ol> </li> <li> <p>Age (years, mean)</p> <ol id="CD008548-lst2-0114"> <li> <p>Intervention group (recombinant human platelet‐derived growth factor): 63.2</p> </li> <li> <p>Control group: 58.3</p> </li> </ol> </li> <li> <p>Gender (male)</p> <ol id="CD008548-lst2-0115"> <li> <p>Intervention group (recombinant human platelet‐derived growth factor): 86.8% (53/61)</p> </li> <li> <p>Control group: 80.7% (46/57)</p> </li> </ol> </li> <li> <p>Inclusion criteria</p> <ol id="CD008548-lst2-0116"> <li> <p>At least 19 years of age</p> </li> <li> <p>At least one ulcer between 1‐100 cm<sup>2</sup> in area </p> </li> <li> <p>Free of infection according to clinical examination and radiographs</p> </li> <li> <p>Adequate arterial blood supply assessed by measuring TcPO2 of ≥ 30 mmHg on the dorsum of the foot, or at the margin of the ulcer if the ulcer was on the plantar surface </p> </li> </ol> </li> <li> <p>Exclusion criteria</p> <ol id="CD008548-lst2-0117"> <li> <p>Women of childbearing potential</p> </li> <li> <p>Nursing mothers</p> </li> <li> <p>Hypersensitivity to any component of the study gel</p> </li> <li> <p>&gt; 3 ulcers</p> </li> <li> <p>Ulcers caused by large‐vessel arterial ischaemia, venous insufficiency, pressure, or necrobiosis lipoidica diabeticorum </p> </li> <li> <p>Osteomyelitis, malignant or terminal disease</p> </li> <li> <p>Alcohol or substance abuse</p> </li> <li> <p>People who had participated in a clinical trial of an investigational drug or device within the previous 30 days </p> </li> <li> <p>Thermal, electrical, or radiation burn wounds at the site of the target ulcer</p> </li> <li> <p>People receiving corticosteroids, immunosuppressive agents, radiation therapy or chemotherapy</p> </li> <li> <p>Vascular reconstruction during the previous 8 weeks</p> </li> </ol> </li> </ol> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Interventions</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p> <ol id="CD008548-lst1-0143"> <li> <p>Intervention group: recombinant human platelet‐derived growth factor (becaplermin) (rhPDGF‐BB (Chiron Corp, Emeryville, CA; Johnson and Johnson, New Brunswick, NJ)) applied to the target ulcer once a day at a dose calculated to approximate 2.2 µg of rhPDGF‐BB/cm<sup>2</sup>&nbsp;ulcer area; 12 hours later the residual gel was removed by mild irrigation with saline </p> </li> <li> <p>Control group: placebo gel administered in the same way as the intervention gel. Details of the nature of the placebo were not reported </p> </li> </ol> </p> <p>Co‐interventions: a saline‐moistened gauze dressing was placed over the target ulcer and gel, and the foot wrapped with a roll of gauze.&nbsp;Pressure relief for the target ulcer achieved by means of crutches, wheelchairs, orthotic shoes, or other methods. Sharp debridement could be performed at each office visit if the investigator thought it was necessary </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Outcomes</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p> <ol id="CD008548-lst1-0144"> <li> <p>Primary: complete healing (100% wound closure with no drainage present and no dressing required) </p> </li> <li> <p>Secondary:</p> <ol id="CD008548-lst2-0118"> <li> <p>Time to complete wound closure</p> </li> <li> <p>Percentage reductions in area of target ulcers</p> </li> </ol> </li> </ol> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Notes</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p> <ol id="CD008548-lst1-0145"> <li> <p>A priori sample size estimation: not reported</p> </li> <li> <p>Sponsor: RW Johnson Pharmaceutical Research Institute (Raritan, NJ)</p> </li> <li> <p>Role of sponsor: the sponsor prepared the computer‐generated randomizations schedule for each centre before study initiation, and was responsible for the conduct of the trial and all analyses </p> </li> </ol> </p> </td> </tr> <tr> <td align="" valign="" colspan="3" rowspan="1" bgcolor="#ffffff"> <p><b><i>Risk of bias</i> </b> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Bias</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Authors' judgement</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Support for judgement</b> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Random sequence generation (selection bias)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Quote " . . . computer generation . . . " (p 73)</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Allocation concealment (selection bias)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Unclear risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Insufficient information provided to permit a judgment of 'low risk' or 'high risk'</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Blinding of participants and personnel (performance bias) <br> All outcomes </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Quote " . . . were no differences of colour, consistency, or odour between the placebo and rhPDGF‐BB gel" (p 72) </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Blinding of outcome assessment (detection bias) <br> All outcomes </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Unclear risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Insufficient information provided to permit a judgment of 'low risk' or 'high risk'</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Incomplete outcome data (attrition bias) <br> All outcomes </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Lost post randomisation: total = 27% (32/118)<br> Intervention group = 23% (14/61); Control group = 32% (18/57) </p> <p>Imbalance between group: 9%</p> <p>Reasons</p> <p> <ol id="CD008548-lst1-0146"> <li> <p>Death: Intervention group = 0/14; Control group = 2/18</p> </li> <li> <p>Adverse experiences: Intervention group = 6/14; Control group = 6/18</p> </li> <li> <p>Treatment failure: Intervention group = 3/14; Control group = 5/18</p> </li> <li> <p>Noncompliance: Intervention group = 1/14; Control group = 1/18</p> </li> <li> <p>Intercurrent medical problem: Intervention group = 2/14; Control group = 2/18</p> </li> <li> <p>Lost to follow up: Intervention group = 2/14; Control group = 1/18</p> </li> <li> <p>Other: Intervention group = 0/14; Control group = 1/18</p> </li> </ol> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Selective reporting (reporting bias)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>High risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>One outcome of interest (time to complete wound closure) in the review was reported incompletely so the data could not be entered in a meta‐analysis </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Other bias</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>High risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Bias of presentation data and design bias, see <a href="appendices#CD008548-sec2-0016">Appendix 1</a> </p> <p>This trial did not report hazard ratio for time to complete wound closure</p> <p>Funding bias</p> </td> </tr> </tbody> </table> </div> <div class="table" id=""> <table> <div class="table-heading"><span class="table-label"></span><span class="table-title">Steed 1995b </span></div> <tbody> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Methods</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p> <ol id="CD008548-lst1-0147"> <li> <p>Parallel‐design (2 arms)</p> </li> <li> <p>Country: USA (10 sites)</p> </li> <li> <p>Follow‐up period: 10 weeks</p> </li> <li> <p>Unit of randomisation: participant</p> </li> <li> <p>Analysis unit: participant</p> </li> </ol> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Participants</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p> <ol id="CD008548-lst1-0148"> <li> <p>Randomised: 65 participants</p> <ol id="CD008548-lst2-0119"> <li> <p>Intervention group (arginine‐glycine‐aspartic acid peptide matrix): 61.5% (40/65)</p> </li> <li> <p>Control group: 38.5% (25/65)</p> </li> </ol> </li> <li> <p>Age (years, means ± SD)</p> <ol id="CD008548-lst2-0120"> <li> <p>Intervention group (arginine‐glycine‐aspartic acid peptide matrix): 61.8 ± 1.9 years</p> </li> <li> <p>Control group: 61.0 ± 2.2 years</p> </li> </ol> </li> <li> <p>Gender (male)</p> <ol id="CD008548-lst2-0121"> <li> <p>Intervention group (arginine‐glycine‐aspartic acid peptide matrix): 72.5% (29/40)</p> </li> <li> <p>Control group: 80% (20/25)</p> </li> </ol> </li> <li> <p>Inclusion criteria</p> <ol id="CD008548-lst2-0122"> <li> <p>People with foot ulcers of at least 1 month's duration that penetrated through the epidermis and into the dermis without exposure of bone or tendon </p> </li> <li> <p>≥ 18 years of age</p> </li> <li> <p>Ulcer surface area of 1‐15 cm<sup>2</sup> </p> </li> <li> <p>Free of infection according to clinical examination and radiographs</p> </li> <li> <p>Adequate arterial blood supply i.e. TcPO2 ≥ 30 mmHg on the dorsum of the foot or at the margin of the ulcer if the ulcer was on the plantar surface </p> </li> </ol> </li> <li> <p>Exclusion criteria</p> <ol id="CD008548-lst2-0123"> <li> <p>People receiving medications that might adversely affect healing (systemic corticosteroids or antineoplastic agents) </p> </li> <li> <p>Medical conditions that might retard healing (immune system diseases, systemic lupus erythematosus, scleroderma, rheumatoid arthritis, osteomyelitis, bleeding disorders, Raynaud's, or cancer requiring chemotherapy) </p> </li> </ol> </li> </ol> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Interventions</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p> <ol id="CD008548-lst1-0149"> <li> <p>Intervention group: arginine‐glycine‐aspartic acid peptide matrix (Argidence Gel, formerly Telio Derm Gel, Telios Pharmaceutics, San Diego, CA) applied with a change of dressing twice/week </p> </li> <li> <p>Control group: normal saline placebo plus standard wound care</p> </li> </ol> </p> <p>Co‐interventions: debridements as required; shoes&nbsp;designed to relieve pressure on the study ulcer </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Outcomes</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p> <ol id="CD008548-lst1-0150"> <li> <p>Completely healed</p> </li> <li> <p>Safety</p> </li> </ol> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Notes</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p> <ol id="CD008548-lst1-0151"> <li> <p>A priori sample size estimation: not reported</p> </li> <li> <p>Sponsor: Telios Pharmaceuticals, San Diego, CA</p> </li> <li> <p>Role of sponsor: supported this research</p> </li> </ol> </p> </td> </tr> <tr> <td align="" valign="" colspan="3" rowspan="1" bgcolor="#ffffff"> <p><b><i>Risk of bias</i> </b> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Bias</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Authors' judgement</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Support for judgement</b> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Random sequence generation (selection bias)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Unclear risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Insufficient information provided to permit a judgment of 'low risk' or 'high risk'</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Allocation concealment (selection bias)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Unclear risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Insufficient information provided to permit a judgment of 'low risk' or 'high risk'</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Blinding of participants and personnel (performance bias) <br> All outcomes </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Quote "A member of the study support staff other than the investigators applied the treatment . . . identical syringes were used to administer RGD peptide matrix and saline placebo" (p 3) </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Blinding of outcome assessment (detection bias) <br> All outcomes </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Unclear risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Insufficient information provided to permit a judgment of 'low risk' or 'high risk'</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Incomplete outcome data (attrition bias) <br> All outcomes </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Lost post randomisation: total = 22% (14/65)<br> Intervention group = 20% (8/40); Control group = 24% (6/25) </p> <p>Imbalance between group: 4%</p> <p>Reasons</p> <p> <ol id="CD008548-lst1-0152"> <li> <p>Adverse events: Intervention group = 4/8; Control group = 2/6</p> </li> <li> <p>Other: Intervention group = 4/8; Control group = 4/6</p> </li> </ol> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Selective reporting (reporting bias)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>High risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>The safety profile was incompletely reported</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Other bias</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>High risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Design bias and bias of presentation of data, see <a href="appendices#CD008548-sec2-0016">Appendix 1</a> </p> <p>Funding bias</p> </td> </tr> </tbody> </table> </div> <div class="table" id=""> <table> <div class="table-heading"><span class="table-label"></span><span class="table-title">Steed 1996 </span></div> <tbody> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Methods</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p> <ol id="CD008548-lst1-0153"> <li> <p>Parallel‐design (2 arms)</p> </li> <li> <p>Country study: USA</p> </li> <li> <p>Follow‐up period: 20 weeks</p> </li> <li> <p>Unit of randomisation: participant</p> </li> <li> <p>Analysis unit: participant</p> </li> </ol> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Participants</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p> <ol id="CD008548-lst1-0154"> <li> <p>Randomised: 36 (number of participants in each arm and number of wounds: not reported)</p> </li> <li> <p>Age: not reported</p> </li> <li> <p>Gender: not reported</p> </li> <li> <p>Inclusion criteria</p> <ol id="CD008548-lst2-0124"> <li> <p>Diabetic</p> </li> <li> <p>Neurotrophic foot ulcers</p> </li> <li> <p>TcPO2 on the dorsum of the foot ≥ 30 mmHg</p> </li> <li> <p>Clinically significant diabetic neuropathy</p> </li> </ol> </li> <li> <p>Exclusion criteria</p> <ol id="CD008548-lst2-0125"> <li> <p>≥ 3 ulcers</p> </li> <li> <p>Infected bone</p> </li> </ol> </li> </ol> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Interventions</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p> <ol id="CD008548-lst1-0155"> <li> <p>Intervention group: growth factors released from platelets (Curative Technologies, Inc., Setauket, N.Y.) were applied to the wound and covered with cotton gauze each evening. The vehicle for the platelet releasate was buffered saline solution, identical in appearance to the placebo. </p> </li> <li> <p>Control group: buffered saline solution was applied to the wound and covered with cotton gauze each evening. </p> </li> </ol> </p> <p>Co‐interventions: half‐shoe to redistribute weight, also used crutches, wheelchairs, or walkers for offloading </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Outcomes</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p>Recurrence rate of the diabetic neurotrophic ulcer</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Notes</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p> <ol id="CD008548-lst1-0156"> <li> <p>This trial did not report the number of participants according to randomisation group or the characteristics of the groups. Trial reported the participants that healed and ulcer recurrence </p> </li> <li> <p>A priori sample size estimation: not reported</p> </li> <li> <p>Sponsor: not reported</p> </li> <li> <p>Email sent to the main author requesting information on data</p> </li> </ol> </p> </td> </tr> <tr> <td align="" valign="" colspan="3" rowspan="1" bgcolor="#ffffff"> <p><b><i>Risk of bias</i> </b> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Bias</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Authors' judgement</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Support for judgement</b> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Random sequence generation (selection bias)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Unclear risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Quote "patients were randomized to receive . . ." (p 231)</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Allocation concealment (selection bias)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Unclear risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Insufficient information provided to permit a judgment of 'low risk' or 'high risk'</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Blinding of participants and personnel (performance bias) <br> All outcomes </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Quote "identical in appearance to the placebo" (p 231)</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Blinding of outcome assessment (detection bias) <br> All outcomes </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Unclear risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Insufficient information provided to permit a judgment of 'low risk' or 'high risk'</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Incomplete outcome data (attrition bias) <br> All outcomes </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Unclear risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Insufficient information provided to permit a judgment of 'low risk' or 'high risk'</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Selective reporting (reporting bias)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>High risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Safety data were not reported</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Other bias</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>High risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Design bias and Bias of presentation data, see <a href="appendices#CD008548-sec2-0016">Appendix 1</a> </p> </td> </tr> </tbody> </table> </div> <div class="table" id=""> <table> <div class="table-heading"><span class="table-label"></span><span class="table-title">Tan 2008 </span></div> <tbody> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Methods</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p> <ol id="CD008548-lst1-0157"> <li> <p>Parallel‐design (2 arms)</p> </li> <li> <p>Country: China</p> </li> <li> <p>Follow‐up period: 6 weeks</p> </li> <li> <p>Unit of randomisation: participant</p> </li> <li> <p>Analysis unit: participant</p> </li> </ol> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Participants</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p> <ol id="CD008548-lst1-0158"> <li> <p>Number enrolled: not reported</p> </li> <li> <p>Randomised:139</p> <ol id="CD008548-lst2-0126"> <li> <p>Intervention group 1 (rhaFGF):104 (75%)</p> </li> <li> <p>Intervention group 2 (rhbFGF): 35 (25%)</p> </li> </ol> </li> <li> <p>Age (mean years (range)): 52.2 ± 17.31 (18‐75), information not reported by comparison group </p> </li> <li> <p>Gender: not reported</p> </li> <li> <p>Inclusion criteria</p> <ol id="CD008548-lst2-0127"> <li> <p>Chronic skin wound without other growth factor treatments (definition of "chronic state" was not reported) </p> </li> <li> <p>Skin wounds of ≥ 2 cm diameter through the full skin thickness</p> </li> <li> <p>Wound unhealed after at least 8 weeks of routine treatments</p> </li> </ol> </li> <li> <p>Exclusion criteria: not reported</p> </li> </ol> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Interventions</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p> <ol id="CD008548-lst1-0159"> <li> <p>Intervention group 1: rhaFGF 100 U/0.1 ml/cm<sup>2</sup> dissolved in normal saline solution and applied topically </p> </li> <li> <p>Intervention group 2: rhbFGF 100 U/0.1 ml/ cm<sup>2</sup> dissolved in normal saline solution and applied topically </p> </li> </ol> </p> <p>Co‐interventions: sterile cotton dressing without antibiotics</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Outcomes</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p>Outcomes were not described explicitly as primary end points<br> Quote "after 6‐week treatment, the wounds were divided into four categories: complete healing, significant healing if more than 50% of the wound are had healed; effective healing, if 20‐50% of the wound area had healed; ineffective healing, if less than 20% of the wound had healed" (p 434) </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Notes</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p> <ol id="CD008548-lst1-0160"> <li> <p>A priori sample size estimation: not reported</p> </li> <li> <p>Sponsor: National Natural Science Foundation, Ministry of Education Incubation Foundation Technology Innovative Project, Program of New Century Excellent Tallents in University, Zhejian Provincial Program for the Cultivation of high‐level Innovative Health Talents, Juvenile Diabetes Research Foundation, and Wenzhou Medical College for the Chinese‐American Research Institute for Diabetic Complications </p> </li> <li> <p>Role of sponsors: to provide grants</p> </li> </ol> </p> </td> </tr> <tr> <td align="" valign="" colspan="3" rowspan="1" bgcolor="#ffffff"> <p><b><i>Risk of bias</i> </b> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Bias</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Authors' judgement</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Support for judgement</b> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Random sequence generation (selection bias)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Unclear risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Quote " . . . prospective study by randomly . . ." (p 433)</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Allocation concealment (selection bias)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Unclear risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Insufficient information provided to permit a judgment of 'low risk' or 'high risk'</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Blinding of participants and personnel (performance bias) <br> All outcomes </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Unclear risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Insufficient information provided to permit a judgment of 'low risk' or 'high risk'</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Blinding of outcome assessment (detection bias) <br> All outcomes </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Unclear risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Insufficient information provided to permit a judgment of 'low risk' or 'high risk'</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Incomplete outcome data (attrition bias) <br> All outcomes </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Unclear risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Insufficient reporting of attrition/exclusions to permit a judgement of ‘low risk’ or ‘high risk’ (i.e. no reasons provided for missing data) </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Selective reporting (reporting bias)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>High risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>One or more outcomes of interest in the review were reported incompletely so that they could not be entered in a meta‐analysis. This trial did not report safety data </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Other bias</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>High risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p> <ol id="CD008548-lst1-0161"> <li> <p>This study did not report baseline characteristics</p> </li> <li> <p>Sampling bias, bias of presentation bias, design bias, see <a href="appendices#CD008548-sec2-0016">Appendix 1</a> </p> </li> </ol> </p> </td> </tr> </tbody> </table> </div> <div class="table" id=""> <table> <div class="table-heading"><span class="table-label"></span><span class="table-title">Tsang 2003 </span></div> <tbody> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Methods</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p> <ol id="CD008548-lst1-0162"> <li> <p>Parallel‐design (3 arms)</p> </li> <li> <p>Country: China (Diabetes Ambulatory Care Centre)</p> </li> <li> <p>Follow‐up period: 24 weeks</p> </li> <li> <p>Unit of randomisation: participant</p> </li> <li> <p>Analysis unit: participant</p> </li> </ol> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Participants</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p> <ol id="CD008548-lst1-0163"> <li> <p>Randomised:48.03% (61/127 enrolled)</p> <ol id="CD008548-lst2-0128"> <li> <p>Intervention group 1 (Actovegin plus recombinant human epidermal growth factor 0.02%): 34.4% (21/61) </p> </li> <li> <p>Intervention group 2 (Actovegin plus recombinant human epidermal growth factor 0.04%): 34.4% (21/61) </p> </li> <li> <p>Control group (Actovegin 5%): 31.2% (19/61)</p> </li> </ol> </li> <li> <p>Age (years)</p> <ol id="CD008548-lst2-0129"> <li> <p>Intervention group 1: 68.76 ± 10.45</p> </li> <li> <p>Intervention group 2: 62.24 ± 13.68</p> </li> <li> <p>Control group: 64.37 ± 11.67</p> </li> </ol> </li> <li> <p>Gender (male)</p> <ol id="CD008548-lst2-0130"> <li> <p>Intervention group 1: 61.9% (13/21)</p> </li> <li> <p>Intervention group 2: 28.57% (6/21)</p> </li> <li> <p>Control group: 52.63% (10/19)</p> </li> </ol> </li> <li> <p>Lost before randomisation: total = 51.96% (66/127). Losses due to:</p> <ol id="CD008548-lst2-0131"> <li> <p>wound healing</p> </li> <li> <p>ulcer above malleoli</p> </li> <li> <p>ulcer grade ≥ 3</p> </li> <li> <p>ABPI &lt; 0.7</p> </li> <li> <p>refused consent</p> </li> </ol> </li> <li> <p>Inclusion criteria</p> <ol id="CD008548-lst2-0132"> <li> <p>Ulcer, Wagner grade 1 or 2</p> </li> <li> <p>Ulcer located below the ankle</p> </li> <li> <p>Ulcer with adequate perfusion, as indicated by an ABPI ≥ 0.7</p> </li> </ol> </li> <li> <p>Exclusion criteria</p> <ol id="CD008548-lst2-0133"> <li> <p>Very poor sugar control</p> </li> <li> <p>Ulcers with severity ≥ grade 3</p> </li> </ol> </li> </ol> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Interventions</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p> <ol id="CD008548-lst1-0164"> <li> <p>Intervention group 1: daily local application of Actovegin plus 0.02% recombinant human epidermal growth factor, covered with sterile gauze </p> </li> <li> <p>Intervention group 2: daily local application of Actovegin plus 0.04% recombinant human epidermal growth factor, covered with sterile gauze </p> </li> <li> <p>Control group: daily local application of Actovegin 5% cream only, covered with sterile gauze </p> </li> </ol> </p> <p>Co‐interventions: standard wound care consisted of debridement of necrotic tissue and reduction of callus </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Outcomes</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p>Complete healing defined as full epithelialisation of the wound with an absence of discharge </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Notes</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p> <ol id="CD008548-lst1-0165"> <li> <p>A priori sample size estimation: not reported</p> </li> <li> <p>Sponsor: Bio‐Click Technologies Ltd, Hong Kong</p> </li> <li> <p>Role of sponsor: provided recombinant human epidermal growth factor</p> </li> <li> <p>Actovegin is a protein free calf blood extract (NYCOMED Austria) (p 1857)</p> </li> </ol> </p> </td> </tr> <tr> <td align="" valign="" colspan="3" rowspan="1" bgcolor="#ffffff"> <p><b><i>Risk of bias</i> </b> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Bias</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Authors' judgement</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Support for judgement</b> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Random sequence generation (selection bias)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Unclear risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Quote "randomization was performed by drawing envelopes" (p 1857)</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Allocation concealment (selection bias)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Unclear risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Insufficient information provided to permit a judgment of 'low risk' or 'high risk'</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Blinding of participants and personnel (performance bias) <br> All outcomes </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Unclear risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Quote " . . . patients and physicians were blind to the hEGF concentrations" (p 1858)</p> <p>This trial did not reported how blinding was performed</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Blinding of outcome assessment (detection bias) <br> All outcomes </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Unclear risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Insufficient information provided to permit a judgment of 'low risk' or 'high risk'</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Incomplete outcome data (attrition bias) <br> All outcomes </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Unclear risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Insufficient reporting of attrition/exclusions to permit a judgement of ‘low risk’ or ‘high risk’ (i.e. no reasons provided for missing data) </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Selective reporting (reporting bias)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>High risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>This trial did not report safety data</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Other bias</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>High risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Design bias, see <a href="appendices#CD008548-sec2-0016">Appendix 1</a> <br> Funding bias </p> <p>This was the first trial by this clinical group that assessed recombinant human epidermal growth factor, however, it did not investigate safety </p> </td> </tr> </tbody> </table> </div> <div class="table" id=""> <table> <div class="table-heading"><span class="table-label"></span><span class="table-title">Uchi 2009 </span></div> <tbody> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Methods</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p> <ol id="CD008548-lst1-0166"> <li> <p>Parallel‐design (3 arms)</p> </li> <li> <p>Country: Japan</p> </li> <li> <p>Follow‐up period: 8 weeks</p> </li> <li> <p>Unit of randomisation: participant</p> </li> <li> <p>Analysis unit: participant</p> </li> </ol> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Participants</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p> <ol id="CD008548-lst1-0167"> <li> <p>Randomised: 150</p> <ol id="CD008548-lst2-0134"> <li> <p>Intervention 1 group (basic fibroblast growth factor 0.001%): 32.7% (49/150), 1 participant withdrew consent before starting treatment </p> </li> <li> <p>Intervention 2 group (basic fibroblast growth factor 0.01%): 33.3% (50/150), 1 participant did not receive growth factor as ulcer healed before starting treatment </p> </li> <li> <p>Control group (placebo): 34.0% (51/150)</p> </li> </ol> </li> <li> <p>Age (years, mean ± SD)</p> <ol id="CD008548-lst2-0135"> <li> <p>Intervention 1 group (basic fibroblast growth factor 0.001%): 61.0 ± 13.0</p> </li> <li> <p>Intervention 2 group (basic fibroblast growth factor 0.01%): 59.8 ± 13.8</p> </li> <li> <p>Control group (placebo): 60.2 ± 11.7</p> </li> </ol> </li> <li> <p>Gender (male)</p> <ol id="CD008548-lst2-0136"> <li> <p>Intervention 1 group (basic fibroblast growth factor 0.001%): 66.6% (32/48)</p> </li> <li> <p>Intervention 2 group (basic fibroblast growth factor 0.01%): 71.4% (35/49)</p> </li> <li> <p>Control group (placebo): 72.5% (37/51)</p> </li> </ol> </li> <li> <p>Inclusion criteria</p> <ol id="CD008548-lst2-0137"> <li> <p>≥ 20 years of age</p> </li> <li> <p>Attending physicians selected a targeted ulcer in presence of multiple ulcers</p> </li> <li> <p>Ulcers measuring &lt; 900 mm<sup>2</sup>, not reaching the periosteum (Wagner grade 2) </p> </li> <li> <p>ABPI at rest ≥ 0.9 in participants with no palpable pulsation in either artery</p> </li> </ol> </li> <li> <p>Exclusion criteria</p> <ol id="CD008548-lst2-0138"> <li> <p>Severe artery calcification due to maintenance haemodialysis or diabetes</p> </li> <li> <p>Malignant tumour or history of malignant tumour</p> </li> <li> <p>History of hypersensitivity to basic fibroblast growth factor</p> </li> <li> <p>Women with confirmed or suspected pregnancy; nursing women; women who desired to become pregnant during the trial </p> </li> <li> <p>Patients receiving oral administration or injection of adrenocortical steroid (equivalent to &gt; 20 mg/day of prednisolone) </p> </li> </ol> </li> </ol> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Interventions</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p> <ol id="CD008548-lst1-0168"> <li> <p>Intervention 1: 5 puffs of basic fibroblastic growth factor at 0.001% (equivalent to 3 µg of basic fibroblastic growth factor) sprayed 5 cm from the target ulcer once a day, for 8 weeks </p> </li> <li> <p>Intervention 2: 5 puffs of basic fibroblastic growth factor at 0.01% (equivalent to 30 µg of basic fibroblastic growth factor) sprayed 5 cm from the target ulcer once a day, for 8 weeks </p> </li> <li> <p>Control: 5 puffs placebo (characteristics not reported) sprayed 5 cm from the target ulcer once a day for 8 weeks </p> </li> </ol> </p> <p>Co‐interventions: appropriate treatments to control blood glucose levels</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Outcomes</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p>Primary outcomes:</p> <p> <ol id="CD008548-lst1-0169"> <li> <p>Ulcer shrinkage</p> </li> <li> <p>Safety</p> </li> </ol> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Notes</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p> <ol id="CD008548-lst1-0170"> <li> <p>A priori sample size estimation: yes (p 463)</p> </li> <li> <p>Sponsor: Kaken Pharmaceutical Co, Ltd</p> </li> <li> <p>Role of sponsor: data collection and pre‐specified statistical analysis</p> </li> </ol> </p> </td> </tr> <tr> <td align="" valign="" colspan="3" rowspan="1" bgcolor="#ffffff"> <p><b><i>Risk of bias</i> </b> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Bias</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Authors' judgement</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Support for judgement</b> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Random sequence generation (selection bias)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Quote " . . . computer‐generated randomisation program" (p 462)</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Allocation concealment (selection bias)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Quote " . . . assigned to groups by telephone or fax at the KCB‐1 Registration Center (ADJUST Co., LTD., Kokkaido, Japan)" (p 462) </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Blinding of participants and personnel (performance bias) <br> All outcomes </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Quote " . . . participants in the blinded trial included physicians, evaluators, patients, and monitor." (p 462) </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Blinding of outcome assessment (detection bias) <br> All outcomes </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Quote " . . . participants in the blinded trial included physicians, evaluators, patients, and monitors." (p 462) </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Incomplete outcome data (attrition bias) <br> All outcomes </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Lost post randomisation (withdrew within 4 weeks): total = 6% (9/150)</p> <p>Reasons</p> <p> <ol id="CD008548-lst1-0171"> <li> <p>Basic fibroblast growth factor 0.001% group: 1 participant withdrew within 4 weeks because of an adverse reaction </p> </li> <li> <p>Basic fibroblast growth factor 0.01% group: 4 withdrawals; 1 participant withdrew within 4 weeks because of an adverse reaction, and 3 were excluded within 4 weeks because of protocol violations </p> </li> <li> <p>Placebo group: 4 withdrawals; 1 adverse reaction; 1 died because of renal failure; 1 withdrew because ulcer healed; and there were no photographs for 1 </p> </li> </ol> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Selective reporting (reporting bias)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>High risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>This trial did not report safety data</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Other bias</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>High risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Bias in presentation of data. see <a href="appendices#CD008548-sec2-0016">Appendix 1</a> </p> <p>Funding bias</p> </td> </tr> </tbody> </table> </div> <div class="table" id=""> <table> <div class="table-heading"><span class="table-label"></span><span class="table-title">Viswanathan 2006 </span></div> <tbody> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Methods</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p> <ol id="CD008548-lst1-0172"> <li> <p>Parallel‐design (2 arms)</p> </li> <li> <p>Phase III trial</p> </li> <li> <p>Country: India</p> </li> <li> <p>Follow‐up period: 15 weeks</p> </li> <li> <p>Unit of randomisation: participant</p> </li> <li> <p>Analysis unit: participant</p> </li> </ol> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Participants</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p> <ol id="CD008548-lst1-0173"> <li> <p>Randomised: 60</p> <ol id="CD008548-lst2-0139"> <li> <p>Intervention group (recombinant human epidermal growth factor): 50% (30/60)</p> </li> <li> <p>Control group: 50% (30/60)</p> </li> </ol> </li> <li> <p>Age (years): not reported</p> </li> <li> <p>Gender (male):not reported</p> </li> <li> <p>Inclusion criteria</p> <ol id="CD008548-lst2-0140"> <li> <p>Target ulcers 2‐50 cm<sup>2</sup> in area </p> </li> <li> <p>People available for the 15‐week study period who could adhere to the treatment regimen</p> </li> <li> <p>Healthy men or women aged 18‐65 years at the time of consent</p> </li> <li> <p>Women of non‐child bearing potential (e.g. surgically sterilised), or, if of child bearing potential, must have a negative pregnancy test, or have used adequate contraceptive precautions (as confirmed by the investigator) 30 days prior to screening and the baseline visit, and agreed to continue such precautions up to week 15 </p> </li> <li> <p>Controlled diabetes mellitus (types 1 and 2) and foot ulcers</p> </li> <li> <p>Ulcers that remained open without healing for more than 2–3 weeks (irrespective of the ambulatory treatment administered) </p> </li> <li> <p>ABPI reading ≥ 0.75</p> </li> </ol> </li> <li> <p>Exclusion criteria</p> <ol id="CD008548-lst2-0141"> <li> <p>Ulcer ≥ Wagner grade 3</p> </li> <li> <p>Those with life‐threatening gastrointestinal, hepatic, renal, endocrine, hematological, or immunologic disorder, or serious cardiac failure (New York Heart Association Grades 3 and 4) </p> </li> <li> <p>Any of the following factors: hypertension grade 3; known case of hypersensitivity to the ingredient(s); uncontrolled diabetes mellitus (type 1 or 2), diabetic ketoacidosis or coma </p> </li> <li> <p>Pregnant women and nursing mothers</p> </li> <li> <p>Past history of, or current, acute or chronic autoimmune disease</p> </li> <li> <p>Chronic alcohol abuse (40 mL/day for at least 6 months)</p> </li> <li> <p>Treatment known to impair wound healing, including but not limited to: corticosteroids, immunosuppressive drugs, cytotoxic agents, radiation therapy, and chemotherapy, within 1 month prior to the initial visit </p> </li> <li> <p>Use of any marketed, investigational, or herbal medicine or non‐registered drug for wounds or burns in the past 6 months </p> </li> <li> <p>Clinically relevant abnormal haematology or biochemistry values (in the opinion of the investigator) </p> </li> <li> <p>Any criteria that, in the opinion of the investigator, suggest non‐compliance with the study </p> </li> <li> <p>Evidence of systemic or local infection, such as purulent drainage, osteomyelitis, or nonviable tissue that cannot be removed by debridement </p> </li> <li> <p>Treatment with a dressing containing any other growth factors or other biological dressings within the 30 days preceding the screening visit </p> </li> <li> <p>Participation in another clinical study within the 30 days preceding the screening visit or during the study </p> </li> </ol> </li> </ol> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Interventions</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p> <ol id="CD008548-lst1-0174"> <li> <p>Intervention group: topical application of recombinant human epidermal growth factor gel twice daily until the wound healed or until the end of week 15, whichever was earlier </p> </li> <li> <p>Control group: topical application of placebo (water based) gel twice daily until the wound healed or until the end of week 15, whichever was earlier </p> </li> </ol> </p> <p>Co‐interventions: normal dose of insulin prescribed; oral and intravenous antibiotics for prevention of infection </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Outcomes</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p> <ol id="CD008548-lst1-0175"> <li> <p>Percentage of healing</p> </li> <li> <p>Duration of healing</p> </li> <li> <p>Quality of healing and epithelisation</p> </li> </ol> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Notes</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p> <ol id="CD008548-lst1-0176"> <li> <p>Trial did not report the baseline characteristics of the groups</p> </li> <li> <p>A priori sample size estimation: not reported</p> </li> <li> <p>Sponsor: Bharat Biotech International Limited, Hyderabad, India</p> </li> <li> <p>Role of sponsor: financial support</p> </li> <li> <p>Conflict of interest: main author was paid an investigator's fee for conducting the study, another author is a consultant for the company that provided the study supplies and that supported study financially </p> </li> </ol> </p> </td> </tr> <tr> <td align="" valign="" colspan="3" rowspan="1" bgcolor="#ffffff"> <p><b><i>Risk of bias</i> </b> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Bias</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Authors' judgement</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Support for judgement</b> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Random sequence generation (selection bias)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Unclear risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Insufficient information provided to permit a judgment of 'low risk' or 'high risk'</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Allocation concealment (selection bias)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Unclear risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Insufficient information provided to permit a judgment of 'low risk' or 'high risk'</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Blinding of participants and personnel (performance bias) <br> All outcomes </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Quote "the tubes containing either rhEGF or placebo were similar"</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Blinding of outcome assessment (detection bias) <br> All outcomes </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Unclear risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Insufficient information provided to permit a judgment of 'low risk' or 'high risk'</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Incomplete outcome data (attrition bias) <br> All outcomes </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Lost: 5% (3/60): Intervention group = 1; Control group = 2</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Selective reporting (reporting bias)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>High risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>One or more outcomes of interest in the review were reported incompletely so that they could not be entered in a meta‐analysis </p> <p>Quote "The recorded adverse events were 1 case of rash, 3 cases of pain, and 2 cases of skin irritation” (p 4/14)<br> This trial did not report adverse event data according to comparison group </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Other bias</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>High risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Design bias and bias of presentation bias, see <a href="appendices#CD008548-sec2-0016">Appendix 1</a> <br> Funding bias: main author was paid an investigator's fee for conducting the study, another author is a consultant for the company that provided the study supplies and that supported study financially </p> </td> </tr> </tbody> </table> </div> <div class="table" id=""> <table> <div class="table-heading"><span class="table-label"></span><span class="table-title">Wieman 1998a </span></div> <tbody> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Methods</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p> <ol id="CD008548-lst1-0177"> <li> <p>Parallel‐design (3 arms)</p> </li> <li> <p>Country: USA (23 sites)</p> </li> <li> <p>Follow‐up period: 20 weeks</p> </li> <li> <p>Unit of randomisation: participant</p> </li> <li> <p>Analysis unit: participant</p> </li> </ol> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Participants</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p> <ol id="CD008548-lst1-0178"> <li> <p>Randomised: 382</p> <ol id="CD008548-lst2-0142"> <li> <p>Intervention 1 (recombinant human platelet‐derived growth factor 30 µg/g): 34.6% (132/382)</p> </li> <li> <p>Intervention 2 (recombinant human platelet‐derived growth factor 100 µg/g): 32.2% (123/382) </p> </li> <li> <p>Control group (placebo): 33.2% (127/382)</p> </li> </ol> </li> <li> <p>Age (years, means ± SD)</p> <ol id="CD008548-lst2-0143"> <li> <p>Intervention 1 (recombinant human platelet‐derived growth factor 30 µg/g): 58 ± 11.3</p> </li> <li> <p>Intervention 2 (recombinant human platelet‐derived growth factor 100 µg/g): 57 ± 11.5</p> </li> <li> <p>Control group (placebo): 58 ± 11.8</p> </li> </ol> </li> <li> <p>Gender (male)</p> <ol id="CD008548-lst2-0144"> <li> <p>Intervention 1 (recombinant human platelet‐derived growth factor 30 µg/g): 62% (82/132)</p> </li> <li> <p>Intervention 2 (recombinant human platelet‐derived growth factor 100 µg/g): 67% (82/123)</p> </li> <li> <p>Control group (placebo): 72% (91/127)</p> </li> </ol> </li> <li> <p>Inclusion criteria</p> <ol id="CD008548-lst2-0145"> <li> <p>Aged ≥19 years with type 1 or type 2 diabetes</p> </li> <li> <p>At least 1 full thickness (stage III or IV, as defined in the International Association of Enterostomal Therapy guide to chronic wound staging chronic ulcer of the lower extremities. If &gt; 1 lower‐extremity ulcer present, the target ulcer was the one that, in the opinion of the investigator, would take the longest time to heal with good wound care practice </p> </li> <li> <p>Target ulcer present for at least 8 weeks despite previous treatment</p> </li> <li> <p>TcPO2 on the limb with the target ulcer = 30 mmHg</p> </li> </ol> </li> <li> <p>Exclusion criteria</p> <ol id="CD008548-lst2-0146"> <li> <p>Osteomyelitis present in the area of the target ulcer</p> </li> <li> <p>Target ulcer area &lt; 1 cm<sup>2</sup> or &gt; 40 cm<sup>2</sup> after debridement </p> </li> <li> <p>Sum of the areas of all ulcers present &gt; 100 cm<sup>2</sup> </p> </li> <li> <p>Ulcers resulting from any cause other than diabetes (e.g. electrical, chemical, or radiation insult) </p> </li> <li> <p>Concomitant diseases (e.g. connective tissue disease), treatment (e.g. radiation therapy), or medication (e.g. corticosteroids, chemotherapy, or immunosuppressive agents) that would present safety hazards or interfere with evaluation of the study medication </p> </li> <li> <p>Women who were pregnant, nursing, or of childbearing potential and not using either an intrauterine device or oral contraception </p> </li> <li> <p>People with cancer</p> </li> </ol> </li> </ol> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Interventions</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p> <ol id="CD008548-lst1-0179"> <li> <p>Intervention group 1: topically applied recombinant human platelet‐derived growth factor gel (becaplermin, 30 µg/g), twice daily, morning and evening </p> </li> <li> <p>Intervention group 2: topically applied recombinant human platelet‐derived growth factor gel (becaplermin, Regranex Gel 0.01%, 100 µg/g), twice daily, morning and evening </p> </li> <li> <p>Control: topically applied placebo gel, twice daily, morning and evening</p> </li> </ol> </p> <p>Co‐intervention: standardised regimen of good wound care</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Outcomes</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p>Primary</p> <p> <ol id="CD008548-lst1-0180"> <li> <p>Percentage of participants that achieved complete healing within the 20‐week study period </p> </li> <li> <p>Safety</p> </li> </ol> </p> <p>Secondary: time required to achieve complete healing</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Notes</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p> <ol id="CD008548-lst1-0181"> <li> <p>A priori sample size estimation: not reported</p> </li> <li> <p>Sponsor: not reported</p> </li> </ol> </p> </td> </tr> <tr> <td align="" valign="" colspan="3" rowspan="1" bgcolor="#ffffff"> <p><b><i>Risk of bias</i> </b> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Bias</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Authors' judgement</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Support for judgement</b> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Random sequence generation (selection bias)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Unclear risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Quote "patients were randomized to one of three . . . " (p 823)</p> <p>Insufficient information provided to permit a judgment of 'low risk' or 'high risk'</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Allocation concealment (selection bias)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Unclear risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Insufficient information provided to permit a judgment of 'low risk' or 'high risk'</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Blinding of participants and personnel (performance bias) <br> All outcomes </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Quote "the placebo gel was identical to the vehicle component of the gel formulation containing the active drug" (p 823) </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Blinding of outcome assessment (detection bias) <br> All outcomes </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Unclear risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Insufficient information provided to permit a judgment of 'low risk' or 'high risk'</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Incomplete outcome data (attrition bias) <br> All outcomes </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Unclear risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Lost post randomisation: total = 19% (73/382)</p> <p> <ol id="CD008548-lst1-0182"> <li> <p>Intervention group 1 = 21% (28/132)</p> </li> <li> <p>Intervention group 2 = 17% (21/123)</p> </li> <li> <p>Control group = 19% (24/127)</p> </li> </ol> </p> <p>Reasons</p> <p> <ol id="CD008548-lst1-0183"> <li> <p>Lost to follow up: Intervention group 1 = 1/28; Intervention group 2 = 1/21; Control group = 2/24 </p> </li> <li> <p>Adverse events: Intervention group 1 = 17/28; Intervention group 2 = 13/21; Control group = 13/24 </p> </li> <li> <p>Non compliance: Intervention group 1 = 4/28; Intervention group 2 = 3/21; Control group = 3/24 </p> </li> <li> <p>Protocol violation: Intervention group 1 = 2/28; Intervention group 2 = 2/21; Control group = 3/24 </p> </li> <li> <p>Other: Intervention group 1 = 4/28; Intervention group 2 = 2/21; Control group = 3/24</p> </li> </ol> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Selective reporting (reporting bias)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>High risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>One or more outcomes of interest in the review were reported incompletely so they could not be entered in a meta‐analysis </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Other bias</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>High risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Quote "the time to complete healing, defined as the number of days until the patients achieved a functional assessment score of 1, was analyzed using Cox's proportional hazards model" (p 824) </p> <p>Design bias and bias of data presentation, see <a href="appendices#CD008548-sec2-0016">Appendix 1</a> </p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p><b>Abbreviations</b> </p> <p>ABPI = ankle‐brachial pressure index<br> CT‐102 = thrombin‐induced platelet‐released platelet‐derived wound healing formula<br> Hb = haemoglobin<br> HbA1c = glycated haemoglobin<br> IAET = The International Association of Enterostomal Therapists (now known as the Wound, Ostomy, Continence Nurses' Society (WOCN))<br> ITT = intention to treat (analysis)<br> IV = intravascular<br> rhaFGF = recombinant human acidic fibroblast growth factor<br> rhbFGF = recombinant human basic fibroblast growth factor<br> rhEGF = recombinant human epidermal growth factor<br> TcPO2 = transcutaneous oxygen tension </p> </div> </div> </p> </section> <section class="characteristicsOfExcludedStudies" lang=""> <div class="section-header" id="CD008548-sec2-0030"> <h3 class="title">Characteristics of excluded studies [ordered by study ID]</h3> <div class="jump-to"> <p>Jump to: </p> <ul class="jump-to-links"> <li><a href="#CD008548-sec2-0029" class="jump-to">included studies</a></li> <li><a href="#CD008548-sec2-0031" class="jump-to">awaiting classification</a></li> <li><a href="#CD008548-sec2-0032" class="jump-to">ongoing studies</a></li> </ul> </div> </div> <p> <div class="table" id=""> <table> <div class="table-heading"><span class="table-title"></span></div> <thead> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Study</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Reason for exclusion</p> </td> </tr> </thead> <tbody> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><a href="references#CD008548-bbs2-0029">Acosta 2006</a> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Case report</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><a href="references#CD008548-bbs2-0030">Aminian 2000</a> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Not an randomised clinical trial</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><a href="references#CD008548-bbs2-0031">Embil 2000</a> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Case series</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><a href="references#CD008548-bbs2-0032">Hong 2006</a> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Case series</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><a href="references#CD008548-bbs2-0033">Miller 1999</a> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Case report</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><a href="references#CD008548-bbs2-0034">Mohan 2007</a> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Phase IV (post‐marketing surveillance study)</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><a href="references#CD008548-bbs2-0035">Saad Setta 2011</a> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Not an randomised clinical trial</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><a href="references#CD008548-bbs2-0036">Tuyet 2009</a> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Case report</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><a href="references#CD008548-bbs2-0037">Yera‐Alos 2013</a> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Phase IV (post‐marketing surveillance study)</p> </td> </tr> </tbody> </table> </div> </p> </section> <section class="characteristicsOfAwaitingStudies" lang=""> <div class="section-header" id="CD008548-sec2-0031"> <h3 class="title">Characteristics of studies awaiting assessment [ordered by study ID]</h3> <div class="jump-to"> <p>Jump to: </p> <ul class="jump-to-links"> <li><a href="#CD008548-sec2-0029" class="jump-to">included studies</a></li> <li><a href="#CD008548-sec2-0030" class="jump-to">excluded studies</a></li> <li><a href="#CD008548-sec2-0032" class="jump-to">ongoing studies</a></li> </ul> </div> </div> <p> <div class="table" id=""> <table> <div class="table-heading"><span class="table-label"></span><span class="table-title">Gomez‐Villa 2014 </span></div> <tbody> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Methods</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Participants</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Interventions</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Outcomes</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Notes</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>awaiting full text retrieval</p> </td> </tr> </tbody> </table> </div> <div class="table" id=""> <table> <div class="table-heading"><span class="table-label"></span><span class="table-title">Morimoto 2013 </span></div> <tbody> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Methods</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Participants</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Interventions</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Outcomes</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Notes</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>awaiting full text retrieval</p> </td> </tr> </tbody> </table> </div> <div class="table" id=""> <table> <div class="table-heading"><span class="table-label"></span><span class="table-title">Singla 2014 </span></div> <tbody> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Methods</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Participants</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Interventions</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Outcomes</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Notes</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>awaiting full text retrieval</p> </td> </tr> </tbody> </table> </div> <div class="table" id=""> <table> <div class="table-heading"><span class="table-label"></span><span class="table-title">Young 1992 </span></div> <tbody> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Methods</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p> <ol id="CD008548-lst1-0184"> <li> <p>Phase I/II, double‐blind, placebo‐controlled, parallel design (3 arms)</p> </li> <li> <p>Country: United Kingdom</p> </li> <li> <p>Intention to treat: unclear</p> </li> <li> <p>Follow‐up period: not reported</p> </li> <li> <p>Unit of randomisation: not reported**</p> </li> <li> <p>Analysis unit: participant</p> </li> </ol> </p> <p>**Neither the title nor abstract of this study indicated whether it was randomised. We have not been able to find the address of the authors, enquiries are ongoing. </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Participants</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p> <ol id="CD008548-lst1-0185"> <li> <p>Participants: 25</p> <ol id="CD008548-lst2-0147"> <li> <p>Intervention 1 (PDGF high dose): 14 (56%)</p> </li> <li> <p>Intervention 2 (low dose and placebo): 11 (44%)</p> </li> </ol> </li> <li> <p>Gender (male): not reported</p> </li> <li> <p>Age (years, means ± SD): not reported</p> </li> <li> <p>Inclusion criteria: not given, so it reported</p> <ol id="CD008548-lst2-0148"> <li> <p>Diabetic participants</p> </li> <li> <p>Neuropathic foot ulceration</p> </li> </ol> </li> <li> <p>Exclusion criteria: not reported</p> </li> </ol> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Interventions</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p> <ol id="CD008548-lst1-0186"> <li> <p>Intervention 1: daily application of PDGF gel 0.2 ml/cm<sup>2</sup> </p> </li> <li> <p>Intervention 2: participants applied placebo, 10 mg/ml, 100 mg/ml or 1000 mg/ml</p> </li> </ol> </p> <p>Co‐interventions: appropriate pressure relief with orthoses or casts and weekly chiropody</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Outcomes</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Not stated, so it reported complete healing, safety</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Notes</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p> <ol id="CD008548-lst1-0187"> <li> <p>Data extracted from abstract</p> </li> <li> <p>A priori sample size estimation: no</p> </li> <li> <p>Sponsor: not reported</p> </li> <li> <p>This trial reported these results:</p> <ol id="CD008548-lst2-0149"> <li> <p>high dose group: complete healing (5/14)</p> </li> <li> <p>low dose group and placebo: complete healing: 1/11</p> </li> <li> <p>Quote: "no significant differences in median healing rates were found"</p> </li> </ol> </li> <li> <p>This trial did not report safety data, however, the authors stated " topical PDGF is well tolerated" </p> </li> <li> <p>It is unclear what the trial authors meant by 'high dose' and 'low dose</p> </li> </ol> </p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p><b>Abbreviation</b> </p> <p>PDGF = platelet‐derived growth factor</p> </div> </div> </p> </section> <section class="characteristicsOfOngoingStudies" lang=""> <div class="section-header" id="CD008548-sec2-0032"> <h3 class="title">Characteristics of ongoing studies [ordered by study ID]</h3> <div class="jump-to"> <p>Jump to: </p> <ul class="jump-to-links"> <li><a href="#CD008548-sec2-0029" class="jump-to">included studies</a></li> <li><a href="#CD008548-sec2-0030" class="jump-to">excluded studies</a></li> <li><a href="#CD008548-sec2-0031" class="jump-to">awaiting classification</a></li> </ul> </div> </div> <p> <div class="table" id=""> <table> <div class="table-heading"><span class="table-label"></span><span class="table-title">NCT00521937 </span></div> <tbody> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Trial name or title</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>A prospective, randomised, multi‐centre, blind‐observer, controlled, parallel‐group study comparing the efficacy and safety of DERMAGEN® versus conventional treatment in the treatment of diabetic neuropathic foot ulcer </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Methods</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p> <ol id="CD008548-lst1-0188"> <li> <p>Allocation: randomised</p> </li> <li> <p>Endpoint classification: efficacy study</p> </li> <li> <p>Intervention model: parallel assignment</p> </li> <li> <p>Masking: single blind (outcomes assessor)</p> </li> <li> <p>Primary purpose: treatment</p> </li> <li> <p>Country: France</p> </li> </ol> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Participants</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p> <ol id="CD008548-lst1-0189"> <li> <p>Enrolled: 388</p> </li> <li> <p>Inclusion criteria</p> <ol id="CD008548-lst2-0150"> <li> <p>Age ≥ 18 years</p> </li> <li> <p>to here Documented, stable type 1 or 2 diabetes mellitus (confirmed by HbA1c at least every 4 months) </p> </li> <li> <p>Neuropathic foot ulcer located on the plantar surface of the forefoot</p> </li> <li> <p>Ulcer surface area 1‐15 cm<sup>2</sup> (after mechanical debridement of the ulcer) </p> </li> <li> <p>Palpable pulse evidenced on both feet (presence of dorsalis pedis pulse and posterior tibial pulse) or in absence of one pulse, an SPI by Doppler &gt; 0.9 on the target limb </p> </li> <li> <p>Presence of diabetic foot ulcer for at least 4 weeks prior to enrolment</p> </li> <li> <p>Ulcer extending through the dermis without exposure of muscle, tendon, bone, or joint capsule </p> </li> </ol> </li> <li> <p>Exclusion criteria</p> <ol id="CD008548-lst2-0151"> <li> <p>Typical Charcot's foot</p> </li> <li> <p>Decrease or increase in the size of the ulcer by ≥ 50% during the run‐in period</p> </li> <li> <p>Presence of osteitis (eq Br osteomyelitis) at the inclusion visit (evidenced with a radiological lesion facing the wound (bone erosion or disappearance of the cortical bone)) </p> </li> <li> <p>Clinical evidence of PEDIS* grade 3, or 4 infection at the inclusion visit</p> </li> <li> <p>People who cannot have/use an offloading method</p> </li> <li> <p>Working people who could not be on sick‐leave during the study period</p> </li> <li> <p>Known allergy to collagen, streptomycin, penicillin and/or products of bovine origin</p> </li> <li> <p>People requiring dialysis</p> </li> <li> <p>Untreated psychiatric disorder</p> </li> <li> <p>Clinical evidence of gangrene on any part of the affected foot</p> </li> <li> <p>People receiving corticosteroids, NSAIDs, immunosuppressive or cytotoxic agents, or systemic agents that could affect wound repair or any treatment that might interfere with the assessment of the study treatment </p> </li> </ol> </li> </ol> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Interventions</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Intervention: Dermagen®</p> <p>Control: Conventional treatment</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Outcomes</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p> <ol id="CD008548-lst1-0190"> <li> <p>Primary outcome measure: complete wound closure at week 12: time‐frame = 12 weeks; not designated as a safety issue </p> </li> <li> <p>Secondary outcome measure: time to complete wound healing: time‐frame = 24 weeks; not designated as a safety issue </p> </li> </ol> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Starting date</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>January 2009 (date of first enrolment)</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Contact information</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Name:&nbsp;Olivier Chosidow, MD, PhD</p> <p>Address:&nbsp;not reported</p> <p>Telephone: not reported</p> <p>Email: not reported</p> <p>Affiliation:&nbsp;Hôpital Tenon, Paris</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Notes</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>* Pedis is a classification system for diabetic foot ulcers in people with diabetes mellitus (<a href="references#CD008548-bbs2-0148">Schaper 2004</a>). See <a href="appendices#CD008548-sec2-0018">Appendix 3</a> for details. </p> <p>Target sample size: 388</p> <p>Register: ClinicalTrials.gov</p> <p>Last refreshed on: 21 December 2010</p> <p>Main ID:&nbsp;<a href="references#CD008548-bbs2-0042">NCT00521937</a> </p> <p>Date of registration: 27 August 2007</p> <p>Primary sponsor: Laboratoires Genévrier</p> <p>Recruitment status: active, not recruiting</p> <p>URL:&nbsp;<a href="references#CD008548-bbs2-0042">NCT00521937</a> </p> <p>Source(s) of monetary support: Laboratoires Genévrier</p> </td> </tr> </tbody> </table> </div> <div class="table" id=""> <table> <div class="table-heading"><span class="table-label"></span><span class="table-title">NCT00709514 </span></div> <tbody> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Trial name or title</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>A phase II, double‐blind, placebo‐controlled clinical evaluation of DCB‐WH1 in healing of chronic diabetic foot ulcers </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Methods</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p> <ol id="CD008548-lst1-0191"> <li> <p>Allocation: randomised</p> </li> <li> <p>Endpoint classification: safety/efficacy study</p> </li> <li> <p>Intervention model: parallel assignment</p> </li> <li> <p>Masking: double blind (subject, caregiver, investigator, outcomes assessor)</p> </li> <li> <p>Primary purpose: treatment</p> </li> <li> <p>Country Taiwan</p> </li> </ol> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Participants</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p> <ol id="CD008548-lst1-0192"> <li> <p>Enrolled: 50</p> </li> <li> <p>Inclusion criteria</p> <ol id="CD008548-lst2-0152"> <li> <p>≥ 20 years with diabetes mellitus (type 1 or 2) and a cutaneous ulcer on the foot that has been present for at least 2 weeks </p> </li> <li> <p>Grade 1 target ulcer according to a modified Wagner system, which includes wounds involving the epidermis, the dermis, the hypodermis or the subcutaneous fat but not the tendon or joint capsule. The thickness of these layers should be approximately 0.2‐8 mm and wounds should have an area of 3‐15 cm<sup>2</sup> post debridement </p> </li> <li> <p>ABPI ≥ 0.80</p> </li> <li> <p>Study ulcer should show "infection control" as judged by the investigator</p> </li> <li> <p>Free of any necrotic or infected soft and bony tissue</p> </li> <li> <p>Signed informed consent form</p> </li> </ol> </li> <li> <p>Exclusion criteria</p> <ol id="CD008548-lst2-0153"> <li> <p>Ulcers caused by venous or arterial insufficiency, osteomyelitis</p> </li> <li> <p>Poor nutritional status (albumin &lt; 3 g/dl), poor diabetic control (HbA1c &gt; 10%), anaemia (Hb &lt; 10 g/dL), leukocyte count &lt; 1000/mm<sup>3</sup> </p> </li> <li> <p>Requiring prostaglandin treatment</p> </li> <li> <p>Requiring treatment with corticosteroids, immunosuppressive or chemotherapeutic agents, radiotherapy </p> </li> <li> <p>Presence of necrosis, purulence or sinus tracts that cannot be removed by debridement</p> </li> <li> <p>Presence of connective tissue disease, renal failure (eGFR ≦ 30 ml/min/1.73 m<sup>2</sup>), abnormal liver function (AST, ALT &gt; 2.5 x upper limit of normal range), malignancy </p> </li> <li> <p>Vascularisation surgery performed &lt; 8 weeks before entry into the study</p> </li> <li> <p>History of cerebrovascular events, coronary intervention (stent or CABG) or myocardial infarction, within 6 months prior to study </p> </li> <li> <p>Female patient with a positive pregnancy test, or breastfeeding, or unwilling to use appropriate contraceptive methods during study </p> </li> </ol> </li> </ol> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Interventions</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p> <ol id="CD008548-lst1-0193"> <li> <p>Experimental intervention: 1.25% DCB‐WH1 ointment topically applied twice daily</p> </li> <li> <p>Placebo intervention: no details reported</p> </li> </ol> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Outcomes</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Primary outcome measure: incidence of complete ulcer closure: time‐frame =&nbsp;12 weeks; designated as a safety issue </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Starting date</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>May 2008 (date of first enrolment)</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Contact information</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Name:&nbsp; David Yeh, Director</p> <p>Address: not reported</p> <p>Telephone: +886 2 26558098</p> <p>Email: <a href="/cdn-cgi/l/email-protection" class="__cf_email__" data-cfemail="600401160904190508200d0903120f02090f4e030f0d4e1417">[email&#160;protected]</a></p> <p>Affiliation:&nbsp;not reported</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Notes</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>PEDIS is</p> <p>Target sample size: 50</p> <p>Register: ClinicalTrials.gov</p> <p>Last refreshed on: 8 March 2011</p> <p>Main ID:&nbsp;<a href="references#CD008548-bbs2-0043">NCT00709514</a> </p> <p>Date of registration: 27 June 2008</p> <p>Primary sponsor: Oneness Biotech Co, Ltd</p> <p>Recruitment status: completed</p> <p>URL:&nbsp;<a href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/http/MNXGT5UJMNRXZ7DTNFRXZ63PM7YYG/show/NCT00709514" target="_blank">http://clinicaltrials.gov/show/NCT00709514</a> </p> <p>Source(s) of monetary support: Oneness Biotech Co, Ltd</p> </td> </tr> </tbody> </table> </div> <div class="table" id=""> <table> <div class="table-heading"><span class="table-label"></span><span class="table-title">NCT00915486 </span></div> <tbody> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Trial name or title</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>A randomized, multi‐center, controlled, parallel group, dose finding study of the efficacy and safety of topically applied I‐020201 as an adjunct to good standard‐of‐care versus good standard‐of‐care alone in patients with chronic diabetic foot ulcers </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Methods</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p> <ol id="CD008548-lst1-0194"> <li> <p>Allocation: randomised</p> </li> <li> <p>Endpoint classification: safety/efficacy study</p> </li> <li> <p>Intervention model: parallel assignment</p> </li> <li> <p>Masking: double blind (subject, caregiver, investigator, outcomes assessor)</p> </li> <li> <p>Primary purpose: treatment</p> </li> <li> <p>Country:Czech Republic, Germany, Hungary, Romania, Russian Federation,Serbia</p> </li> </ol> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Participants</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Enrolled: 210</p> <p> <ol id="CD008548-lst1-0195"> <li> <p>Inclusion criteria</p> <ol id="CD008548-lst2-0154"> <li> <p>Age ≥ 18 years</p> </li> <li> <p>Provided written informed consent</p> </li> <li> <p>Women of childbearing potential with a negative result from pregnancy test at screening who agree to use an acceptable birth control method (hormonal or IUD), or abstinence, throughout the trial </p> </li> <li> <p>Type 1 or type 2 diabetes mellitus with HbA1c ≦ 12%</p> </li> <li> <p>Only 1 diabetic foot ulcer on the foot to be treated, on or below the ankle</p> </li> </ol> </li> <li> <p>Exclusion criteria</p> <ol id="CD008548-lst2-0155"> <li> <p>Pregnant or breast‐feeding</p> </li> <li> <p>Known or suspected allergies to any of the components of the I‐020201</p> </li> <li> <p>Uncontrolled anaemia (Hb &lt; 9 g/dL in women and &lt; 10 g/dL in men)</p> </li> <li> <p>Hypoalbuminaemia (albumin &lt; 3 g/dL)</p> </li> <li> <p>Overtly infected target ulcer (as judged by investigator)</p> </li> <li> <p>Highly exuding wounds (wounds that require a daily dressing change)</p> </li> <li> <p>Osteomyelitis</p> </li> <li> <p>Systemic infections</p> </li> <li> <p>Acute Charcot foot and severe chronic Charcot deformity</p> </li> <li> <p>ABPI &lt; 0.7 or ankle systolic pressure &lt; 70 mmHg</p> </li> <li> <p>One of the following:</p> <ol id="CD008548-lst3-0005"> <li> <p>monophasic or biphasic flow (with loss of reverse flow) in either foot artery, or a toe on Doppler waveform analysis on the dorsalis pedis and posterior tibial arteries </p> </li> <li> <p>brachial index &lt; 0.7</p> </li> <li> <p>TcPO2 &lt; 40 mmHg</p> </li> </ol> </li> <li> <p>Suspicion, presence or history of systemic or local cancer or tumour of any kind</p> </li> </ol> </li> </ol> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Interventions</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p> <ol id="CD008548-lst1-0196"> <li> <p>Group 1: Good Standard of Care: Experimental (GSoC): twice per week</p> </li> <li> <p>Group 2: GSoC + vehicle (topical fibrin as an adjunct to GSoC twice per week)</p> </li> <li> <p>Group 3: GSoC + I‐020201 (33 μg) topical as an adjunct to GSoC twice per week</p> </li> <li> <p>Group 4: GSoC + I‐020201 (100 μg) topical as an adjunct to GSoC twice per week</p> </li> <li> <p>Group 5: GSoC + I‐020201 (300 μg) topical as an adjunct to GSoC twice per week</p> </li> </ol> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Outcomes</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p> <ol id="CD008548-lst1-0197"> <li> <p>Primary outcome: percentage reduction in ulcer surface area: time‐frame = 4 weeks after start of treatment </p> </li> <li> <p>Secondary outcomes</p> <ol id="CD008548-lst2-0156"> <li> <p>Changes in systemic PDGF‐AB and antibody levels against TG‐PDGF.AB and aprotinin: time‐frame: 1, 4, 12, 16 and 20 weeks after start of treatment </p> </li> <li> <p>Changes in vital signs, body weight, physical examination and laboratory parameters: time‐frame: throughout the study and 28 weeks after start of treatment </p> </li> <li> <p>Incidence of complete wound closure (full re‐epithelialisation with confirmation 4 weeks afterwards): time‐frame = 12 and 16 weeks after start of treatment </p> </li> <li> <p>Incidence of complete wound closure (full re‐epithelialisation with confirmation 4 weeks afterwards): time‐frame = whole study period (28 weeks after start of treatment) </p> </li> <li> <p>Incidence of participants with ulcer recurrence: time‐frame = up to 16 and 28 weeks after start of treatment </p> </li> <li> <p>Incidence of treatment failure defined as &lt; 30% decrease in ulcer size: time‐frame = after 8 weeks of treatment </p> </li> <li> <p>Incidence of treatment‐related AEs (systemic and at the target ulcer) and all AEs/SAEs: time‐frame = whole study period </p> </li> <li> <p>Time to complete wound closure (full re‐epithelialisation with confirmation 4 weeks afterwards): time‐frame = at any time during the study </p> </li> </ol> </li> </ol> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Starting date</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>May 2009 (date of first enrolment)</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Contact information</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Name: Mitra Safari</p> <p>Address: not reported&nbsp;</p> <p>Telephone: +41 44 200 5600</p> <p>Email: <a href="/cdn-cgi/l/email-protection" class="__cf_email__" data-cfemail="85e8ecf1f7e4abf6e4e3e4f7ecc5eef0f7eaf6abe6ed">[email&#160;protected]</a></p> <p>Affiliation:&nbsp;not reported</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Notes</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p> <ol id="CD008548-lst1-0198"> <li> <p>Target sample size: 210</p> </li> <li> <p>Register: ClinicalTrials.gov</p> </li> <li> <p>Last refreshed on: 25 January 2011</p> </li> <li> <p>Main ID: <a href="references#CD008548-bbs2-0044">NCT00915486</a> </p> </li> <li> <p>Date of registration: 5 June 2009</p> </li> <li> <p>Primary sponsor: Kuros Biosurgery AG</p> </li> <li> <p>Recruitment status: completed</p> </li> <li> <p>URL: <a href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/http/MNXGT5UJMNRXZ7DTNFRXZ63PM7YYG/show/NCT00915486" target="_blank">http://clinicaltrials.gov/show/NCT00915486</a> </p> </li> <li> <p>Source(s) of monetary support: Kuros Biosurgery AG</p> </li> </ol> </p> </td> </tr> </tbody> </table> </div> <div class="table" id=""> <table> <div class="table-heading"><span class="table-label"></span><span class="table-title">NCT00926068 </span></div> <tbody> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Trial name or title</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Safety and efficacy of HO/03/03 10 µg in the treatment of plantar neuropathic diabetic foot ulcers (Truheal) </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Methods</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p> <ol id="CD008548-lst1-0199"> <li> <p>Allocation: randomised</p> </li> <li> <p>Endpoint classification: safety/efficacy study</p> </li> <li> <p>Intervention model: parallel assignment</p> </li> <li> <p>Masking: double blind (subject, investigator)</p> </li> <li> <p>Primary purpose: treatment</p> </li> <li> <p>Country: USA</p> </li> </ol> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Participants</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p> <ol id="CD008548-lst1-0200"> <li> <p>Enrolled: 196</p> </li> <li> <p>Inclusion criteria</p> <ol id="CD008548-lst2-0157"> <li> <p>Age 18‐80 years, extremes included</p> </li> <li> <p>Diagnosed with diabetes mellitus type 1 or 2</p> </li> <li> <p>A documented single, target, non‐healing, plantar neuropathic diabetic foot ulcer with a minimal duration of 4 weeks prior to giving informed consent </p> </li> <li> <p>Ulcer size at randomisation: Wagner grade 1, 2.0 ‐10 cm<sup>2</sup> extremes included, or Wagner grade 2, 1.0‐10 cm<sup>2</sup> extremes included </p> </li> <li> <p>Single target ulcer on the study foot: Wagner grade 1 or 2 (does not involve abscess or osteomyelitis) </p> </li> <li> <p>Target ulcer area decreased by ≤ 30%, or ≤ 0.1 cm/week edge healing rate measured, between post‐debridement values at screening and at randomisation, if debridement clinically indicated </p> </li> <li> <p>HbA1c ≤ 12%</p> </li> <li> <p>Ankle to Brachial Index (ABI) on study foot: 0.7 ≤ ABI ≤ 1.2 or ABI &gt; 1.2 and toe pressure &gt; 50 mm Hg (ABI measured by Doppler; toe blood pressure measured by toe cuff) </p> </li> <li> <p>Diabetic neuropathy confirmed by neurological testing</p> </li> <li> <p>Participants available for entire study period, and able and willing to adhere to protocol requirements </p> </li> <li> <p>Signed informed consent form prior to any study protocol‐related procedure</p> </li> </ol> </li> <li> <p>Exclusion criteria</p> <ol id="CD008548-lst2-0158"> <li> <p>Medical history, current or within the last 2 years, of abuse of alcohol, barbiturates, benzodiazepines, amphetamines, narcotics, cocaine, psychoactive drugs or other substances that interfere with treatment compliance </p> </li> <li> <p>Use of growth factors, skin graft or participation in an investigational study within 30 days prior to the start of the screening period </p> </li> <li> <p>Women who are pregnant, lactating, of childbearing potential, or post‐menopausal for &lt; 2 years and not using a medically approved method of contraception, or who test positive on a blood‐based pregnancy test </p> </li> <li> <p>A documented medical history of HIV, HBV or HCV</p> </li> <li> <p>A documented significant cardiac, pulmonary, gastrointestinal, endocrine (other than diabetes mellitus type 1 or 2), metabolic, neurological, hepatic or nephrologic disease and/or receiving dialysis </p> </li> <li> <p>Anaemia (Hb &lt; 9 g/dL for women, or &lt; 10 g/dL for men) or white blood cell count &gt; 11,000/μL or platelet count &lt; 100,000/μL or impaired renal function (creatinine &gt; 3 mg/dL) or liver function tests &gt; 3 times upper normal laboratory values or any indication of malnourishment (albumin &lt; 2.8 g/dL) or any other clinically significant biochemistry, haematology and urinalysis tests </p> </li> <li> <p>Any clinically significant illness during the 4 weeks preceding the screening period</p> </li> <li> <p>Current or previous (within last 5 years) malignancy, other than basal cell carcinoma, or is treated by radio/chemotherapy </p> </li> <li> <p>Any signs of clinical infection in the wound (which could be linked to raised body temperature, abscess, osteomyelitis, necrosis or erythema) </p> </li> <li> <p>Received any antibiotic treatment during the screening period</p> </li> <li> <p>Evidence of infection or osteomyelitis on a plain foot X‐ray at screening</p> </li> <li> <p>Bed‐ridden or unable to come to the clinic</p> </li> <li> <p>&gt; 1 target non‐healing diabetic foot ulcer per subject</p> </li> <li> <p>Plantar neuropathic diabetic foot ulcer is located on an active Charcot foot</p> </li> <li> <p>Hind foot ulcer or foot deformity/condition that prevents the use of offloading footwear</p> </li> <li> <p>Revascularisation leg surgery within the last 6 months, or a candidate for revascularisation surgery during the course of the study </p> </li> <li> <p>Glucocorticosteroid treatment (prednisone &gt; 10 mg/day or equivalent)</p> </li> <li> <p>Inability to stop alternative wound healing treatment (e.g. becaplermin or other topical products) following debridement </p> </li> </ol> </li> </ol> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Interventions</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p> <ol id="CD008548-lst1-0201"> <li> <p>Intervention: HO/03/03 10 µg</p> </li> <li> <p>Control: placebo comparator</p> </li> </ol> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Outcomes</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p> <ol id="CD008548-lst1-0202"> <li> <p>Primary outcome measures</p> <ol id="CD008548-lst2-0159"> <li> <p>Complete ulcer closure: time‐frame = up to 14 weeks inclusive; not designated as a safety issue </p> </li> <li> <p>Time to event analysis to determine time for incidence of 100% study wound closure per unit of time (days) and the incidence of 100% wound closure per unit of time using the log rank test </p> </li> </ol> </li> <li> <p>Secondary outcome measures</p> <ol id="CD008548-lst2-0160"> <li> <p>Percentage change in wound area at 4 weeks: time‐frame = 4 weeks; not designated as a safety issue </p> </li> <li> <p>75% wound closure by or on study week 14: time‐frame = up to 14 weeks inclusive: not designated as a safety issue </p> </li> <li> <p>Incidence of AEs, changes in vital signs, physical examination, electrocardiogram and laboratory tests from baseline to termination: time‐frame = 14 weeks; designated as a safety issue </p> </li> <li> <p>Incidence of 100% closure according to the Fisher exact 2‐tailed test: time‐frame = up to 14 weeks inclusive; not designated as a safety issue </p> </li> <li> <p>Percentage change in granulation tissue at 4 weeks: time‐frame = 4 weeks; not designated as a safety issue </p> </li> <li> <p>Incidence of improved ulcers; not designated as a safety issue</p> </li> </ol> </li> </ol> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Starting date</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>February 2010 (date of first enrolment)</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Contact information</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Name: Talma Gotteiner, MPharm</p> <p>Address:&nbsp;not reported</p> <p>Telephone: +97289407188</p> <p>Email: <a href="/cdn-cgi/l/email-protection" class="__cf_email__" data-cfemail="3347525f5e52735b56525f5c411d505c5e">[email&#160;protected]</a></p> <p>Affiliation: not reported&nbsp;</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Notes</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p> <ol id="CD008548-lst1-0203"> <li> <p>Target sample size: 146</p> </li> <li> <p>Register: ClinicalTrials.gov</p> </li> <li> <p>Last refreshed on: 22 March 2011</p> </li> <li> <p>Main ID: <a href="references#CD008548-bbs2-0045">NCT00926068</a> </p> </li> <li> <p>Date of registration: 22 June 2009</p> </li> <li> <p>Primary sponsor: HealOr</p> </li> <li> <p>Recruitment status: recruiting</p> </li> <li> <p>URL: <a href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/http/MNXGT5UJMNRXZ7DTNFRXZ63PM7YYG/show/NCT00926068" target="_blank">http://clinicaltrials.gov/show/NCT00926068</a> </p> </li> <li> <p>Source(s) of monetary support: HealOr</p> </li> </ol> </p> </td> </tr> </tbody> </table> </div> <div class="table" id=""> <table> <div class="table-heading"><span class="table-label"></span><span class="table-title">NCT01060670 </span></div> <tbody> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Trial name or title</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>A multi‐center, randomized, controlled clinical trial to evaluate the safety and effectiveness of Integra® Dermal Regeneration Template for the treatment of neuropathic diabetic foot ulcers </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Methods</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p> <ol id="CD008548-lst1-0204"> <li> <p>Allocation: randomised</p> </li> <li> <p>Endpoint classification: safety/efficacy study</p> </li> <li> <p>Intervention model: parallel assignment</p> </li> <li> <p>Masking: open label</p> </li> <li> <p>Primary purpose: treatment</p> </li> <li> <p>Country: USA</p> </li> </ol> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Participants</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p> <ol id="CD008548-lst1-0205"> <li> <p>Enrolled: 350</p> </li> <li> <p>Inclusion criteria</p> <ol id="CD008548-lst2-0161"> <li> <p>Type 1 or 2 diabetes mellitus</p> </li> <li> <p>HbA1c ≤ 12%</p> </li> <li> <p>Diabetic foot ulcer located below the ankle and/or on the bottom of the foot that has been present for 30 days and is of sufficient size to qualify for the study </p> </li> <li> <p>Good vascular perfusion of the affected limb</p> </li> </ol> </li> <li> <p>Exclusion criteria</p> <ol id="CD008548-lst2-0162"> <li> <p>Gangrene, infection, or osteomyelitis</p> </li> <li> <p>Sensitivity to bovine collagen or chondroitin, or both</p> </li> <li> <p>Ulcers resulting from other health conditions besides diabetes</p> </li> <li> <p>Conditions or laboratory values that are not within the specified ranges</p> </li> </ol> </li> </ol> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Interventions</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p> <ol id="CD008548-lst1-0206"> <li> <p>Intervention: dermal replacement device. Application in diabetic foot ulcer</p> </li> <li> <p>Control: moist wound therapy</p> </li> <li> <p>Co‐intervention: saline plus secondary dressing and conventional wound therapy</p> </li> </ol> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Outcomes</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p> <ol id="CD008548-lst1-0207"> <li> <p>Primary outcome measure: incidence of complete wound closure: time‐frame = 16 weeks; not designated as a safety issue </p> </li> <li> <p>Secondary outcome measures</p> <ol id="CD008548-lst2-0163"> <li> <p>Time to complete wound closure: time‐frame = 28 weeks; not designated as a safety issue </p> </li> <li> <p>Incidence of recurrence: time‐frame = 28 weeks; not designated as a safety issue</p> </li> <li> <p>Incidence of adverse events: time‐frame = 28 weeks; designated as a safety issue</p> </li> </ol> </li> </ol> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Starting date</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>April 2010 (date of first enrolment)</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Contact information</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Name: Nicola Fenty‐Stewart, PhD</p> <p>Address:&nbsp;not reported</p> <p>Telephone: 1‐609‐275‐0500 (http://www.integralife.com/index.aspx?redir=contact) Accessed on 3 September 2014 </p> <p>Email: <a href="/cdn-cgi/l/email-protection" class="__cf_email__" data-cfemail="3c52555f53505d5a4f7c5d515d4e59445f4e53125f5351">[email&#160;protected]</a></p> <p>Affiliation:&nbsp;not reported</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Notes</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p> <ol id="CD008548-lst1-0208"> <li> <p>Target sample size: 350</p> </li> <li> <p>Register: ClinicalTrials.gov</p> </li> <li> <p>Last refreshed on: 3 June 2010</p> </li> <li> <p>Main ID: <a href="references#CD008548-bbs2-0046">NCT01060670</a> </p> </li> <li> <p>Date of registration: 31 January 2010</p> </li> <li> <p>Primary sponsor: Integra LifeSciences Corporation</p> </li> <li> <p>Recruitment status: completed</p> </li> <li> <p>URL: <a href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/http/MNXGT5UJMNRXZ7DTNFRXZ63PM7YYG/show/NCT01060670" target="_blank">http://clinicaltrials.gov/show/NCT01060670</a> </p> </li> <li> <p>Source(s) of monetary support: Integra LifeSciences Corporation</p> </li> </ol> </p> </td> </tr> </tbody> </table> </div> <div class="table" id=""> <table> <div class="table-heading"><span class="table-label"></span><span class="table-title">NCT01098357 </span></div> <tbody> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Trial name or title</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>A phase I/II, multicentre, randomised, controlled, and open‐label trial comparing the efficacy and safety of three dose regimens of BioChaperone PDGF‐BB to becaplermin gel for the treatment of diabetic foot ulcer </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Methods</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p> <ol id="CD008548-lst1-0209"> <li> <p>Allocation: randomised</p> </li> <li> <p>Endpoint classification: safety/efficacy study</p> </li> <li> <p>Intervention model: parallel assignment</p> </li> <li> <p>Masking: open label</p> </li> <li> <p>Primary purpose: treatment</p> </li> <li> <p>Country: India</p> </li> </ol> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Participants</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p> <ol id="CD008548-lst1-0210"> <li> <p>Enrolled 192</p> </li> <li> <p>Inclusion criteria</p> <ol id="CD008548-lst2-0164"> <li> <p>Aged ≥ 18 years, with type 1 or 2 diabetes mellitus</p> </li> <li> <p>Single full‐thickness plantar ulcer of the extremity (below the malleolus) extending through the epidermis and dermis, but not involving bone, tendons, ligaments or muscles (grade IA as defined by University of Texas Diabetic Wound Classification) </p> </li> <li> <p>Chronic ulcer of at least 6 weeks duration despite appropriate wound care</p> </li> <li> <p>Ulcer area (greatest length by greatest width), following sharp debridement, of 1‐10 cm² </p> </li> <li> <p>Well‐controlled infection or cellulitis (systemic antibiotic therapy)</p> </li> <li> <p>Peripheral neuropathy assessed by Semmes‐Weinstein monofilament test or by bio esthesimeter (vibration perception threshold) </p> </li> <li> <p>Adequate arterial blood supply measured by (colour) doppler ultrasonography, ABPI &gt; 0.60, or ankle systolic pressure &gt; 70 mmHg, or toe pressure &gt; 30 mmHg. ABPI should be &lt; 1.3 (which is frequently related to medial artery calcification </p> </li> <li> <p>Women required to be surgically sterile, post‐menopausal, or be non‐nursing and agree to practice adequate contraception and have a negative pregnancy test at screening </p> </li> <li> <p>Provide signed informed consent before any study procedure</p> </li> </ol> </li> <li> <p>Exclusion criteria</p> <ol id="CD008548-lst2-0165"> <li> <p>Ulcer of non‐diabetic cause or origin, e.g. electrical, chemical or radiation insult, bedsores, vascular ulcer or Charcot deformity ulcers </p> </li> <li> <p>Active ulcer infection assessed by clinical examination and radiographically, if necessary. Presence of necrosis, purulence or sinus tracts that cannot be removed by debridement </p> </li> <li> <p>Active osteomyelitis affecting the area of the target ulcer</p> </li> <li> <p>Poorly‐controlled diabetes (uncontrolled glycaemia: HbA1c ≥ 12%), renal failure (serum creatinine &gt; 3.0 mg/dL), poor nutritional status (albumin &lt; 3.0 g/dL or total protein &lt; 6.5 g/dL) </p> </li> <li> <p>Known connective tissue or malignant disease</p> </li> <li> <p>Concomitant treatment with corticosteroids, immunosuppressive agents, radiation therapy, or anticancer chemotherapy </p> </li> <li> <p>Use of investigational drug/device within 30 days</p> </li> <li> <p>Topical application of any advance wound care on this wound (growth factor, antiseptics, antibiotics or debriders) within 7 days </p> </li> <li> <p>Vascular reconstruction within 8 weeks.</p> </li> <li> <p>Expected noncompliance with the protocol (i.e. not available for the duration of the trial, or noncompliant with treatment or wound care), or felt to be unsuitable by the Investigator for any other reason </p> </li> </ol> </li> </ol> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Interventions</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>After the screening visit, the eligible participant population randomly receive 1 of the following: </p> <p> <ol id="CD008548-lst1-0211"> <li> <p>Intervention 1: BioChaperone™ PDGF‐BB 25 µg/cm² applied as a spray every 2 days for 20 weeks </p> </li> <li> <p>Intervention 2: BioChaperone™ PDGF‐BB 12.5 µg/cm² applied as a spray every 2 days for 20 weeks </p> </li> <li> <p>Intervention 3: BioChaperone™ PDGF‐BB 4 µg/cm² applied as a spray every 2 days for 20 weeks </p> </li> <li> <p>Intervention 4: beclapermin (Regranex) gel 6.25 µg/cm² applied daily for 20 weeks</p> </li> </ol> </p> <p>Experimental BioChaperone PDGF‐BB is a new formulation of the B isoform dimer of recombinant human platelet‐derived growth factor (rhPDGF‐BB) containing the new excipient Biochaperone, a dextran modified polymer. The finished product is administered as a sterile spray </p> <p>Regranex: active comparator becaplermin gel (Regranex® Gel 0.01%, Systagenix, formerly and Johnson &amp; Johnson) is a topical gel of rhPDGF‐BB contained in a gel tube </p> <p>All 4 groups to be assessed weekly till the 8th week (visit 10); then once every 2 weeks (14 day duration) thereafter till the end of study. The maximum number of visits expected is 16. The study data will be presented at the end of 20 weeks </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Outcomes</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p> <ol id="CD008548-lst1-0212"> <li> <p>Primary outcome measures:</p> <ol id="CD008548-lst2-0166"> <li> <p>Incidence of complete wound closure: time‐frame = 20 weeks; not designated as a safety issue </p> </li> <li> <p>Incidence of complete wound closure</p> </li> </ol> </li> <li> <p>Secondary outcome measures</p> <ol id="CD008548-lst2-0167"> <li> <p>Time to achieve complete wound closure: time‐frame = 20 weeks (duration of study); not designated as a safety issue </p> </li> <li> <p>Time to achieve complete wound closure</p> </li> <li> <p>Percentage reduction in total ulcer surface area at each visit: time‐frame = 20 weeks (study duration); not designated as a safety issue </p> </li> <li> <p>Incidence of complete wound healing at week 10: time‐frame = 10 weeks; not designated as a safety issue </p> </li> <li> <p>Safety measures: time‐frame = 20 weeks (duration of study); designated as a safety issue </p> <ol id="CD008548-lst3-0006"> <li> <p>Treatment‐related adverse events with investigator's assessment of seriousness, severity, duration and relationship to study medication </p> </li> <li> <p>Wound‐related infections</p> </li> <li> <p>Changes in standard laboratory tests (haematology, biochemistry and detection of antibodies)</p> </li> </ol> </li> </ol> </li> </ol> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Starting date</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>June 2010 (date of first enrolment)</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Contact information</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Not reported</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Notes</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Target sample size: 192</p> <p>Register: ClinicalTrials.gov</p> <p>Last refreshed on: 2 November 2010</p> <p>Main ID:&nbsp;<a href="references#CD008548-bbs2-0047">NCT01098357</a> </p> <p>Date of registration: 1 April 2010</p> <p>Primary sponsor: Virchow Group</p> <p>Recruitment status: completed</p> <p>URL:&nbsp;<a href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/http/MNXGT5UJMNRXZ7DTNFRXZ63PM7YYG/show/NCT01098357" target="_blank">http://clinicaltrials.gov/show/NCT01098357</a> </p> <p>Source(s) of monetary support: Virchow Group, and Adocia</p> <p>Secondary sponsor(s): Adocia</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p><b>Abbreviations</b> </p> <p>ABPI = ankle‐brachial pressure index<br> AE = adverse event<br> ALT = alanine transaminase<br> AST = aspartate transaminase<br> CABG = coronary artery bypass graft<br> eGFR = epidermal growth factor receptor<br> Hb = haemoglobin<br> HbA1c = glycated haemoglobin<br> HBV = Hepatitis B virus<br> HCV = Hepatitis C virus<br> HIV = human immunodeficiency virus<br> PDGF = platelet‐derived growth factor<br> PDGF‐AB = platelet‐derived growth factor (specific form)<br> rhPEGF‐BB = recombinant human platelet‐derived growth factor<br> min = minute(s)<br> NSAID = non‐steroidal anti‐inflammatory<br> SAE = serious adverse event<br> SPI = systolic pressure index<br> TcPO2 = transcutaneous oxygen tension<br> TG‐PDGF.AB = transglutaminase‐ platelet‐derived growth factor AB </p> </div> </div> </p> </section> </section> <section class="dataAndAnalyses" id="dataAndAnalyses"> <section class="dataAndAnalyses" lang="en"> <div class="section-header section-collapse-header" id="CD008548-sec1-0011"> <h2 class="title section-collapse-title">Data and analyses<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <div class="table" id="CD008548-tbl-0002"> <table class="comparison"><a href="#0" class="open-table-viewer open-in-figure-viewer">Open in table viewer</a><div class="table-heading"><span class="table-label">Comparison 1.</span>&nbsp;<span class="table-title">Any growth factor versus placebo or no growth factor</span></div> <thead> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Outcome or subgroup title</p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>No. of studies</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>No. of participants</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Statistical method</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">1 Complete wound closure <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>12</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1139</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1.51 [1.31, 1.73]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"> <div class="figure" id="CD008548-fig-00101"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <li><a href="#0" class="open-in-figure-viewer">Open in figure viewer</a></li> <li><a class="btn btn-link" target="_blank" href="/cdsr/doi/10.1002/14651858.CD008548.pub2/ppt/CDSR/CD008548/image_n/nCD008548-CMP-001-01.png?filename=nCD008548-CMP-001-01.ppt&amp;title=1.1&amp;caption=Comparison%201%20Any%20growth%20factor%20versus%20placebo%20or%20no%20growth%20factor%2C%20Outcome%201%20Complete%20wound%20closure.&amp;citation=Mart%C3%AD%E2%80%90Carvajal AJ, Gluud C, Nicola S, Simancas%E2%80%90Racines D, Reveiz L, Oliva P, Cede%C3%B1o%E2%80%90Taborda J. Growth factors for treating diabetic foot ulcers. Cochrane Database of Systematic Reviews 2015, 10. Art. No.: CD008548. DOI: http://dx.doi.org/10.1002/14651858.CD008548.pub2"> Download as PowerPoint </a></li> </nav> <div class="figure-label">Analysis 1.1</div> </div> <hr class="top"><img data-id="CD008548-fig-00101" src="/cdsr/doi/10.1002/14651858.CD008548.pub2/media/CDSR/CD008548/image_n/nCD008548-CMP-001-01.png" alt="Comparison 1 Any growth factor versus placebo or no growth factor, Outcome 1 Complete wound closure."><hr class="bottom"> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Comparison 1 Any growth factor versus placebo or no growth factor, Outcome 1 Complete wound closure. </p> </div> </div> </div> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">2 Lower limb amputation (minimum of one toe) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>2</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>219</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0.74 [0.39, 1.39]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"> <div class="figure" id="CD008548-fig-00102"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <li><a href="#0" class="open-in-figure-viewer">Open in figure viewer</a></li> <li><a class="btn btn-link" target="_blank" href="/cdsr/doi/10.1002/14651858.CD008548.pub2/ppt/CDSR/CD008548/image_n/nCD008548-CMP-001-02.png?filename=nCD008548-CMP-001-02.ppt&amp;title=1.2&amp;caption=Comparison%201%20Any%20growth%20factor%20versus%20placebo%20or%20no%20growth%20factor%2C%20Outcome%202%20Lower%20limb%20amputation%20%28minimum%20of%20one%20toe%29.&amp;citation=Mart%C3%AD%E2%80%90Carvajal AJ, Gluud C, Nicola S, Simancas%E2%80%90Racines D, Reveiz L, Oliva P, Cede%C3%B1o%E2%80%90Taborda J. Growth factors for treating diabetic foot ulcers. Cochrane Database of Systematic Reviews 2015, 10. Art. No.: CD008548. DOI: http://dx.doi.org/10.1002/14651858.CD008548.pub2"> Download as PowerPoint </a></li> </nav> <div class="figure-label">Analysis 1.2</div> </div> <hr class="top"><img data-id="CD008548-fig-00102" src="/cdsr/doi/10.1002/14651858.CD008548.pub2/media/CDSR/CD008548/image_n/nCD008548-CMP-001-02.png" alt="Comparison 1 Any growth factor versus placebo or no growth factor, Outcome 2 Lower limb amputation (minimum of one toe)."><hr class="bottom"> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Comparison 1 Any growth factor versus placebo or no growth factor, Outcome 2 Lower limb amputation (minimum of one toe). </p> </div> </div> </div> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">3 Ulcer‐free days following treatment for diabetic foot ulcers (free from any recurrence) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Hazard Ratio (Fixed, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0.64 [0.14, 2.94]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"> <div class="figure" id="CD008548-fig-00103"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <li><a href="#0" class="open-in-figure-viewer">Open in figure viewer</a></li> <li><a class="btn btn-link" target="_blank" href="/cdsr/doi/10.1002/14651858.CD008548.pub2/ppt/CDSR/CD008548/image_n/nCD008548-CMP-001-03.png?filename=nCD008548-CMP-001-03.ppt&amp;title=1.3&amp;caption=Comparison%201%20Any%20growth%20factor%20versus%20placebo%20or%20no%20growth%20factor%2C%20Outcome%203%20Ulcer%E2%80%90free%20days%20following%20treatment%20for%20diabetic%20foot%20ulcers%20%28free%20from%20any%20recurrence%29.&amp;citation=Mart%C3%AD%E2%80%90Carvajal AJ, Gluud C, Nicola S, Simancas%E2%80%90Racines D, Reveiz L, Oliva P, Cede%C3%B1o%E2%80%90Taborda J. Growth factors for treating diabetic foot ulcers. Cochrane Database of Systematic Reviews 2015, 10. Art. No.: CD008548. DOI: http://dx.doi.org/10.1002/14651858.CD008548.pub2"> Download as PowerPoint </a></li> </nav> <div class="figure-label">Analysis 1.3</div> </div> <hr class="top"><img data-id="CD008548-fig-00103" src="/cdsr/doi/10.1002/14651858.CD008548.pub2/media/CDSR/CD008548/image_n/nCD008548-CMP-001-03.png" alt="Comparison 1 Any growth factor versus placebo or no growth factor, Outcome 3 Ulcer‐free days following treatment for diabetic foot ulcers (free from any recurrence)."><hr class="bottom"> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Comparison 1 Any growth factor versus placebo or no growth factor, Outcome 3 Ulcer‐free days following treatment for diabetic foot ulcers (free from any recurrence). </p> </div> </div> </div> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">4 Adverse events (non‐serious and serious) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>4</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>385</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0.98 [0.79, 1.22]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"> <div class="figure" id="CD008548-fig-00104"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <li><a href="#0" class="open-in-figure-viewer">Open in figure viewer</a></li> <li><a class="btn btn-link" target="_blank" href="/cdsr/doi/10.1002/14651858.CD008548.pub2/ppt/CDSR/CD008548/image_n/nCD008548-CMP-001-04.png?filename=nCD008548-CMP-001-04.ppt&amp;title=1.4&amp;caption=Comparison%201%20Any%20growth%20factor%20versus%20placebo%20or%20no%20growth%20factor%2C%20Outcome%204%20Adverse%20events%20%28non%E2%80%90serious%20and%20serious%29.&amp;citation=Mart%C3%AD%E2%80%90Carvajal AJ, Gluud C, Nicola S, Simancas%E2%80%90Racines D, Reveiz L, Oliva P, Cede%C3%B1o%E2%80%90Taborda J. Growth factors for treating diabetic foot ulcers. Cochrane Database of Systematic Reviews 2015, 10. Art. No.: CD008548. DOI: http://dx.doi.org/10.1002/14651858.CD008548.pub2"> Download as PowerPoint </a></li> </nav> <div class="figure-label">Analysis 1.4</div> </div> <hr class="top"><img data-id="CD008548-fig-00104" src="/cdsr/doi/10.1002/14651858.CD008548.pub2/media/CDSR/CD008548/image_n/nCD008548-CMP-001-04.png" alt="Comparison 1 Any growth factor versus placebo or no growth factor, Outcome 4 Adverse events (non‐serious and serious)."><hr class="bottom"> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Comparison 1 Any growth factor versus placebo or no growth factor, Outcome 4 Adverse events (non‐serious and serious). </p> </div> </div> </div> </td> </tr> </tbody> </table> </div> <div class="table" id="CD008548-tbl-0003"> <table class="comparison"><a href="#0" class="open-table-viewer open-in-figure-viewer">Open in table viewer</a><div class="table-heading"><span class="table-label">Comparison 2.</span>&nbsp;<span class="table-title">Any growth factor versus placebo or no growth factor (subgroup analysis of trials with follow‐up &lt; 20 weeks versus follow‐up ≥ 20 weeks)</span></div> <thead> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Outcome or subgroup title</p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>No. of studies</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>No. of participants</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Statistical method</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">1 Participants with complete wound closure <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>12</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1139</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1.51 [1.31, 1.73]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"> <div class="figure" id="CD008548-fig-00201"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <li><a href="#0" class="open-in-figure-viewer">Open in figure viewer</a></li> <li><a class="btn btn-link" target="_blank" href="/cdsr/doi/10.1002/14651858.CD008548.pub2/ppt/CDSR/CD008548/image_n/nCD008548-CMP-002-01.png?filename=nCD008548-CMP-002-01.ppt&amp;title=2.1&amp;caption=Comparison%202%20Any%20growth%20factor%20versus%20placebo%20or%20no%20growth%20factor%20%28subgroup%20analysis%20of%20trials%20with%20follow%E2%80%90up%20%3C%2020%20weeks%20versus%20follow%E2%80%90up%20%E2%89%A5%2020%20weeks%29%2C%20Outcome%201%20Participants%20with%20complete%20wound%20closure.&amp;citation=Mart%C3%AD%E2%80%90Carvajal AJ, Gluud C, Nicola S, Simancas%E2%80%90Racines D, Reveiz L, Oliva P, Cede%C3%B1o%E2%80%90Taborda J. Growth factors for treating diabetic foot ulcers. Cochrane Database of Systematic Reviews 2015, 10. Art. No.: CD008548. DOI: http://dx.doi.org/10.1002/14651858.CD008548.pub2"> Download as PowerPoint </a></li> </nav> <div class="figure-label">Analysis 2.1</div> </div> <hr class="top"><img data-id="CD008548-fig-00201" src="/cdsr/doi/10.1002/14651858.CD008548.pub2/media/CDSR/CD008548/image_n/nCD008548-CMP-002-01.png" alt="Comparison 2 Any growth factor versus placebo or no growth factor (subgroup analysis of trials with follow‐up < 20 weeks versus follow‐up ≥ 20 weeks), Outcome 1 Participants with complete wound closure."><hr class="bottom"> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Comparison 2 Any growth factor versus placebo or no growth factor (subgroup analysis of trials with follow‐up &lt; 20 weeks versus follow‐up ≥ 20 weeks), Outcome 1 Participants with complete wound closure. </p> </div> </div> </div> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1.1 Trials with length of follow‐up &lt; 20 weeks</p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>5</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>286</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1.24 [1.00, 1.55]</p> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1.2 Trials with length of follow up ≥ 20 weeks</p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>7</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>853</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1.65 [1.38, 1.98]</p> </td> </tr> </tbody> </table> </div> <div class="table" id="CD008548-tbl-0004"> <table class="comparison"><a href="#0" class="open-table-viewer open-in-figure-viewer">Open in table viewer</a><div class="table-heading"><span class="table-label">Comparison 3.</span>&nbsp;<span class="table-title">Any growth factor versus placebo or no growth factor (subgroup analysis by type of growth factor)</span></div> <thead> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Outcome or subgroup title</p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>No. of studies</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>No. of participants</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Statistical method</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">1 Complete wound closure <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>12</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1137</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1.50 [1.30, 1.73]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"> <div class="figure" id="CD008548-fig-00301"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <li><a href="#0" class="open-in-figure-viewer">Open in figure viewer</a></li> <li><a class="btn btn-link" target="_blank" href="/cdsr/doi/10.1002/14651858.CD008548.pub2/ppt/CDSR/CD008548/image_n/nCD008548-CMP-003-01.png?filename=nCD008548-CMP-003-01.ppt&amp;title=3.1&amp;caption=Comparison%203%20Any%20growth%20factor%20versus%20placebo%20or%20no%20growth%20factor%20%28subgroup%20analysis%20by%20type%20of%20growth%20factor%29%2C%20Outcome%201%20Complete%20wound%20closure.&amp;citation=Mart%C3%AD%E2%80%90Carvajal AJ, Gluud C, Nicola S, Simancas%E2%80%90Racines D, Reveiz L, Oliva P, Cede%C3%B1o%E2%80%90Taborda J. Growth factors for treating diabetic foot ulcers. Cochrane Database of Systematic Reviews 2015, 10. Art. No.: CD008548. DOI: http://dx.doi.org/10.1002/14651858.CD008548.pub2"> Download as PowerPoint </a></li> </nav> <div class="figure-label">Analysis 3.1</div> </div> <hr class="top"><img data-id="CD008548-fig-00301" src="/cdsr/doi/10.1002/14651858.CD008548.pub2/media/CDSR/CD008548/image_n/nCD008548-CMP-003-01.png" alt="Comparison 3 Any growth factor versus placebo or no growth factor (subgroup analysis by type of growth factor), Outcome 1 Complete wound closure."><hr class="bottom"> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Comparison 3 Any growth factor versus placebo or no growth factor (subgroup analysis by type of growth factor), Outcome 1 Complete wound closure. </p> </div> </div> </div> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1.1 Autologous growth factor (AGF)</p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>14</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>2.0 [0.23, 17.34]</p> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1.2 Platelet‐derived wound‐healing formula (PDWHF)</p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>2</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>83</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>2.45 [1.27, 4.74]</p> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1.3 Recombinant human platelet‐derived growth factor (rHuPDGF)</p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>5</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>763</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1.47 [1.23, 1.76]</p> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1.4 Recombinant human basic fibroblast growth factor (rHubFBGF)</p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>2</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>165</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1.23 [0.88, 1.72]</p> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1.5 Recombinant human epidermal growth factor (rHuEGF)</p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>57</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1.72 [1.16, 2.57]</p> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1.6 Recombinant human vascular endothelial growth factor (rHuVEGF)</p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>55</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1.49 [0.79, 2.82]</p> </td> </tr> </tbody> </table> </div> <div class="table" id="CD008548-tbl-0005"> <table class="comparison"><a href="#0" class="open-table-viewer open-in-figure-viewer">Open in table viewer</a><div class="table-heading"><span class="table-label">Comparison 4.</span>&nbsp;<span class="table-title">Any growth factor versus placebo or no growth factor (sensitivity analyses considering attrition)</span></div> <thead> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Outcome or subgroup title</p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>No. of studies</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>No. of participants</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Statistical method</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">1 Complete wound closure <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>12</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"> <div class="figure" id="CD008548-fig-00401"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <li><a href="#0" class="open-in-figure-viewer">Open in figure viewer</a></li> <li><a class="btn btn-link" target="_blank" href="/cdsr/doi/10.1002/14651858.CD008548.pub2/ppt/CDSR/CD008548/image_n/nCD008548-CMP-004-01.png?filename=nCD008548-CMP-004-01.ppt&amp;title=4.1&amp;caption=Comparison%204%20Any%20growth%20factor%20versus%20placebo%20or%20no%20growth%20factor%20%28sensitivity%20analyses%20considering%20attrition%29%2C%20Outcome%201%20Complete%20wound%20closure.&amp;citation=Mart%C3%AD%E2%80%90Carvajal AJ, Gluud C, Nicola S, Simancas%E2%80%90Racines D, Reveiz L, Oliva P, Cede%C3%B1o%E2%80%90Taborda J. Growth factors for treating diabetic foot ulcers. Cochrane Database of Systematic Reviews 2015, 10. Art. No.: CD008548. DOI: http://dx.doi.org/10.1002/14651858.CD008548.pub2"> Download as PowerPoint </a></li> </nav> <div class="figure-label">Analysis 4.1</div> </div> <hr class="top"><img data-id="CD008548-fig-00401" src="/cdsr/doi/10.1002/14651858.CD008548.pub2/media/CDSR/CD008548/image_n/nCD008548-CMP-004-01.png" alt="Comparison 4 Any growth factor versus placebo or no growth factor (sensitivity analyses considering attrition), Outcome 1 Complete wound closure."><hr class="bottom"> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Comparison 4 Any growth factor versus placebo or no growth factor (sensitivity analyses considering attrition), Outcome 1 Complete wound closure. </p> </div> </div> </div> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1.1 All trials</p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>12</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1139</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1.51 [1.31, 1.73]</p> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1.2 Best‐worst case scenario</p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>8</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1049</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>2.06 [1.79, 2.38]</p> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1.3 Worst‐best case scenario</p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>8</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1043</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1.05 [0.93, 1.19]</p> </td> </tr> </tbody> </table> </div> <div class="table" id="CD008548-tbl-0006"> <table class="comparison"><a href="#0" class="open-table-viewer open-in-figure-viewer">Open in table viewer</a><div class="table-heading"><span class="table-label">Comparison 5.</span>&nbsp;<span class="table-title">Platelet derived wound healing formula (PDWHF) versus control</span></div> <thead> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Outcome or subgroup title</p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>No. of studies</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>No. of participants</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Statistical method</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">1 Complete wound closure <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>2</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>83</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>2.45 [1.27, 4.74]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"> <div class="figure" id="CD008548-fig-00501"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <li><a href="#0" class="open-in-figure-viewer">Open in figure viewer</a></li> <li><a class="btn btn-link" target="_blank" href="/cdsr/doi/10.1002/14651858.CD008548.pub2/ppt/CDSR/CD008548/image_n/nCD008548-CMP-005-01.png?filename=nCD008548-CMP-005-01.ppt&amp;title=5.1&amp;caption=Comparison%205%20Platelet%20derived%20wound%20healing%20formula%20%28PDWHF%29%20versus%20control%2C%20Outcome%201%20Complete%20wound%20closure.&amp;citation=Mart%C3%AD%E2%80%90Carvajal AJ, Gluud C, Nicola S, Simancas%E2%80%90Racines D, Reveiz L, Oliva P, Cede%C3%B1o%E2%80%90Taborda J. Growth factors for treating diabetic foot ulcers. Cochrane Database of Systematic Reviews 2015, 10. Art. No.: CD008548. DOI: http://dx.doi.org/10.1002/14651858.CD008548.pub2"> Download as PowerPoint </a></li> </nav> <div class="figure-label">Analysis 5.1</div> </div> <hr class="top"><img data-id="CD008548-fig-00501" src="/cdsr/doi/10.1002/14651858.CD008548.pub2/media/CDSR/CD008548/image_n/nCD008548-CMP-005-01.png" alt="Comparison 5 Platelet derived wound healing formula (PDWHF) versus control, Outcome 1 Complete wound closure."><hr class="bottom"> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Comparison 5 Platelet derived wound healing formula (PDWHF) versus control, Outcome 1 Complete wound closure. </p> </div> </div> </div> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">2 Lower limb amputation (minimum of one toe) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>70</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>2.2 [0.11, 43.95]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"> <div class="figure" id="CD008548-fig-00502"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <li><a href="#0" class="open-in-figure-viewer">Open in figure viewer</a></li> <li><a class="btn btn-link" target="_blank" href="/cdsr/doi/10.1002/14651858.CD008548.pub2/ppt/CDSR/CD008548/image_n/nCD008548-CMP-005-02.png?filename=nCD008548-CMP-005-02.ppt&amp;title=5.2&amp;caption=Comparison%205%20Platelet%20derived%20wound%20healing%20formula%20%28PDWHF%29%20versus%20control%2C%20Outcome%202%20Lower%20limb%20amputation%20%28minimum%20of%20one%20toe%29.&amp;citation=Mart%C3%AD%E2%80%90Carvajal AJ, Gluud C, Nicola S, Simancas%E2%80%90Racines D, Reveiz L, Oliva P, Cede%C3%B1o%E2%80%90Taborda J. Growth factors for treating diabetic foot ulcers. Cochrane Database of Systematic Reviews 2015, 10. Art. No.: CD008548. DOI: http://dx.doi.org/10.1002/14651858.CD008548.pub2"> Download as PowerPoint </a></li> </nav> <div class="figure-label">Analysis 5.2</div> </div> <hr class="top"><img data-id="CD008548-fig-00502" src="/cdsr/doi/10.1002/14651858.CD008548.pub2/media/CDSR/CD008548/image_n/nCD008548-CMP-005-02.png" alt="Comparison 5 Platelet derived wound healing formula (PDWHF) versus control, Outcome 2 Lower limb amputation (minimum of one toe)."><hr class="bottom"> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Comparison 5 Platelet derived wound healing formula (PDWHF) versus control, Outcome 2 Lower limb amputation (minimum of one toe). </p> </div> </div> </div> </td> </tr> </tbody> </table> </div> <div class="table" id="CD008548-tbl-0007"> <table class="comparison"><a href="#0" class="open-table-viewer open-in-figure-viewer">Open in table viewer</a><div class="table-heading"><span class="table-label">Comparison 6.</span>&nbsp;<span class="table-title">Recombinant human platelet‐derived growth factor (rHuPDGF) versus placebo</span></div> <thead> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Outcome or subgroup title</p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>No. of studies</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>No. of participants</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Statistical method</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">1 Complete wound closure <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>5</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>753</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1.45 [1.21, 1.73]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"> <div class="figure" id="CD008548-fig-00601"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <li><a href="#0" class="open-in-figure-viewer">Open in figure viewer</a></li> <li><a class="btn btn-link" target="_blank" href="/cdsr/doi/10.1002/14651858.CD008548.pub2/ppt/CDSR/CD008548/image_n/nCD008548-CMP-006-01.png?filename=nCD008548-CMP-006-01.ppt&amp;title=6.1&amp;caption=Comparison%206%20Recombinant%20human%20platelet%E2%80%90derived%20growth%20factor%20%28rHuPDGF%29%20versus%20placebo%2C%20Outcome%201%20Complete%20wound%20closure.&amp;citation=Mart%C3%AD%E2%80%90Carvajal AJ, Gluud C, Nicola S, Simancas%E2%80%90Racines D, Reveiz L, Oliva P, Cede%C3%B1o%E2%80%90Taborda J. Growth factors for treating diabetic foot ulcers. Cochrane Database of Systematic Reviews 2015, 10. Art. No.: CD008548. DOI: http://dx.doi.org/10.1002/14651858.CD008548.pub2"> Download as PowerPoint </a></li> </nav> <div class="figure-label">Analysis 6.1</div> </div> <hr class="top"><img data-id="CD008548-fig-00601" src="/cdsr/doi/10.1002/14651858.CD008548.pub2/media/CDSR/CD008548/image_n/nCD008548-CMP-006-01.png" alt="Comparison 6 Recombinant human platelet‐derived growth factor (rHuPDGF) versus placebo, Outcome 1 Complete wound closure."><hr class="bottom"> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Comparison 6 Recombinant human platelet‐derived growth factor (rHuPDGF) versus placebo, Outcome 1 Complete wound closure. </p> </div> </div> </div> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">2 Adverse event: infection <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>2</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>222</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>2.05 [1.41, 2.97]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"> <div class="figure" id="CD008548-fig-00602"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <li><a href="#0" class="open-in-figure-viewer">Open in figure viewer</a></li> <li><a class="btn btn-link" target="_blank" href="/cdsr/doi/10.1002/14651858.CD008548.pub2/ppt/CDSR/CD008548/image_n/nCD008548-CMP-006-02.png?filename=nCD008548-CMP-006-02.ppt&amp;title=6.2&amp;caption=Comparison%206%20Recombinant%20human%20platelet%E2%80%90derived%20growth%20factor%20%28rHuPDGF%29%20versus%20placebo%2C%20Outcome%202%20Adverse%20event%3A%20infection.&amp;citation=Mart%C3%AD%E2%80%90Carvajal AJ, Gluud C, Nicola S, Simancas%E2%80%90Racines D, Reveiz L, Oliva P, Cede%C3%B1o%E2%80%90Taborda J. Growth factors for treating diabetic foot ulcers. Cochrane Database of Systematic Reviews 2015, 10. Art. No.: CD008548. DOI: http://dx.doi.org/10.1002/14651858.CD008548.pub2"> Download as PowerPoint </a></li> </nav> <div class="figure-label">Analysis 6.2</div> </div> <hr class="top"><img data-id="CD008548-fig-00602" src="/cdsr/doi/10.1002/14651858.CD008548.pub2/media/CDSR/CD008548/image_n/nCD008548-CMP-006-02.png" alt="Comparison 6 Recombinant human platelet‐derived growth factor (rHuPDGF) versus placebo, Outcome 2 Adverse event: infection."><hr class="bottom"> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Comparison 6 Recombinant human platelet‐derived growth factor (rHuPDGF) versus placebo, Outcome 2 Adverse event: infection. </p> </div> </div> </div> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">3 Adverse event: cellulitis <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>2</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>292</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0.49 [0.23, 1.01]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"> <div class="figure" id="CD008548-fig-00603"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <li><a href="#0" class="open-in-figure-viewer">Open in figure viewer</a></li> <li><a class="btn btn-link" target="_blank" href="/cdsr/doi/10.1002/14651858.CD008548.pub2/ppt/CDSR/CD008548/image_n/nCD008548-CMP-006-03.png?filename=nCD008548-CMP-006-03.ppt&amp;title=6.3&amp;caption=Comparison%206%20Recombinant%20human%20platelet%E2%80%90derived%20growth%20factor%20%28rHuPDGF%29%20versus%20placebo%2C%20Outcome%203%20Adverse%20event%3A%20cellulitis.&amp;citation=Mart%C3%AD%E2%80%90Carvajal AJ, Gluud C, Nicola S, Simancas%E2%80%90Racines D, Reveiz L, Oliva P, Cede%C3%B1o%E2%80%90Taborda J. Growth factors for treating diabetic foot ulcers. Cochrane Database of Systematic Reviews 2015, 10. Art. No.: CD008548. DOI: http://dx.doi.org/10.1002/14651858.CD008548.pub2"> Download as PowerPoint </a></li> </nav> <div class="figure-label">Analysis 6.3</div> </div> <hr class="top"><img data-id="CD008548-fig-00603" src="/cdsr/doi/10.1002/14651858.CD008548.pub2/media/CDSR/CD008548/image_n/nCD008548-CMP-006-03.png" alt="Comparison 6 Recombinant human platelet‐derived growth factor (rHuPDGF) versus placebo, Outcome 3 Adverse event: cellulitis."><hr class="bottom"> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Comparison 6 Recombinant human platelet‐derived growth factor (rHuPDGF) versus placebo, Outcome 3 Adverse event: cellulitis. </p> </div> </div> </div> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">4 Adverse event: peripheral oedema <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>2</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>292</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0.44 [0.20, 0.96]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"> <div class="figure" id="CD008548-fig-00604"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <li><a href="#0" class="open-in-figure-viewer">Open in figure viewer</a></li> <li><a class="btn btn-link" target="_blank" href="/cdsr/doi/10.1002/14651858.CD008548.pub2/ppt/CDSR/CD008548/image_n/nCD008548-CMP-006-04.png?filename=nCD008548-CMP-006-04.ppt&amp;title=6.4&amp;caption=Comparison%206%20Recombinant%20human%20platelet%E2%80%90derived%20growth%20factor%20%28rHuPDGF%29%20versus%20placebo%2C%20Outcome%204%20Adverse%20event%3A%20peripheral%20oedema.&amp;citation=Mart%C3%AD%E2%80%90Carvajal AJ, Gluud C, Nicola S, Simancas%E2%80%90Racines D, Reveiz L, Oliva P, Cede%C3%B1o%E2%80%90Taborda J. Growth factors for treating diabetic foot ulcers. Cochrane Database of Systematic Reviews 2015, 10. Art. No.: CD008548. DOI: http://dx.doi.org/10.1002/14651858.CD008548.pub2"> Download as PowerPoint </a></li> </nav> <div class="figure-label">Analysis 6.4</div> </div> <hr class="top"><img data-id="CD008548-fig-00604" src="/cdsr/doi/10.1002/14651858.CD008548.pub2/media/CDSR/CD008548/image_n/nCD008548-CMP-006-04.png" alt="Comparison 6 Recombinant human platelet‐derived growth factor (rHuPDGF) versus placebo, Outcome 4 Adverse event: peripheral oedema."><hr class="bottom"> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Comparison 6 Recombinant human platelet‐derived growth factor (rHuPDGF) versus placebo, Outcome 4 Adverse event: peripheral oedema. </p> </div> </div> </div> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">5 Adverse event: pain <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>2</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>290</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0.77 [0.41, 1.48]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"> <div class="figure" id="CD008548-fig-00605"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <li><a href="#0" class="open-in-figure-viewer">Open in figure viewer</a></li> <li><a class="btn btn-link" target="_blank" href="/cdsr/doi/10.1002/14651858.CD008548.pub2/ppt/CDSR/CD008548/image_n/nCD008548-CMP-006-05.png?filename=nCD008548-CMP-006-05.ppt&amp;title=6.5&amp;caption=Comparison%206%20Recombinant%20human%20platelet%E2%80%90derived%20growth%20factor%20%28rHuPDGF%29%20versus%20placebo%2C%20Outcome%205%20Adverse%20event%3A%20pain.&amp;citation=Mart%C3%AD%E2%80%90Carvajal AJ, Gluud C, Nicola S, Simancas%E2%80%90Racines D, Reveiz L, Oliva P, Cede%C3%B1o%E2%80%90Taborda J. Growth factors for treating diabetic foot ulcers. Cochrane Database of Systematic Reviews 2015, 10. Art. No.: CD008548. DOI: http://dx.doi.org/10.1002/14651858.CD008548.pub2"> Download as PowerPoint </a></li> </nav> <div class="figure-label">Analysis 6.5</div> </div> <hr class="top"><img data-id="CD008548-fig-00605" src="/cdsr/doi/10.1002/14651858.CD008548.pub2/media/CDSR/CD008548/image_n/nCD008548-CMP-006-05.png" alt="Comparison 6 Recombinant human platelet‐derived growth factor (rHuPDGF) versus placebo, Outcome 5 Adverse event: pain."><hr class="bottom"> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Comparison 6 Recombinant human platelet‐derived growth factor (rHuPDGF) versus placebo, Outcome 5 Adverse event: pain. </p> </div> </div> </div> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">6 Adverse event: skin ulceration <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>2</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>292</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1.08 [0.49, 2.37]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"> <div class="figure" id="CD008548-fig-00606"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <li><a href="#0" class="open-in-figure-viewer">Open in figure viewer</a></li> <li><a class="btn btn-link" target="_blank" href="/cdsr/doi/10.1002/14651858.CD008548.pub2/ppt/CDSR/CD008548/image_n/nCD008548-CMP-006-06.png?filename=nCD008548-CMP-006-06.ppt&amp;title=6.6&amp;caption=Comparison%206%20Recombinant%20human%20platelet%E2%80%90derived%20growth%20factor%20%28rHuPDGF%29%20versus%20placebo%2C%20Outcome%206%20Adverse%20event%3A%20skin%20ulceration.&amp;citation=Mart%C3%AD%E2%80%90Carvajal AJ, Gluud C, Nicola S, Simancas%E2%80%90Racines D, Reveiz L, Oliva P, Cede%C3%B1o%E2%80%90Taborda J. Growth factors for treating diabetic foot ulcers. Cochrane Database of Systematic Reviews 2015, 10. Art. No.: CD008548. DOI: http://dx.doi.org/10.1002/14651858.CD008548.pub2"> Download as PowerPoint </a></li> </nav> <div class="figure-label">Analysis 6.6</div> </div> <hr class="top"><img data-id="CD008548-fig-00606" src="/cdsr/doi/10.1002/14651858.CD008548.pub2/media/CDSR/CD008548/image_n/nCD008548-CMP-006-06.png" alt="Comparison 6 Recombinant human platelet‐derived growth factor (rHuPDGF) versus placebo, Outcome 6 Adverse event: skin ulceration."><hr class="bottom"> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Comparison 6 Recombinant human platelet‐derived growth factor (rHuPDGF) versus placebo, Outcome 6 Adverse event: skin ulceration. </p> </div> </div> </div> </td> </tr> </tbody> </table> </div> <div class="table" id="CD008548-tbl-0008"> <table class="comparison"><a href="#0" class="open-table-viewer open-in-figure-viewer">Open in table viewer</a><div class="table-heading"><span class="table-label">Comparison 7.</span>&nbsp;<span class="table-title">Recombinant human basic fibroblast growth factor (rHubFBGF) versus placebo</span></div> <thead> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Outcome or subgroup title</p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>No. of studies</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>No. of participants</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Statistical method</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">1 Complete wound closure <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>2</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>165</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0.81 [0.59, 1.11]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"> <div class="figure" id="CD008548-fig-00701"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <li><a href="#0" class="open-in-figure-viewer">Open in figure viewer</a></li> <li><a class="btn btn-link" target="_blank" href="/cdsr/doi/10.1002/14651858.CD008548.pub2/ppt/CDSR/CD008548/image_n/nCD008548-CMP-007-01.png?filename=nCD008548-CMP-007-01.ppt&amp;title=7.1&amp;caption=Comparison%207%20Recombinant%20human%20basic%20fibroblast%20growth%20factor%20%28rHubFBGF%29%20versus%20placebo%2C%20Outcome%201%20Complete%20wound%20closure.&amp;citation=Mart%C3%AD%E2%80%90Carvajal AJ, Gluud C, Nicola S, Simancas%E2%80%90Racines D, Reveiz L, Oliva P, Cede%C3%B1o%E2%80%90Taborda J. Growth factors for treating diabetic foot ulcers. Cochrane Database of Systematic Reviews 2015, 10. Art. No.: CD008548. DOI: http://dx.doi.org/10.1002/14651858.CD008548.pub2"> Download as PowerPoint </a></li> </nav> <div class="figure-label">Analysis 7.1</div> </div> <hr class="top"><img data-id="CD008548-fig-00701" src="/cdsr/doi/10.1002/14651858.CD008548.pub2/media/CDSR/CD008548/image_n/nCD008548-CMP-007-01.png" alt="Comparison 7 Recombinant human basic fibroblast growth factor (rHubFBGF) versus placebo, Outcome 1 Complete wound closure."><hr class="bottom"> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Comparison 7 Recombinant human basic fibroblast growth factor (rHubFBGF) versus placebo, Outcome 1 Complete wound closure. </p> </div> </div> </div> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">2 Adverse event: infection <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>2</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>165</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0.75 [0.18, 3.20]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"> <div class="figure" id="CD008548-fig-00702"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <li><a href="#0" class="open-in-figure-viewer">Open in figure viewer</a></li> <li><a class="btn btn-link" target="_blank" href="/cdsr/doi/10.1002/14651858.CD008548.pub2/ppt/CDSR/CD008548/image_n/nCD008548-CMP-007-02.png?filename=nCD008548-CMP-007-02.ppt&amp;title=7.2&amp;caption=Comparison%207%20Recombinant%20human%20basic%20fibroblast%20growth%20factor%20%28rHubFBGF%29%20versus%20placebo%2C%20Outcome%202%20Adverse%20event%3A%20infection.&amp;citation=Mart%C3%AD%E2%80%90Carvajal AJ, Gluud C, Nicola S, Simancas%E2%80%90Racines D, Reveiz L, Oliva P, Cede%C3%B1o%E2%80%90Taborda J. Growth factors for treating diabetic foot ulcers. Cochrane Database of Systematic Reviews 2015, 10. Art. No.: CD008548. DOI: http://dx.doi.org/10.1002/14651858.CD008548.pub2"> Download as PowerPoint </a></li> </nav> <div class="figure-label">Analysis 7.2</div> </div> <hr class="top"><img data-id="CD008548-fig-00702" src="/cdsr/doi/10.1002/14651858.CD008548.pub2/media/CDSR/CD008548/image_n/nCD008548-CMP-007-02.png" alt="Comparison 7 Recombinant human basic fibroblast growth factor (rHubFBGF) versus placebo, Outcome 2 Adverse event: infection."><hr class="bottom"> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Comparison 7 Recombinant human basic fibroblast growth factor (rHubFBGF) versus placebo, Outcome 2 Adverse event: infection. </p> </div> </div> </div> </td> </tr> </tbody> </table> </div> <div class="table" id="CD008548-tbl-0009"> <table class="comparison"><a href="#0" class="open-table-viewer open-in-figure-viewer">Open in table viewer</a><div class="table-heading"><span class="table-label">Comparison 8.</span>&nbsp;<span class="table-title">Recombinant human epidermal growth factor versus active control</span></div> <thead> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Outcome or subgroup title</p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>No. of studies</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>No. of participants</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Statistical method</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">1 Lower limb amputation (minimum of one toe) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>3</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"> <div class="figure" id="CD008548-fig-00801"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <li><a href="#0" class="open-in-figure-viewer">Open in figure viewer</a></li> <li><a class="btn btn-link" target="_blank" href="/cdsr/doi/10.1002/14651858.CD008548.pub2/ppt/CDSR/CD008548/image_n/nCD008548-CMP-008-01.png?filename=nCD008548-CMP-008-01.ppt&amp;title=8.1&amp;caption=Comparison%208%20Recombinant%20human%20epidermal%20growth%20factor%20versus%20active%20control%2C%20Outcome%201%20Lower%20limb%20amputation%20%28minimum%20of%20one%20toe%29.&amp;citation=Mart%C3%AD%E2%80%90Carvajal AJ, Gluud C, Nicola S, Simancas%E2%80%90Racines D, Reveiz L, Oliva P, Cede%C3%B1o%E2%80%90Taborda J. Growth factors for treating diabetic foot ulcers. Cochrane Database of Systematic Reviews 2015, 10. Art. No.: CD008548. DOI: http://dx.doi.org/10.1002/14651858.CD008548.pub2"> Download as PowerPoint </a></li> </nav> <div class="figure-label">Analysis 8.1</div> </div> <hr class="top"><img data-id="CD008548-fig-00801" src="/cdsr/doi/10.1002/14651858.CD008548.pub2/media/CDSR/CD008548/image_n/nCD008548-CMP-008-01.png" alt="Comparison 8 Recombinant human epidermal growth factor versus active control, Outcome 1 Lower limb amputation (minimum of one toe)."><hr class="bottom"> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Comparison 8 Recombinant human epidermal growth factor versus active control, Outcome 1 Lower limb amputation (minimum of one toe). </p> </div> </div> </div> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1.1 Recombinant human epidermal growth factor versus actovegin</p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>61</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0.45 [0.07, 2.98]</p> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1.2 Recombinant human epidermal growth factor 75 μg dose versus 25 μg dose</p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>2</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>142</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0.79 [0.43, 1.47]</p> </td> </tr> </tbody> </table> </div> </section> </section> <div class="figures-list"> <div class="figure" id="CD008548-fig-0001"> <img data-id="CD008548-fig-0001" src="/cdsr/doi/10.1002/14651858.CD008548.pub2/media/CDSR/CD008548/image_n/nCD008548-AFig-FIG01.png" alt="Study flow diagram."> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD008548.pub2/full#CD008548-fig-0001" class="figureList">Navigate to figure in Review</a><button href="#" class="print-figure">Print figure</button><a class="" target="_blank" href="/cdsr/doi/10.1002/14651858.CD008548.pub2/ppt/CDSR/CD008548/image_n/nCD008548-AFig-FIG01.png?filename=nCD008548-AFig-FIG01.ppt&amp;title=1&amp;caption=Study%20flow%20diagram.&amp;citation=Mart%C3%AD%E2%80%90Carvajal AJ, Gluud C, Nicola S, Simancas%E2%80%90Racines D, Reveiz L, Oliva P, Cede%C3%B1o%E2%80%90Taborda J. Growth factors for treating diabetic foot ulcers. Cochrane Database of Systematic Reviews 2015, 10. Art. No.: CD008548. DOI: http://dx.doi.org/10.1002/14651858.CD008548.pub2"> Download as PowerPoint </a><a class="figure-viewer-isolate" target="_blank" href="/cdsr/doi/10.1002/14651858.CD008548.pub2/media/CDSR/CD008548/image_n/nCD008548-AFig-FIG01.png">Open in new tab</a></div> </div> <div class="figure" id="CD008548-fig-0002"><img data-id="CD008548-fig-0002" src="/cdsr/doi/10.1002/14651858.CD008548.pub2/media/CDSR/CD008548/image_n/nCD008548-AFig-FIG02.png" alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies."> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD008548.pub2/full#CD008548-fig-0002" class="figureList">Navigate to figure in Review</a><button href="#" class="print-figure">Print figure</button><a class="" target="_blank" href="/cdsr/doi/10.1002/14651858.CD008548.pub2/ppt/CDSR/CD008548/image_n/nCD008548-AFig-FIG02.png?filename=nCD008548-AFig-FIG02.ppt&amp;title=2&amp;caption=Risk%20of%20bias%20graph%3A%20review%20authors%27%20judgements%20about%20each%20risk%20of%20bias%20item%20presented%20as%20percentages%20across%20all%20included%20studies.&amp;citation=Mart%C3%AD%E2%80%90Carvajal AJ, Gluud C, Nicola S, Simancas%E2%80%90Racines D, Reveiz L, Oliva P, Cede%C3%B1o%E2%80%90Taborda J. Growth factors for treating diabetic foot ulcers. Cochrane Database of Systematic Reviews 2015, 10. Art. No.: CD008548. DOI: http://dx.doi.org/10.1002/14651858.CD008548.pub2"> Download as PowerPoint </a><a class="figure-viewer-isolate" target="_blank" href="/cdsr/doi/10.1002/14651858.CD008548.pub2/media/CDSR/CD008548/image_n/nCD008548-AFig-FIG02.png">Open in new tab</a></div> </div> <div class="figure" id="CD008548-fig-0003"><img data-id="CD008548-fig-0003" src="/cdsr/doi/10.1002/14651858.CD008548.pub2/media/CDSR/CD008548/image_n/nCD008548-AFig-FIG03.png" alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study."> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD008548.pub2/full#CD008548-fig-0003" class="figureList">Navigate to figure in Review</a><button href="#" class="print-figure">Print figure</button><a class="" target="_blank" href="/cdsr/doi/10.1002/14651858.CD008548.pub2/ppt/CDSR/CD008548/image_n/nCD008548-AFig-FIG03.png?filename=nCD008548-AFig-FIG03.ppt&amp;title=3&amp;caption=Risk%20of%20bias%20summary%3A%20review%20authors%27%20judgements%20about%20each%20risk%20of%20bias%20item%20for%20each%20included%20study.&amp;citation=Mart%C3%AD%E2%80%90Carvajal AJ, Gluud C, Nicola S, Simancas%E2%80%90Racines D, Reveiz L, Oliva P, Cede%C3%B1o%E2%80%90Taborda J. Growth factors for treating diabetic foot ulcers. Cochrane Database of Systematic Reviews 2015, 10. Art. No.: CD008548. DOI: http://dx.doi.org/10.1002/14651858.CD008548.pub2"> Download as PowerPoint </a><a class="figure-viewer-isolate" target="_blank" href="/cdsr/doi/10.1002/14651858.CD008548.pub2/media/CDSR/CD008548/image_n/nCD008548-AFig-FIG03.png">Open in new tab</a></div> </div> <div class="figure" id="CD008548-fig-0004"><img data-id="CD008548-fig-0004" src="/cdsr/doi/10.1002/14651858.CD008548.pub2/media/CDSR/CD008548/image_n/nCD008548-AFig-FIG04.png" alt="Funnel plot for comparison effect of any growth factor versus placebo or no growth factor on 100% complete wound closure.P‐value (two tailed) for Egger's test = 0.43"> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 4</div> <div class="figure-caption"> <p>Funnel plot for comparison effect of any growth factor versus placebo or no growth factor on 100% complete wound closure. </p> <p>P‐value (two tailed) for Egger's test = 0.43</p> </div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD008548.pub2/full#CD008548-fig-0004" class="figureList">Navigate to figure in Review</a><button href="#" class="print-figure">Print figure</button><a class="" target="_blank" href="/cdsr/doi/10.1002/14651858.CD008548.pub2/ppt/CDSR/CD008548/image_n/nCD008548-AFig-FIG04.png?filename=nCD008548-AFig-FIG04.ppt&amp;title=4&amp;caption=Funnel%20plot%20for%20comparison%20effect%20of%20any%20growth%20factor%20versus%20placebo%20or%20no%20growth%20factor%20on%20100%25%20complete%20wound%20closure.%20P%E2%80%90value%20%28two%20tailed%29%20for%20Egger%27s%20test%20%3D%200.43&amp;citation=Mart%C3%AD%E2%80%90Carvajal AJ, Gluud C, Nicola S, Simancas%E2%80%90Racines D, Reveiz L, Oliva P, Cede%C3%B1o%E2%80%90Taborda J. Growth factors for treating diabetic foot ulcers. Cochrane Database of Systematic Reviews 2015, 10. Art. No.: CD008548. DOI: http://dx.doi.org/10.1002/14651858.CD008548.pub2"> Download as PowerPoint </a><a class="figure-viewer-isolate" target="_blank" href="/cdsr/doi/10.1002/14651858.CD008548.pub2/media/CDSR/CD008548/image_n/nCD008548-AFig-FIG04.png">Open in new tab</a></div> </div> <div class="figure" id="CD008548-fig-00101"><img data-id="CD008548-fig-00101" src="/cdsr/doi/10.1002/14651858.CD008548.pub2/media/CDSR/CD008548/image_n/nCD008548-CMP-001-01.png" alt="Comparison 1 Any growth factor versus placebo or no growth factor, Outcome 1 Complete wound closure."> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1 Any growth factor versus placebo or no growth factor, Outcome 1 Complete wound closure. </p> </div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD008548.pub2/references#CD008548-fig-00101" class="figureList">Navigate to figure in Review</a><button href="#" class="print-figure">Print figure</button><a class="" target="_blank" href="/cdsr/doi/10.1002/14651858.CD008548.pub2/ppt/CDSR/CD008548/image_n/nCD008548-CMP-001-01.png?filename=nCD008548-CMP-001-01.ppt&amp;title=1.1&amp;caption=Comparison%201%20Any%20growth%20factor%20versus%20placebo%20or%20no%20growth%20factor%2C%20Outcome%201%20Complete%20wound%20closure.&amp;citation=Mart%C3%AD%E2%80%90Carvajal AJ, Gluud C, Nicola S, Simancas%E2%80%90Racines D, Reveiz L, Oliva P, Cede%C3%B1o%E2%80%90Taborda J. Growth factors for treating diabetic foot ulcers. Cochrane Database of Systematic Reviews 2015, 10. Art. No.: CD008548. DOI: http://dx.doi.org/10.1002/14651858.CD008548.pub2"> Download as PowerPoint </a><a class="figure-viewer-isolate" target="_blank" href="/cdsr/doi/10.1002/14651858.CD008548.pub2/media/CDSR/CD008548/image_n/nCD008548-CMP-001-01.png">Open in new tab</a></div> </div> <div class="figure" id="CD008548-fig-00102"><img data-id="CD008548-fig-00102" src="/cdsr/doi/10.1002/14651858.CD008548.pub2/media/CDSR/CD008548/image_n/nCD008548-CMP-001-02.png" alt="Comparison 1 Any growth factor versus placebo or no growth factor, Outcome 2 Lower limb amputation (minimum of one toe)."> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1 Any growth factor versus placebo or no growth factor, Outcome 2 Lower limb amputation (minimum of one toe). </p> </div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD008548.pub2/references#CD008548-fig-00102" class="figureList">Navigate to figure in Review</a><button href="#" class="print-figure">Print figure</button><a class="" target="_blank" href="/cdsr/doi/10.1002/14651858.CD008548.pub2/ppt/CDSR/CD008548/image_n/nCD008548-CMP-001-02.png?filename=nCD008548-CMP-001-02.ppt&amp;title=1.2&amp;caption=Comparison%201%20Any%20growth%20factor%20versus%20placebo%20or%20no%20growth%20factor%2C%20Outcome%202%20Lower%20limb%20amputation%20%28minimum%20of%20one%20toe%29.&amp;citation=Mart%C3%AD%E2%80%90Carvajal AJ, Gluud C, Nicola S, Simancas%E2%80%90Racines D, Reveiz L, Oliva P, Cede%C3%B1o%E2%80%90Taborda J. Growth factors for treating diabetic foot ulcers. Cochrane Database of Systematic Reviews 2015, 10. Art. No.: CD008548. DOI: http://dx.doi.org/10.1002/14651858.CD008548.pub2"> Download as PowerPoint </a><a class="figure-viewer-isolate" target="_blank" href="/cdsr/doi/10.1002/14651858.CD008548.pub2/media/CDSR/CD008548/image_n/nCD008548-CMP-001-02.png">Open in new tab</a></div> </div> <div class="figure" id="CD008548-fig-00103"><img data-id="CD008548-fig-00103" src="/cdsr/doi/10.1002/14651858.CD008548.pub2/media/CDSR/CD008548/image_n/nCD008548-CMP-001-03.png" alt="Comparison 1 Any growth factor versus placebo or no growth factor, Outcome 3 Ulcer‐free days following treatment for diabetic foot ulcers (free from any recurrence)."> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1 Any growth factor versus placebo or no growth factor, Outcome 3 Ulcer‐free days following treatment for diabetic foot ulcers (free from any recurrence). </p> </div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD008548.pub2/references#CD008548-fig-00103" class="figureList">Navigate to figure in Review</a><button href="#" class="print-figure">Print figure</button><a class="" target="_blank" href="/cdsr/doi/10.1002/14651858.CD008548.pub2/ppt/CDSR/CD008548/image_n/nCD008548-CMP-001-03.png?filename=nCD008548-CMP-001-03.ppt&amp;title=1.3&amp;caption=Comparison%201%20Any%20growth%20factor%20versus%20placebo%20or%20no%20growth%20factor%2C%20Outcome%203%20Ulcer%E2%80%90free%20days%20following%20treatment%20for%20diabetic%20foot%20ulcers%20%28free%20from%20any%20recurrence%29.&amp;citation=Mart%C3%AD%E2%80%90Carvajal AJ, Gluud C, Nicola S, Simancas%E2%80%90Racines D, Reveiz L, Oliva P, Cede%C3%B1o%E2%80%90Taborda J. Growth factors for treating diabetic foot ulcers. Cochrane Database of Systematic Reviews 2015, 10. Art. No.: CD008548. DOI: http://dx.doi.org/10.1002/14651858.CD008548.pub2"> Download as PowerPoint </a><a class="figure-viewer-isolate" target="_blank" href="/cdsr/doi/10.1002/14651858.CD008548.pub2/media/CDSR/CD008548/image_n/nCD008548-CMP-001-03.png">Open in new tab</a></div> </div> <div class="figure" id="CD008548-fig-00104"><img data-id="CD008548-fig-00104" src="/cdsr/doi/10.1002/14651858.CD008548.pub2/media/CDSR/CD008548/image_n/nCD008548-CMP-001-04.png" alt="Comparison 1 Any growth factor versus placebo or no growth factor, Outcome 4 Adverse events (non‐serious and serious)."> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1 Any growth factor versus placebo or no growth factor, Outcome 4 Adverse events (non‐serious and serious). </p> </div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD008548.pub2/references#CD008548-fig-00104" class="figureList">Navigate to figure in Review</a><button href="#" class="print-figure">Print figure</button><a class="" target="_blank" href="/cdsr/doi/10.1002/14651858.CD008548.pub2/ppt/CDSR/CD008548/image_n/nCD008548-CMP-001-04.png?filename=nCD008548-CMP-001-04.ppt&amp;title=1.4&amp;caption=Comparison%201%20Any%20growth%20factor%20versus%20placebo%20or%20no%20growth%20factor%2C%20Outcome%204%20Adverse%20events%20%28non%E2%80%90serious%20and%20serious%29.&amp;citation=Mart%C3%AD%E2%80%90Carvajal AJ, Gluud C, Nicola S, Simancas%E2%80%90Racines D, Reveiz L, Oliva P, Cede%C3%B1o%E2%80%90Taborda J. Growth factors for treating diabetic foot ulcers. Cochrane Database of Systematic Reviews 2015, 10. Art. No.: CD008548. DOI: http://dx.doi.org/10.1002/14651858.CD008548.pub2"> Download as PowerPoint </a><a class="figure-viewer-isolate" target="_blank" href="/cdsr/doi/10.1002/14651858.CD008548.pub2/media/CDSR/CD008548/image_n/nCD008548-CMP-001-04.png">Open in new tab</a></div> </div> <div class="figure" id="CD008548-fig-00201"><img data-id="CD008548-fig-00201" src="/cdsr/doi/10.1002/14651858.CD008548.pub2/media/CDSR/CD008548/image_n/nCD008548-CMP-002-01.png" alt="Comparison 2 Any growth factor versus placebo or no growth factor (subgroup analysis of trials with follow‐up < 20 weeks versus follow‐up ≥ 20 weeks), Outcome 1 Participants with complete wound closure."> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.1</div> <div class="figure-caption"> <p>Comparison 2 Any growth factor versus placebo or no growth factor (subgroup analysis of trials with follow‐up &lt; 20 weeks versus follow‐up ≥ 20 weeks), Outcome 1 Participants with complete wound closure. </p> </div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD008548.pub2/references#CD008548-fig-00201" class="figureList">Navigate to figure in Review</a><button href="#" class="print-figure">Print figure</button><a class="" target="_blank" href="/cdsr/doi/10.1002/14651858.CD008548.pub2/ppt/CDSR/CD008548/image_n/nCD008548-CMP-002-01.png?filename=nCD008548-CMP-002-01.ppt&amp;title=2.1&amp;caption=Comparison%202%20Any%20growth%20factor%20versus%20placebo%20or%20no%20growth%20factor%20%28subgroup%20analysis%20of%20trials%20with%20follow%E2%80%90up%20%3C%2020%20weeks%20versus%20follow%E2%80%90up%20%E2%89%A5%2020%20weeks%29%2C%20Outcome%201%20Participants%20with%20complete%20wound%20closure.&amp;citation=Mart%C3%AD%E2%80%90Carvajal AJ, Gluud C, Nicola S, Simancas%E2%80%90Racines D, Reveiz L, Oliva P, Cede%C3%B1o%E2%80%90Taborda J. Growth factors for treating diabetic foot ulcers. Cochrane Database of Systematic Reviews 2015, 10. Art. No.: CD008548. DOI: http://dx.doi.org/10.1002/14651858.CD008548.pub2"> Download as PowerPoint </a><a class="figure-viewer-isolate" target="_blank" href="/cdsr/doi/10.1002/14651858.CD008548.pub2/media/CDSR/CD008548/image_n/nCD008548-CMP-002-01.png">Open in new tab</a></div> </div> <div class="figure" id="CD008548-fig-00301"><img data-id="CD008548-fig-00301" src="/cdsr/doi/10.1002/14651858.CD008548.pub2/media/CDSR/CD008548/image_n/nCD008548-CMP-003-01.png" alt="Comparison 3 Any growth factor versus placebo or no growth factor (subgroup analysis by type of growth factor), Outcome 1 Complete wound closure."> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.1</div> <div class="figure-caption"> <p>Comparison 3 Any growth factor versus placebo or no growth factor (subgroup analysis by type of growth factor), Outcome 1 Complete wound closure. </p> </div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD008548.pub2/references#CD008548-fig-00301" class="figureList">Navigate to figure in Review</a><button href="#" class="print-figure">Print figure</button><a class="" target="_blank" href="/cdsr/doi/10.1002/14651858.CD008548.pub2/ppt/CDSR/CD008548/image_n/nCD008548-CMP-003-01.png?filename=nCD008548-CMP-003-01.ppt&amp;title=3.1&amp;caption=Comparison%203%20Any%20growth%20factor%20versus%20placebo%20or%20no%20growth%20factor%20%28subgroup%20analysis%20by%20type%20of%20growth%20factor%29%2C%20Outcome%201%20Complete%20wound%20closure.&amp;citation=Mart%C3%AD%E2%80%90Carvajal AJ, Gluud C, Nicola S, Simancas%E2%80%90Racines D, Reveiz L, Oliva P, Cede%C3%B1o%E2%80%90Taborda J. Growth factors for treating diabetic foot ulcers. Cochrane Database of Systematic Reviews 2015, 10. Art. No.: CD008548. DOI: http://dx.doi.org/10.1002/14651858.CD008548.pub2"> Download as PowerPoint </a><a class="figure-viewer-isolate" target="_blank" href="/cdsr/doi/10.1002/14651858.CD008548.pub2/media/CDSR/CD008548/image_n/nCD008548-CMP-003-01.png">Open in new tab</a></div> </div> <div class="figure" id="CD008548-fig-00401"><img data-id="CD008548-fig-00401" src="/cdsr/doi/10.1002/14651858.CD008548.pub2/media/CDSR/CD008548/image_n/nCD008548-CMP-004-01.png" alt="Comparison 4 Any growth factor versus placebo or no growth factor (sensitivity analyses considering attrition), Outcome 1 Complete wound closure."> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.1</div> <div class="figure-caption"> <p>Comparison 4 Any growth factor versus placebo or no growth factor (sensitivity analyses considering attrition), Outcome 1 Complete wound closure. </p> </div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD008548.pub2/references#CD008548-fig-00401" class="figureList">Navigate to figure in Review</a><button href="#" class="print-figure">Print figure</button><a class="" target="_blank" href="/cdsr/doi/10.1002/14651858.CD008548.pub2/ppt/CDSR/CD008548/image_n/nCD008548-CMP-004-01.png?filename=nCD008548-CMP-004-01.ppt&amp;title=4.1&amp;caption=Comparison%204%20Any%20growth%20factor%20versus%20placebo%20or%20no%20growth%20factor%20%28sensitivity%20analyses%20considering%20attrition%29%2C%20Outcome%201%20Complete%20wound%20closure.&amp;citation=Mart%C3%AD%E2%80%90Carvajal AJ, Gluud C, Nicola S, Simancas%E2%80%90Racines D, Reveiz L, Oliva P, Cede%C3%B1o%E2%80%90Taborda J. Growth factors for treating diabetic foot ulcers. Cochrane Database of Systematic Reviews 2015, 10. Art. No.: CD008548. DOI: http://dx.doi.org/10.1002/14651858.CD008548.pub2"> Download as PowerPoint </a><a class="figure-viewer-isolate" target="_blank" href="/cdsr/doi/10.1002/14651858.CD008548.pub2/media/CDSR/CD008548/image_n/nCD008548-CMP-004-01.png">Open in new tab</a></div> </div> <div class="figure" id="CD008548-fig-00501"><img data-id="CD008548-fig-00501" src="/cdsr/doi/10.1002/14651858.CD008548.pub2/media/CDSR/CD008548/image_n/nCD008548-CMP-005-01.png" alt="Comparison 5 Platelet derived wound healing formula (PDWHF) versus control, Outcome 1 Complete wound closure."> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.1</div> <div class="figure-caption"> <p>Comparison 5 Platelet derived wound healing formula (PDWHF) versus control, Outcome 1 Complete wound closure. </p> </div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD008548.pub2/references#CD008548-fig-00501" class="figureList">Navigate to figure in Review</a><button href="#" class="print-figure">Print figure</button><a class="" target="_blank" href="/cdsr/doi/10.1002/14651858.CD008548.pub2/ppt/CDSR/CD008548/image_n/nCD008548-CMP-005-01.png?filename=nCD008548-CMP-005-01.ppt&amp;title=5.1&amp;caption=Comparison%205%20Platelet%20derived%20wound%20healing%20formula%20%28PDWHF%29%20versus%20control%2C%20Outcome%201%20Complete%20wound%20closure.&amp;citation=Mart%C3%AD%E2%80%90Carvajal AJ, Gluud C, Nicola S, Simancas%E2%80%90Racines D, Reveiz L, Oliva P, Cede%C3%B1o%E2%80%90Taborda J. Growth factors for treating diabetic foot ulcers. Cochrane Database of Systematic Reviews 2015, 10. Art. No.: CD008548. DOI: http://dx.doi.org/10.1002/14651858.CD008548.pub2"> Download as PowerPoint </a><a class="figure-viewer-isolate" target="_blank" href="/cdsr/doi/10.1002/14651858.CD008548.pub2/media/CDSR/CD008548/image_n/nCD008548-CMP-005-01.png">Open in new tab</a></div> </div> <div class="figure" id="CD008548-fig-00502"><img data-id="CD008548-fig-00502" src="/cdsr/doi/10.1002/14651858.CD008548.pub2/media/CDSR/CD008548/image_n/nCD008548-CMP-005-02.png" alt="Comparison 5 Platelet derived wound healing formula (PDWHF) versus control, Outcome 2 Lower limb amputation (minimum of one toe)."> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.2</div> <div class="figure-caption"> <p>Comparison 5 Platelet derived wound healing formula (PDWHF) versus control, Outcome 2 Lower limb amputation (minimum of one toe). </p> </div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD008548.pub2/references#CD008548-fig-00502" class="figureList">Navigate to figure in Review</a><button href="#" class="print-figure">Print figure</button><a class="" target="_blank" href="/cdsr/doi/10.1002/14651858.CD008548.pub2/ppt/CDSR/CD008548/image_n/nCD008548-CMP-005-02.png?filename=nCD008548-CMP-005-02.ppt&amp;title=5.2&amp;caption=Comparison%205%20Platelet%20derived%20wound%20healing%20formula%20%28PDWHF%29%20versus%20control%2C%20Outcome%202%20Lower%20limb%20amputation%20%28minimum%20of%20one%20toe%29.&amp;citation=Mart%C3%AD%E2%80%90Carvajal AJ, Gluud C, Nicola S, Simancas%E2%80%90Racines D, Reveiz L, Oliva P, Cede%C3%B1o%E2%80%90Taborda J. Growth factors for treating diabetic foot ulcers. Cochrane Database of Systematic Reviews 2015, 10. Art. No.: CD008548. DOI: http://dx.doi.org/10.1002/14651858.CD008548.pub2"> Download as PowerPoint </a><a class="figure-viewer-isolate" target="_blank" href="/cdsr/doi/10.1002/14651858.CD008548.pub2/media/CDSR/CD008548/image_n/nCD008548-CMP-005-02.png">Open in new tab</a></div> </div> <div class="figure" id="CD008548-fig-00601"><img data-id="CD008548-fig-00601" src="/cdsr/doi/10.1002/14651858.CD008548.pub2/media/CDSR/CD008548/image_n/nCD008548-CMP-006-01.png" alt="Comparison 6 Recombinant human platelet‐derived growth factor (rHuPDGF) versus placebo, Outcome 1 Complete wound closure."> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.1</div> <div class="figure-caption"> <p>Comparison 6 Recombinant human platelet‐derived growth factor (rHuPDGF) versus placebo, Outcome 1 Complete wound closure. </p> </div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD008548.pub2/references#CD008548-fig-00601" class="figureList">Navigate to figure in Review</a><button href="#" class="print-figure">Print figure</button><a class="" target="_blank" href="/cdsr/doi/10.1002/14651858.CD008548.pub2/ppt/CDSR/CD008548/image_n/nCD008548-CMP-006-01.png?filename=nCD008548-CMP-006-01.ppt&amp;title=6.1&amp;caption=Comparison%206%20Recombinant%20human%20platelet%E2%80%90derived%20growth%20factor%20%28rHuPDGF%29%20versus%20placebo%2C%20Outcome%201%20Complete%20wound%20closure.&amp;citation=Mart%C3%AD%E2%80%90Carvajal AJ, Gluud C, Nicola S, Simancas%E2%80%90Racines D, Reveiz L, Oliva P, Cede%C3%B1o%E2%80%90Taborda J. Growth factors for treating diabetic foot ulcers. Cochrane Database of Systematic Reviews 2015, 10. Art. No.: CD008548. DOI: http://dx.doi.org/10.1002/14651858.CD008548.pub2"> Download as PowerPoint </a><a class="figure-viewer-isolate" target="_blank" href="/cdsr/doi/10.1002/14651858.CD008548.pub2/media/CDSR/CD008548/image_n/nCD008548-CMP-006-01.png">Open in new tab</a></div> </div> <div class="figure" id="CD008548-fig-00602"><img data-id="CD008548-fig-00602" src="/cdsr/doi/10.1002/14651858.CD008548.pub2/media/CDSR/CD008548/image_n/nCD008548-CMP-006-02.png" alt="Comparison 6 Recombinant human platelet‐derived growth factor (rHuPDGF) versus placebo, Outcome 2 Adverse event: infection."> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.2</div> <div class="figure-caption"> <p>Comparison 6 Recombinant human platelet‐derived growth factor (rHuPDGF) versus placebo, Outcome 2 Adverse event: infection. </p> </div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD008548.pub2/references#CD008548-fig-00602" class="figureList">Navigate to figure in Review</a><button href="#" class="print-figure">Print figure</button><a class="" target="_blank" href="/cdsr/doi/10.1002/14651858.CD008548.pub2/ppt/CDSR/CD008548/image_n/nCD008548-CMP-006-02.png?filename=nCD008548-CMP-006-02.ppt&amp;title=6.2&amp;caption=Comparison%206%20Recombinant%20human%20platelet%E2%80%90derived%20growth%20factor%20%28rHuPDGF%29%20versus%20placebo%2C%20Outcome%202%20Adverse%20event%3A%20infection.&amp;citation=Mart%C3%AD%E2%80%90Carvajal AJ, Gluud C, Nicola S, Simancas%E2%80%90Racines D, Reveiz L, Oliva P, Cede%C3%B1o%E2%80%90Taborda J. Growth factors for treating diabetic foot ulcers. Cochrane Database of Systematic Reviews 2015, 10. Art. No.: CD008548. DOI: http://dx.doi.org/10.1002/14651858.CD008548.pub2"> Download as PowerPoint </a><a class="figure-viewer-isolate" target="_blank" href="/cdsr/doi/10.1002/14651858.CD008548.pub2/media/CDSR/CD008548/image_n/nCD008548-CMP-006-02.png">Open in new tab</a></div> </div> <div class="figure" id="CD008548-fig-00603"><img data-id="CD008548-fig-00603" src="/cdsr/doi/10.1002/14651858.CD008548.pub2/media/CDSR/CD008548/image_n/nCD008548-CMP-006-03.png" alt="Comparison 6 Recombinant human platelet‐derived growth factor (rHuPDGF) versus placebo, Outcome 3 Adverse event: cellulitis."> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.3</div> <div class="figure-caption"> <p>Comparison 6 Recombinant human platelet‐derived growth factor (rHuPDGF) versus placebo, Outcome 3 Adverse event: cellulitis. </p> </div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD008548.pub2/references#CD008548-fig-00603" class="figureList">Navigate to figure in Review</a><button href="#" class="print-figure">Print figure</button><a class="" target="_blank" href="/cdsr/doi/10.1002/14651858.CD008548.pub2/ppt/CDSR/CD008548/image_n/nCD008548-CMP-006-03.png?filename=nCD008548-CMP-006-03.ppt&amp;title=6.3&amp;caption=Comparison%206%20Recombinant%20human%20platelet%E2%80%90derived%20growth%20factor%20%28rHuPDGF%29%20versus%20placebo%2C%20Outcome%203%20Adverse%20event%3A%20cellulitis.&amp;citation=Mart%C3%AD%E2%80%90Carvajal AJ, Gluud C, Nicola S, Simancas%E2%80%90Racines D, Reveiz L, Oliva P, Cede%C3%B1o%E2%80%90Taborda J. Growth factors for treating diabetic foot ulcers. Cochrane Database of Systematic Reviews 2015, 10. Art. No.: CD008548. DOI: http://dx.doi.org/10.1002/14651858.CD008548.pub2"> Download as PowerPoint </a><a class="figure-viewer-isolate" target="_blank" href="/cdsr/doi/10.1002/14651858.CD008548.pub2/media/CDSR/CD008548/image_n/nCD008548-CMP-006-03.png">Open in new tab</a></div> </div> <div class="figure" id="CD008548-fig-00604"><img data-id="CD008548-fig-00604" src="/cdsr/doi/10.1002/14651858.CD008548.pub2/media/CDSR/CD008548/image_n/nCD008548-CMP-006-04.png" alt="Comparison 6 Recombinant human platelet‐derived growth factor (rHuPDGF) versus placebo, Outcome 4 Adverse event: peripheral oedema."> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.4</div> <div class="figure-caption"> <p>Comparison 6 Recombinant human platelet‐derived growth factor (rHuPDGF) versus placebo, Outcome 4 Adverse event: peripheral oedema. </p> </div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD008548.pub2/references#CD008548-fig-00604" class="figureList">Navigate to figure in Review</a><button href="#" class="print-figure">Print figure</button><a class="" target="_blank" href="/cdsr/doi/10.1002/14651858.CD008548.pub2/ppt/CDSR/CD008548/image_n/nCD008548-CMP-006-04.png?filename=nCD008548-CMP-006-04.ppt&amp;title=6.4&amp;caption=Comparison%206%20Recombinant%20human%20platelet%E2%80%90derived%20growth%20factor%20%28rHuPDGF%29%20versus%20placebo%2C%20Outcome%204%20Adverse%20event%3A%20peripheral%20oedema.&amp;citation=Mart%C3%AD%E2%80%90Carvajal AJ, Gluud C, Nicola S, Simancas%E2%80%90Racines D, Reveiz L, Oliva P, Cede%C3%B1o%E2%80%90Taborda J. Growth factors for treating diabetic foot ulcers. Cochrane Database of Systematic Reviews 2015, 10. Art. No.: CD008548. DOI: http://dx.doi.org/10.1002/14651858.CD008548.pub2"> Download as PowerPoint </a><a class="figure-viewer-isolate" target="_blank" href="/cdsr/doi/10.1002/14651858.CD008548.pub2/media/CDSR/CD008548/image_n/nCD008548-CMP-006-04.png">Open in new tab</a></div> </div> <div class="figure" id="CD008548-fig-00605"><img data-id="CD008548-fig-00605" src="/cdsr/doi/10.1002/14651858.CD008548.pub2/media/CDSR/CD008548/image_n/nCD008548-CMP-006-05.png" alt="Comparison 6 Recombinant human platelet‐derived growth factor (rHuPDGF) versus placebo, Outcome 5 Adverse event: pain."> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.5</div> <div class="figure-caption"> <p>Comparison 6 Recombinant human platelet‐derived growth factor (rHuPDGF) versus placebo, Outcome 5 Adverse event: pain. </p> </div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD008548.pub2/references#CD008548-fig-00605" class="figureList">Navigate to figure in Review</a><button href="#" class="print-figure">Print figure</button><a class="" target="_blank" href="/cdsr/doi/10.1002/14651858.CD008548.pub2/ppt/CDSR/CD008548/image_n/nCD008548-CMP-006-05.png?filename=nCD008548-CMP-006-05.ppt&amp;title=6.5&amp;caption=Comparison%206%20Recombinant%20human%20platelet%E2%80%90derived%20growth%20factor%20%28rHuPDGF%29%20versus%20placebo%2C%20Outcome%205%20Adverse%20event%3A%20pain.&amp;citation=Mart%C3%AD%E2%80%90Carvajal AJ, Gluud C, Nicola S, Simancas%E2%80%90Racines D, Reveiz L, Oliva P, Cede%C3%B1o%E2%80%90Taborda J. Growth factors for treating diabetic foot ulcers. Cochrane Database of Systematic Reviews 2015, 10. Art. No.: CD008548. DOI: http://dx.doi.org/10.1002/14651858.CD008548.pub2"> Download as PowerPoint </a><a class="figure-viewer-isolate" target="_blank" href="/cdsr/doi/10.1002/14651858.CD008548.pub2/media/CDSR/CD008548/image_n/nCD008548-CMP-006-05.png">Open in new tab</a></div> </div> <div class="figure" id="CD008548-fig-00606"><img data-id="CD008548-fig-00606" src="/cdsr/doi/10.1002/14651858.CD008548.pub2/media/CDSR/CD008548/image_n/nCD008548-CMP-006-06.png" alt="Comparison 6 Recombinant human platelet‐derived growth factor (rHuPDGF) versus placebo, Outcome 6 Adverse event: skin ulceration."> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.6</div> <div class="figure-caption"> <p>Comparison 6 Recombinant human platelet‐derived growth factor (rHuPDGF) versus placebo, Outcome 6 Adverse event: skin ulceration. </p> </div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD008548.pub2/references#CD008548-fig-00606" class="figureList">Navigate to figure in Review</a><button href="#" class="print-figure">Print figure</button><a class="" target="_blank" href="/cdsr/doi/10.1002/14651858.CD008548.pub2/ppt/CDSR/CD008548/image_n/nCD008548-CMP-006-06.png?filename=nCD008548-CMP-006-06.ppt&amp;title=6.6&amp;caption=Comparison%206%20Recombinant%20human%20platelet%E2%80%90derived%20growth%20factor%20%28rHuPDGF%29%20versus%20placebo%2C%20Outcome%206%20Adverse%20event%3A%20skin%20ulceration.&amp;citation=Mart%C3%AD%E2%80%90Carvajal AJ, Gluud C, Nicola S, Simancas%E2%80%90Racines D, Reveiz L, Oliva P, Cede%C3%B1o%E2%80%90Taborda J. Growth factors for treating diabetic foot ulcers. Cochrane Database of Systematic Reviews 2015, 10. Art. No.: CD008548. DOI: http://dx.doi.org/10.1002/14651858.CD008548.pub2"> Download as PowerPoint </a><a class="figure-viewer-isolate" target="_blank" href="/cdsr/doi/10.1002/14651858.CD008548.pub2/media/CDSR/CD008548/image_n/nCD008548-CMP-006-06.png">Open in new tab</a></div> </div> <div class="figure" id="CD008548-fig-00701"><img data-id="CD008548-fig-00701" src="/cdsr/doi/10.1002/14651858.CD008548.pub2/media/CDSR/CD008548/image_n/nCD008548-CMP-007-01.png" alt="Comparison 7 Recombinant human basic fibroblast growth factor (rHubFBGF) versus placebo, Outcome 1 Complete wound closure."> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.1</div> <div class="figure-caption"> <p>Comparison 7 Recombinant human basic fibroblast growth factor (rHubFBGF) versus placebo, Outcome 1 Complete wound closure. </p> </div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD008548.pub2/references#CD008548-fig-00701" class="figureList">Navigate to figure in Review</a><button href="#" class="print-figure">Print figure</button><a class="" target="_blank" href="/cdsr/doi/10.1002/14651858.CD008548.pub2/ppt/CDSR/CD008548/image_n/nCD008548-CMP-007-01.png?filename=nCD008548-CMP-007-01.ppt&amp;title=7.1&amp;caption=Comparison%207%20Recombinant%20human%20basic%20fibroblast%20growth%20factor%20%28rHubFBGF%29%20versus%20placebo%2C%20Outcome%201%20Complete%20wound%20closure.&amp;citation=Mart%C3%AD%E2%80%90Carvajal AJ, Gluud C, Nicola S, Simancas%E2%80%90Racines D, Reveiz L, Oliva P, Cede%C3%B1o%E2%80%90Taborda J. Growth factors for treating diabetic foot ulcers. Cochrane Database of Systematic Reviews 2015, 10. Art. No.: CD008548. DOI: http://dx.doi.org/10.1002/14651858.CD008548.pub2"> Download as PowerPoint </a><a class="figure-viewer-isolate" target="_blank" href="/cdsr/doi/10.1002/14651858.CD008548.pub2/media/CDSR/CD008548/image_n/nCD008548-CMP-007-01.png">Open in new tab</a></div> </div> <div class="figure" id="CD008548-fig-00702"><img data-id="CD008548-fig-00702" src="/cdsr/doi/10.1002/14651858.CD008548.pub2/media/CDSR/CD008548/image_n/nCD008548-CMP-007-02.png" alt="Comparison 7 Recombinant human basic fibroblast growth factor (rHubFBGF) versus placebo, Outcome 2 Adverse event: infection."> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.2</div> <div class="figure-caption"> <p>Comparison 7 Recombinant human basic fibroblast growth factor (rHubFBGF) versus placebo, Outcome 2 Adverse event: infection. </p> </div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD008548.pub2/references#CD008548-fig-00702" class="figureList">Navigate to figure in Review</a><button href="#" class="print-figure">Print figure</button><a class="" target="_blank" href="/cdsr/doi/10.1002/14651858.CD008548.pub2/ppt/CDSR/CD008548/image_n/nCD008548-CMP-007-02.png?filename=nCD008548-CMP-007-02.ppt&amp;title=7.2&amp;caption=Comparison%207%20Recombinant%20human%20basic%20fibroblast%20growth%20factor%20%28rHubFBGF%29%20versus%20placebo%2C%20Outcome%202%20Adverse%20event%3A%20infection.&amp;citation=Mart%C3%AD%E2%80%90Carvajal AJ, Gluud C, Nicola S, Simancas%E2%80%90Racines D, Reveiz L, Oliva P, Cede%C3%B1o%E2%80%90Taborda J. Growth factors for treating diabetic foot ulcers. Cochrane Database of Systematic Reviews 2015, 10. Art. No.: CD008548. DOI: http://dx.doi.org/10.1002/14651858.CD008548.pub2"> Download as PowerPoint </a><a class="figure-viewer-isolate" target="_blank" href="/cdsr/doi/10.1002/14651858.CD008548.pub2/media/CDSR/CD008548/image_n/nCD008548-CMP-007-02.png">Open in new tab</a></div> </div> <div class="figure" id="CD008548-fig-00801"><img data-id="CD008548-fig-00801" src="/cdsr/doi/10.1002/14651858.CD008548.pub2/media/CDSR/CD008548/image_n/nCD008548-CMP-008-01.png" alt="Comparison 8 Recombinant human epidermal growth factor versus active control, Outcome 1 Lower limb amputation (minimum of one toe)."> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.1</div> <div class="figure-caption"> <p>Comparison 8 Recombinant human epidermal growth factor versus active control, Outcome 1 Lower limb amputation (minimum of one toe). </p> </div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD008548.pub2/references#CD008548-fig-00801" class="figureList">Navigate to figure in Review</a><button href="#" class="print-figure">Print figure</button><a class="" target="_blank" href="/cdsr/doi/10.1002/14651858.CD008548.pub2/ppt/CDSR/CD008548/image_n/nCD008548-CMP-008-01.png?filename=nCD008548-CMP-008-01.ppt&amp;title=8.1&amp;caption=Comparison%208%20Recombinant%20human%20epidermal%20growth%20factor%20versus%20active%20control%2C%20Outcome%201%20Lower%20limb%20amputation%20%28minimum%20of%20one%20toe%29.&amp;citation=Mart%C3%AD%E2%80%90Carvajal AJ, Gluud C, Nicola S, Simancas%E2%80%90Racines D, Reveiz L, Oliva P, Cede%C3%B1o%E2%80%90Taborda J. Growth factors for treating diabetic foot ulcers. Cochrane Database of Systematic Reviews 2015, 10. Art. No.: CD008548. DOI: http://dx.doi.org/10.1002/14651858.CD008548.pub2"> Download as PowerPoint </a><a class="figure-viewer-isolate" target="_blank" href="/cdsr/doi/10.1002/14651858.CD008548.pub2/media/CDSR/CD008548/image_n/nCD008548-CMP-008-01.png">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table data-id="CD008548-tbl-0001" class="summary-of-findings framed"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span>&nbsp;<span class="table-title">Any growth factor compared with placebo or no growth factor for diabetic foot ulcer</span></div> <tbody> <tr class="separated"> <td align="" valign="" colspan="7" rowspan="1" bgcolor="#ffffff"> <p><b>Any growth factor compared with placebo or no growth factor for diabetic foot ulcer</b> </p> </td> </tr> <tr class="separated"> <td align="" valign="" colspan="7" rowspan="1" bgcolor="#ffffff"> <p><b>Patient or population:</b> foot ulcers in people with diabetes<br> <b>Settings:</b> outpatient<br> <b>Intervention:</b> any growth factor<br> <b>Comparison:</b> placebo or no growth factor </p> </td> </tr> <tr class="table-header separated"> <td align="left" valign="top" colspan="1" rowspan="3" class="table-header"> <p><b>Outcomes</b> </p> </td> <td align="left" valign="top" colspan="2" rowspan="1" class="table-tint table-highlight"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" valign="top" colspan="1" rowspan="3" class="table-header"> <p><b>Relative effect<br> (95% CI)</b> </p> </td> <td align="left" valign="top" colspan="1" rowspan="3" class="table-header"> <p><b>No of Participants<br> (studies)</b> </p> </td> <td align="left" valign="top" colspan="1" rowspan="3" class="table-header"> <p><b>Quality of the evidence<br> (GRADE)</b> </p> </td> <td align="left" valign="top" colspan="1" rowspan="3" class="table-header"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" valign="top" colspan="1" rowspan="1" class="table-tint table-highlight"> <p><b>Assumed risk</b> </p> </td> <td align="left" valign="top" colspan="1" rowspan="1" class="table-tint table-highlight"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" valign="top" colspan="1" rowspan="1" class="table-tint table-highlight"> <p><b> Placebo or no intervention</b> </p> </td> <td align="left" valign="top" colspan="1" rowspan="1" class="table-tint table-highlight"> <p><b> Any growth factor</b> </p> </td> </tr> <tr class="separated"> <td align="left" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Complete wound closure</b> <br> Follow‐up: 4 to 24 weeks </p> </td> <td align="" valign="top" colspan="1" rowspan="1" class="table-tint table-highlight"> <p><b>346 per 1000</b><sup>1</sup> </p> </td> <td align="" valign="top" colspan="1" rowspan="1" class="table-tint table-highlight"> <p><b>523 per 1000</b> <br> (454 to 599) </p> </td> <td align="left" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>RR 1.51</b> <br> (1.31 to 1.73) </p> </td> <td align="left" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1316<br> (12 studies) </p> </td> <td align="left" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>⊕⊕⊝⊝<br> <b>low</b><sup>2,3</sup> </p> </td> <td align="left" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1.‐ Growth factors investigated included autologous growth factor (1 trial); platelet‐derived wound healing formula (2 trials); recombinant human platelet‐derived growth factor (becaplermin) (5 trials), recombinant human basic fibroblast growth factor (2 trials), recombinant human epidermal growth factor (1 trial), and transforming growth factor (1 trial). </p> <p>2.‐ Trials differed in quality.</p> </td> </tr> <tr class="separated"> <td align="left" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Lower limb amputation (minimum of one toe)</b> <br> Follow‐up: 8 to 20 weeks </p> </td> <td align="" valign="top" colspan="1" rowspan="1" class="table-tint table-highlight"> <p><b>174 per 1000</b><sup>1</sup> </p> </td> <td align="" valign="top" colspan="1" rowspan="1" class="table-tint table-highlight"> <p><b>123 per 1000</b> <br> (64 to 235) </p> </td> <td align="left" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>RR 0.74</b> <br> (0.39 to 1.39) </p> </td> <td align="left" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>219<br> (2 studies) </p> </td> <td align="left" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>⊕⊝⊝⊝<br> <b>very low</b><sup>4,5</sup> </p> </td> <td align="left" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Platelet‐derived wound healing formula (1 trial), and recombinant human epidermal growth factor (1 trial) </p> </td> </tr> <tr class="separated"> <td align="left" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Ulcer‐free days following treatment for diabetic foot ulcers (free from any recurrence)</b> <br> Follow‐up: 12 weeks </p> </td> <td align="" valign="top" colspan="1" rowspan="1" class="table-tint table-highlight"> <p>See comment</p> </td> <td align="" valign="top" colspan="1" rowspan="1" class="table-tint table-highlight"> <p>See comment</p> </td> <td align="left" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Not estimable</p> </td> <td align="left" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>55<br> (1 study) </p> </td> <td align="left" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>See comment</p> </td> <td align="left" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Trial authors reported recurrence of ulcer in 27% (4/15) of participants receiving growth factor (recombinant human vascular endothelial growth factor) versus 33% (3/9) in placebo group. Hazard ratio was calculated using data transformation. </p> </td> </tr> <tr class="separated"> <td align="left" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Time to complete healing of the diabetic foot ulcer</b> </p> </td> <td align="" valign="top" colspan="1" rowspan="1" class="table-tint table-highlight"> <p>See comment</p> </td> <td align="" valign="top" colspan="1" rowspan="1" class="table-tint table-highlight"> <p>See comment</p> </td> <td align="left" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Not estimable</p> </td> <td align="left" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0<br> (0) </p> </td> <td align="left" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>See comment</p> </td> <td align="left" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Meta‐analysis was not possible due to the unique comparisons within each trial, failure to report data, with or without a high rate of withdrawals. </p> </td> </tr> <tr class="separated"> <td align="left" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Quality of life</b> </p> </td> <td align="" valign="top" colspan="1" rowspan="1" class="table-tint table-highlight"> <p>See comment</p> </td> <td align="" valign="top" colspan="1" rowspan="1" class="table-tint table-highlight"> <p>See comment</p> </td> <td align="left" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Not estimable</p> </td> <td align="left" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0<br> (0) </p> </td> <td align="left" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>See comment</p> </td> <td align="left" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>None of the trials assessed this outcome.</p> </td> </tr> <tr class="separated"> <td align="left" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Adverse events (non‐serious and serious)</b> <br> Follow‐up: 5 to 20 weeks </p> </td> <td align="" valign="top" colspan="1" rowspan="1" class="table-tint table-highlight"> <p><b>412 per 1000</b><sup>1</sup> </p> </td> <td align="" valign="top" colspan="1" rowspan="1" class="table-tint table-highlight"> <p><b>404 per 1000</b> <br> (325 to 502) </p> </td> <td align="left" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>RR 0.98</b> <br> (0.79 to 1.22) </p> </td> <td align="left" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>385<br> (4 studies) </p> </td> <td align="left" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>⊕⊕⊝⊝<br> <b>low</b><sup>4,6</sup> </p> </td> <td align="left" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Recombinant human epidermal growth factor (1 trial), recombinant human platelet‐derived growth factor (1 trial), recombinant human vascular endothelial growth factor (1 trial), thrombin‐induced, platelet‐released platelet‐derived wound healing formula (1 trial). </p> </td> </tr> <tr class="separated"> <td align="" valign="" colspan="7" rowspan="1" bgcolor="#ffffff"> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br> <b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio; <b>HR:</b> Hazard ratio; </p> </td> </tr> <tr class="separated"> <td align="" valign="" colspan="7" rowspan="1" bgcolor="#ffffff"> <p>GRADE Working Group grades of evidence<br> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Assumed risk is based on the risks for the control group in the meta‐analysis.<br> <sup>2</sup> Downgraded one level for limitations in design and execution: Eleven out thirteen trials assessing this outcome have high risk for selection bias. And outcome assessment was performed in unclear fashion.<br> <sup>3</sup> Downgraded one level for inconsistency (I<sup>2</sup>: 51%).<br> <sup>4</sup> Downgraded one level for limitations in design and execution.<br> <sup>5</sup> Downgraded two levels for imprecision: small sample size and very low rate of events conducting to wide confidence intervals.<br> <sup>6</sup> Downgraded one level for imprecision: Low rate of adverse events resulting in wide confidence intervals. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span>&nbsp;<span class="table-title">Any growth factor compared with placebo or no growth factor for diabetic foot ulcer</span></div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD008548.pub2/full#CD008548-tbl-0001" class="tableList">Navigate to table in Review</a></div> </div> <div class="table"> <table data-id="CD008548-tbl-0002" class="comparison"> <div class="table-heading"><span class="table-label">Comparison 1.</span>&nbsp;<span class="table-title">Any growth factor versus placebo or no growth factor</span></div> <thead> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Outcome or subgroup title</p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>No. of studies</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>No. of participants</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Statistical method</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">1 Complete wound closure <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>12</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1139</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1.51 [1.31, 1.73]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">2 Lower limb amputation (minimum of one toe) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>2</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>219</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0.74 [0.39, 1.39]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">3 Ulcer‐free days following treatment for diabetic foot ulcers (free from any recurrence) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Hazard Ratio (Fixed, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0.64 [0.14, 2.94]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">4 Adverse events (non‐serious and serious) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>4</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>385</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0.98 [0.79, 1.22]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span>&nbsp;<span class="table-title">Any growth factor versus placebo or no growth factor</span></div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD008548.pub2/references#CD008548-tbl-0002" class="tableList">Navigate to table in Review</a></div> </div> <div class="table"> <table data-id="CD008548-tbl-0003" class="comparison"> <div class="table-heading"><span class="table-label">Comparison 2.</span>&nbsp;<span class="table-title">Any growth factor versus placebo or no growth factor (subgroup analysis of trials with follow‐up &lt; 20 weeks versus follow‐up ≥ 20 weeks)</span></div> <thead> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Outcome or subgroup title</p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>No. of studies</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>No. of participants</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Statistical method</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">1 Participants with complete wound closure <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>12</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1139</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1.51 [1.31, 1.73]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1.1 Trials with length of follow‐up &lt; 20 weeks</p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>5</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>286</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1.24 [1.00, 1.55]</p> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1.2 Trials with length of follow up ≥ 20 weeks</p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>7</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>853</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1.65 [1.38, 1.98]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 2.</span>&nbsp;<span class="table-title">Any growth factor versus placebo or no growth factor (subgroup analysis of trials with follow‐up &lt; 20 weeks versus follow‐up ≥ 20 weeks)</span></div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD008548.pub2/references#CD008548-tbl-0003" class="tableList">Navigate to table in Review</a></div> </div> <div class="table"> <table data-id="CD008548-tbl-0004" class="comparison"> <div class="table-heading"><span class="table-label">Comparison 3.</span>&nbsp;<span class="table-title">Any growth factor versus placebo or no growth factor (subgroup analysis by type of growth factor)</span></div> <thead> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Outcome or subgroup title</p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>No. of studies</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>No. of participants</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Statistical method</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">1 Complete wound closure <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>12</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1137</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1.50 [1.30, 1.73]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1.1 Autologous growth factor (AGF)</p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>14</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>2.0 [0.23, 17.34]</p> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1.2 Platelet‐derived wound‐healing formula (PDWHF)</p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>2</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>83</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>2.45 [1.27, 4.74]</p> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1.3 Recombinant human platelet‐derived growth factor (rHuPDGF)</p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>5</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>763</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1.47 [1.23, 1.76]</p> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1.4 Recombinant human basic fibroblast growth factor (rHubFBGF)</p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>2</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>165</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1.23 [0.88, 1.72]</p> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1.5 Recombinant human epidermal growth factor (rHuEGF)</p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>57</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1.72 [1.16, 2.57]</p> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1.6 Recombinant human vascular endothelial growth factor (rHuVEGF)</p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>55</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1.49 [0.79, 2.82]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 3.</span>&nbsp;<span class="table-title">Any growth factor versus placebo or no growth factor (subgroup analysis by type of growth factor)</span></div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD008548.pub2/references#CD008548-tbl-0004" class="tableList">Navigate to table in Review</a></div> </div> <div class="table"> <table data-id="CD008548-tbl-0005" class="comparison"> <div class="table-heading"><span class="table-label">Comparison 4.</span>&nbsp;<span class="table-title">Any growth factor versus placebo or no growth factor (sensitivity analyses considering attrition)</span></div> <thead> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Outcome or subgroup title</p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>No. of studies</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>No. of participants</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Statistical method</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">1 Complete wound closure <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>12</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1.1 All trials</p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>12</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1139</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1.51 [1.31, 1.73]</p> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1.2 Best‐worst case scenario</p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>8</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1049</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>2.06 [1.79, 2.38]</p> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1.3 Worst‐best case scenario</p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>8</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1043</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1.05 [0.93, 1.19]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 4.</span>&nbsp;<span class="table-title">Any growth factor versus placebo or no growth factor (sensitivity analyses considering attrition)</span></div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD008548.pub2/references#CD008548-tbl-0005" class="tableList">Navigate to table in Review</a></div> </div> <div class="table"> <table data-id="CD008548-tbl-0006" class="comparison"> <div class="table-heading"><span class="table-label">Comparison 5.</span>&nbsp;<span class="table-title">Platelet derived wound healing formula (PDWHF) versus control</span></div> <thead> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Outcome or subgroup title</p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>No. of studies</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>No. of participants</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Statistical method</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">1 Complete wound closure <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>2</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>83</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>2.45 [1.27, 4.74]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">2 Lower limb amputation (minimum of one toe) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>70</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>2.2 [0.11, 43.95]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 5.</span>&nbsp;<span class="table-title">Platelet derived wound healing formula (PDWHF) versus control</span></div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD008548.pub2/references#CD008548-tbl-0006" class="tableList">Navigate to table in Review</a></div> </div> <div class="table"> <table data-id="CD008548-tbl-0007" class="comparison"> <div class="table-heading"><span class="table-label">Comparison 6.</span>&nbsp;<span class="table-title">Recombinant human platelet‐derived growth factor (rHuPDGF) versus placebo</span></div> <thead> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Outcome or subgroup title</p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>No. of studies</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>No. of participants</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Statistical method</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">1 Complete wound closure <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>5</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>753</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1.45 [1.21, 1.73]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">2 Adverse event: infection <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>2</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>222</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>2.05 [1.41, 2.97]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">3 Adverse event: cellulitis <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>2</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>292</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0.49 [0.23, 1.01]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">4 Adverse event: peripheral oedema <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>2</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>292</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0.44 [0.20, 0.96]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">5 Adverse event: pain <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>2</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>290</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0.77 [0.41, 1.48]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">6 Adverse event: skin ulceration <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>2</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>292</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1.08 [0.49, 2.37]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 6.</span>&nbsp;<span class="table-title">Recombinant human platelet‐derived growth factor (rHuPDGF) versus placebo</span></div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD008548.pub2/references#CD008548-tbl-0007" class="tableList">Navigate to table in Review</a></div> </div> <div class="table"> <table data-id="CD008548-tbl-0008" class="comparison"> <div class="table-heading"><span class="table-label">Comparison 7.</span>&nbsp;<span class="table-title">Recombinant human basic fibroblast growth factor (rHubFBGF) versus placebo</span></div> <thead> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Outcome or subgroup title</p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>No. of studies</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>No. of participants</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Statistical method</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">1 Complete wound closure <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>2</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>165</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0.81 [0.59, 1.11]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">2 Adverse event: infection <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>2</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>165</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0.75 [0.18, 3.20]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 7.</span>&nbsp;<span class="table-title">Recombinant human basic fibroblast growth factor (rHubFBGF) versus placebo</span></div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD008548.pub2/references#CD008548-tbl-0008" class="tableList">Navigate to table in Review</a></div> </div> <div class="table"> <table data-id="CD008548-tbl-0009" class="comparison"> <div class="table-heading"><span class="table-label">Comparison 8.</span>&nbsp;<span class="table-title">Recombinant human epidermal growth factor versus active control</span></div> <thead> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Outcome or subgroup title</p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>No. of studies</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>No. of participants</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Statistical method</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">1 Lower limb amputation (minimum of one toe) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>3</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1.1 Recombinant human epidermal growth factor versus actovegin</p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>61</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0.45 [0.07, 2.98]</p> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1.2 Recombinant human epidermal growth factor 75 μg dose versus 25 μg dose</p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>2</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>142</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0.79 [0.43, 1.47]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 8.</span>&nbsp;<span class="table-title">Recombinant human epidermal growth factor versus active control</span></div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD008548.pub2/references#CD008548-tbl-0009" class="tableList">Navigate to table in Review</a></div> </div> </div> <section class="translation-notes-modal" style="display: none" data-modal-title="Translation notes" data-modal-class="translation-notes" data-ok-btn-selector=".ok-btn"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="de#CD008548-note-1204">Deutsch</a> </li> <li class="section-language"> <a class="" href="es#CD008548-note-1208">Español</a> </li> <li class="section-language"> <a class="" href="fr#CD008548-note-1207">Français</a> </li> <li class="section-language"> <a class="" href="hr#CD008548-note-1206">Hrvatski</a> </li> <li class="section-language"> <a class="" href="ru#CD008548-note-1205">Русский</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" id="citeProcText" data-load-error="Unable to load citation data"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a href="#" class="addthis_button_citeulike at300b btn btn-link">CiteULike</a></li> <li><a href="#" class="addthis_button_mendeley at300b btn btn-link">Mendeley</a></li> <li><a href="#" class="citation-btn-refworks at300b btn btn-link" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <h4>Copy or download citation</h4> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button type="button" class="btn btn-link">Plain text</button></li> <li class="citation-option" data-option="endnote"><button type="button" class="btn btn-link">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button type="button" class="btn btn-link">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button type="button" class="btn btn-link">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button type="button" class="btn btn-link">BibteX</button></li> </nav> <div class="citation-content"> <pre id="citationContent" tabindex="0" data-load-error="Unable to load citation data"></pre> </div> <div class="clearfix"> <form class="download-citation-form" method="GET" target="citation-download-iframe" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=citation-citeproc&p_p_cacheability=cacheLevelPage&p_p_col_id=column-1&p_p_col_count=1"> <input type="hidden" id="siteId" name="siteId" value="" /> <input type="hidden" id="downloadType" name="downloadType" value="" /> <input type="hidden" id="style" name="style" value="" /> <input type="hidden" id="articleId" name="articleId" value="" /> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay" /><input name="p_p_lifecycle" type="hidden" value="2" /><input name="p_p_state" type="hidden" value="normal" /><input name="p_p_mode" type="hidden" value="view" /><input name="p_p_resource_id" type="hidden" value="citation-download" /><input name="p_p_cacheability" type="hidden" value="cacheLevelPage" /><input name="p_p_col_id" type="hidden" value="column-1" /><input name="p_p_col_count" type="hidden" value="1" /> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withAbstract"> <input class="checkbox" type="checkbox" name="withAbstract" /> <span class="checkbox-label">Include abstract</span> </label> </div> </form> <iframe title="Citation download frame" name="citation-download-iframe" src="" style="display: none; visibility: hidden" aria-hidden="true"></iframe> </div> </div> </div> </div> <div class="print-modal" style="display: none;" data-modal-title="Print this review"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input title="Select/deselect all" type="checkbox" class="print-options-select-all" checked="checked" /> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i class="fa fa-print" aria-hidden="true"></i> Print</button> </div> </div> <div class="download-stats-data-modal" style="display: none;" data-modal-title="Download statistical data"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <p> Downloaded data can only be viewed using <a class="external" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/http/MNYX45LWN3VYI8JPMNYXG4DTMFYGKLUQPJUB/tools/review-production-tools/revman-5" target="_blank">Review Manager software.</a> </p> <p> Please note that: <ul> <li>data are only available for Cochrane Reviews that contain one or more forest plots; and</li> <li>data in the downloaded RevMan file are editable and therefore the review data can be amended without warning.</li> </ul> </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input type="hidden" name="content-disposition" value="attachment" /> <input type="hidden" name="mime-type" value="application/octet-stream" /> <p class="print-options-controls"> <input type="checkbox" class="download-stats-data-toc-check-box" aria-label="I agree to these terms and conditions" /> <span class="checkbox-label" aria-hidden="true">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i class="fa fa-download" aria-hidden="true"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" style="display:none;" data-modal-title="Share this review"> <div class="add-this"> <div class="addthis_toolbox addthis_default_style addthis_32x32_style"> <nav class="stacked-nav-list"> <li> <a href="#" class="addthis_button_twitter at300b" title="Tweet">Twitter</a> </li> <li> <a href="#" class="addthis_button_mendeley at300b" target="_blank" title="Mendeley">Mendeley</a> </li> <li> <a href="#" class="addthis_button_facebook at300b" title="Facebook">Facebook</a> </li> <li> <a href="#" class="addthis_button_linkedin at300b" target="_blank" title="LinkedIn">LinkedIn</a> </li> <li> <a href="#" class="addthis_button_email at300b" target="_blank" title="Email">Email</a> </li> <li> <a href="#" class="addthis_button_whatsapp at300b" target="_blank" title="WhatsApp">WhatsApp</a> </li> <li class="clearfix"> <a href="#" class="addthis_button_more btn primary pull-right" target="_blank" title="View more"> <i class="fa fa-plus" aria-hidden="true"></i> View more</a> </li> </ul> </div> </div> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button type="button" class="btn btn-link" id="figureOptionBtn">Figures</button></li> <li class="table-options-btn-container"><button type="button" class="btn btn-link" id="tableOptionBtn">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div id="figureThumbnails" class="figure-thumbnails is-visible"></div> <div id="tableThumbnails" class="table-thumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a href="#" class="figure-viewer-menu-toggle"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-table-show-text="Show table list" data-table-hide-text="Hide table list" data-figure-show-text="Show thumbnails" data-figure-hide-text="Hide thumbnails">Hide thumbnails</span> </a> <a href="#" class="figure-viewer-zoomin"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a href="#" class="figure-viewer-zoomout"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a href="#" class="figure-viewer-nav previous"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a href="#" class="figure-viewer-nav next"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input type="hidden" name="freelabel" id="freelabel" value='Free access'>
<input type="hidden" name="openlabel" id="openlabel" value='Open access'>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_  portlet-static portlet-static-end kaleo-designer-portlet " id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a title="Cochrane logo" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/http/P75YPLUDN7SXR6UBN3TT655TMH/">
<img class="footer-logo logo-part-1" src="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/cochrane-theme/images/footer-logo-part-1.png" alt="Cochrane logo" /> <img class="footer-logo logo-part-2" src="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/cochrane-theme/images/footer-logo-part-2.png" alt="" /> </a> </div> <nav class="footer-links"> <ul class="root"> <li class="footer-item"> <a class="footer-item-link" href="/about-cochrane1">About Cochrane</a> <ul class="child"> <li class="footer-item"> <a class="footer-item-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TT655TMH/evidence" target="_blank">Cochrane.org</a> </li> <li class="footer-item"> <a class="footer-item-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TT655TMH/about-us" target="_blank">Who we are</a> </li> <li class="footer-item"> <a class="footer-item-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/NJYXT5SPMNYXG4DTMFYGKLUQPJUB/" target="_blank">Get involved</a> </li> <li class="footer-item"> <a class="footer-item-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/MNYX665WNWTYE63PMNYXG4DTMFYGKLUQPJUB/" target="_blank">Consumer Network</a> </li> <li class="footer-item"> <a class="footer-item-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TT655TMH/about-us/our-funders-and-partners" target="_blank">Partners</a> </li> <li class="footer-item"> <a class="footer-item-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/MNYXZ5DQPF4XT7LNF3SX8Z5IPJRX63JPN73GH/" target="_blank">Colloquium</a> </li> <li class="footer-item"> <a class="footer-item-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TT655TMH/news" target="_blank">In the news</a> </li> </ul> </li> <li class="footer-item"> <a class="footer-item-link" href="/publications">Publications</a> <ul class="child"> <li class="footer-item"> <a class="footer-item-link" href="/library">Cochrane Library</a> <ul class="child"> <li class="footer-item"> <a class="footer-item-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/" target="_blank">Library Homepage</a> </li> <li class="footer-item"> <a class="footer-item-link" href="cdsr/about-cdsr" target="_blank">Cochrane Reviews (CDSR)</a> </li> <li class="footer-item"> <a class="footer-item-link" href="/central" target="_blank">Trials (CENTRAL)</a> </li> <li class="footer-item"> <a class="footer-item-link" href="/cca/about" target="_blank">Cochrane Clinical Answers</a> </li> </ul> </li> <li class="footer-item"> <a class="footer-item-link" href="/about/cochrane-library-app" target="_blank">Cochrane Library App</a> </li> <li class="footer-item"> <a class="footer-item-link" href="/cdsr/journal-club" target="_blank">Journal Club</a> </li> <li class="footer-item"> <a class="footer-item-link" href="/about/podcasts" target="_blank">Podcasts</a> </li> </ul> </li> <li class="footer-item"> <a class="footer-item-link" href="/community">Community</a> <ul class="child"> <li class="footer-item"> <a class="footer-item-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/http/MNYX45LWN3VYI8JPMNYXG4DTMFYGKLUQPJUB/" target="_blank">Community</a> </li> <li class="footer-item"> <a class="footer-item-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/MF3GG4DJMVYGG55DNB3GC5UFF3YYE3D/" target="_blank">Archie log-in</a> </li> <li class="footer-item"> <a class="footer-item-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/http/PS3GC4LPNFYGPLUDN7SXR6UBN3TT655TMH/" target="_blank">Training and support</a> </li> <li class="footer-item"> <a class="footer-item-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/http/NWTYI4DQMS3T6Z5QMNVHEZLPMVYG86UH/" target="_blank">Methods</a> </li> <li class="footer-item"> <a class="footer-item-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/MNYX45LWN3VYI8JPMNYXG4DTMFYGKLUQPJUB/help" target="_blank">Software</a> </li> <li class="footer-item"> <a class="footer-item-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TT655TMH/news/jobs" target="_blank">Jobs and opportunities</a> </li> </ul> </li> <li class="footer-item"> <a class="footer-item-link" href="/contact-us">Contact Us</a> <ul class="child"> <li class="footer-item"> <a class="footer-item-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/http/P75YPLUDN7SXR6UBN3TT655TMH/contact" target="_blank">General enquiries</a> </li> <li class="footer-item"> <a class="footer-item-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/help/contact-us" target="_blank">Cochrane Library support</a> </li> <li class="footer-item"> <a class="footer-item-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/MNYX45LWN3VYI8JPMNYXG4DTMFYGKLUQPJUB/organizational-info/people/central-executive-team/chief-executive-officers-office/team" target="_blank">Chief Executive Officer</a> </li> <li class="footer-item"> <a class="footer-item-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/http/MNYX45LWN3VYI8JPMNYXG4DTMFYGKLUQPJUB/organizational-info/people/central-executive-team/editorial-methods/team" target="_blank">Editor in Chief</a> </li> <li class="footer-item"> <a class="footer-item-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TT655TMH/about-us/our-global-community" target="_blank">Cochrane groups</a> </li> <li class="footer-item"> <a class="footer-item-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/http/P75YPLUDN7SXR6UBN3TT655TMH/media" target="_blank">Media</a> </li> <li class="footer-item"> <a class="footer-item-link" href="/accessibility" target="_blank">Accessibility</a> </li> </ul> </li> </ul> </nav> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/N7YGZ4LPMWXGTZUTMF3HTLUYNFXGK8JPMNYXN/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/N7YGZ4LPMWXGTZUTMF3HTLUYNFXGK8JPMNYXN/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/N7YGZ4LPMWXGTZUTMF3HTLUYNFXGK8JPMNYXN/advertisers">Advertisers & Agents</a></li> <li><a class="aux-footer-nav-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/NB4XELUYNFXGK8JPMNYXN/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/NB4XELUYNFXGK8JPMNYXN/community/support/cochrane-library">Help & Support</a></li> <li><a class="aux-footer-nav-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/N7YGZ4LPMWXGTZUTMF3HTLUYNFXGK8JPMNYXN/terms-and-conditions">Terms & Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright &copy; 2000 - 2020 by <a href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/http/P75YPLUYNFXGK8JPMNYXN/" class="">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br /> Review our <a href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUYNFXGK8JPMNYXN/en-gb/privacy"><strong>Privacy Policy</strong></a> </p> <a href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/http/MW4T675JNSTYTLUDN7XB/"><img class="logo" src="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/cochrane-theme/images/en-US_wiley-footer-logo.png" alt="Wiley logo" /></a> </div> </div> <span class="wiley-semi-circle"></span> </div> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" style="display: none" data-modal-title="Feature in English only" data-modal-class="english-only-modal"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script src="/cochrane-theme/vendor/ie9.js?t=1581422282000" type="text/javascript"></script> <!--<![endif]--> <script src="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/cochrane-theme/js/theme.js?t=1581422282000" type="text/javascript"></script> <script src="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/MNYX67DFN34C66UFMFTGG7LCMVYGG55N/cochrane/checkout.js"></script> <script src="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/MNYX67DFN34C66UFMFTGG7LCMVYGG55N/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/MN3G865UNWRYE43NMNTG6LUDPJYYG65TMWUC655TMH/widget/v2.0/widget.js" type="text/javascript"></script> <script src="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/MRZXE8DIHB4XC63SNWYHPN3PMNXG87LEM33G85UVF3YGK7A/assets/embed.js" type="text/javascript"></script> <script src="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1581718153000" type="text/javascript"></script> <script src="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1581718153000" type="text/javascript"></script> <script src="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1581718153000" type="text/javascript"></script> <script src="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1581718153000" type="text/javascript"></script> <script src="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1581718153000" type="text/javascript"></script> <script src="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1581718153000" type="text/javascript"></script> <script src="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1581718153000" type="text/javascript"></script> <script src="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1581718153000" type="text/javascript"></script> <script src="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1581718153000" type="text/javascript"></script> <script src="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1581718153000" type="text/javascript"></script> <script src="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1581718153000" type="text/javascript"></script> <script src="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1581718173000" type="text/javascript"></script> <script src="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1581718249000" type="text/javascript"></script> <script src="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1581718249000" type="text/javascript"></script> <script src="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1581718173000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dreferences\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008548\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD008548\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dreferences\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008548\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD008548\x2epub2"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dreferences\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008548\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD008548\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dreferences\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008548\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD008548\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dreferences\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008548\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD008548\x2epub2"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dreferences\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008548\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD008548\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dreferences\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008548\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD008548\x2epub2"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dreferences\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008548\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD008548\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dreferences\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008548\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD008548\x2epub2"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1581422282000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a href="#" class="rh-nav-close-btn"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a href="#" class="rh-nav-open-btn"> <span>Review tools & navigation</span> </a> </div> <iframe title="Print frame" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" aria-hidden="true"></iframe> <div class="mobile-navigation"> <div class="close-container"> <a href="#" class="main-nav-back-btn" aria-label="Navigate back"><i class="fa fa-chevron-left"></i></a> <a href="#" class="main-nav-close-btn" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end " id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img id="ymag__null__null" src="/scolaris-search/icon.png" alt="" /> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class=" portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/en/content?p_auth=EfT7x5RD&p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=1&p_p_state=normal&p_p_mode=view&_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input type="hidden" name="searchType" value="basic" /> <input type="hidden" name="facetDisplayName" value="" /> <input type="hidden" name="facetQueryTerm" value="" /> <input type="hidden" name="facetQueryField" value="" /> <input type="hidden" name="facetCategory" value="" /> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select title="Search by options" aria-label="Search by options" name="searchBy" class="custom-select-enabled search-type"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" style="display: none;" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=topics-list&p_p_cacheability=cacheLevelPage"> <select class="search-select-topic-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input type="text" size="30" class="field browser-search search-text ui-autocomplete-input" value="" aria-label="Enter search term" id="searchText" name="searchText" placeholder="Search">
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button type="submit" class="searchByBtn" aria-label="Search">
<i class="fa fa-search" aria-hidden="true"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=references&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD008548.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD008548.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input type="hidden" name="freelabel" id="freelabel" value='Free access'>
<input type="hidden" name="openlabel" id="openlabel" value='Open access'>
</div>
</section>
</div>
<a href="/en/browse-by-topic" class="btn secondary">Browse </a>
<a href="/en/advanced-search" class="btn secondary advanced-search-button">Advanced search</a>
</div>
<div class="menu-items parent">
<ul>
<li class="nav-root-item parent">
<a href="#" title="Select language" class="language-selection-title-link">
<span class="mobile-nav-language-title">Select your preferred language</span><span class="icon fa fa-caret-down"></span>
<ul class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_  portlet-static portlet-static-end  " id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img id="fdkn__null__null" src="/scolaris-language-portlet/icon.png" alt="" /> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class=" portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hr, ja, ko, ms, pl, pt, ru, ta, th, zh, za]"> <a title="Select your preferred language" class="language-select-mobile" href="#"> <i class="fa fa-file-text"></i> English </a> <a title="Select your preferred language" class="language-select-mobile" href="#"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane Review language</h3> <p>Select your preferred language for Cochrane Reviews. You will see translated Review sections in your preferred language. Sections without translation will be in English.</p> <div id="active-content-language" class="dropdown-trigger"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=set-content-language&p_p_cacheability=cacheLevelPage&_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de" class="content-language-selector " data-languagecode="de">Deutsch</a> <a href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=set-content-language&p_p_cacheability=cacheLevelPage&_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en" class="content-language-selector is-active" data-languagecode="en">English</a> <a href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=set-content-language&p_p_cacheability=cacheLevelPage&_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es" class="content-language-selector " data-languagecode="es">Español</a> <a href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=set-content-language&p_p_cacheability=cacheLevelPage&_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa" class="content-language-selector " data-languagecode="fa">فارسی</a> <a href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=set-content-language&p_p_cacheability=cacheLevelPage&_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr" class="content-language-selector " data-languagecode="fr">Français</a> <a href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=set-content-language&p_p_cacheability=cacheLevelPage&_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr" class="content-language-selector " data-languagecode="hr">Hrvatski</a> <a href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=set-content-language&p_p_cacheability=cacheLevelPage&_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja" class="content-language-selector " data-languagecode="ja">日本語</a> <a href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=set-content-language&p_p_cacheability=cacheLevelPage&_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko" class="content-language-selector " data-languagecode="ko">한국어</a> <a href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=set-content-language&p_p_cacheability=cacheLevelPage&_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms" class="content-language-selector " data-languagecode="ms">Bahasa Malaysia</a> <a href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=set-content-language&p_p_cacheability=cacheLevelPage&_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl" class="content-language-selector " data-languagecode="pl">Polski</a> <a href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=set-content-language&p_p_cacheability=cacheLevelPage&_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt" class="content-language-selector " data-languagecode="pt">Português</a> <a href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=set-content-language&p_p_cacheability=cacheLevelPage&_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru" class="content-language-selector " data-languagecode="ru">Русский</a> <a href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=set-content-language&p_p_cacheability=cacheLevelPage&_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta" class="content-language-selector " data-languagecode="ta">தமிழ்</a> <a href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=set-content-language&p_p_cacheability=cacheLevelPage&_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th" class="content-language-selector " data-languagecode="th">ภาษาไทย</a> <a href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=set-content-language&p_p_cacheability=cacheLevelPage&_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh" class="content-language-selector " data-languagecode="zh">简体中文</a> <a href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=set-content-language&p_p_cacheability=cacheLevelPage&_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=za" class="content-language-selector " data-languagecode="za">繁體中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div id="active-portal-language" class="dropdown-trigger"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a href="/en/cdsr/doi/10.1002/14651858.CD008548.pub2/references/en" class="portal-language-selector is-active" data-portallanguage="en">English</a> <a href="/es/cdsr/doi/10.1002/14651858.CD008548.pub2/references/es" class="portal-language-selector " data-portallanguage="es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=set-content-language&p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input type="hidden" name="freelabel" id="freelabel" value='Free access'>
<input type="hidden" name="openlabel" id="openlabel" value='Open access'>
</div>
</section>
</div>
</ul>
</a>
</li>
<li class="parent">
<a class="mobile-link signin" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/c/portal/login?p_l_id=20757&redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD008548.pub2%2Freferences" data-redirect="false" rel="nofollow">
Sign In
</a>
</li>
</ul>
<div class="menu-items-footer">
<div class="utility-links">
<a href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/http/P75YPLUDN7SXR6UBN3TT655TMH/" class="cochrane-link" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
<div class="basic-login-form-content" style="display: none;" data-modal-title="Sign in">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_  portlet-static portlet-static-end portlet-login " id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img id="dbam__null__null" src="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/cochrane-theme/images/spacer.png" alt="" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;" /> <span class="taglib-text hide-accessible">Sign In</span> </span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class=" portlet-content-container"> <div class="portlet-body"> <form action="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" class="form sign-in-form " id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm" autocomplete="on"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1583244159407" /> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false" /> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="&#x2f;cdsr&#x2f;doi&#x2f;10&#x2e;1002&#x2f;14651858&#x2e;CD008548&#x2e;pub2&#x2f;references" /> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false" /> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value="" /> </div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value="" /> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true" /> <input checked class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onClick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true" /> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/N7YGZ4LPMWXGTZUTMF3HTLUYNFXGK8JPMNYXN/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button type="submit" class="btn primary">Sign in</button> <a href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/N7YGZ4LPMWXGTZUTMF3HTLUYNFXGK8JPMNYXN/user-registration" target="_blank" class="btn secondary">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&p_p_lifecycle=0&p_p_state=normal&p_p_mode=view&_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </fieldset> </form> </div> </div> </div> <div style="display:none"> <input type="hidden" name="freelabel" id="freelabel" value='Free access'>
<input type="hidden" name="openlabel" id="openlabel" value='Open access'>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" style="display: none;" data-modal-title="Institutional login">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_  portlet-static portlet-static-end scolaris-content-display-portlet " id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img id="obft__null__null" src="/scolaris-content-display/icon.png" alt="" /> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class=" portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form method="post" action="/shibboleth" id="institutionLoginForm"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" name="institutionName" id="institutionName" value="" type="text">
</div>
<button class="btn primary" type="submit" name="button">Go</button>
</div>
<div id="institutionLookupErrorDiv" class="message error" style="display:none">
'<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
</div>
</div>
<input type="hidden" id="entityId" name="entityId" value="">
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input type="hidden" name="freelabel" id="freelabel" value='Free access'>
<input type="hidden" name="openlabel" id="openlabel" value='Open access'>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_  portlet-static portlet-static-end portlet-login " id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img id="joiu__null__null" src="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/cochrane-theme/images/spacer.png" alt="" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;" /> <span class="taglib-text hide-accessible">Sign In</span> </span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class=" portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" class="form sign-in-form " id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm" autocomplete="on"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1583244159411" /> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false" /> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="&#x2f;cdsr&#x2f;doi&#x2f;10&#x2e;1002&#x2f;14651858&#x2e;CD008548&#x2e;pub2&#x2f;references" /> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false" /> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value="" /> </div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value="" /> </div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true" /> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button type="submit" class="btn primary">Sign in</button> </div> </div> </fieldset> </form> </div> </div> </div> <div style="display:none"> <input type="hidden" name="freelabel" id="freelabel" value='Free access'>
<input type="hidden" name="openlabel" id="openlabel" value='Open access'>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" style="display: none;" data-modal-title="Unlock the potential of Cochrane evidence">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_  portlet-static portlet-static-end scolaris-content-display-portlet " id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img id="wpdq__null__null" src="/scolaris-content-display/icon.png" alt="" /> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class=" portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form method="post" action="/shibboleth" id="institutionLoginForm"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" name="institutionName" id="institutionName" value="" type="text"> </div> <button class="btn primary" type="submit" name="button">Go</button> </div> <div id="institutionLookupErrorDiv" class="message error" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input type="hidden" id="entityId" name="entityId" value=""> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input type="hidden" name="freelabel" id="freelabel" value='Free access'> <input type="hidden" name="openlabel" id="openlabel" value='Open access'> </div> </section> </div> </div>  <script>window.urlTitle="/cdsr/doi/10.1002/14651858.CD008548.pub2";addthis_config={pubid:"ra-593597d01cdf9a55",ui_508_compliant:true};addthis_share={url:window.location.href,title:document.title};</script> <script src="//s7.addthis.com/js/300/addthis_widget.js#pubid=ra-593597d01cdf9a55"></script> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> </body> </html> 